

Van Poppel Hendrik - Adjunct Secretary General of European Association of Urology, Faculty Member of the European Society of Medical Oncology

Latin-Greek humanities: St. Rombouts College, Mechelen.

Candidate Medicine: Facultés Universitaires Notre-Dame de la Paix, Namur, July 1971.

Satisfaction, Magna cum laude, Cum laude.

Doctor in Medicine: Katholieke Universiteit Leuven, July 1975.

Satisfaction, Cum laude, Magna cum laude, Magna cum laude.

Registration Belgian medical authorities: September 1975.

Married: Croon Conny, April 1976. Three daughters: Elke, Loesje, Ineke.

Specialist in General Surgery: July 1980 (after 5 years training K.U.Leuven, Prof. Dr. A. Laquet, Prof. Dr. J.A. Gruwez).

Specialist in Urology: 10.08.1983 (after 3 years training K.U.Leuven, Prof. Dr. H. Verduyn, Prof. Dr. R. Vereecken).

Postgraduate urological education London, Barcelona, Copenhagen, Mainz, Rotterdam 1983-1984.

Lecturer in Urology K.U.Leuven: September 1987.

Adjunct-Kliniekhoofd, University Hospitals K.U.Leuven: May 1988.

Ph.D. in Medical Sciences K.U.Leuven: June 1988.

Kliniekhoofd Urology, University Hospitals K.U.Leuven: October 1992.

Gewoon Hoogleraar, Urologie, K.U.Leuven: October 1998

Professor in Urology, K.U.Leuven, October 1993.

Chairman Dept. of Urology, University Hospitals KU Leuven: July 2002

Stagemeester Urologie, April 2003

I. Assisted courses, symposia, scientific meetings and congresses

1. Symposium on colo-rectal cancer, Leyden, June 1979.
2. A.O. traumatology course, Davos, December 1980.
3. Urologische Funktionsdiagnostik, Berufsverband Deutscher Urologen, Bad Dürkheim, November 1980.
4. Modern urologic diagnosis, K.U.Leuven, November 1980.
5. Electromedical instrumentation in urology, Universitaire Instelling Antwerpen, November 1980.
6. Workshop on bladder cancer, Vrije Universiteit Brussel, December 1980.
7. Symposium on enuresis, Rotterdam, February 1981.
8. 8th International Course of Urology, Barcelona, June 1981.
9. Urology research society meeting, Leyden, August 1981.
10. Recent progress in renal stone surgery, Université Libre de Bruxelles, November 1981.
11. First international symposium on kidney tumors, Paris, November 1981.
12. 5th congress of the European Association of Urology, Vienna, May 1982.
13. Jubilee Conference on Multiple Sclerosis, Copenhagen, June 1982.
14. 24. Tagung der Vereinigung Norddeutschen Urologen, Kassel, June 1982.
15. International Continence Society, Leyden, September 1982.
16. Progress in gastro-enterology (Retroperitoneum), Brussels, October 1982.
17. EORTC symposium, Brussels, October 1982.
18. 25th Anniversary Symposium of the Belgian Research Group on Multiple Sclerosis, Brussels, March 1983.
19. First world congress on percutaneous renal surgery, Institute of Urology, London, April 1983.
20. Workshop on bladder cancer, Vrije Universiteit Brussel, May 1983.
21. Female urinary incontinence, Soc. Belge d'Urologie, Brussels, June 1983.
22. Therapeutic advances in the treatment of prostate cancer, Helsingborg, Sweden, June 1983.
23. Journées de Cochin, Paris, June 1983.
24. Ilième cours international de technologie urologique, Lyon, June 1983.
25. International practical course on microsurgery, K.U.Leuven, July 1983.
26. Course in practical percutaneous renal surgery and radiology, Institute of Urology, London, September 1983.
27. Course in endoscopic urology, Institute of Urology, London, October 1983.
28. Radionuclids in nephro-urology, Institute of Urology, London, October 1983.
29. Topics in Multiple Sclerosis, Royal College of Physicians, London, November 1983.

30. Cytotoxic chemotherapy in urological practice, Institute of Urology, London, November 1983.
31. The female urethra, Royal College of Gynecol. Obstet., London, November 1983.
32. Uroradiology week-end, Institute of Urology, London, December 1983.
33. Sexually transmitted diseases, Royal College of Physicians, London, December 1983.
34. La contracepcio no quirurgica a l'home, Academia de sciences mediques, Barcelona, January 1984.
35. Meeting Associacion Trasplante Renal Catalana, Barcelona, March 1984.
36. 6th Congress European Association Urology, Copenhagen, May 1984.
37. International symposium practical aspects of urinary incontinence, Nijmegen, June 1984.
38. Advances in Renal Stone Management. Meeting Belg. Veren.Urol. Antwerp, September 1984.
39. 4th Mediterranean Congress of Chemotherapy, Rhodos Greece, October 1984.
40. Postgraduate Meeting on Bladder Cancer, Prof. E. Zingg Bern, Rotterdam, November 1984.
41. 1st. Symposium on Physiotherapy and Revalidation. Kath. Univ. Leuven, November 1984.
42. Round table on varicocele, Soc. Belg. Urol., Brussels, March 1985.
43. Postgraduate international symposium, Ghent, April 1985.
44. Congress testicular tumors, Soc. Belge Urol., Brussels, June 1985.
45. Symposium International d'Urologie, Brussels, June 1985.
46. Studiedag Multiple Sclerose, Melsbroek, September 1985.
47. Symposium Neurophysiologie clinique et Révalidation neurologique, Ottignies, September 1985.
48. Round table on pediatric urology, Rotterdam, October 1985.
49. Prosthesis and Multiple Sclerosis, Internat. Soc. Prosthetics and Orthotics, Melsbroek, October 1985.
50. 1st. International Workshop on Ciproflaxin, Leverkusen, November 1985.
51. Symposium International d'Urologie Pédiatrique, Brussels, November 1985.
52. International Oncologic Symposium on Bladder Cancer, Antwerp, November 1985
53. Symposium on Bladder Reeducation, Brussels, November 1985
54. Workshop on Urinary Tract Infection, Brussels, December 1985
55. Postgraduate Meeting on Prostate Cancer, Rotterdam, February 1986
56. Symposium on Hormonal Treatment of Prostate Cancer, Brussels, March 1986
57. First International Symposium on Primary Prevention and Cancer, Antwerp, March 1986

58. Praktische urologie voor de huisarts, Leuven, april 1986
59. Belgian Society of Pathology Meeting, Antwerp, May 1986
60. International Symposium on Hormonal Manipulation of Cancer, Rotterdam, June 1986
61. 51st Congress of the Société Belge d'Urologie, Brussels, June 1986
62. 2nd International Symposium on Prostatic Cancer, Paris, June 1986
63. 38. Tagung der Deutschen Gesellschaft für Urologie, Würzburg, September 1986
64. EORTC Genitourinary Group meeting, Leeds, October 1986
65. 3rd Congress of the European Society of Surgical Oncology, Lisboa, October 1986
66. Percutaneous Renal Surgery, Soc. Belge d'Urologie, Brussels, February 1987
67. Symposium on Prostate Specific Antigen, Leuven, February 1987
68. Progress and Controversies in Oncological Urology, Amsterdam, March 1987
69. Congress of the Belgian Society of Urology, Leuven, April 1987
70. Workshop on Flexible Endourology, Leuven, June 1987
71. Symposium on Fotodynamic Therapy and Fibertips, Nederlands Medisch Lasergenootschap, Rotterdam, September 1987
72. EORTC Genitourinary Group Meeting, Antwerp, November 1987
73. Journées d'Entraide Médicale Internationale, Brussels, October 1987
74. EORTC Genitourinary Group Meeting, London, May 1988
75. 4th Congress European Society of Surgical Oncology, Paris, October 1988
76. International Symposium on Invasive Bladder Cancer, Leuven, October 1988
77. International Symposium on APD, Lugano, October 1988
78. EORTC Genitourinary Group Meeting, Strasbourg, November 1988
79. 36th Oncology Meeting on Conservative Cancer Treatment, Antwerp, November 1988.
80. Belgische Vereniging Urologie, Parke-Davis Price, Oostende, November 1988.
81. Instruction and Training in Mainz Pouch Performance, Mainz, 4-8 December 1988.
82. 5. Internationale Arbeitstagung: Infektionsverhütung im Krankenhaus. Zürich, December 1988.
83. External Reference Meeting on Prostate Cancer, Rotterdam, January 1988.
84. Prostate and Bladder Cancer Symposium, Oostende, January 1989.
85. Workshop: Neurostimulation and -modulation of the lower urinary tract. Maastricht, February 1989.
86. Symposium: Carcinoma of the prostate: new aspects, Brussels, March 18, 1989.
87. EORTC Genitourinary Group meeting, Hull, April 11-12, 1989.
88. Consensus Conference on Prostate and Testes Cancer, Hull, April 12-15, 1989.
89. Symposium: Treatment of Prostate Cancer anno 1989, Luxembourg, April 15-16, 1989.

90. Investigative Meeting on Prostatitis Multicenter Study, New York, May 15, 1989.
91. Lecture: Is radical prostatectomy the treatment of choice for curable prostate cancer, M. Bressel, Leuven, May 16, 1989.
92. Workshop: Is prevention and early detection of bladder cancer possible ? Leuven, June 5, 1989.
93. Lecture: Aspect neurologique du SIDA, L. Boccon Gibod, Leuven, June 23, 1989.
94. First International Workshop and Symposium on New Urological Technology, Leuven, September 6-9, 1989.
95. New Trends in Urology, Nijmegen, September 13-16, 1989.
96. EORTC Genitourinary Group Meeting, Nijmegen, September 16-17, 1989.
97. Facts and controversies on treatment of prostatic cancer, Sorrento, October 12-15, 1989.
98. 83ième Congrès Français d'Urologie, Paris, November 15-17, 1989.
99. A.P.D. for advanced prostate cancer. Investigation meeting, Brussels, November 17, 1989.
100. Belgische Vereniging Urologie, Parke-Davis Price, Aalst, November 25, 1989.
101. Collegium Chirurgicum Belgicum. General assembly, Brussels, November 29, 1989.
102. Mini-symposium: What's new in Urology ? St.-Truiden, November 30, 1989.
103. International Symposium on Female Urinary Incontinence. Leuven, December 9, 1989.
104. Research and Multiple Sclerosis, Academic session, Brussels, December 13, 1989.
105. 20th. Anniversary Symposium Pediatric Nephrology of the K.U.Leuven, Leuven, December 16, 1989.
106. Microsymposium: Aetiologic concepts in motor instability of the urinary bladder, Rotterdam, Erasmus University, March 16, 1990.
107. International course on urological oncology - reconstructive surgery, organ conservation and functional restoration in urological oncology. Erice, Italy, March 25-31, 1990.
108. Radiosensitizing activity of microtubule inhibitors. Workshops, Brussels, April 5, 1990.
109. International symposium to celebrate 1000 renal transplants performed at the K.U.Leuven, Leuven, April 30, 1990.
110. First Meeting of the European Study Group on Urological Disturbances in Multiple Sclerosis, Nijmegen, June 8-9, 1990.
111. Second International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment. Paris, June 27-29, 1990.
112. Second Meeting of the European Study Group on Urological Disturbances in Multiple Sclerosis, Brussels, August 24, 1990.

113. Autumn Meeting of the EORTC GU Group, Prague, September 12-15, 1990.
114. One day symposium on urological oncology. Prague, September 15, 1990.
115. 42. Kongress der Deutschen Gesellschaft für Urologie, Hamburg, September 26-29, 1990.
116. Fifth Congress of the ESSO, Brussels, October 17-20, 1990.
117. Avondsymposium: Screening, diagnose en therapie van het beperkte prostaatacarcinoom, Antwerpen, October 26, 1990.
118. 2nd International Workshop on the hormonal treatment of prostatic cancer. Thailand, November 24-30, 1990.
119. 2nd Winter Symposium Urologic Oncology, Zermatt, February 10-16, 1991.
120. Pilot-Live-Operations Demonstrationen zwischen Mainz und Hannover via Medkom, Mainz, February 21-23, 1991.
121. National Symposium on Prostate Cancer: Recent Aspects, Brussels, March 9, 1991.
122. 6ième Séminaire d'Urologie: Les problèmes de continence, Brussels, March 16, 1991.
123. 1st European Workshop: Sexual and urological disturbances in M.S., Leuven, March 28-30, 1991.
124. Weekend Symposium on PSA and endocrine therapy for prostate cancer. Chantilly, April 6-7, 1991.
125. Spring Meeting of the EORTC GU Group, Paris, April 11-13, 1991.
126. 32° Tagung der Südwestdeutschen Gesellschaft für Urologie, Koblenz, May 9-11, 1991.
127. 56ième Congrès de la Société d'Urologie, May 25-26, 1991.
128. 1st. International Congress of the Dutch Urological Association "Progress and Controversies in Oncological Urologie III", Rotterdam, October 9-13, 1991.
129. Autumn meeting of the EORTC GU Group, Rotterdam, October 1991.
130. Elaut Price competition, Belgische Vereniging Urologie, Leuven, October 26, 1991.
131. Colloquium Lovaniensium Chirurgorum, Leuven, November 9, 1991.
132. Meeting of the Standing Committee of the European Study Group on SUDIMS, London, November 15, 1991.
133. 1st National Multidisciplinary Congress of the Collegium Chirurgicum Belgicum, Antwerp, November 30, 1991.
134. Spring Meeting of the EORTC GU Group, Aachen, March 17-19, 1992.
135. Developments in the treatment of prostate cancer. M. Soloway, R. Janknegt, Brussels, April 14, 1992.
136. Role of PSA in the diagnosis of prostate cancer, Prof. Blankenstein, Brussels, April 28, 1992.

137. American Urological Association, Washington, May 9-12, 1992.
138. Second meeting of the European Study Group of SUDIMS, Copenhagen, May 22-24, 1992.
139. Second international workshop and symposium on New Urological Technology, Leuven, June 4-5, 1992.
140. 3rd International symposium on recent advances in urological cancer diagnosis and treatment, Paris, June 17-19, 1992.
141. European Board of Urology Examination, Genua, July 20, 1992.
142. Brainstorming meeting EORTC GU Group, Amsterdam, August 28, 1992.
143. Euro-American Conference on Urological Cancer, Athens, September 15-18, 1992.
144. EORTC GU Group meeting, Modena, Italy, September 24-26, 1992.
145. International Meeting on Uro-Oncology, Modena, Italy, September 26-27, 1992.
146. Early detection and treatment of localized carcinoma of the prostate, Christiaens Award, Bruges, October 3, 1992.
147. First meeting of the Belgian EORTC GU Group, Brussels, February 10, 1993.
148. Locally advanced bladder cancer, Aachen, February 26-27, 1993.
149. Polish Professors in Urology meeting, Warsaw, March 5-6, 1993.
150. Academic session, 10th Anniversary Belgische Vereniging voor Kankerbestrijding. Brussels, March 13, 1993.
151. EORTC General Assembly, Brussels, March 19, 1993.
152. Fourth International Consensus Meeting on Bladder Cancer, Antwerp, March 24-26, 1993.
153. EORTC GU Group Spring Meeting, Antwerp, March 26-27, 1993.
154. Prostate Cancer Workshop on Casodex, Paris, April 16-18, 1993.
155. Onkologicko-Urologické Symposium, Praha, April 29, 1993.
156. Grupo Portugues Genito-urinario EORTC Meeting, Castelo Branco, Portugal, May 28, 1993.
157. EORTC GU Group Kidney Subcommittee Meeting, Brussels, July 5, 1993.
158. EORTC GU Group Prostate Cancer Subcommittee Meeting, Amsterdam, September 2, 1993.
159. Cambridge Prostate Cancer Meeting, Cambridge, September 5, 1993.
160. 11ième Journée Urologique de Lille, Lille, October 8-9, 1993.
161. 8th International Symposium of Urology Update 1993, Espinho, October 25-28, 1993.
162. EORTC GU Group Autumn Meeting Istanbul, November 10-13, 1993.
Participation in Clinical Trial Committee, National Coordinators Meeting, Quality of Life Committee, Quality Control Committee, Prostate Cancer Committee and Chairman of the Kidney Cancer Committee.

163. 87ième Congrès Français d'Urologie, Paris, November 18-19, 1993.
164. Prostate Cancer Subcommittee Meeting EORTC GU Group, Brussels, January 28, 1994.
165. European School of Oncology. Operative Uro-Onkologie, Aachen, March 2-4, 1994.
166. EORTC GU Group Spring Meeting, Rome, April 7-10, 1994.
167. 4th International Symposium on Recent Advances in Urological Cancer, Diagnosis and Treatment, Paris, June 22-24, 1994.
168. XIth EAU Congress (European Association of Urology), Berlin, July 13-16, 1994.
169. 24th Congress of the Polish Urological Association, Cracow, September 1-3, 1994.
170. 9th Congress of the Society of Hungarian Urologists, Budapest, October 13-15, 1994.
171. Workshop: Multiple Sclerosis and Rehabilitation, Care and Health Services in Europe (MARCH), Tenerife, December 1-4, 1994.
172. Prof. Elaut Price of Urology - Belgische Vereniging Urologie, Zottegem, December 17, 1994.
173. Congress of the VVOV, Leuven, January 28, 1995.
174. MARCH meeting, Brussels, February 3-4, 1995.
175. Prostate Cancer Subcommittee Meeting, EORTC GU Group, Brussels, February 3, 1995.
176. Kidney Cancer Subcommittee Meeting, EORTC GU Group, Brussels, February 10, 1995.
177. Symposium Urology, Lisboa, Portugal, March 18, 1995.
178. EORTC GU Group Spring meeting Den Bosch, March 23-25, 1995.
179. 43rd Annual Meeting of the Radiation Research Society/15th Annual Meeting of the North American Hyperthermia Society, San Jos California, April 1-6, 1995.
180. XIième Congrès de la Société Internationale Francophone de Chirurgie Pelvienne, Lyon, April 7-8, 1995.
181. American Urological Association Meeting, Las Vegas, April 23-28, 1995.
182. International Congress of the Belgian Urological Association, Gent, May 12-13, 1995.
183. Third Congress New Urological Technology, Leuven, June 1-3, 1995.
184. Urology meeting, general practitioners, Leuven, June 8, 1995.
185. Casodex Investigators Meeting, Geneva, June 10, 1995.
186. Château de la Bretesche Symposium Prostate Cancer, July 8-12, 1995.
187. Prostate Cancer Subcommittee Meeting, EORTC GU Group, Brussels, September 8, 1995.
188. Advanced prostate cancer meeting, Shanghai, September 20, 1995.
189. Roentgen Centenary Meeting on Prostate Cancer, Brussels, October 7, 1995.

190. Fifth International Conference of Anticancer Research, Corfu, October 17-22, 1995.
191. The European Cancer Conference ECCO 8, Paris, October 29-30, 1995.
192. 3rd International Congress of the Dutch Urological Association, November 1, 1995.
193. EORTC GU Group Autumn meeting, Brugge, November 9-11, 1995.
194. Prostate DOG EORTC meeting, Brussels, January 26, 1996.
195. Belgische Vereniging Urologie meeting, Lier, January 27, 1996.
196. Le point sur le traitement du cancer de la prostate. Meeting with the urologists from Luxemburg, Bruges, February 3, 1996.
197. Meeting of the European Group for Guidelines in Onco-Urology, Paris, February 23-24, 1996.
198. European School of Oncology, Operative Uro-Onkologie, Aachen, March 6-8, 1996.
199. Meeting with other urological departments: Heerlen De Wever ziekenhuis, May 17, 1996.
200. EORTC GU Group Spring meeting, Warsaw, April 25-27, 1996.
201. Research programs on prostate pathology, Prof. Petrovich Dr. Honoris Causa, Leuven, April 29, 1996.
202. Belgian Urological Congress: Adjuvant treatment in urological cancer, Brussels, May 31-June 1, 1996.
203. First International Consultation on Prostate Cancer, Monaco, June 20-22, 1996.
204. European Association of Urology, XIIth Congress, September 1-4, 1996.
205. International Symposium on Carcinoma of the Bladder, Leuven, September 12-13, 1996.
206. Symposium of the Cancerology Section of the French Urological Association, Paris, September 27-28, 1996.
207. European School of Urology. Update in Urological Oncology, Izmir, October 4-5, 1996.
208. 14th Congress of the Turkish Urological Society, Marmaris, October 20-23, 1996.
209. EORTC GU Group autumn meeting, Palermo, November 7-9, 1996.
210. 24th Meeting of the International Society for Oncodevelopmental Biology and Medicine, San Diego, November 17-22, 1996.
211. EORTC GU Group executive committee meeting, Brussel, January 17, 1997
212. Belgische Vereniging voor Urologie: Prof. Elautprijis, Turnhout, January 25, 1997.
213. VI International symposium on biology and clinical usefulness of tumor markers, Barcelona, February 12-15, 1997.
214. Sixth European Urological Winter Forum, Davos Switzerland, February 16-21, 1997.

215. Simposio Internacional de Urologia: "Controversias en Urologia", Tenerife, March 7-8, 1997.
216. EORTC Genitourinary Group Spring Meeting, Malta, March 20-23, 1997.
217. EORTC GU Group Executive Committee Meeting, Malta, March 20, 1997
218. Wetenschappelijke bijeenkomst: 30 jaar urologische praktijk Dr. V. Morelle, Aalst, May 1, 1997.
219. Renal Cell Carcinoma/Operative and Theoretical Course. Affiliated course of the European School of Urology, an educational programme of the European Association of Urology and the European Board of Urology, Helsinki, May 29-30, 1997.
220. European School of Urology Satellite Course on Reconstructive Urology, Genova, June 1, 1997.
221. International congress of the Belgian Society of Urology : "Ureter Pathology and Male Infertility", Oostende, June 6-7, 1997.
222. 3 de Urologisch Verpleegkundig Congres: "Prostaataandoeningen, pathologie en therapie", Oostende, June 7, 1997.
223. EORTC GU Group Executive Committee, Brussels, June 13, 1997
224. Recent developments in the field of prostate cancer, Cliniques Universitaires St. Luc, Bruxelles, June 13, 1997.
225. Avondsymposium "PSA: een stand van zaken", Sint-Maartens-Latem, June 24, 1997.
226. International Baltic Uro-Oncologic Symposium on Prostate Cancer, Kiel, June 26-28, 1997.
227. European Cancer Conference (ECCO), Hamburg, September 15-18, 1997.
228. EORTC Genito-Urinary Group Autumn meeting, Lisbon, October 9-11, 1997.
229. EORTC GU Group Executive Committee Meeting, Lisbon, October 9, 1997
230. MRC Urological Cancer Residential Open Meeting, York, October 23-24, 1997.
231. Vth International Consensus meeting on bladder cancer, Tokyo, November 6-8, 1997.
232. International Symposium: Carcinoma of Kidney and Testis, Leuven, November 15, 1997.
233. 91ième Congrès Français d'Urologie, Paris, November 18, 1997.
234. Visiting Professor Linz, Austria, November 19-22, 1997.
235. 9th International Hamburg symposium on tumor markers, December 7-9, 1997.
236. Belgian Uro-Oncological Study Group meeting, Milan, December 19, 1997.
237. Early prostate cancer. Developing a strategy for the next two decades, Miami, January 3, 1998.
238. EORTC GU Group Executive Committee Meeting, Brussels, January 16, 1998

239. Meeting of the Group for recommendations and guidelines in onco-urology (EAU), Paris, January 23-24, 1998.
240. Teaching course on bladder substitution in females, Innsbruck, February 16, 1998.
241. EORTC Spring Meeting, Oslo-Norway, March 12-14, 1998.
242. EORTC GU Group Executive Committee Meeting, Oslo, March 12, 1998.
243. EAU XIIIth Congres, Barcelona, March 21-25, 1998.
244. Therapeutic insights. Prostate Cancer, Amsterdam, April 23, 1998.
245. Lessenreeks Belgische vereniging voor Radiotherapie-Oncologie, UZ Gasthuisberg, Leuven, April 25, 1998.
246. Controversial and Practical Urology (BSU), Kortrijk, May 8-9, 1998.
247. Belgische vereniging voor Pathologische Ontleedkunde, UZ Gasthuisberg, Leuven May 16, 1998.
248. EORTC GU Group Executive Committee Meeting, June 19, 1998.
249. Insights in urology: Relevant aspects in the practice of modern urology (ESU), Lisbon, July 2-4, 1998.
250. Meeting Belgische Vereniging voor Urologie and Turkish Urological Association. Kusadasi, September 25-27, 1998.
251. Uropathology Debate and Controversy, Edinburgh, October 6-7, 1998.
252. EORTC Autumn Meeting, Varese-Italy, October 8-11, 1998.
253. EORTC Executive Committee Meeting, October 9, 1998.
254. Progress and Controversies in Oncological Urology V, an update of renal bladder and prostate cancer, Rotterdam, October 15-17, 1998.
255. Symposium Incontinentie en Impotentie na prostaatoperatie, UZ Gasthuisberg Leuven, October 23, 1998.
256. Onco-Uro Congres II: Hematurie, Niertumoren, Blaastumoren, UZ Antwerpen, October 24, 1998.
257. VII Jornadas Internacionales de Actualizacion Urologica, Madrid, November 1-4, 1998.
258. International course on functional urology, Tenerife December 4-6, 1998.
259. Externe refereeravond: New Concepts in the treatment of urologic cancers, Nijmegen, December 10, 1998.
260. Clinical use of PET in Oncology, UZ Gasthuisberg, Leuven, December 12, 1998.
261. EORTC GU Group Executive Committee Meeting, January 12, 1999
262. Belgische Vereniging voor Urologie: Prof. Elautprijjs, Roeselare, January 23, 1999.
263. Seminarie Heelkunde, UZ Gasthuisberg, Leuven, January 25, 1999.
264. 8ste Serruys Symposium Oncologie, Impact van de initiële multi modale aanpak op tumorale respons en overleven van de oncologische patiënt, Oostende, February 6, 1999.

265. Lessencyclus radioprotectie en dosimetrie, KU Leuven 1997-1998.
266. EORTC Scientific Strategy Meeting, Brussels, March 25-26, 1999.
267. Belgian Society of Urology meeting, Ghent, March 26, 1999.
268. EORTC GU Group Spring Meeting, Ghent, March 24, 25 & 27, 1999.
269. EORTC GU Group Executive Committee Meeting, Ghent, March 24, 1999.
270. Second UICC Cancer Management Meeting, "The team approach to cancer management", Antwerp, April 14-18, 1999.
271. XIV th Congress of the European Association of Urology, Stockholm, April 7-11, 1999.
272. XXième Congrès de la Société Française d'Application des Ultrasons à la Médecine et à la Biologie (SFAUMB), Lille, May 5-7, 1999.
273. 3rd International symposium on prostatic surgery L'Aquila, 23-25 Maggio 1999.
274. Diagnostische aanwinsten in de oncologie, Roeselare, March 20, 1999.
275. EORTC GU Group Executive Committee Meeting, Brussels, June 6, 1999
276. 2nd International Consultation on Prostate Cancer, Paris, June 27-29, 1999.
277. ECCO 10 The European Cancer Conference, Vienna, September 12-16, 1999.
278. Schorn '60 Meeting, Linz, September 18, 1999.
279. 2nd Iberian Course of Urological Oncology, Barcelona, 1999.
280. EORTC GU Group Autumn Meeting Izmir-Turkey, October 21-23, 1999.
281. EORTC GU Group Executive Committee Meeting, Izmir, October 21, 1999
282. EBU meeting, London, November 5-6, 1999.
283. 2nd Annual Meeting BAUS Section of oncology, Renal Tumors Manchester, November 11-12, 1999.
284. .EAU Group for Recommendations and Guidelines in Onco-Urology Meeting, Paris, November 12-13, 1999.
285. EAU Scientific Committee meeting, Krasnapolsky Hotel Amsterdam, November 26-27, 1999.
286. 8 ste Symposium Praktische Urologie voor de Huisarts, Kortrijk, November 27, 1999.
287. European Group on Tumor Markers. 10. Hamburger Symposium über Tumormarker, Hamburg, December 5-7, 1999.
288. Abbott teaching course, December 14, 1999.
289. EORTC GU Group Executive Committee Meeting, Brussels, January 21, 2000.
290. Curso Internacional de Urologia, Zaragoza, 31/1-3/2/2000.
291. Workshop Treatment of Localised Prostate Cancer, Jönköping, Sweden, February 18, 2000.
292. EORTC GU Group Spring Meeting Newcastle Upon Tyne, UK, March 16-18, 2000.

293. EORTC GU Group Executive Committee, Newcastle Upon Tyne, UK, March 16, 2000
294. XV th Congress of the European Association of Urology, Brussels, Belgium, April 12-15, 2000.
295. EBU Meeting, Helsinki, Finland, May 26-27, 2000.
- 296 EORTC meeting Malta (Site Visit), May 29-30, 2000.
- 297 Roumanian society of uro-oncology, Bucharest, Roumania. May 11, 2000.
- 298 Public Health and Clinical Significance of Premalignant Alterations in the Genito-Urinary Tract. WHO collaborative project and consensus conference, Stockholm, Sweden, June 8-9, 2000.
- 299 EORTC GU Group Executive Committee Meeting, Brussels, June 13, 2000.
- 300 Preventieve gezondheidszorg in Vlaanderen, Meeting Vlaams Geneeskundigenverbond Heverlee, June 17, 2000.
- 301 Prostate Brachytherapy Teaching Course Cookridge Hospital, Leeds, Ireland, July 6-7, 2000.
- 302 Fortbildungsveranstaltung Klinische Onkologie, Uni-Klinik Düsseldorf, Germany, June 26 – July 1, 2000.
- 303 Update on pelvic oncological surgery: prevention and treatment of complications, Genoa, Italy, September 7-9, 2000.
- 304 EORTC Pet for anticancer drug development, Brussels, Belgium, September 15, 2000.
- 305 Begeleiding bij het levenseinde, Therapiedag, October 7, 2000
- 306 ESU teaching course “Urological trauma and onco-urology”, Chisinau, Moldova, October 21, 2000.
- 307 EBU Residency Review Committee and General Assembly, Bratislava, November 11, 2000.
- 308 EORTC GU Group Fall meeting Erice, November 23-25, 2000.
- 309 EORTC GU Group Executive Committee Meeting, Erice, June 13, 2000.
- 310 9 th Course Urology 2000: Yesterday, today and tomorrow, Erice, November 26-30, 2000.
- 311 BUOS meeting, Sofitel Brussel, January 11, 2001.
- 312 Prof. Elautprijns 2001, Oudenaarde, January 20, 2001.
- 313 EORTC GU Group Executive Committee Meeting, Brussels, 26 January, 2001.
- 314 EORTC Prostate DOG , Brussels, January 27, 2001.
- 315 Immunotherapy in cancer: from laboratory to clinical practice, UZ Gasthuisberg Leuven, February 16, 2001.
- 316 Externe refereeravond afdeling urologie: niercelcarcinoom, AZ Maastricht, February 13, 2001.

- 317 Vergadering Belgische vereniging Oncologische Heelkunde, Brussel, March 3, 2001.
- 318 Investigator's Meeting Casodex 150, Brussel, March 8, 2001.
- 319 EORTC GU Group Spring Meeting, Nijmegen, March 15-17, 2001.
- 320 EORTC GU Group Executive Committee Meeting, Nijmegen, March 15, 2001.
- 321 Avondsymposium prostaatanker, Integrerende Stichting voor Kankerbestrijding Vlaams Brabant (ISKA), Beersel, March 29, 2001.
- 322 Zin en onzin van vroege detectie en chemopreventie van prostaatanker, UZ Gasthuisberg, Leuven, April 28, 2001.
- 323 XVIth EAU Congress, Geneva, April 7-10, 2001.
- 324 Le cancer de la vessie: options therapeutiques, Société Luxembourgoise d'Oncologie, Luxembourg, May 2, 2001.
- 325 EBU Meeting Milan, May 11-12, 2001.
- 326 22nd Plenary Meeting of EGTm, Prague, May 26, 2001.
- 327 The first EORTC translational research meeting, Brussels, June 7-8, 2001.
- 328 EORTC GU Group Executive Committee Meeting, June 28, 2001.
- 329 Urologische avond, Gavere, July 5, 2001.
- 330 Annual meeting British Associations of Urological Surgeons, Dublin, June 25-29, 2001.
- 331 6th Annual European Course in Urology (AECU), Rome, September 1-5, 2001.
- 332 Complications in Urologic Surgery, Prevention and Management, De Montil-Essene, September 8, 2001.
- 333 EORTC prostate DOG meeting, Brussels, September 15, 2001.
- 334 Symposium: Behandelopties gelocaliseerd prostaatacarcinoom: de plaats van radicale prostatectomie, brachytherapie en uitwendige bestraling. AZR-Daniel, Rotterdam, September 28, 2001.
- 335 EORTC GU Group Executive Committee Meeting, Lisbon, September 23, 2001
- 336 Renal Cancer ESO NN Blokhin cancer research center of Russian federation, Moscow, October 9-10, 2001.
- 337 Workshop Les techniques laparoscopiques en urologie, UCL Mont-Godinne Namur, October 12-13, 2001.
- 338 6th International Congress of the Dutch Urological Association, Leiden/Noordwijkerhout, The Netherlands, October 25-27, 2001.
- 339 Radical cystectomy with or without urethrectomy? Perspectives in bladder cancer, Monte Carlo, Monaco, November 16-17, 2001.
- 340 EORTC GU Group Autumn meeting, Modena, Italy, November 22-24, 2001.
- 341 Consensus on screening of prostate cancer – Myth or reality, Modena, Italy, November 25, 2001.
- 342 EORTC Prostate DOG meeting, Brussels, January 12, 2002.

- 343 Prof. Elautprijns 2002, Vilvoorde, January 19, 2002.
- 344 Prostate Cancer: The right treatment for the right patient, Amsterdam, January 17-18, 2002.
- 345 XVII th EAU Congress, Birmingham, February 23-26, 2002.
- 346 EORTC GU Group Executive Committee meeting, Birmingham, February 25, 2002.
- 347 ESU Course at EAU Congress, Birmingham, February 25, 2002.
- 348 Section meeting of the European Society of Oncological Urology (ESOU) at EAU Congress, Birmingham, February 23, 2002.
- 349 IX th Meeting of the European Society of Residents in Urology (ESRU) at EAU Congress, Birmingham, February 23, 2002.
- 350 Meeting Prostate Cancer Working Party at EAU Congress, Birmingham, February 24, 2002.
- 351 Meeting of the board members of ESOU at EAU Congress, Birmingham, February 23, 2002.
- 352 Algemene Vergadering Belgische Vereniging voor Heelkundige Oncologie, Brussels, March 2, 2002.
- 353 Vergadering academisering, Gent, March 5, 2002.
- 354 EORTC Scientific Audit Committee meeting, Brussel, March 8, 2002.
- 355 EORTC Scientific Strategy Meeting/40 years of the EORTC, Brussel, March 26-28, 2002.
- 356 EORTC GU Group Spring meeting, Vienna, March 21-23, 2002.
- 357 Stig Colleen 65 symposium, Lund, April 4, 2002.
- 358 Atrasentan: A new treatment concept in prostate cancer, Diegem, April 15, 2002.
- 359 Hospital Governance: regels van goed bestuur in de ziekenhuizen, Leuven, April 25, 2002.
- 360 EBU Board meeting, Innsbruck, May 10-11, 2002.
- 361 Pentalfa. PSA en de tijdige detectie van prostaatkanker bij mannen tussen 50 en 70 jaar, Leuven, May 23, 2002.
- 362 Innovators in Urology, Portugal, June 4-9, 2002.
- 363 EORTC GU Group Executive Committee Meeting, Brussels, June 14, 2002.
- 364 3rd International consultation on Prostate Cancer, Paris, June 21-23, 2002.
- 365 National Symposium, Viagra Young Program, October 5, 2002.
- 366 EORTC Chairmen meeting, Brussels, October 10, 2002.
- 367 Urologisch Symposium: "Prostaatcacinoma, blaascarcinoma, een update", Oostende, October 10, 2002.
- 368 Current Controversies in the management of Genitourinary Malignancies. Marburg, Oostenrijk, October 24-26, 2002.
- 369 EORTC GU Group Fall meeting, Vienna, September, November 7-9, 2002.

- 370 State of the Art in the management of urological malignancies, Barcelona, November 10, 2002.
- 371 9de Urologisch Herfstsymposium, Prostaatcarcinoma: actuele behandeling, Hasselt, November 23, 2002.
- 372 First meeting of the Association of Academic European Urologists (AAEU), Vienna, December 5-7, 2002.
- 373 8th European Winter Oncology conference, Flims, Switzerland, January 19-24, 2003.
- 374 Prof. Elautprijns, Aalst, Belgium, January 25, 2003.
- 375 XVIIIth EAU Congress, Barcelona, Spain, March 12-15, 2003.
- 376 XIVth ESPU Congress, Barcelona, Spain, March 12-15, 2003.
- 377 EORTC GU Group Spring meeting, Ghent, Belgium, March 27-29, 2003.
- 378 EORTC GU Group/Belgische Vereniging voor Urologie symposium, State of the art lectures on urological malignancies, Ghent, March 30, 2003.
- 379 Cancers de la prostate actualités thérapeutiques, Grenoble, France, April 5, 2003.
- 380 13th International meeting of the European Society of Gynaecological Oncology (ESGO), Brussels, Belgium, April 6-10, 2003.
- 381 Lokgroep: Nieuwe kijk op behandeling van gemetastaseerde prostaatcarcinoom, Hasselt, April 23, 2003.
- 382 EAU meets national urological societies, May 9-10, 2003.
- 383 ESRU.be day, La Tournette, Belgium, June 7, 2003.
- 384 Uro-pathology Workshop, Florence, Italy, June 15, 2003.
- 385 EORTC Drug Development meeting, Brussels, Belgium, June 18-20, 2003.
- 386 GSK Summer Forum 2003, Genval, August 25, 2003.
- 387 EUREP meeting, Prague, Czech Republic, August 29 – September 3, 2003.
- 388 BAU congress 2003 –Seeds, Needles and Ports in Urology, Essene, September 13, 2003.
- 389 ECCO12 meeting, Copenhagen, September 21-25, 2003.
- 390 Interuniversitair Symposium, Organon, BCG in de behandeling van oppervlakkige blaastumoren, October 11, Groot-Bijgaarden, 2003.
- 391 1st International Consultation on Parasitic Bladder Cancer, Sharm El-Sheikh, Egypt, October 19-22, 2003.
- 392 SIU Congress on Uro-Oncology, October 19-23, 2003.
- 393 EORTC GU Group Fall meeting, Antalya, Turkey, October 15-19, 2003.
- 394 EORTC GU Group Executive meeting, Antalya, Turkey, October 15, 2003.
- 395 EAU Guidelines meeting, Paris, France, November 3, 2003.
- 396 EBU-RRC meeting Amsterdam, The Netherlands, November 8th, 2003.
- 397 Annual symposium, Genitourinary Imaging, Antwerpen, November 8th, 2003.
- 398 EORTC board meeting Brussels, November 14, 2003.

- 399 LUC meeting, Leuven, November 14, 2003.
- 400 Open vraagstelling over PSA en vroege detectie, Wijgmaal, November 28, 2003.
- 401 Europa Uomo meeting, Antwerpen, November 29, 2003.
- 402 2nd European Urological Winter “Escape meeting”, November 30 – December 3, 2003.
- 403 “Prostaatcarcinoom: Diagnose en nieuwe behandelingstechnieken”, Tienen, December 16, 2003.
- 404 Association of Academic European Urologists (AAEU/GCCU), Brussel, December 11-13, 2003.
- 405 Leuvense dagen, Oncologie, Leuven, December 11-13, 2003.
- 406 Journée de cancérologie urologique de l’hôpital Bichat, Le cancer de la prostate localement évolué c/pT3, Paris, January 13, 2004.
- 407 Professor Elautprijs, Dendermonde, January 24, 2004.
- 408 Pentalfa, Radicale of partiële nefrectomie voor nierkanker, Leuven, January 22, 2004.
- 409 Baus section of oncology, Kidney and testis cancer, Spring educational meeting, March 1-2, 2004.
- 410 EORTC Board meeting, Brussels, March 11-12, 2004.
- 411 EORTC DOG meeting, Brussels, March 12, 2004.
- 412 L’urologue et la competence en oncology, Liège, March 13, 2004.
- 413 XIXth EAU meeting, Vienna, March 24-27, 2004.
- 414 EORTC Groups Annual Meeting, April 21-23, 2004.
- 415 EAU Board meeting, Paris, May 4, 2004.
- 416 Refereeravond urologie, Renal cell cancer facing the challenges, Amsterdam, May 4, 2004.
- 417 10th Course “Advances and Controversies in Urological Oncology”, Erice, May 18-23, 2004.
- 418 Seminarium Urologie, Leuven, 24 Mei, 2004.
- 419 ESU Brainstorming meeting board European School of Urology, Prague, May 29-30, 2004.
- 420 Europa Uomo meeting, Milan, June 10-12, 2004.
- 421 Masterclass on cancer patient advocacy, Milan, June 12, 2004.
- 422 EORTC Executive committee meeting, Brussels, June 25, 2004.
- 423 Gebruik van Zometa bij prostaatcarcinooma: state of the art, Beveren Leie, September 14, 2004.
- 424 2004 Annual Congress of Belgian Association of Urology, September 25, 2004.
- 425 Global GU Oncology Conference, Hawaii, October 2-3, 2004.
- 426 EORTC GU Group Autumn Meeting, Italy, October 28-30, 2004.
- 427 GU-meeting datamanagers/research nurses, Italy, October 29, 2004.

- 428 Studiedag Ongewild Urineverlies Prostaatlijden, Brussels, November 6, 2004.
- 429 4th Annual Perspectives in Bladder Cancer, Spain, November 12-13, 2004.
- 430 10 jaar Thoraxheelkunde, Leuven, November 19, 2004.
- 431 ESU Board Meeting, Paris, January 19, 2005.
- 432 ESOU Meeting, Bologna, January 21-23, 2005.
- 433 ELAUT Prijs, Hasselt, January 22, 2005.
- RFA : de partiële nefrectomie van de toekomst ?
Goeman Lieven, co-auteurs : S. Joniau, R. Oyen, K. Vekemans, R. Vandeurzen, A.
Valcke, H. Van Poppel
 - De “salvage” radicale prostactectomie : indicaties en resultaten
Jochen Darras, co-auteurs : S. Joniau, H. Van Poppel
 - Partiële nefrectomie : chirurgische hemostase of hemostatische patch ?
Karl Lesage, co-auteurs : S. Joniau, H. Van Poppel
- 434 14th European Urological Winter Forum, Switzerland, February 5-9, 2005.
- 435 Big final investigators’ meeting, Brussels, February 17, 2005.
- 436 Efec, Cancers de la prostate localisés et localement avancés, Paris , March 31 - April 1, 2005.
- 437 EAU: Development and validation of a new questionnaire to assess gynaecolmastia and breast pain in patients receiving bicalutamide, Istanbul, March 16-19, 2005.
- 438 EORTC GU group Spring Meeting, Milano, April 21-23, 2005.
- 439 ESU Brainstorm Meeting, Milan, April 24-25, 2005.
- 440 Europa UOMO general assembly, Milan, May 27, 2005.
- 441 Themanamiddag: Wat na de diagnose prostaatkanker?, May 31, 2005.
- 442 EORTC General Assembly, Brussels, June 1, 2005.
- 443 Symposium Ipsen, Brussels, June 4, 2005.
- 444 Conference of Fundació Puigvert, Barcelona, June 10, 2005.
- 445 Bone Health in Prostate Cancer: Diagnostic and Therapeutic Challenges, Bordeaux, June 27, 2005.
- 446 New Hope for Hormone Refractory Prostate Cancer Patients, Bordeaux, June 27, 2005.
- 447 7th Ankara Urooncology Course, Turkey, September 22-25, 2005.
- 448 Bijscholingsavond, Haacht, September 29, 2005.
- 449 EORTC GU-autumn meeting, Bremen, October 6-8, 2005.
- 450 GU-meeting datamanagers/research nurses, Bremen, October 7, 2005.
- 451 Highlights in Urologic Oncology, Prague, October 14, 2005.
- 452 Nieuwe medicijnen in de Urologie, Pentalfa (Leuven), October 20, 2005.
- 453 Informatiedag over Prostaatkanker, Antwerpen, October 22, 2005.

- 454 Ecco 13 Patients Programme, France, October 29-31, 2005.
- 455 Educational symposium, Paris, November 3, 2005.
- 456 Renal Cell Carcinoma Urologist Meeting, Milan, November 8, 2005.
- 457 Prex, Leuven, November 16-18, 2005.
- 458 EAU Board Meeting, Paris, November 28, 2005.
- 459 Sixth Annual SUO meeting to discuss current topics and strategies in Urologic Oncology, Maryland USA, December 2-3, 2005.
- 460 The many faces of prostate cancer : A view of patient types, Tenerife, December 11, 2005.
- 461 AAEU Meeting, Edinburgh, December 16-18, 2005.
- 462 Prof. Elaut Price of Urology - Belgische Vereniging Urologie. Antwerpen, January 2006.
- 463 EORTC meeting, January 11, 2006.
- 464 ESOU, Brussels, January 13 -14, 2006.
- 465 Scientific Committee Meeting, Paris, January 30, 2006.
- 466 Urogynaecological surgery, February 3 – 4, 2006.
- 467 Prostaatdag, Gent, February 4, 2006.
- 468 15th European Urological Winter Forum, Davos, February 11-15, 2006.
- 469 EORTC NOCI Meeting, Brussels, March 8-9, 2006.
- 470 EORTC Board Meeting, Brussels, March 9, 2006.
- 471 Informatie-avond voor huisartsen: Prostaatcarcinoom, vroegtijdige opsporing en behandeling, Prostaatcentrum Maria Middelaes Gent, March 14, 2006.
- 472 EORTC GU Group Spring meeting, Salzburg, March 23-25, 2006.
- 473 Workshop Bayer, Knokke, April 1, 2006.
- 474 EAU Meeting, Paris, April 4 – 8, 2006.
- 475 Advisory board Sorafenib in renal cell cancer, Groot-Bijgaarden, April 19, 2006.
- 476 Europa Uomo, Milano, May 12, 2006.
- 477 EBU Board Meeting/UEMS section of Urology, Residency Review Committee (closed meeting), Stockholm Slussen, Sweden, May 5-6, 2006.
- 478 Final Meeting Eprofex, Genova, May 27 – 28, 2006.
- 479 Meeting GU Group, Amsterdam, May 30, 2006.
- 480 EAU Scientific Committee Meeting, Paris, May 31, 2006.
- 481 ESU Brainstorming, Paris, June 9 – 10, 2006.
- 482 EORTC Board Meeting, Brussels, June 15, 2006.
- 483 EORTC General Assembly, Brussels, June 16, 2006.
- 484 EORTC GU Group Executive Committee Meeting, Brussels, June 17, 2006.
- 485 BAU General Meeting, Leuven, June 29, 2006.
- 486 ESU Masterclass Seminar, Salzburg, July 16 – 19, 2006.
- 487 Advisory Board “Sutent” – Pfizer, Brussels, July 26, 2006.

- 488 EAU Board Meeting, Paris, September 11, 2006.
- 489 EORTC Treasurer Meeting, Brussels, September 20, 2006.
- 490 BAU, Liège, September 22-23, 2006.
- 491 EAU Masterclass for practising urologists on medical tumour treatment, Course Director, Barcelona, September 29 – October 1, 2006.
- 492 EBU Fall Meeting, Tbilisi, Georgia, October 5-7, 2006.
- 493 EORTC GU Group Meeting, Amsterdam, October 12-14, 2006.
- 494 ESU Board Meeting, Nijmegen, October 25, 2006.
- 495 Symposium Urology Beyond Boundaries, Nijmegen, October 26 – 27, 2006.
- 496 Expert Meeting on VTP : A new alternative for focal treatment of localized prostate cancer, Nijmegen, October 27, 2006.
- 497 2nd GU Oncology Conference, Cape Town, South Africa, November 11-12, 2006.
- 498 28th Congress of the Société Internationale d'Urologie, Cape Town, South Africa, November 12-16, 2006.
- 499 State of the Art in Urology, International Symposium, Leuven, November 24-25, 2006.
- 500 13th Congress of the European Society of Surgical Oncology, Venice, Italy, November 30 – December 2, 2006.
- 501 5th Meeting of the Association of Academic European Urologists (AAEU), Amsterdam, December 7-10, 2006.
- 502 5th European Urological Winter Escape Meeting in conjunction with the 5th Meeting of the European Society of Uro-Technology (ESUT), Tenerife, December 10-13, 2006.
- 503 Advisory Board Meeting PCA3, Brussels, December 14, 2006.
- 504 European Urology Forum 2007, Challenge the experts, Davos, Switzerland, February 10 – 14, 2007.
- 505 Executive Committee, NOCI, Chairmen meeting, February 15, 2007.
- 506 EORTC Board Meeting, Brussels, February 16, 2007.
- 507 PCA3 Advisory Meeting, Brussels, February 16, 2007.
- 508 Degarelix International Advisory Board: Shaping the future of hormonal prostate cancer treatment, NH Grand Hotel Krasnapolsky, Amsterdam, March 2, 2007.
- 509 EORTC GU Group Scientific Board Meeting, Sheraton Brussels, March 6, 2007.
- 510 EORTC GENITO-URINARY GROUP MEETING, Sheraton Brussels, March 7, 2007.
- 511 EORTC GU Group Executive Committee Meeting, Sheraton Brussels, March 7, 2007.
- 512 EORTC Groups Annual Meeting, EGAM 2007, Sheraton Brussels, March 7 – 10, 2007.
- 513 EAU Board Meeting, Adlon Hotel, Berlin, Germany, March 20, 2007.

- 514 22nd Annual EAU Congress, Berlin, Germany, March 21-24, 2007.
- 515 Debate: Surgical volume and quality of results, ICC-Messe Berlin, March 23, 2007.
- 516 Europa Uomo, Steering Committee Meeting - EAU Annual Meeting, Berlin, March 23, 2007.
- 517 EAU General Assembly, ICC Messe Berlin, March 24, 2007.
- 518 International Workshop on Radio-Frequency Ablation of Kidney Tumors, University Hospital Leuven, April 27, 2007.
- 519 Ipsen in Urology – “Update in Prostate Cancer” a multidisciplinary approach”, Symposium Hotel Conrad Brussels, May 05, 2007.
- 520 AstraZeneca Press Conference “Zolacoach program”, Sodehotel Brussels, April 25, 2007.
- 521 Challenges in Laparoscopy 2007 – The European Congress of Laparoscopy 2007, Bordeaux, France, June 7-8-9 2007.
- 522 EORTC GU Group Executive Committee Meeting, EORTC Data Center, Brussels, June 21, 2007.
- 523 EORTC Board Meeting, EORTC Headquarters, Brussels, June 21, 2007.
- 524 Prostate cancer key-note lectures: Meet the experts, Lamot Congress Centre, Mechelen, June 23, 2007.
- 525 2nd ESU Masterclass on Medical Oncology for Urologists, Barcelona, Spain, June 29 – July 1, 2007.
- 526 EAU lecture: What’s new in Pca diagnosis and treatment? General Assembly, Europa Uomo, Oncology Centre Antwerp, Belgium, August 4, 2007.
- 527 3rd Conference of the World Urologic Oncology Federation, Palais des Congrès, Paris, September 1 – 2, 2007.
- 528 29th Congress of the Société Internationale D’Urologie, Paris, September 2 – 6, 2007.
- 529 European Robotic Urology Symposium, 4th edition, Latest Developments in Robotic Surgery, Brussels, September 12-14, 2007.
- 530 Lancering van PROGENSA™ PCA3, Marriott Hotel Brussels, September 18, 2007.
- 531 Antigenics European Advisory Board Meeting, Barcelona, September 27-29, 2007.
- 532 ESU Board Meeting, Sheraton Airport Hotel, Brussels, October 7, 2007.
- 533 Vlaamse Liga tegen Kanker, Themanamiddag: ‘Blaaspoliepen, blaaskanker en bloedplassen’, VLK-inloophuis Leuven, October 9, 2007.
- 534 EORTC Board Meeting, EORTC Headquarters Brussels, October 12, 2007.
- 535 MIAU Meeting, Château du Lac, Genval, Belgium, October 12, 2007.
- 536 EAU Board Meeting, Sheraton Hotel CDG Airport Paris, October 15, 2007.
- 537 EAU 1st Eastern Mediterranean Meeting in Antalya, Turkey, October 19-20, 2007.

- 538 EORTC GU Group Meeting, Cardiff Hilton Hotel, October 25-27, 2007.
- 539 EORCT GU Group General Assembly, Cardiff Hilton Hotel, October 27, 2007.
- 540 EORTC GU Group Executive Committee Meeting, Cardiff Hilton Hotel, October 27, 2007.
- 541 Advisory Board Meeting PCA3, Barcelona, Spain, November 1, 2007.
- 542 Embracing Excellence in Prostate and Kidney Cancer, Barcelona, Spain, November 2-3, 2007.
- 543 Advisory Board Meeting ZD4054 AstraZeneca, Barcelona, Spain, November 3, 2007.
- 544 WWPCC, Barcelona, Spain, November 1-4, 2007.
- 545 Update in Urology 2007, ESU Course, National Congress of the Russian Urological Association, Moscow, Russia, November 6-8, 2007.
- 546 Dendreon European Advisory Board, Amsterdam, November 10, 2007.
- 547 AFU, Palais des Congrès, Paris, France, November 14-17, 2007.
- 548 Alles wat u wilt weten over de prostaat, UZ Leuven, Leuven, November 20, 2007.
- 549 Nycomed scientific meeting, Nycomed Belgium, Brussels, November 22, 2007.
- 550 18e Congrès de la société française de radiothérapie oncologique Paris, Palais des Congrès, November 28-30, 2007.
- 551 6th Meeting of the Association of Academic European Urologists (AAEU), Prague, Czech Republic, December 6-9, 2007.
- 552 7th Annual Congress of the Belgian Association of Urology, BAU 2007, Kortrijk, Belgium, December 14-15, 2007.
- 553 Antigenics European Advisory Board, Hotel Le Meridien Etoile, Paris, France, December 20-21, 2007.
- 554 EORTC GU Group Executive Committee Meeting, EORTC Data Center, Brussels, January 9, 2008.
- 555 Symposium Innovatieve Heelkundige Technieken in de Kankerchirurgie, UZ Leuven, January 11, 2008.
- 556 Ferring International Advisory Board, Improving hormonal treatment for prostate cancer: Moving Degarelix towards launch, Royal Windsor Hotel, Brussels, January 23-24, 2008.
- 557 Elautprijs 2008, Casino Koksijde, February 16, 2008.
- 558 Controversies, Preconceptions and Reality of Visually Directed High Intensity Focussed Ultrasound (HIFU), UZ Leuven, February 29, 2008.
- 559 EORTC Strategy Meeting 2008, Dolce Hotel, La Hulpe, Belgium, March 13-14, 2008.
- 560 23rd Annual Eau Congress, Milan, Italy, March 26 – 29, 2008.
- 561 EAU Board Meeting, Milan, Italy, March 25, 2008.

- 562 Eligard Symposium (Hormone Therapy: When and How?), Milan, Italy, March 26, 2008.
- 563 American Association of Genitourinary Surgeons (AAGUS), Naples, Florida, April 9-12, 2008.
- 564 Leading lights in urology 2008, Radisson SAS, Oslo, Norway, April 17-19, 2008.
- 565 Visiting Professorship to Guy's Hospital, Urology Department, London, April 23-24, 2008.
- 566 EBU Board Meeting, Urological Training Program Committee, Hotel Marriott, Copenhagen, May 2, 2008.
- 567 EBU Board Meeting, U.E.M.S. Section of Urology, Hotel Marriott, Copenhagen, May 3, 2008.
- 568 EORTC GU Group Meeting, Hospital de Mar, Barcelona, May 8– 10, 2008.
- 569 SORCE/RE05 EORTC Launch Meeting, Barcelona, May 9, 2008.
- 570 EORTC GU Group Executive Committee Meeting, Hospital de Mar, Barcelona, May 10, 2008.
- 571 European Prostate Cancer Advisory Board Celgene, SAS Radisson, Amsterdam Airport, May 13, 2008.
- 572 AUA Annual Meeting 2008, Orlando, Florida, May 18-21, 2008.
- 573 Brainstorming Meeting Board European School of Urology, Klooster Hotel, Leuven, May 23-24, 2008.
- 574 Adult reconstructive urology, state of the art lectures, University Hospitals Leuven, Campus Gasthuisberg, May 26, 2008.
- 575 National congress of the Romanian Association of Urology, Bucharest, Romania, June 13, 2008.
- 576 Meeting EAU Scientific Congress Office, Hotel Princesa Sofia, Barcelona, Spain, June 16, 2008.
- 577 EORTC Board Meeting, EORTC Headquarters Brussels, June 19-20, 2008.
- 578 3rd ESU Masterclass on Medical treatment for urological cancer (Course Director), Barcelona, Spain, June 28-29, 2008.
- 579 First European Advisory Board Meeting on Abiraterone Acetate, Lugano, Switzerland, July 2, 2008.
- 580 Masterclass Salzburg, Schloss Arenberg, Salzburg, July 20-26, 2008.
- 581 International Union Against Cancer, UICC World Cancer Congress, Geneva, Switzerland, August 27-31, 2008.
- 582 EORTC GU Group Executive Committee Meeting, Faculty Club Leuven, September 2, 2008.
- 583 6th European Urology Residents Education Programme (EUREP), Course Director Prague, Czech Republic, September 5-10, 2008.
- 584 33rd ESMO Congress Stockholm, Sweden, September 12-16, 2008.

- 585 International Advanced Symposium: Laparoscopic Treatment of Urological Pelvic Cancers: Prostate and Bladder, Strasbourg, September 18-20, 2008.
- 586 EORTC Board Meeting, EORTC Headquarters Brussels, September 26, 2008.
- 587 Oncological Urology: Challenge the experts – K-nal Brussels – 27 September 2008
- 588 19th Panhellenic Congress of Urology, Porto Carras Grand Resort, Chalkidiki, Greece, October 1-5, 2008.
- 589 Refereeravond Urologie, Thema: niercelcarcinoom, visiting Professor Hein Van Poppel, Erasmus MC Rotterdam, October 6, 2008.
- 590 EORTC GU Group Autumn Meeting, Grande Albergo Sole, Palermo, Italy, October 9-11, 2008.
- 591 BAU 2008, 8th edition, Dolce Hotel La Hulpe, Brussels, October 17-18, 2008.
- 592 EORTC SORCE protocol information session during BAU 2008 congress, Dolce La Hulpe, Brussels, October 17, 2008.
- 593 ProgenSA PCA3 Round Table for the Media, Breakthrough in the diagnosis of prostate cancer, Hotel Crowne Plaza Brussels, October 29, 2008.
- 594 BAUS Section of Oncology Annual Meeting, Renal Cancer: A Time of Change SECC Glasgow, November 13-14, 2008.
- 595 II Course of Urology of the Spanish Urology Association, Madrid, Spain, November 12-14, 2008.
- 596 SIU World Uro-Oncology Update, Santiago de Chile, November 19-22, 2008.
- 597 ICUD Penile Cancer Consultation, SIU World Uro-Oncology Update, Santiago Convention Center, Santiago de Chile, November 19, 2008.
- 598 6th Meeting of the European Society of Oncological Urology (ESOU), Istanbul, Turkey, January 16-19, 2009.
- 599 EORTC GU Group Executive Committee Meeting, Schiphol Airport Meeting Centre, Amsterdam, January 21, 2009.
- 600 15de Elautprijs, Salons de Romrée, Grimbergen, January 24, 2009.
- 601 Jaarlijkse Statutaire Vergadering van de BVU, Salons de Romrée, Grimbergen, January 24, 2009.
- 602 Ferring International Advisory Board, Degarelix, an improved Androgen, Deprivation Therapy Current results and future directions, Frankfurt am Main, Germany, January 27-28, 2009.
- 603 3e Interdisciplinaire Congres van de NVCO, NVMO en NVRO, Hotel en Congrescentrum Papendal Arnhem, February 5-6, 2009.
- 604 6^{de} Antwerpse Oncologiedag (AOD), Genito-urinaire Maligniteiten, Update en nieuwigheden, Congrescentrum Ter Els, Edegem, March 6, 2009.
- 605 EAU Board Meeting, SAS Royal Viking Hotel, Stockholm, Sweden, March 16, 2009.
- 606 ICUD meeting, SAS Royal Viking Hotel, Stockholm, Sweden, March 16, 2009.

- 607 24th Annual EAU Congress, Stockholm, March 17-21, 2009.
- 608 PCA3 Cystoprostatectomy Study Investigator's Meeting at the EAU Congress, Radisson SAS Strand Hotel, Stockholm, Sweden, March 18, 2009.
- 609 AstraZeneca Renal Carcinoma Advisory Board Meeting, Hotel Clarion Stockholm,, Sweden, March 18, 2009.
- 610 Europa Uomo Steering Committee Meeting during EAU Congress Stockholm, Sweden, March 18, 2009.
- 611 Ipsen Symposium: Prostate Cancer: Targeting androgen receptor and beyond, Stockholm International Fairs, March 19, 2009.
- 612 Minisymposium: "Prostaatanker en de Chirurgische Behandeling", Surf Side Marina, Aruba, April 7, 2009.
- 613 ESU Brainstorm Meeting, Kloosterhotel Leuven, April 17-18, 2009.
- 614 Meeting BBVU/APBU, Carestel Motel, Groot Bijgaarden, May 16, 2009.
- 615 EORTC GU Group Meeting, Hotel Bernini Bristol, Rome, Italy, May 21-23, 2009.
- 616 Challenges in Laparoscopy & Robotics 2009, Palais des Congrès, Paris, France, May 25-27, 2009.
- 617 EAU Scientific Congress Office Meeting, Said Business School, Oxford, June 5, 2009.
- 618 What's new in uro-oncology? Update EAU, ASCO en AUA 2009, Kasteel Groenhoven, Londerzeel, June 6, 2009.
- 619 Focal Therapy and Imaging in Prostate & Kidney Cancer, Hotels van Oranje, Noordwijk, Amsterdam, The Netherlands, June 10-13, 2009.
- 620 Consensus Meeting on Focal Therapy in Kidney Cancer, Hotels van Oranje, Noordwijk, Amsterdam, The Netherlands, June 13, 2009.
- 621 EORTC Board Meeting, EORTC Headquarters, June 18, 2009.
- 622 EORTC GU Group Executive Committee Meeting, Faculty Club Leuven, July 7, 2009.
- 623 ICUD/Steering Committee Meeting, Palais des Congres, Paris, July 10, 2009.
- 624 ESU Weill Cornell Masterclass in Urology, Salzburg, Austria, July 19-25, 2009.
- 625 Antigenics Preparatory Meeting for EMEA Oral Explanation, Sheraton Paris Airport Hotel, August 4, 2009.
- 626 10th National Prostate Cancer Symposium, The Royal Melbourne Hospital, Australia, August 19-21, 2009.
- 627 7th European Urology Residents Education Programme, Prague, Czech Republik, August 28 - September 2, 2009.
- 628 Introductiesymposium Firmagon (Degarelix), Utrecht, The Netherlands, September 15, 2009.
- 629 EAU-ESU Forum at DGU-Congress, Dresden, Germany, September 18, 2009.

- 630 Joint ECCO 15 – 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009.
- 631 EBU Board Meeting, Crete, Greece, October 1-3, 2009.
- 632 2nd Aegean Urology Symposium “Office Urology”, Crete, Greece, October 1-4, 2009.
- 633 9th International Prostate Forum, Izmir, Turkey, October 8-10, 2009.
- 634 CUEP, Hangzhou, China, October 30-31, 2009.
- 635 30th congress of the Société Internationale d’Urologie, Shanghai, China, November 1-5, 2009.
- 636 Amgen Advisory Board, Hotel Crown Plaza Brussels Airport, November 12, 2009.
- 637 Embracing Excellence in Prostate, Bladder and Kidney Cancer (EMUC), 2nd European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, November 26-29, 2009.
- 638 A multidisciplinary approach in prostate cancer: Synergy or antagonism?, Symposium Astellas (during EMUC), Barcelona, Spain, November 26, 2009.
- 639 Astellas Expert Meeting during EMUC, Barcelona, Spain, November 27, 2009.
- 640 9th Annual BAU Congress, State of the art in urology, Brabant, Leuven, December 11-12, 2009, Congress President.
- 641 Clinical roundtable: a scientific discussion on castrate-resistant prostate cancer, Sheraton Hotel CDG Paris, January 12, 2010.
- 642 7th Meeting of the EAU Section of Oncological Urology (ESOU), Vienna, Austria, January 15-17, 2010.
- 643 EAU Board Meeting, Sheraton Hotel Frankfurt International Airport, January 21, 2010.
- 644 EORTC GU Group Executive Committee Meeting, Faculty Club Leuven, January 22, 2010.
- 645 16de Elautprijs, Alden Biesen, January 23, 2010.
- 646 21st International congress on anti-cancer treatment, Palais de Congrès de Paris, France, February 1-5, 2010.
- 647 Renal Cell carcinoma. Where do we stand in 2010? Auditorio Agostinho Da Silva, Lisboa, February 19-20, 2010.
- 648 AstraZeneca Prostate Cancer Disease Area Advisory Board, San Francisco, March 4, 2010.
- 649 Genitourinary Cancers Symposium, Progress in Multidisciplinary Management, San Francisco Marriott, California, March 5-7, 2010.
- 650 OncoMethylomes’Bladder Cancer Advisory Board – San Francisco Marriott, California, March 5, 2010.
- 651 BeNeLug Days, KUL & UCL, March 12 & 12, 2010.

- 652 EORTC GU Group Scientific Board Meeting, Van der Valk Hotel, Brussels Airport, Belgium, March 25, 2010.
- 653 EORTC GU Group Symposium, Multidisciplinary case discussion on the management of lymph node disease in Prostate Cancer
- 654 EORTC GU Group Executive Committee Meeting, Van der Valk Hotel, Brussels Airport, Belgium, March 27, 2010.
- 655 EORTC GU Group General Assembly, Van der Valk Hotel, Brussels Airport, Belgium, March 27, 2010.
- 656 Proactive Prostate Coalition Task Force Meeting Hosted by Europa Uomo, Sheraton Hotel, Brussels Airport, March 31, 2010.
- 657 Third International Workshop on Radio-Frequency Ablation of Kidney Tumors, University Hospitals Leuven, April 2, 2010.
- 658 EAU Board Meeting, Hotel Rey Juan Carlos, Barcelona, Spain, April 15, 2010.
- 659 EAU-ACME Committee Meeting, Hotel Regen Carlos, Barcelona, Spain, April 15, 2010.
- 660 Int. Denosumab Advisory Board Amgen, Barcelona, Spain, April 16, 2010.
- 661 “Urology beyond Europe” during the 25th Anniversary EAU Congress, Barcelona, Spain, April 16, 2010.
- 662 EAU General Assembly, Barcelona, Spain, April 17, 2010.
- 663 Symposium Ferring: New perspectives
- 664 Europa Uomo: Key Points Program, during 25th Annual EAU Congress, Barcelona, Spain, April 19, 2010.
- 665 25th Annual EAU Congress, Barcelona, Spain, April 16-20, 2010.
- 666 5th European International Kidney Cancer Symposium, London, May 7-8, 2010.
- 667 Multidyscyplinarne leczenie raka pecherza moczowego, Hotel Astor, Jastrzebia Gora, Poland, May 21-22, 2010.
- 668 ESU Board Meeting, Cyprus, June 11-12, 2010.
- 669 EORCT GU Group Executive Committee Meeting, Faculty Club Leuven, July 2, 2010.
- 670 ESU Will Cornell Masterclass Salzburg, Salzburg, Austria, July 6-10, 2010.
- 671 EUREP Prague, September 2-8, 2010.
- 672 EAU Board Meeting, London, UK, September 14, 2010.
- 673 Masterclass & General Assembly EUOMO, Krakow, Poland, September 19-22, 2010 (Masterclass), September 23-24, 2010 (General Assembly).
- 674 EORTC Symposium State-of-the- Art in Bladder Cancer, The Hilton Amsterdam, The Netherlands, September 23, 2010.
- 675 EORTC GU Group Meeting, Amsterdam, The Netherlands, September 24-25, 2010.
- 676 EBU Board Meeting, Lucerne, Switzerland, October 1-3, 2010.

- 677 Proactive Prostate Coalition Task Force, Europa Uomo, Brussels Marriot Hotel, Brussels, Belgium, November 9, 2010.
- 678 Symposium: The history of urology, BVU, Faculty Club Leuven, November 13, 2010.
- 679 BAU 2010, 10th Annual Congress, Louvain-la-Neuve, Belgium, December 10-11, 2010, Congress President.
- 680 EORTC GU Executive Meeting, Sheraton Amsterdam Airport Hotel, January 11, 2011.
- 681 EAU Board Meeting, Sheraton Amsterdam Airport Hotel, January 18, 2011.
- 682 Elautprijs 2011, Constant Vanden Stock stadion, Brussels, January 29, 2011.
- 683 BVU Statutaire Vergadering, Constant Vanden Stock stadion, Brussels, January 29, 2011.
- 684 22nd International Congress on Anti-Cancer Treatment (ICACT), Palais des Congrès, Paris, France, 1-3 February 1-3, 2011.
- 685 24th Fűvészkeri Urológus Napok, UROCARNEVAL 2011, Budapest, Hungary, February 18-19, 2011.
- 686 EAU Board Meeting, Vienna, Austria, March 17, 2011.
- 687 26th Annual EAU Congress, Vienna, Austria, March 18-22, 2011.
- 688 2nd Conference “Prostate Cancer: Predictive models for Decision Making”, MSKCC, New York US, April 7-9, 2011.
- 689 120th Annual meeting of the American Association of Genitourinary Surgeons, Charleston, South Carolina, April 13-16, 2011.
- 690 LOK vergadering, Paal-Beringen, May 3, 2011.
- 691 EBU Board Meeting, Istanbul, May 5-7, 2011.
- Meeting urological training programma Cie
 - Board meeting/ General Assembly
 - Status reports: European School of Urology
- 692 ESO Educational Cancer Convention Lugano: What’s new and what’s true in genitor-urinary oncology, May 12-14, 2011.
- 693 Scientific Office meeting EAU, Portugal, May 27-28, 2011.
- 694 ESU Board Meeting, Portugal, May 27-28, 2011.
- 695 Ferring: 5th Degarelix International Advisory Board Meeting, Lausanne, Switzerland, May 30-31, 2011.
- 696 Portugese Urological Meeting 2011, Ofir, Portugal, June 17-19, 2011.
- 697 BAUS Meeting, Liverpool, UK, June 21, 2011.
- 698 5th CUEP meeting, Beijing, China, July 6-8, 2011.
- 699 Robotic-Assisted Radical Prostatectomy Consensus Meeting, Pasadena, US, September 9-10, 2011.
- 700 34th ECCO-ESMO Congress, Stockholm, September 25-27, 2011.

- 701 Bristol-Myers Squibb Prostate Advisory Board Meeting, Stockholm, September 26, 2011.
- 702 Belgian Oncoforum Meeting, Brussels, September 29, 2011.
- 703 Meeting UEMS section of Urology/European Board of Urology, Malta, October 7-8, 2011.
- 704 8e Studiedag voor de Stagemeeesters-Opleiders Faculteit Geneeskunde, K.U. Leuven, UZ Leuven, Oktober 13, 2011.
- 705 The XXVIIth National Congress of Urology, ROMURO 2011, Timisoara, Romania, November 26-27, 2011.
- 706 Dendreon Advisory Board Meeting, Barcelona, Spain, November 3, 2011.
- 707 EMUC 2011, Embracing excellence in prostate, bladder and kidney cancer – 3rd European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, November 4-6, 2011.
- 708 ERUS – EAU Executive Meeting, Barcelona, Spain, November 6, 2011.
- 709 12th Annual Meeting of the Society of Urologic Oncology in Conjunction with the World Urological Oncology Federation, Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland, November 30 – December 2, 2011.
- 710 11th Annual Congress of the Belgian Association of Urology – BAU 2011, Ghent, Belgium, December 9-10, 2011.
- 711 How to avoid and manage complications in lap and robot surgery? Faculty Club Leuven, December 17, 2011.
- 712 Individualisation of therapy for patients with prostate carcinoma – Prof. Dr. J Schalken – Seminarie Leuvens Kankerinstituut, UZ Leuven, January 10, 2012.
- 713 PhD research seminar: High- risk localized prostate cancer – role of surgery and development of clinical outcome prediction models – Dr. S. Joniau, UZ Leuven, January 10, 2012.
- 714 Professor Elautprijs, Overpelt, January 21, 2012.
- 715 Visiting Professor Department of Urology, Heidelberg University, Medical School – Special topics: Urologic Oncology Surgery, January 26-28, 2012.
- 716 27th EAU Annual Congress, Paris, 24-28 February 24-28, 2012.
- 717 EAU General Assembly, Paris, February 25, 2012.
- 718 Alles wat u wilt weten over de prostaat, UZ Leuven, March 13, 2012.
- 719 EAU Executive Meeting, Arnhem, March 19-20, 2012.
- 720 9th meeting of the EAU Section of Oncological Urology (ESOU), Hamburg, Germany, April 20-22, 2012.
- 721 Meeting of the American Association of Genitourinary Surgeons, California, April 25-28, 2012.
- 722 3rd Firmagon Advisory Board Meeting (Ferring), Van der Valk Hotel Diegem, May 2, 2012.

- 723 Janssens EMEA Medical Affairs Prostate Cancer Advisory Board, Sheraton Amsterdam Airport Hotel, May 3, 2012.
- 724 5th Pomeranian Uro-Oncology Meeting, Jastrzebia Gora, May 11-12, 2012.
- 725 EAU Scientific Congress Office Meeting, Mallorca, May 30 – June 2, 2012.
- 726 EAU Knowledge Base Steering Committee, Amsterdam, The Netherlands, June 15, 2012.
- 727 Global Congress on Prostate Cancer (Local organizing committee), Brussels, June 28-30, 2012.
- 728 Gen-Probe Satellite Symposium: Risk Evaluation in Prostate Cancer PCA3 as a diagnostic tool in clinical routine (Chair), June 28, 2012.
- 729 EAU Executive Meeting, Anholt, Germany, June 30 – July 1, 2012.
- 730 EU ACME Committee Meeting, Amsterdam, The Netherlands, July 20, 2012.
- 731 13th Australian Prostate Cancer Conference 2012, Melbourne, Australia, July 31– August 3, 2012.
- 732 Third International Symposium State-of-the Art in Urology, Leuven, Belgium, September 14-15, 2012.
- 733 6th Degarelix International Advisory Board, Amsterdam, The Netherlands, September 18, 2012.
- 734 European Prostate Cancer Awareness Day – EPAD, Brussels, Belgium, September 19, 2012.
- 735 32nd Congress of the SIU, Fukuoka, Japan, September 30– October 4, 2012.
- 736 Annual Meeting of the Hungarian Society of Urologists, Szeged, Hungary, October 19-20, 2012.
- 737 Symposium: Cutting Edge – Prostate Cancer, Malmö, Sweden, November 9-10, 2012.
- 738 Radium RA223 Dichloride Advisory Board Meeting, Barcelona, Spain, November 15, 2012.
- 739 Embracing Excellence in Prostate, Bladder and Kidney Cancer (EMUC), Barcelona, Spain, November 16-18, 2012.
- 740 International workshop on muscle invasive bladder cancer and kidney cancer, Surabaya, Indonesia, November 21-23, 2012.
- 741 Visiting Professor at the Auckland City Hospital, Auckland, New Zealand, November 28, 2012.
- 742 Eurostars: Oncology & Continence update meeting, UZ Leuven Pentalfa, Belgium, December 3, 2012.
- 743 11th Meeting of the Association of Academic European Urologists (AAEU), Salzburg, December 7-8, 2012.
- 744 EAU Abstract Selection Meeting (SPO + IRO meeting), Schiphol, The Netherlands, December 14-15, 2012.

- 745 EAU Guidelines Office Meeting, London, UK, December 19, 2012.
- 746 EUSP Board Meeting, München, Germany, January 12, 2013.
- 747 10th Meeting of the EAU Section of Oncological Urology (ESOU), Rome, Italy, January 18-19, 2013.
- 748 Second EAU-IUA Educational Meeting on Kish Island Uro-oncology/Infertility Updates, Kish Island, Iran, January 25-26, 2013.
- 749 24th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 5-7, 2013.
- 750 28th Annual EAU Congress, Milan, Italy, March 15-19, 2013.
- 751 EAU General Assembly, Milan, Italy, March 16, 2013.
- 752 Europa Uomo meeting during 28th Annual EAU Congress, Milan, March 17, 2013.
- 753 XVIII Workshop on Oncological Urology, Brage, Portugal, April 12-13, 2013.
- 754 Avondsymposium voor urologen en verpleegkundigen E660-E661, De 2 Charels, Dorpsstraat 50, Kampenhout, April 16, 2013.
- 755 101st Annual Meeting of the Japanese Urological Association, Sapporo, Japan, April 25-28, 2013.
- 756 American Urological Association Annual Meeting, San Diego, US, May 4-8, 2013.
- 757 EAU National Societies Meeting, Noordwijk, The Netherlands, May 15-18, 2013.
- 758 Visiting Professor University Medical Center Johannes Gutenberg University Mainz, Mainz, Germany, June 2-4, 2013.
- 759 EAU 6th leading lights in urology meeting, Lisbon, Portugal, June 6-7, 2013.
- 760 Afscheidssymposium Dr. Karl Delaere, Auberge de Rousch, Heerlen, June 14, 2013.
- 761 ESU – Weill Cornell Masterclass in General Urology, Salzburg, Austria, July 7-13, 2013.
- 762 43rd Congress of the Polish Urological Association in Jachranka, Jachranka, Poland, September 5-6, 2013.
- 763 Congres 'Prostaat': Incontinentie en seksuele disfuncties na robot en retropubische radicale prostatectomie, KU Leuven, Faculteit Bewegings- en Revalidatiewetenschappen, September 17, 2013.
- 764 8ste Europese Patiëntendag Prostaatkanker, Universiteit Antwerpen, September 21, 2013.
- 765 European Prostate Cancer Awareness Day, Brussels, Belgium, September 25, 2013.
- 766 1st International "State-of-the-Art" Conference on Prostate and Kidney Cancers, Amsterdam, The Netherlands, September 26-27, 2013.
- 767 86° Congresso Nazionale SIU, Riccione, Italy, October 5-8, 2013.
- 768 ESU Medical Oncology course on Genitourinary Cancer (MOGUC), Marseille, France, November 14, 2013.

- 769 5th European Multidisciplinary Meeting on Urological Cancers (EMUC),
Marseille, France, November 15-17, 2013.
- 770 CUA 2013 Annual meeting – Beijing, China – 19-21 December 2013.
- 771 11th Meeting of the EAU Section of Oncological Urology (ESOU) – Prague, Czech
Republic – 17-19 January 2014
- 772 Elautprijs 2014 – De Montil, Affligem – 25 januari 2014
- 773 25th International Congress on Anti-Cancer Treatment – ICACT 2014 – Paris,
France – 4-6 February 2014
- 774 EMUC Scientific Committee meeting – Schiphol, Amsterdam – 11 February 2014
- 775 Annual Scientific Meeting of the Urological Society of Australia and New Zealand
– Brisbane, Australia – 15-19 March 2014
- 776 ESTRO 33 – Vienna, Austria – 4-5 April 2014
- 777 ESTRO Board meeting – Vienna, Austria – 5 April 2014
- 778 29th Annual EAU Congress – Stockholm, Sweden – 11-15 April 2014
- 779 3-daagse URO-ONCO – Urobel – Novotel Leuven – 28-30 april 2014
- 780 Infovoormiddag Prostaatcancer – Stichting Tegen Kanker – Universiteit
Antwerpen, Campus Middelheim, Antwerpen – 10 mei 2014
- 781 Prostaatcarcinoom – Geneeskundige Kring van Sint-Truiden -15 mei 2014
- 782 EAU Executive Meeting – Arnhem, The Netherlands – 5 June 2014
- 783 EAU National Societies Meeting – Arnhem, The Netherlands – 6 – 8 June 2014
- 784 Prostaatcancer Actuele Inzichten – Imeldaziekenhuis Bonheiden – 13 september
2014
- 785 66. Kongress der Deutschen Gesellschaft für Urologie e.V. – Düsseldorf, Germany
– 1-4 October 2014
- 786 SIU 2014 – Glasgow, Scotland – 12-14 October 2014
- 787 ESUI 2014 – 3rd Meeting of the EAU Section of Urological Imaging – Lisbon,
Portugal – 13 November 2014
- 788 EAU-ICUD consensus meeting on Medical Treatment of Urological Malignancies
– Lisbon, Portugal – 13 November 2014
- 789 6th European Multidisciplinary Meeting on Urological Cancers – Lisbon, Portugal
– 13 – 16 November 2014
- 790 Ferring Regional Conference of Urology Experts (FOCUS) – Unlock the secrets
from paediatrics to geriatrics – Abu Dhabi UAE – 27-28 November 2014
- 791 13th Meeting of the Association of Academic European Urologists, 4 - 7
December 2014, Porto, Portugal
- 792 12th Meeting of the EAU Section of Oncological Urology (ESOU), 16-18 January
2015, Munich, Germany
- 793 ELAUT 2015 – Roeselaere, Belgium – 24 January 2015

- 794 26th International Congress on Anti-Cancer Treatment, Paris, France – 3-5 February 2015
- 795 International Rare Kidney Cancer Consortium (IRKCC) session – Paris, France – 3 February 2015
- 796 30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015
- 797 Cystectomy Course – Timisoara, Romania – 2-3 April 2015
- 798 103rd Annual Meeting of the Japanese Urological Association – Kanazawa, Japan – 18 – 21 April 2015
- 799 10th European International Kidney Cancer Symposium – Lyon, France – 24-25 April 2015
- 800 Urologic Oncology and Robotic Surgery on the Beach – Miami, US – 13-14 May 2015
- 801 EAU National Societies Meeting – Noordwijk, The Netherlands – 5-6 June 2015
- 802 LXXX Congreso Nacional de Urologia – Salamanca, Spain – 10-13 June 2015
- 803 BAUS Annual Meeting 2015 – Manchester, UK – 15-18 June 2015
- 804 ICPS: Prostate Cancer Roundtable – Brussels – 23 June 2015
- 805 Symposium ‘Advanced prostate cancer: Are GnRH antagonists really superior to LHRH agonists?’ – Leuven – 25 June 2015
- 806 European Alliance for Personalised Medicine: Advancing the road to cancer treatment through clinical trials high – Brussels – 1 July 2015
- 807 XVII Annual Meeting – XXI International Urological Oncology Symposium of the Mexican Urologic Oncology Association – Acapulco, Mexico – 22-25 July 2015
- 808 Seminarie over prostaatkanker - St. Joris-Winge – 22 augustus 2015
- 809 Personalized cure and care in urology – 50 years of academic urology in Nijmegen – Nijmegen, The Netherlands – 11-12 September 2015
- 810 EAU executive meeting – Brussels – 14 September 2015
- 811 30 years of EU action against cancer – Luxemburg – 15 September 2015
- 812 Increasing Male Life Expectancy – European Prostate Cancer Awareness Day – European Parliament Brussels – 16 September 2015
- 813 XV Congress of the Russian Society of Urology “Urology in the XXI Century” – 18-20 September 2015
- 814 18th ECCO – 40th ESMO European Cancer Congress Vienna, Austria, 25-29 September 2015
- 815 BLUG Meeting – Uccle – 15 October 2015
- 816 ESU course at the national congress of the Moldavian Association of Urology – Chisinau, Moldova – 23 October 2015
- 817 EAPM Internal Meeting: Public consultation on the preliminary opinion on the “Access to health services in the European Union” – Brussels, 26 October 2015

- 818 Oberbank Donau-Forum – Linz – 6-7 November 2016
- 819 ESO Conference: Personalized approach to prostate cancer management – Barcelona, Spain – 12 November 2015
- 820 EMUC 2015 – Barcelona, Spain – 12-15 November 2015
- 821 Tribute to Uro-Oncology – Leuven – 20-21 November 2015
- 822 50th Annual Meeting of the Egyptian Urological Association – Cairo, Egypt – 30 November 2016-4 December 2015
- 823 MJ. Marberger Ehrenveranstaltung: a life dedicated to urology – Vienna – 18 December 2016
- 824 49th Annual Conference of Urological Society of India – Hyderabad, India – 7-10 January 2016.
- 825 UROBEL – Lier – 12 January 2016
- 826 ESOU16 – 13th meeting of the EAU Section of Oncological Urology – 15-17 January 2016, Warsaw, Poland
- 827 Gemeinsame Sitzung des AUO und des AK ‘Prostata’ der ÖGU – 23 January 2016
- 828 3rd EAU-IUA Educational Meeting – Kish Island, Iran – 28-29 January 2016
- 829 27th International Congress on Anti-Cancer Treatment – Paris – 2-4 February 2016
- 830 Media training EAU Press Committee – Davos – 15 February 2016
- 831 Editorial Board Meeting Belgian Journal of Medical Oncology (BJMO) – Brussels – 24 February 2016
- 832 21st Annual EAU Congress – Munich – 10-15 March 2016
- 833 Innovations in diagnosis and treatment of prostate cancer – 1 April 2016 – Nis, Serbia
- 834 American Association of Genitourinary Surgeons Annual Meeting – 6-10 April 2016 – San Antonio, Texas
- 835 William Guy Forbeck Research Foundation Focus Meeting – 21-23 April 2016 – Nashville, US
- 836 National & EU scientific regulatory support mechanisms and initiatives for innovation in drug development (Workshop famhp) – Brussels – 2 May 2016
- 837 American Urological Association – San Diego, CA – 6-10 May 2016
- 838 ECCO Board Meeting – Amsterdam, The Netherlands – 10-11 May 2016
- 839 ECOP 2016 – European Conference of Oncology Pharmacy – Dubrovnik, Croatia – 19-21 May 2016
- 840 3rd EAU Baltic meeting – Tallinn – 27-28 May 2016
- 841 Annual meeting of the Slovak Urological Society – Zilina, Slovakia – 15-17 June 2016
- 842 Bladder Cancer Europe Roundtable – International Centre for Parliamentary Studies, Brussels – 21 June 2016

- 843 Salzburg Weill Cornell Seminar – ESU Master Class in Urology – Salzburg, Austria – 26 June 2016 – 2 July 2016
- 844 10th Forum of Prostate Disease – Shanghai, China – 29-30 July 2016
- 845 EAU Executive Meeting – Zurich – 4 September 2016
- 846 ECCO Board Meeting – Brussels – 7 September 2016
- 847 Controversies in urological surgical oncology – Torino – 22 – 23 September 2016
- 848 EPAD – Krakow – 29 September 2016-1 October 2016
- 849 14th International Prostate Forum – Antalya – 4 – 10 October 2016
- 850 EUSP meeting – Munich – 13 October 2016
- 851 EAU Board meeting – Munich – 14 October 2016
- 852 89th Annual SIU Congress – Venice, Italy – 16-18 October 2016
- 853 EAU Executive Meeting – Venice, Italy – 17 October 2016
- 854 36th Congress of the SIU – 19-22 October 2016
- 855 EAU Guidelines Office Chairmen Meeting – Lisbon, Portugal – 28-29 October 2016
- 856 3rd National Urological Surgery Congress – Antalya, Turkey – 2-6 November 2016
- 857 Second International Focus on Oncology – Lymphadenectomy in Urological Surgery – Bergamo, Italy – 4 November 2016
- 858 Challenges in the application of Guidelines in Genitourinary Cancer Congress – Athens, Greece – 18-19 November 2016
- 859 EAU Executive Meeting – Milan, Italy – 26 November 2016
- 860 8th European Multidisciplinary Meeting on Urological Cancers – Milan, Italy – 24-27 November 2016
- 861 ECCO General Assembly – Brussels, Belgium – 30 November 2016
- 862 YOU Board meeting – Amsterdam, The Netherlands – 1 December 2016
- 863 European Alliance for Personalised Medicine (EAPM) General Meeting – Brussels, Belgium – 7 December 2016
- 864 EAU Executive Meeting – Amsterdam, The Netherlands – 8 December 2016
- 865 EAU Scientific Congress Office (SCO) Meeting – Amsterdam, The Netherlands – 9-10 December 2016
- 866 EAU Executive Meeting – Arnhem, The Netherlands – 9 January 2017
- 867 International Francqui-Collen Inaugural lecture: “Targeted Radionuclide Therapy”, Prof. Dr. Michael Zalutsky, Duke University – Forum VUB, Campus Jette, Brussels – 12 January 2017
- 868 ESOU17 – 14th Meeting of the EAU Section of Oncological Surgery – Barcelona, Spain, 20-22 January 2017
- 869 International Centre for Parliamentary Studies (iCPS) – Brussels, Belgium – 24 January 2017
- 870 EUSP Board Meeting – Munich, Germany – 25 January 2017

- 871 ECCO congress – Amsterdam, The Netherlands – 27-30 January 2017
- 872 Scientific Committee Meeting – Amsterdam, The Netherlands – 30 January 2017
- 873 European Urology Forum – Davos, Switzerland – 4-7 February 2017
- 874 SNC interviews – Frankfurt, Germany – 10 February 2017
- 875 Comprehensive Cancer Control (CanCon) – Malta – 14-15 February 2017
- 876 IV Jornadas Médico Quirúrgicas en Cáncer de Próstata – Sevilla, Spain – 16-17 February 2017
- 877 WIN-O symposium : Multidisciplinair symposium Niercelcarcinoom – ReeHorst, Ede, The Netherlands – 14 March 2017
- 878 EAU17 – London, UK – 24-28 March 2017
- 879 IKCC meeting – Warsaw, Poland – 6 April 2017
- 880 American Association of Genitourinary Surgeons Annual Meeting – The Ritz-Carlton Key Biscayne, Miami – 27-30 April 2017
- 881 Postgraduaat AZ Klina: Prostaatkanker: visie, retrospectief, indicaties, trends, wanneer, robot meerwaarde enz... - AZ Klina Brasschaat – 3 May 2017
- 882 Minutes of the Guidelines Office Chair meeting – Hotel Radisson Blu – Amsterdam- 18-19 May 2017
- 883 ECCO Board Meetig – Brussels – 22 May 2017
- 884 EAU Back office: Panorama 7 – Noordwijk, The Netherlands – 06-10 June 2017
- 885 ECPC Annual Meeting 2017 – Hotel Renaissance – Brussels, Belgium 16-18 June 2017
- 886 iCPS – Bladder Cancer Europe Roundtable – Brussels, Belgium – 20 June 2017
- 887 ECCO Oncopolicy Face to Face Meeting – Brussels, Belgium – 27 June 2017
- 888 Brainstorming Meeting EAU Executive meets ESU, Guidelines Office – Vienna – 07 July 2017
- 889 1st Congress of Chinese Urology and Andrology Consortiums Union (CUACU); 11th Forum of Prostate Disease – Shangai – 11-13 August 2017
- 890 Annual meeting of the Taiwan Urological Association (TUA) – Kaohsiung, Taiwan – 19-20 August 2017
- 891 Kölner Urologentag 2017 – Köln, Germany – 02 September 2017
- 892 Uro Azhar Conference: The Golden Jubilee – Cairo – 8-10 September 2017
- 893 Porto Ass Urology 2017 – Portugal – 22-24 September 2017
- 894 The First International Congress of Georgian Association of Oncological Urology – Georgia – 4-5 October 2017
- 895 26th National Congress of Urology – Kyrenia, TRNC – 12-15 October 2017
- 896 37th Congress of the Société Internationale d’Urologie (SIU) – Lisboa – 19-22 October 2017
- 897 Editorial Board Meeting – Brussels, Belgium – 24 October 2017
- 898 GO Board Meeting – Budapest, Hungary – 26 October 2017

- 899 GO Chairmen Meeting – Budapest, Hungary – 27 October 2017
- 900 GO Senior Associates Meeting – Budapest, Hungary – 26 October 2017
- 901 ESOR – Rome, Italy – 2-3 November 2017
- 902 ECCO Oncopolicy Committee – Brussels, Belgium – 10 November 2017
- 903 EPCCCM – EAU Prostate Cancer Centre Consensus Meeting – Barcelona, Spain – 16 November 2017
- 904 EMUC Symposium on Genitourinary Pathology and Molecular Diagnostocs (ESUP) – Barcelona, Spain – 16 November 2017
- 905 9th Eurpean Multidisciplinary Meeting on Urological Cancers (EMUC17) – Barcelona, Spain – 17 November 2017
- 906 3iPathways in Urological cancers: optimising patient care – Brussels, Belgium – 24-26 November 2017
- 907 EAPM – Belfast, Northern Ireland – 27-30 November 2017
- 908 17th BAU Annual Congress – Zuid-West Limburg, Belgium – 1-2 December 2017
- 909 European Parliament – Brussels, Belgium – 5 December 2017
- 910 Exec EAU meeting – Amsterdam, The Netherlands – 7 December 2017
- 911 SCO EAU meeting – Amsterdam, The Netherlands – 8-9 December 2017
- 912 AAEU meeting – Dresden, Germany – 14-17 December 2017
- 913 EAU Executive Meeting – Arnhem, The Netherlands – 8 January 2018
- 914 Elautprijs 2018 – Leuven, Belgium – 20-21 January 2018
- 915 Prostate Cancer Europe, Roundtable – Brussels, Belgium – 23 January 2018
- 916 ESOU meeting – Amsterdam, The Netherlands – 26-28 January 2018
- 917 MEP's Against Cancer – Brussels, Belgium – 30 January 2018
- 918 EANM Focus meeting – Valencia, Spain – 1-3 February 2018
- 919 EAU Executive Meeting – Frankfurt, Germany – 6 February 2018

II. Lectures and communications

1. Cross-leg pedicles, postgraduate lecture, K.U.Leuven, 1975
2. Gastro-intestinal complications in burns, postgraduate lecture, K.U.Leuven, 1975
3. Congenital cystic adenomatoid malformation, postgraduate lecture, K.U.Leuven, 1976
4. Malformation adénomatoïde congénitale, postgraduate lecture, Société Belge de Chirurgie Pédiatrique, Liège, 1976
5. Ectopic goiter, postgraduate lecture, K.U.Leuven, 1979
6. Axillary surgery, Société Belge de Sénologie, Brussels, 1980
7. Treatment of colo-rectal polyps, postgraduate lecture, K.U.Leuven, 1980
8. Clinical semeiology of the breast, medical student course, K.U.Leuven, 1980
9. Axillary lymph node dissection for breast cancer, postgraduate lecture, K.U.Leuven, 1980

10. Treatment of oesophageal cancer, postgraduate lecture, Roeselare, 1980
11. Proctology, postgraduate lecture, Heist-op-den-Berg, 1980
12. Anal actinomycosis, postgraduate lecture, K.U.Leuven, 1980
13. Modern exploration techniques in urology, postgraduate lecture, K.U.Leuven, November 1980
14. Infections in urology, postgraduate lecture, Aarschot, September 1981
15. Congenital cysts of the prostate, postgraduate lecture, K.U.Leuven, October 1981
16. Kidney tumours in childhood, postgraduate lecture, K.U.Leuven, November 1981
17. Hemospermia, Soc. Belge d'Urologie, Brussels, November 1981
18. Kidney tumours in the adult, postgraduate lecture, K.U.Leuven, December 1981
19. Exploration and treatment of dysuria, postgraduate lecture, Leuven, Kortrijk and Hasselt, December 1981 and January 1982
20. Voiding disorders in Multiple Sclerosis, postgraduate lecture, Melsbroek, January 1982
21. Urologic emergencies, postgraduate lecture, Heist-op-den Bergh, March 1982
22. Vesico-urethral dysfunction in Multiple Sclerosis, Jubilee Conference on Multiple Sclerosis, Kopenhagen, June 1982
23. Ileo-ureteral reflux in Bricker derivations. 24. Tagung der Vereinigung der Norddeutschen Urologen, Kassel, June 1982
24. Long-term alpha-adrenergic blocking therapy in detrusor-urethra dyssynergia International Congress of the Soc. Int. d'Urologie, San Francisco, September 1982
25. Estracyt in the treatment of advanced prostate cancer. EORTC Symposium, Brussels, October 1982
26. Value of DMSA scintigraphy, Belg. Veren. Urologie, Leuven, November 1982
27. Importance du reflux iléo-rénal dans les dérivations urinaires, Soc. Belge d'Urologie, Brussels, November 1982
28. Neuro-urological problems in Multiple Sclerosis; diagnosis and treatment, Symposium of the Belgian Research Group on M.S., Brussels, March 1983
29. Local chemotherapy for superficial bladder tumours, Belg. Veren. Urologie, Oostende, March 1983
30. Pseudomonas infections in Multiple Sclerosis, Ned. Veren. Microbiologie, Antwerp, April 1983
31. Penile and scrotal pathology, postgraduate lecture, Mol, April 1983
32. Estracyt in the treatment of prostate cancer; effect on metastatic bone pain. Congress on Therapeutic Advances in the Treatment of Prostate Cancer, Helsingborg, Sweden, June 1983
33. External spinal cord stimulation in neuropathic detrusor dysfunction. European Association Urology, Kopenhagen, May 1984

34. Assessment of neuropathic urethral dysfunction by static pressure recording, European Assoc. Urology, Copenhagen, May 1984
35. Non-invasive external spinal cord stimulation in M.S. patients with incontinence caused by overactive bladder dysfunction, International Symposium on Practical Aspects of Urinary Incontinence, Nijmegen, June 1984
36. Heavy urinary tract infections in neurogenic bladders treated with ciprofloxacin, 4th Mediterranean Congress of Chemotherapy, Rhodos, Greece, October 1984
37. New trends in the treatment of nephrolithiasis, postgraduate lecture, Lier, June 1985
38. Sphincteric disorders and their treatment in Multiple Sclerosis, National Symposium on M.S., Melsbroek, September 1985
39. Sexually transmitted diseases, postgraduate lecture, Heist-op-den-Berg, October 1985
40. Troubles vésico-sphinctériens en sclérose en plaques, Society for Prosthetics and Orthotics, Melsbroek, October 1985
41. Efficacy of Ciprofloxacin on U.T.I. in Multiple Sclerosis and neurogenic bladder, 1st International Workshop on Ciprofloxacin, Leverkusen, November 1985
42. Treatment of sexually transmitted diseases, postgraduate lecture, Bilzen, November 1985
43. Vessie neurologique par sclérose en plaques, Symposium on vesico-urethral reeducation, November 1985
44. Urinary tract infection, postgraduate lecture, Brussels, December 1985
45. Bromocriptine for benign prostatic hyperplasia, Belgische Vereniging Urologie, Brussels, January 1986
46. Tumours of the urinary excretory system, uroradiological postgraduate meeting, Leuven, February 1986
47. Percutaneous kidney stone removal, Expomed, Brussels, March 1986
48. Modified Nesbith procedure for Peyronie's disease, Expomed, Brussels, March 1986
49. Update diagnosis and treatment of prostate cancer, postgraduate lecture, Lier, March 1986
50. Penile pathology, postgraduate lecture, Antwerp, April 1986
51. Urinary incontinence in the elderly. Diagnosis and treatment, postgraduate lecture, Gent, April 1986
52. Incontinence in geriatric patients, postgraduate lecture, Leuven, April 1986
53. Urologic pathology in the general practitioner's office, postgraduate lecture, Antwerp, 1986
54. Troubles mictionnels en sclérose en plaques, Melsbroek, April 1986
55. Sexual impotence in multiple sclerosis, Melsbroek, April 1986

56. Importance de l'urographie intraveineuse dans le diagnostic des tumeurs des voies excrétrices, 51^e Congrès de la Société Belge d'Urologie, Brussels, June 1986
57. Genital herpes infections and treatment, postgraduate lecture, Mol, June 1986
58. Late complications of Multiple Fraction Radiotherapy for Prostate Cancer, 38 Tagung Deutschen Gesellschaft Urologie, Würzburg, September 1986
59. Preoperative evaluation of small renal masses, 3rd Congress of the European Society of Surgical Oncology, Lissabon, October 1986
60. Diagnostic and therapeutic artefacts of small renal nodules, postgraduate lecture, Leuven, October 1986
61. Revolution in the treatment of urolithiasis, postgraduate lecture, Leuven, October 1986
62. Prostate specific antigen: a new tumor marker for prostate cancer? Symposium on PSA, Leuven, February 1987
63. Uro-oncological surgery, postgraduate lecture, Leuven, February 1987
64. Ciprofloxacin for multiresistant urinary tract infections. Efficacy, tolerance and resistance induction. Workshop on quinolones, Eindhoven, March 1987
65. Micturition and sexual disorders in M.S., postgraduate lecture, Leuven, April 1987 and Diest, September 1987
66. Urinary incontinence in the elderly, postgraduate lecture, Leuven, April 1987
67. Echography of scrotal pathology, Belgian Society of Urology, Leuven, April 1987
68. Prostate specific antigen: one year experience, postgraduate lecture, Leuven, May 1987
69. Prostate specific antigen: methodological and clinical aspects. European Nuclear Medicine Congress, Budapest, August 1987
70. Biotyping and susceptibility behaviour of pathogens in patients treated with ciprofloxacin. First International Conference of the Hospital Infection Society, London, September 1987
71. Urological and sexual problems in patients with Multiple Sclerosis. Invited lecture, Retie, October 1987
72. Bromocriptine et le comportement sexuel de l'homme d'âge moyen. 5^{ème} Congrès de la Société d'Andrologie de langue française, Paris, October 1987
73. Schwann cell hyperplasia in Multiple Sclerosis bladder: an indication of peripheral neuropathy? Congress of the Nederlandse Organisatie Wetenschappelijk Onderzoek Multiple Sclerose (NOWOMS), Houthalen, October 1987
74. Urethrectomy in bladder cancer surgery, Belgische Vereniging voor Urologie, Antwerp, November 1987
75. Diagnostic and therapeutic approach concerning small renal tumors, Belgische Vereniging voor Urologie, Antwerp, November 1987

76. Iridium implantation for bladder cancer, Belgische Vereniging voor Urologie, Antwerp, November 1987
77. Relevance of dynamic cavernosography to the diagnosis of venous leak in erectile dysfunctions, 6th Forum of International Andrology, Paris, May 1988
78. Biotyping and susceptibility behaviour of pathogens in patients treated with ciprofloxacin, 6th Mediterranean Congress of Chemotherapy, Taormina, May 1988
79. Study of the autonomic nerve fibers of the urinary bladder wall. An enzyme- and immunohistochemical study of the intrinsic innervation on cystoscopic biopsies with special attention to Multiple Sclerosis and Diabetes. Thesis submitted in partial fulfillment of the requirements for the degree of Doctor in de Medische Wetenschappen of the Katholieke Universiteit Leuven, Leuven, June 1988
80. Neoadjuvant Mitomycin C in metastasized prostate cancer, Brussels, June 1988
81. Urological and sexual problems in patients with Multiple Sclerosis, Meeting of the Belgian M.S. Liga, Kortrijk, October 1988
82. Iridium implantation for bladder cancer. International symposium on invasive bladder cancer treatment, Leuven, October 1988
83. Progress in urological oncology. Diagnosis and treatment. Postgraduate course, Pellenberg, November 1988
84. Infektionsverhütung im Krankenhaus. 5. Internationale Arbeitstagung. Zürich, December 1988
85. Neurogenic bladder treatment. Seminars of Neurology and Neurosurgery, Leuven, December 1988
86. Kidney, bladder and prostate cancer. Recent progress in diagnosis and therapy. Postgraduate lecture, Heist-op-den-Berg, December 1988
87. Multiple Sclerosis and neurogenic bladder dysfunction. Invited lecture, Melsbroek, February 1989
88. Bladder conserving treatment with interstitial implantation for invasive bladder cancer. European School Oncology, Loutraki, Greece, May 4-6, 1989
89. The significance of bladder carcinoma. Workshop: Is prevention and early detection of bladder cancer possible? Leuven, June 5, 1989
90. Etiopathogenesis, histology, diagnosis and conservative treatment of benign prostatic hypertrophy. Postgraduate lecture, Bree, November 7, 1989
91. Diagnosis and treatment of inflammatory prostatic disorders. Postgraduate lecture, Leuven, November 8, 1989
92. Prostate cancer. State of the Art Lecture. Mini-symposium: What's new in Urology? St.-Truiden, November 30, 1989
93. Actual diagnostic and therapeutic approach for prostate cancer. Medi-Intel, Grindelwald, Zwitserland, January 1990

94. Urological problems in Multiple Sclerosis. Belgian M.S. Liga, Brussels, February 1990
95. Prepubic urethrectomy, International Course on Urological Oncology, Erice, Italy, March 1990
96. Percutaneous gastrostomy in uro-oncological surgery, International Course on Urological Oncology, Erice, Italy, March 1990
97. The present role of estramustine phosphate and bromocriptine in advanced prostate cancer, International Course on Urological Oncology, Erice, Italy, March 1990
98. Update in Urology: PSA and ultrasonography in prostate cancer, postgraduate lecture, Heist-op-den-Berg, March 15, 1990
99. Urinary incontinence. Medical aspects. Postgraduate lecture, Postuniversitair Centrum West-Vlaanderen, Knokke, May 17, 1990
100. Research on urological disturbances in Multiple Sclerosis, First meeting of the European Study Group on Urological Disturbances in M.S., Nijmegen, June 8-9, 1990
101. Bladder dysfunction in Multiple Sclerosis, Belgian M.S. Liga, Leuven, June 11, 1990
102. Prepubic urethrectomy. Second international symposium on recent advances in urological cancer diagnosis and treatment, Paris, June 27-29, 1990
103. Interstitial radiotherapy with Iridium for invasive bladder cancer. Second international symposium on recent advances in urological cancer diagnosis and treatment, Paris, June 27-29, 1990
104. Percutaneous gastrostomy. Second international symposium on recent advances in urological cancer diagnosis and treatment, Paris, June 27-29, 1990
105. Conservative surgery for renal cancer. Second international symposium on recent advances in urological cancer diagnosis and treatment, Paris, June 27-29, 1990
106. Protocol proposal to the EORTC GU Group on: Conservative surgery for renal cancer. Autumn meeting of the EORTC GU Group, Prague, September 12-15, 1990
107. Präpubische Urethra-Resektion. 42. Kongress der Deutsche Gesellschaft für Urologie, Hamburg, September 26-29, 1990
108. Interstitial radiotherapy for invasive bladder cancer. Fifth Congress of the ESSO, Brussels, October 17-20, 1990
109. Urological and sexual disorders in Multiple Sclerosis. M.S. School, Mechelen, November 13, 1990
110. Conservative renal and bladder tumor surgery. Symposium for General Practitioners, Leuven, November 17, 1990

111. Accuracy of CT and CT guided puncture in the node staging of localized prostate cancer. Parke Davis Award, Ieper, November 24, 1990
112. Screening and staging of prostate cancer. Treatment of localized prostate carcinoma. Chiang Ray, Thailand, November 29, 1990
113. Urostomy: anatomy, physiology, pathology, therapy. Medical complications and nursing aspects. Symposium on stoma care in hospital and at home, Brussels, January 18, 1991
114. Evaluation of subtrigonal phenolisation for neurogenic bladder overactivity in 20 M.S. patients. M.S. Research Workshop, Leuven, February 22, 1991
115. Controversies on radical prostatectomy for localized prostate cancer. National Symposium Urology: Carcinoma of the prostate: recent aspects, Brussels, March 9, 1991
116. Place de dérivations urinaires continentes et incontinentes. 6° Séminaire d'Urologie, Hôpital Français, Les Problèmes de Continence, Brussels, March 16, 1991
117. Treatment of urological disorders in M.S. 1st European workshop on Sexual and Urological Disorders in M.S., Leuven, March 29, 1991
118. Perkutane operative Gastrostomie zur postoperativen Magendrainage. 32. Tagung der Südwestdeutschen Gesellschaft für Urologie, Koblenz, May 9-11, 1991
119. En bloc Urethra-Resektion während Zysto-Prostatektomie mittels präpubischen Zugangsweges. 32. Tagung der Südwestdeutschen Gesellschaft für Urologie, Koblenz, May 9-11, 1991
120. Transuretero-pyelostomy for ureteral necrosis after continent umbilical Mainz pouch urinary diversion. 56th Congress of the Société Belge d'Urologie, Brussels, May 25-26, 1991
121. Urological and sexual problems in M.S. patients. Provincial meeting M.S. Liga, Roeselare, June 6, 1991
122. Diagnostic and therapeutic approach for prostate cancer. General practitioner oncologic meeting, Leuven, June 8, 1991
123. Partial tumor nephrectomy. Prepubic urethrectomy. Postgraduate course, Leuven, June 15, 1991
124. Case study meeting general practitioners, Keerbergen, June 19, 1991
125. Proposal National Multicenter Protocol: Neo-adjuvant hormonotherapy before radical prostatectomy, Brussels, September 4, 1991
126. Radical prostatectomy for prostate cancer. T.V. interview, Mimi, VTM, September 7, 1991
127. Hormonal therapy for advanced prostate cancer, Therapiedag Alumni, K.U.Leuven, October 5, 1991

128. The case for conservative surgery for renal tumors. Invited lecture. 1st International Congress of the Dutch Urological Association "Progress and Controversies in Oncological Urology III", Rotterdam, October 9-13, 1991
129. Radical prostatectomy for localized prostate cancer. Colloquium Lovaniensium Chirurgorum, Leuven, November 9, 1991
130. Treatment of prostate cancer. Postgraduate course hospital pharmacists, Antwerp, November 19, 1991
131. Diagnosis and treatment of benign prostatic hypertrophy and prostate cancer. Postgraduate course, Wezembeek-Oppem, November 28, 1991
132. Prostate cancer. Diagnosis and treatment options in early and advanced stage. Training course, Abbott, Leuven, January 28 and February 11, 1992
133. Considerations after 150 radical prostatectomies. Postgraduate meeting, Heerlen, The Netherlands, April 8, 1992
134. Prostate cancer. Early diagnosis and treatment of early and advanced prostate cancer. Postgraduate lecture, Heist-op-den-Berg, May 14, 1992
135. S.U.D.I.M.S., Present position. Second meeting of the European Study Group on Sexual and Urological Disorders in Multiple Sclerosis, Copenhagen, May 22-24, 1992
136. Urological and sexual disorders in M.S. M.S. School, Heist-op-den-Berg, May 26, 1992
137. Prepubic urethrectomy. Second International Workshop and Symposium on New Urological Technology, Leuven, June 4-5, 1992
138. Percutaneous operative gastrostomy. Second International Workshop and Symposium on New Urological Technology, Leuven, June 4-5, 1992
139. Longterm follow-up of metallic urethral stents. L. Verhamme, H. Van Poppel, L. Baert. Second International Workshop and Symposium on New Urological Technology, Leuven, June 4-5, 1992
140. Longterm results of interstitial radiotherapy for invasive bladder cancer. Euro-American Conference on Urological Cancer, Athens, September 16, 1992
141. Cytogenetic investigations in normal and malignant kidney tissues. Euro-American Conference on Urological Cancer, Athens, September 17, 1992
142. Sense or non-sense of neo-adjuvant hormone therapy before radical prostatectomy. Euro-American Conference on Urological Cancer, Athens, September 18, 1992
143. Is neo-adjuvant hormonal treatment before radical prostatectomy of any help? International meeting on uro-oncology, Modena, September 27, 1992
144. (Non)Sense of downstaging. Symposium: Early detection and treatment of localized carcinoma of the prostate, Brugge, October 3, 1992

145. Hormonal treatment of prostate cancer. Postgraduate lecture, Overpelt, October 22, 1992
146. Valeur de la lymphadénectomie dans le cancer du rein non-métastatique. D. Jacqmin, J. Blom, H. Van Poppel et al. Association française d'Urologie, Paris, October 21-23, 1992
147. Partiële nierresectie bij nierceltumor. Oncologische en praktische consequenties. Nederlandse Vereniging Urologie, 's Hertogenbosch, October 31, 1992
148. Hedendaagse strategie voor diagnose en behandeling van prostaatkanker. Clinico-pathologische conferentie. Aanwinsten inzake prostaatkanker, Leuven, December 4, 1992
149. Prostate cancer. Early diagnosis, screening and treatment, anno 1993. Postgraduate lecture, Brugge, January 28, 1993
150. Urethrectomy: How and when? Symposium on "Locally advanced bladder cancer", Aachen, February 26-27, 1993
151. Partial kidney resection for renal cell carcinoma. State of the Art Lecture, Workshop and meeting Professors of Urology Poland, Warsaw, March 5, 1993
152. Round table, workshop Prostate Cancer, Warsaw, March 5, 1993
153. Is the goal of bladder preservation always worthwhile. M. Koiso et al., H. Van Poppel. Fourth International Consensus Meeting on Bladder Cancer, Antwerp, March 25, 1993
154. Report of the Kidney Cancer Subcommittee. EORTC GU Group Meeting, Antwerp, March 27, 1993
155. Urological and sexual dysfunctions in Multiple Sclerosis. M.S. School, Antwerp, April 20, 1993
156. Prostate Cancer Update. Postgraduate course MCH Leuven, April 21, 1993
157. Round table on Prostate Cancer Diagnosis and Treatment, Praha, April 28, 1993
158. Problematika nadoru prostaty, oncologic-urologic symposium, Praha, April 29, 1993
159. Lymph node staging by CT scan before radical prostatectomy. Genito-Urinary EORTC GU Group, Portugal meeting, Castelo Branco, Portugal, May 28-29, 1993
160. Estracyt in prostate cancer. Genito-Urinary EORTC Group Portugal meeting, Castelo Branco, Portugal, May 28-29, 1993
161. Actuele topics in de Urologie. Postgraduate lecture, Hasselt, June 9, 1993
162. Actual topics in Urology. Postgraduate lecture, Leuven, June 23, 1993
163. Adjuvant therapy after radical prostatectomy. Cambridge Prostate Cancer Meeting, Cambridge, September 5, 1993
164. Indication et technique de l'urétréctomie associée à la cystectomie pour cancer vésical. 11ième Journée Urologique de Lille, October 8, 1993

165. Treatment of bladder cancer. My philosophy. W. Fair discussion. 11ième Journée Urologique de Lille, October 9, 1993
166. Conservative surgery for renal cell cancer. 8th International Symposium of Urology Update 1993, Espinho, October 25, 1993
167. Urological and sexual dysfunction in Multiple Sclerosis. M.S. School, Deinze, November 9, 1993
168. Conservative kidney cancer surgery. Presentation of the kidney cancer subcommittee of the EORTC GU Group. Istanbul, November 12, 1993
169. Conduite à tenir devant un cancer de prostate pT₂. 87ième Congrès Français d'Urologie. Paris, November 18, 1993
170. Diagnostic and therapeutic approach in localized prostate cancer. Postgraduate course in hematology and oncology, genito-urinary cancer, Brussels, December 3, 1993
171. Prostate cancer. Postgraduate lecture, St.-Niklaas, December 3, 1993
172. Diagnosis and treatment of localized prostate cancer. Interuniversity course in Urology, Leuven, December 8, 1993
173. Diagnosis, detection and treatment of bladder cancer. Postgraduate course, Leuven, January 20, 1994
174. Anatomic considerations, detection, diagnosis and treatment of localized prostate cancer. Postgraduate course, Kortrijk, January 28, 1994, Hasselt, February 10, 1994, Leuven, March 10, 1994
175. The K.U.Leuven experience with elective kidney sparing surgery in 35 patients. Meeting of the Belgian Association of Urology, Brussels, January 29, 1994
176. Nephrektomie beim metastasierten Nierenzellkarzinom und Metastasen Resektion. European School of Oncology. Operative Uro-Onkologie, Aachen, March 2, 1994
177. Urethrektomie. European School of Oncology. Operative Uro-Onkologie, Aachen, March 3, 1994
178. Locally advanced prostate cancer. Definition, implication and proposal for a Phase III trial in cooperation with the University of South California. Prostate cancer research meeting. University of South California - University of Leuven, Los Angeles, March 12, 1994
179. Urological tumors. Screening, diagnosis and treatment. General practitioners meeting, Leuven, March 19, 1994
180. Urological and sexual dysfunctions in Multiple Sclerosis, M.S. School, Aartselaar, April 19, 1994
181. Prostate cancer. General practitioners meeting, Diest, May 5, 1994
182. Possibilities and restrictions of the treatment of prostate cancer in the overaged patient. Postgraduate course, Leuven, May 19, 1994

183. Bricker urinary diversion after cysto(prostato)-urethrectomy. Still an acceptable diversion. XIth Congress of the European Association of Urology, July 13, 1994
184. Hormonal treatment before radical prostatectomy is beneficial only in clinical T2 patients. XIth Congress of the European Association of Urology, July 14, 1994
185. Mitomycin-C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: interim results on a randomized trial. XIth Congress of the European Association of Urology, July 15, 1994
186. Trisomy 7 and trisomy 10 in the healthy parenchyma of RCC bearing kidneys is not a premalignant lesion. XIth Congress of the European Association of Urology, July 15, 1994
187. Non-papillary renal cell carcinoma is characterized by monosomy 3p and papillary renal cell carcinoma by trisomy 17 and other chromosome changes. XIth Congress of the European Association of Urology, July 15, 1994
188. CT-scan and fine needle aspiration cytology for lymph node staging in 285 radical prostatectomy candidates. XIth Congress of the European Association of Urology, July 15, 1994
189. Chairman Oral Session Renal Cell Cancer Treatment II. XIth Congress of the European Association of Urology, July 15, 1994
190. Elective kidney sparing surgery for renal cell carcinoma in 33 patients. XIth Congress of the European Association of Urology, July 15, 1994
191. Endoscopically assisted nephro-ureterectomy. XIth Congress of the European Association of Urology, July 15, 1994
192. T₃pT₃ prostate cancer. Situation of the problem. 24th Congress of the Polish Urological Association, Cracow, September 2, 1994
193. Radical retropubic prostatectomy. H. Van Poppel. Postgraduate lecture. University Hospital Maastricht, September 13, 1994
194. Clinical results of Estracyt in single treatment and combination. 9th Congress of the Society of Hungarian Urologists, Budapest, October 14, 1994
195. Prostate cancer: actual status on diagnosis and treatment. Postgraduate course, Tienen, October 18, 1994
196. The significance fo a hypoechoic lesion in the prostate gland. R. Oyen, P. Knapen, H. Van Poppel, L. Baert, A.L. Baert. Annual Symposium of the Royal Belgian Radiological Society, Liège, November 5, 1994
197. Urostomy and pouches. 5th WCS Congress, Brussels, November 10, 1994
198. Prostate cancer. Integrale Kankerstichting Vlaams Brabant, Leuven, November 17, 1994
199. Surgical treatment of bladder cancer. Belgische Vereniging Radiotherapie Oncologie, Leuven, November 19, 1994

200. Overview on diagnosis and treatment of urinary disorders in Multiple Sclerosis. H. Van Poppel, D. De Ridder, L. Baert. Workshop Multiple Sclerosis and Rehabilitation, Care and Health Services in Europe (MARCH), Tenerife, December 2, 1994
201. Superficial and invasive bladder tumors. Postgraduate course, Leuven, December 12, 1994
202. Chromosoom afwijkingen in tumor infiltrerende lymfocyten in nieradenocarcinoma en omgevend nierweefsel. M. Van den Heuvel, P. Dalcin, H. Van Poppel, L. Baert. Prof. Elaut Price of Urology. Belgische Vereniging voor Urologie, Zottegem, December 17, 1994
203. Urostoma and continent diversion. Vlaamse Vereniging Operatiezaal Verpleegkundigen, Leuven, January 28, 1995
204. Management of small kidney tumors. Postgraduate Urology Course, Leuven, February 11, 1995
205. Surgical treatment of bladder cancer. Seminars in Oncology, Gasthuisberg, Leuven, March 7, 1995
206. Neoadjuvant treatment before radical prostatectomy. Symposium Urology, Lisboa, Portugal, March 18, 1995
207. Nieuws over nier, blaas en prostaatkanker. Leuvense Dagen Urologie en Nefrologie, Pellenberg, March 24, 1995
208. Report of the Kidney Cancer Subcommittee EORTC GU Group meeting, Den Bosch, The Netherlands, March 25, 1995
209. Surgical aspects of urinary diversion, stoma and bladder replacement. Seminars Nephrology, Gasthuisberg, Leuven, March 28, 1995
210. Traitement du cancer métastatique du prostate. Séminaire Interhospitalier d'Urologie, Bruxelles, March 29, 1995
211. Radiotherapy-Hyperthermia combination for localized carcinoma of the prostate, 1995
212. 43rd Annual Meeting of the Radiation Research Society/15th Annual Meeting of the North American Hyperthermia Society, San Jos California, April 1-6, 1995
213. Cystectomie totale et type de dérivation. IXième Congrès de la Société Internationale Francophone de Chirurgie Pelvienne, Lyon, April 7-8, 1995
214. Urinary and sexual problems in Multiple Sclerosis. M.S. School Zemst, April 18, 1995
215. Microscopic vascular invasion: the most significant prognostic factor in renal cell carcinoma. American Urological Association, Las Vegas, April 23-28, 1995
216. Cystectomy and continent diversion. International Congress of the Belgian Urological Association, Gent, May 15, 1995

217. Surgical treatment of prostatic carcinoma. Château de la Bretesche Symposium on Prostate Cancer, July 10, 1995
218. Patterns of failure in surgically treated patients. Château de la Bretesche Symposium on Prostate Cancer, July 10, 1995
219. Chemohormonal therapy in advanced prostatic cancer. Hong Kong Urological Association, September 18, 1995
220. Chemohormonal therapy in advanced prostatic cancer. Shanghai Urological Association, September 20, 1995
221. A surgeon's view on the treatment of prostatic cancer. Roentgen Centenary Congress, October 7, 1995
222. The use of serum tissue polypeptide antigen as a tumor marker for bladder cancer. H. Van Poppel, J. Billen, M. De Roo, L. Baert. Abstr. Fifth International Conference of Anticancer Research, Corfu, October 22, 1995
223. Radical prostatectomy. H. Van Poppel, W. Van de Voorde, R. Oyen, L. Baert. Abstr. The European Cancer Conference ECCO 8, Paris, October 30, 1995
224. Prostate cancer, need and future options for adjuvant and neo-adjuvant drug treatment with radical prostatectomy. Meet the Professor Session. 3rd International Congress of the Dutch Urological Association, Nijmegen, November 1, 1995
225. Estracyt in the management of prostate cancer. Round table discussion. 3rd International Congress of the Dutch Urological Association, Nijmegen, November 1, 1995
226. Report of the Kidney Cancer Subcommittee EORTC GU Group meeting, Brugge, November 11, 1995
227. Actuality of prostate cancer management. Postgraduate course in urology, Reims, December 2, 1995
228. La prostatectomie radicale. Urology meeting. Le point sur le traitement du cancer de la prostate. Meeting with the Urological Association Luxemburg, Brugge, February 3, 1996
229. Nierenteilresektion European School of Urology, Aachen, March 6-9, 1996
230. Neoadjuvante Therapie beim Prostatakarzinom European School of Urology, Aachen, March 7, 1996
231. Radical prostatectomy in T1c prostate cancer: the Leuven experience. Symposium Research Programmes on Prostate Pathology, Leuven, April 29, 1996
232. Prostaatcarcinoom. Postgraduate Urology, Turnhout, May 7, 1996
233. Prostate cancer in the elderly. Postgraduate geriatrics, Leuven, May 28, 1996
234. Surgery for local recurrence and metastatic renal cell carcinoma. Belgian Urological Congress Adjuvant Treatment for Urological Cancer, Brussels, May 31, 1996

235. Radical versus nephron sparing surgery in adult kidney tumors. EAU Congress, Paris, September 2, 1996
236. Randomized clinical trials in kidney cancer: a waste of time? EAU Congress, Paris, September 3, 1996
237. Alterations in the morphology of prostate cancer after neoadjuvant treatment. EAU Congress, Paris, September 4, 1996
238. T1c prostaat carcinoom. Refereeravond Utrecht, September 10, 1996
239. Long-term results of partial cystectomy combined with Iridium 192 brachytherapy. International Symposium on Carcinoma of the Bladder, Leuven, September 12, 1996
240. Les cancers de prostate T3 cliniques. Symposium du Comité de Cancérologie de l'Association française d'Urologie, Paris, September 27, 1996
241. Principles of urinary diversion after radical cystectomy. European School of Urology. Izmir, October 4, 1996
242. Nephron sparing surgery for localized renal cell carcinoma. European School of Urology, Izmir, October 4, 1996
243. Is serum TPA a valuable marker for transitional cell carcinoma? I.S.O.B.M., San Diego, November 20, 1996
244. PSA: overdiagnose prostaatcarcinoma? 7de Symposium Praktische Urologie voor de Huisarts, Kortrijk, November 30, 1996
245. Instillatie van capsaïcine in de blaas bij MS patienten met onbehandelbare detrusor hyperreflexie: resultaten bij 41 patiënten. Prof. Elautprijs, Turnhout, January 25, 1997
246. Genetica van Wilms tumoren. Prof. Elautprijs, Turnhout, January 25, 1997
247. Is serum tissue polypeptide antigen (TPA) a valuable marker for transitional cell carcinoma? VI International symposium on biology and clinical usefulness of tumor markers, Barcelona, February 12-15, 1997
248. Partial Nephrectomy. Hospital Universitario Canarias, Tenerife, March 6, 1997
249. Radical retropubic prostatectomy. Simposio Internacional de Urologia: "Controversias en Urologia", Tenerife, March 7-8, 1997
250. Bladder cancer. Which type of diversion to prefer. Simposio Internacional de Urologia: "Controversias en Urologia", Tenerife, March 7-8, 1997
251. P.S.A.: overdiagnose van prostaatca? 30 jaar urologische praktijk Dr. Morelle, Aalst, May 1, 1997
252. Is adrenalectomy necessary? Renal Cell Carcinoma/Operative and Theoretical Course. Affiliated course of the European School of Urology, an educational programme of the European Association of Urology and the European Board of Urology, Helsinki, May 29-30, 1997

253. Nephron sparing surgery, indications and results. Renal Cell Carcinoma/Operative and Theoretical Course. Affiliated course of the European School of Urology, an educational programme of the European Association of Urology and the European Board of Urology, Helsinki, May 29-30, 1997
254. Renal reconstructive surgery. European School of Urology Satellite Course on Reconstructive Urology , Genova, June 1, 1997
255. Prostatectomie voor prostaatkanker. 3 de Urologisch Verpleegkundig Congres: "Prostaataandoeningen, pathologie en therapie", Oostende, June 7, 1997
256. Hoe significant zijn tumoren ontdekt door PSA stijging? Avondsymposium PSA: een stand van zaken, Sint-Maartens-Latem, June 24, 1997
257. Neoadjuvant Treatment for T3 Prostate Cancer. International Baltic Uro-Oncologic Symposium on Prostate Cancer, Kiel, June 26-28, 1997
258. Serum tissue polypeptide antigen: a valuable marker for monitoring transitional cell carcinoma. Société Internationale d'Urologie, Montreal, September 11, 1997
259. Radical prostatectomy for clinical T3. Neoadjuvant treatment. European Cancer Conference, ECCO, Hamburg, September 15, 1997
260. Bladder and prostate cancer. Rapport. European Cancer Conference, ECCO, Hamburg, September 15, 1997
261. Renal cancer: role of surgery and update of the EORTC randomized trials. Medical Research Council. Urological Cancer Residential Open Meeting, York, October 24, 1997
262. The role of pelvic lymph node dissection for bladder cancer. 5th International Consensus Meeting on Bladder Cancer, Tokyo, November 6-8, 1997
263. Surgery for renal cell carcinoma: indications and complications. International Symposium: Carcinoma of kidney and testis, Leuven, November 15, 1997
264. Kidney sparing surgery for renal cell carcinoma. 91^o Congress of the Association Française d'Urologie, Paris, November 18, 1997
265. Conservative surgery for kidney cancer. Linz, November 20, 1997
266. Serum tissue polypeptide antigen (TPA): a valuable marker for monitoring transitional cell carcinoma. 9th International Hamburg Symposium on Tumor Markers, December 8, 1997
267. Update on BUOS II protocol. Meeting of the Belgian Uro-Oncological Study Group, Milan, December 17, 1997
268. Quality control of radical prostatectomy for early prostate cancer detection. Developing a strategy for the next two decades, Miami, January 3, 1998
269. Urinary stoma and pouches. WCS cursus, Gasthuisberg Leuven, February 9, 1998
270. Results of partial nephrectomy for renal cell carcinoma. Single center experience in 76 patients. EAU Congres, Barcelona, March 22, 1998

271. Is there still a place for clinical research outside trials? EAU Congress, Barcelona, March 23, 1998
272. Incontinence after radical prostatectomy: Results of a randomised trial comparing pelvic floor physiotherapy versus no treatment. EAU Congress, Barcelona, March 24, 1998
273. How I manage PSA recurrence after radical prostatectomy. EAU Congress Barcelona, March 24, 1998
274. Treatment of vascular involvement in renal cell carcinoma. EAU Congress Barcelona, March 25, 1998
275. Treatment of early disease. Therapeutic insights. Prostate Cancer, Amsterdam, April 23, 1998
276. Case presentations. Therapeutic insights. Prostate Cancer, Amsterdam, April 23, 1998
277. Locoregional treatment of prostate cancer. Lessenreeks Belgische vereniging voor Radiotherapie-Oncologie, UZ Gasthuisberg, Leuven, April 25, 1998
278. Round table discussion: How to deal with problems in radical prostatectomy? Controversial and Practical Urology (BSU), Kortrijk, May 8-9, 1998
279. Moderator session: Surgery of Renal Cancer. Controversial and Practical Urology (BSU), Kortrijk, May 8-9, 1998
280. Structured debate: Partial versus Radical Nephrectomy. Controversial and Practical Urology (BSU), Kortrijk, May 8-9, 1998
281. Prostate Cancer: to screen or not to screen. Belgische vereniging voor Pathologische Ontleedkunde, UZ Gasthuisberg, Leuven May 16, 1998
282. Nephron Sparing Surgery of RCC. Usefulness in daily practice and limits. Insights in urology: relevant aspects in the practice of modern urology (ESU), Lisbon, July 2-4, 1998
283. Behandeling van prostaatcarcinoma. Seminaria Oncologie, Dienst Gezwelziekten KULeuven, September 29, 1998
284. Partial Nephrectomy is an under-utilised procedure. Urology Debate and Controversy, Edinburgh, October 6, 1998
285. Organ sparing surgery: magic bullet or tragic insanity? Progress and Controversies in Oncological Urology V, an update of renal bladder and prostate cancer, Rotterdam, October 15, 1998
286. Prostaataandoeningen en prostaatoperaties. Symposium Incontinentie en Impotentie na prostaatoperatie, UZ Gasthuisberg Leuven, October 23, 1998
287. Partiële of volledige nefrectomie bij patiënten met een niertumor en een gezonde contralaterale nier? Onco-Uro Congres II: Hematurie, Niertumoren, Blaastumoren, UZ Antwerpen, October 24, 1998

288. Es la nefrectomia parcial un enfoque aceptable en el Ca. Renal? VII Jornadas Internacionales de Actualizacion Urologica, Madrid, November 2 1998
289. PSA-Vrije PSA. Lok vergadering, SOMEDI, Heist o/d Berg, November 26, 1998
290. Is there any role for neoadjuvant therapy in prostate cancer? International course on functional urology, Tenerife, December 4-6, 1998
291. Changing attitude towards surgery for Renal Cell Carcinoma. Externe refereeravond: New concepts in the treatment of urological cancers, Nijmegen, December 10, 1998
292. Chairman Session: PET in urogenital cancer. Clinical use of PET in Oncology, UZ Gasthuisberg, Leuven, December 12, 1998
293. EORTC GU Group Spring Meeting, Kidney Cancer report Belgium
294. Radicale prostatectomie voor T1 en T3 prostaatcarcinoma, 8ste Serruys Symposium Oncologie Oostende, February 6, 1999
295. Most Important Achievements of the EORTC GU Group, A. Van der Meijden, A. Bono, Z. Kirkali, H. Van Poppel and R.Sylvester, EORTC Scientific Strategy Meeting, Brussels, 25-26 March, 1999
296. Projects/strategies for the next 5 years, A. Van der Meijden, A. Bono, Z. Kirkali, H. Van Poppel and R.Sylvester, EORTC Scientific Strategy Meeting, Brussels, March 25-26, 1999
297. Testicular Cancer: Postchemotherapy surgery: always removal or risk-directed strategy. S. Fossa, H. Van Poppel, XIV th Congress of the European Association of Urology, Stockholm, April 7-11, 1999
298. Management of small kidney tumors (T1 N0 M0), XIV th Congress of the European Association of Urology, Stockholm, April 7-11, 1999
299. Damage Control in Prostate Surger, V. Pansadoro, H. Van Poppel, XIV th Congress of the European Association of Urology, Stockholm, April 7-11, 1999
300. Cancer prostatique : données récentes sur le PSA, XXIème Congrès de la Société Française d'Application des Ultrasons à la Médecine et à la Biologie (SFAUMB), Lille, May 5-7, 1999
301. Structured debate radical prostatectomy: retropubic/perineal. Arguments in favour of Rad. Retropubic Prostatectomy, 3rd International Symposium on Prostatic Surgery, L'Aquila, May 23-25, 1999
302. Waarde van transrectale echografie, CAT-scan en NMR bij staging van prostaatkliecarcinoma. Diagnostische aanwinsten in de oncologie. Roeselare, March 20, 1999
303. Can surgery provide cure in clinical T3? ECCO 10, The European Cancer Conference, September 12-16, 1999
304. Controversial Issues in surgical management of kidney cancer, Schorn Meeting, Linz, September 18, 1999

305. Controversies in the surgical management of kidney cancer at the presentation of the Folke Edsmyr Award 1999 to Prof. Dr. H. Van Poppel, Karolinska Hospital, Stockholm, October 1, 1999
306. Can surgery provide cure for cT3? 2nd Iberian Course of Urological Oncology, Barcelona, October 13-15, 1999
307. Management of small kidney tumours. 2nd Iberian Course of Urological Oncology, Barcelona, October 13-15, 1999
308. The place of nephrectomy for metastatic renal cell carcinoma. BAUS Section of Oncology, 2nd annual meeting. Renal tumors, Manchester, November 11-12, 1999
309. Surgery for locally advanced disease. Lymph node involvement. BAUS Section of Oncology, 2nd annual meeting. Renal tumors. Manchester, November 11-12, 1999
310. PSA en PIN na het jaar 2000. 8ste Symposium Praktische urologie voor de huisarts, Kortrijk, November 27, 1999
311. Prostate Cancer, Abbott teaching Course, December 14, 1999
312. "Is conservative surgery an acceptable treatment for RCC" IX Curso Internacional de Urologia, Zaragoza, January 31- February 3, 2000
313. Points of technique in radical retropubic prostatectomy, Workshop Treatment of Localised Prostate Cancer, Jönköping, February 18, 2000
314. Damage control in radical retropubic prostatectomy, Workshop Treatment of Localised Prostate Cancer, Jönköping, February 18, 2000
315. Radical versus partial nephrectomy in low stage RCC, EORTC GU Group Spring Meeting Newcastle Upon Tyne, UK, March 16-18, 2000
316. Chemopreventie bij prostaatkanker, LOK, Brugge, March 27, 2000
317. Nephron sparing surgery in kidney cancer. ESRU state of the art lecture, XVth EAU congress, Brussels, April 12, 2000
318. Neoadjuvant hormone therapy prior to surgery: A missed opportunity?. XVth EAU congress, Brussels, April 13, 2000
319. How I perform a partial nephrectomy. XVth EAU congress, Brussels, April 14, 2000
320. Chairman session: Retropubic versus perineal versus laparoscopic radical prostatectomy. XVth EAU congress, Brussels, April 15, 2000
321. Chemopreventie bij prostaatkanker, LOK, Aalst, 15-05-2000
322. Chemohormonal treatment for prostate cancer in the next millennium, Roumanian Society of Uro-Oncology, Bucharest, May 11, 2000
323. Premalignant lesions in the kidney, Public Health and Clinical Significance of Premalignant Alterations in the Genito-Urinary Tract. WHO Collaborative Project and Consensus Conference Stockholm, Sweden, June 8-10, 2000

324. Chemopreventie bij prostaatkanker, LOK, Hasselt, September 21, 2000
325. Can surgery provide cure in clinical T3, Fortbildungsveranstaltung Klinische Onkologie, Düsseldorf, Germany June 30, 2000
326. Radical retropubic prostatectomy, Update on pelvic oncological surgery: prevention and treatment of complications, Genoa, Italy, September 7-9, 2000
327. How to prevent and treat complications in: prostate cancer surgery: clinical case discussion, Update on pelvic oncological surgery: prevention and treatment of complications, Genoa, Italy, September 7-9, 2000
328. Prostaatkankerpreventie, Wemmel, September 20, 2000
329. Prostaatkankerpreventie, Herent, September 26, 2000
330. Surgical treatment of early prostate cancer and adjuvant treatment options, ESU teaching course, Urological trauma and onco-urology, Chisinau, Moldova, October 21, 2000
331. Urologische Oncologie, Geneesherenkring Noord-Limburg, October 26, 2000
332. Radical prostatectomy: quality control and outcome variability, 9th course Urology 2000: Yesterday, today and tomorrow, Erice, 28 November, 2000
333. Kwaliteitscontrole van radicale retropubische prostatectomie, Bosch Medisch Centrum, 'S Hertogenbosch, December 2000
334. Chemopreventie prostaatkanker, Huisartsen Tienen, December 5, 2000
335. Nerfronsparende behandeling: indicatie, techniek, pitfalls.Externe referereeravond afdeling urologie: niercelcarcinoom, AZ Maastricht, February 13, 2001
336. Oncologische casus: "Een zwelling in de lies", UZ Gasthuisberg Leuven, March 13, 2001
337. Prostaatacarcinoma, avondsymposium Integrerende Stichting voor Kankerbestrijding Vlaams Brabant (ISKA), Beersel, March 29, 2001
338. How do I do it session 3 – Nephrectomy for malignant disease, XVI th Congress of EAU, Geneva, April 7-10, 2001
339. ESU course: Partial nephrectomy, XVI th Congress of EAU, Geneva, April 7-10, 2001
340. EORTC 30904 – a surgical preference, Meeting of the EORTC, XVI th Congress of EAU, Geneva, April 7-10, 2001
341. Member of panel:The residents nightmare! An interactive debate with questions that have troubled or perplexed residents over the previous year, XVI th Congress of EAU, Geneva, April 7-10, 2001
342. Symposium Chemopreventie?, UZ Leuven, April 28, 2001
343. Traitement chirurgical du cancer de la vessie, Luxembourg, May 2, 2001
344. Zin en onzin van vroege detectie en chemopreventie van prostaatkanker, Dendermonde, May 22, 2001
345. Prostaatacarcinoma- State of the Art, Somedi Heist-op-den-Berg, June 21, 2001

346. Prostaatkanker: Interactieve sessie, Gavere, July 5, 2001
347. Is radical nefrectomy an outdated operation? ESU course at the Annual Meeting BAUS, Dublin, June 26-27, 2001
348. Session: A strategy for urological cancer follow-up – towards consensus. Annual Meeting BAUS, Dublin, June 26-27, 2001
349. Testicular Tumours, EBU, 6 th Annual European Course in Urology (AECU), Rome, September 1-5, 2001
350. Renal tumours, EBU, 6 th Annual European Course in Urology (AECU), Rome, September 1-5, 2001
351. Aanbevelingen bij diagnose, therapie en opvolging van renaal cel carcinoma, LOK Antwerpen, September 12, 2001
352. What are the limits for partial nephrectomy? Renal Cancer ESO NN Blokhin cancer research center of Russian federation. Moscow, October 9-10, 2001
353. Is adrenalectomy a part of radical nefrectomy? Renal Cancer ESO NN Blokhin cancer research center of Russian federation. Moscow, October 9-10, 2001
354. Chairman of the congress and Moderator of morning session October 9 Renal Cancer ESO NN Blokhin cancer research center of Russian federation. Moscow, October 9-10, 2001
355. Reste-t-il un avenir pour les techniques chirurgicales “classiques”? Workshop Les techniques laparoscopiques en urologie. UCL Mont Godinne Namur, October 12-13, 2001
356. Partial versus radical nephrectomy, 6th International Congress of the Dutch Urological Association, Leiden/Noordwijkerhout, The Netherlands, October 25-27, 2001
357. Radical cystectomy with or without urethrectomy? Perspectives in bladder cancer. Monte Carlo, Monaco, November 16-17, 2001
358. Zin en onzin van vroege detectie van prostaatkanker en gebruik van voedings-supplementen. Ronde tafel gesprek. AZ St. Lucas, Brugge, November 27, 2001
359. Prostaatcarcinoom: Recente inzichten in verband met vroege detectie, diagnostiek & behandeling. Medische Kring Diest en Omgeving, December 6, 2001
360. Chemische preventie prostaatkanker, Huisartsenkring West-Hageland, December 20, 2001
361. Ct3 prostate cancer: surgery or radiotherapy, Prostate Cancer: The right treatment for the right patient, Amsterdam, January 17-18, 2002
362. Troubleshooting in radical prostatectomy, ESRU meeting at the XVII th EAU Congress, Birmingham, February 23-26, 2002

363. Indications of partial nephrectomy in 2002. ESU Course at EAU Congress, Birmingham, February 25, 2002
364. Moderator Renal cell carcinoma. Section Meeting of the European Society of Oncological Urology (ESOU) at EAU congress, Birmingham, February 26, 2002
365. Postop. RT ± HoT in pT3 N0 – phase III, EORTC GU Group Spring Meeting, Vienna, 2002
366. Present status of treatment of hormone resistant prostate cancer, Atrasentan: A new treatment concept in prostate cancer, Brussels, April 15, 2002
367. Parenchymal sparing surgery. Stig Colleen 65 symposium, Lund, April 4, 2002
368. Epidemiologie en etiologie van prostaatcancer. De plaats van PSA. Pentalfa. PSA en de tijdige detectie van prostaatcancer bij mannen tussen 50 en 70 jaar, 2002
369. Is the efficacy of hormonal therapy affected by lymph node status? Innovators in Urology, Portugal June 4-6, 2002
370. Committee member of Management of disseminated prostate cancer. 3rd International consultation on Prostate Cancer, Paris, June 21-23, 2002
371. PSA en de vroegdetectie van prostaatcarcinoom. Urologisch Symposium: “Prostaatcacinoma, blaascarcinoom, een update”, Oostende, October 10, 2002
372. Surgery in renal cell carcinoma. State of the Art in the management of urological malignancies, Barcelona, November 10, 2002
373. Het uitgebreide, gemetastaseerde prostaatcarcinoom. 9de Urologisch Herfstsymposium, Prostaatcarcinoom: actuele behandeling, Hasselt, November 23, 2002
374. The surgeon who performs the radical prostatectomy matters. First meeting of the Association of Academic European Urologists (AAEU), Vienna, December 5-7, 2002
375. Hormonal treatment of prostate cancer. 8th European Winter Oncology conference, Flims, Switzerland, January 19-24, 2003
376. Is radical prostatectomy advisable?
XVIIIth EAU Congress, Barcelona, Spain, March 12-15, 2003
377. Quality control in radical prostatectomy
XVIIIth EAU Congress, Barcelona, Spain, March 12-15, 2003
378. How severe is acute and late toxicity of post-operative radiation treatment for pT3N0 prostate cancer? EORTC trial 22911
XVIIIth EAU Congress, Barcelona, Spain, March 12-15, 2003
379. Imaging for prostate cancer: The optimal use of available techniques.
XVIIIth EAU Congress, Barcelona, Spain, March 12-15, 2003
380. Technical aspects of radical prostatectomy – Retropubic
XVIIIth EAU Congress, Barcelona, Spain, March 12-15, 2003

381. Prostatectomie radicale rétro-pubienne, Cancers de la prostate actualités thérapeutiques, Grenoble, France, April 5, 2003
382. Prostate cancer and nerve sparing surgery, 13th International meeting of the European society of gynaecological oncology, Brussels, Belgium, April 6-10, 2003
383. Nieuwe kijk op behandeling van gemetastaseerde prostaatacarcinoom, LOK limburg/Vl. Brabant, Hasselt, April 23, 2003
384. New look on hormonal therapy, ESRU.be-day, La Tournette, Belgium, June 7, 2003
385. Handling and pathology reporting of renal and adrenal specimens with tumor, Florence, Italy, June 15, 2003
386. Prostate cancer management, GSK Summer Forum 2003, Genval, August 25, 2003
386. Diagnosis and staging of Renal Cell Carcinoma
EUREP meeting, Prague, Czech Republic, August 29– September 3, 2003
387. Invasive cancer surgery and combination therapy
EUREP meeting, Prague, Czech Republic, August 29– September 3, 2003
388. Prognosis and outcome of testis cancer
EUREP meeting, Prague, Czech Republic, August 29– September 3, 2003
389. Therapeutic management of penile cancer
EUREP meeting, Prague, Czech Republic, 29 August – 3 September, 2003
390. Brachytherapy for prostatic carcinoma BAU congress 2003 –Seeds, Needles and Ports in Urology, Essene, September 13, 2003
391. Vroegdetectie van prostaatkanker, MCH stichting Leuven, September 18, 2003
391. Surgical quality, prostate cancer, ECCO12 meeting, Copenhagen, September 21-25, 2003
392. Efficacy and tolerability of radiotherapy as treatment for bicalutamide induced breast pain and gynaecomastia in prostate cancer, ECCO12 meeting, Copenhagen, September 21-25, 2003
393. BCG in superficial bladder cancer, Interuniversitair Symposium, Organon, BCG in de behandeling van oppervlakkige blaastumoren, Groot-Bijgaarden, October 11, 2003
394. State of the art lecture: Prophylactic urethrectomy, 1st International Consultation on Parasitic Bladder Cancer, Sharm El-Sheikh, Egypt, October 19-22, 2003
395. Chairman podium session, 1st International Consultation on Parasitic Bladder Cancer, Sharm El-Sheikh, Egypt, October 19-22, 2003
396. Chairman Bladder Consensus Conference “Carcinoma of the bladder in the Tropics”, 1st International Consultation on Parasitic Bladder Cancer, Sharm El-Sheikh, Egypt, October 19-22, 2003
397. Press conference AstraZeneca, October 31, Brussel, 2003
Press releases in: Het Volk, 03/11/2003

Het Nieuwsblad, 03/11/2003
 De Gentenaar, 03/11/2003
 Gazet van Antwerpen, 03/11/2003
 La Nouvelle Gazette, 03/11/2003
 La Capitale, 03/11/2003
 Grenz Echo, 03/11/2003
 La Libre Belgique, 04/11/2003
 Le Soir, 05/11/2003
 La Meuse, 08/11/2003
 TV Familie, 12/11/2003
 Het Belang van Limburg 22/12/2003

398. Open vraagstelling over PSA en vroege detectie, Wijgmaal, November 28, 2003
399. Transrectal ultrasonography of the prostate: what radiologists have to know, Annual Symposium of genito-urinary imaging, Antwerpen, November 8, 2003
400. PIN – significance and management, 2nd European Urological Winter Escape meeting, Tenerife, November 30-December 3, 2003
401. Indications for prophylactic urethrectomy in 2004. 2nd European Urological Winter Escape meeting, Tenerife, November 30-December 3, 2003
402. Nephron sparing surgery for renal cell carcinoma – when and how? 2nd European Urological Winter Escape meeting, Tenerife, November 30-December 3, 2003
403. Vroegtijdige detectie prostaatkarcinoom: geen onzin, Leuvense dagen oncologie, December 11-13, 2003
404. De nieuwe kijk op hormonale therapie voor prostaatkanker. Leuvense dagen oncologie, December 11-13, 2003
405. Fatty Acid Synthase (FAS) in the development of prostate cancer, Association of Academic European Urologists (AAEU), December 11-13, 2003
406. “Prostaatkarcinoom: Diagnose & nieuwe behandelingstechnieken”, Tienen, December 16, 2003
407. Prostatectomie radicale: Quel élargissement pour l’exérèse prostatique, Le cancer de la prostate localement évolué c/p T3, Paris, January 13, 2004
408. Prostatectomie radicale + hormonothérapie néoadjuvante, Le cancer de la prostate localement évolué c/p T3, Paris January 13, 2004
409. Radicale of partiële nefrectomie voor nierkanker, Pentalfa, Leuven, January 22, 2004
410. Radical nephrectomy/lymph node dissection, BAUS section of oncology, Spring educational meeting, London, March 1-2, 2004
411. Nephron sparing surgery, the European trial, BAUS section of oncology, Spring educational meeting, London, March 1-2, 2004
412. Monti: continent en content? Prof. Elautprijs, Dendermonde, January 24, 2004

413. Is radiologische classificatie van niertumoren mogelijk en zinvol? Prof. Elautprijs, Dendermonde, January 24, 2004
414. Trouble-shooting “na partiële nefrectomie, Prof. Elautprijs, Dendermonde, January 24, 2004
415. De rol van mondmucosa bij urethrareconstructie, Prof. Elautprijs, Dendermonde, January 24, 2004
416. PUJ stenose met polair bloedvat: “to clip or not to clip”, Prof. Elautprijs, Dendermonde, January 24, 2004
417. “Calcium imaging” van de interstitiële cellen van de blaas brengt licht in de duisternis, Prof. Elautprijs, Dendermonde, January 24, 2004
418. PIN: minder onschuldig dan het lijkt, Prof. Elautprijs, Dendermonde, January 24, 2004
419. Biomechanica van zacht weefsel: preliminaire resultaten, Prof. Elautprijs, Dendermonde, January 24, 2004
420. Poster presentation: The effects of chemoprevention on PSA and clinical management in patients with high grade prostatic intraepithelial neoplasia XIXth EAU Congress, Vienna, March 24-27, 2004
421. Poster presentation: Results of a randomized trial comparing radical and partial nephrectomy for small kidney neoplasms: EORTC GU Group protocol 30904 XIXth EAU Congress, Vienna, March 24-27, 2004
422. Place of radical nephrectomy in metastatic renal cancer, XIXth EAU Congress, Vienna, March 24-27, 2004
423. Selective endothelin A receptor antagonism: Beyond HRPC, XIXth EAU Congress, Vienna, March 24-27, 2004
424. Radical prostatectomy, ESU Course, XIXth EAU Congress, Vienna, March 24-27, 2004
425. Therapeutic strategy in pT3 disease, XIXth EAU Congress, Vienna, March 24-27, 2004
426. Indications and outcome of partial nephrectomy, Refereeravond Renal Cell Cancer facing the challenges, Amsterdam, May 4, 2004
427. Tumorectomy versus partial nephrectomy, 10 th Course “Advances and controversies in urological oncology”, Erice, May 18-23, 2004
428. Implications of the Taxotere Study, Global GU Oncology Conference, Hawaii, October 2-3, 2004
429. Basic principles of oncological urology : lower tract cancers GU-meeting datamanagers/research nurses, Lago D’Orta, Italy, October 29, 2004
430. Biological Variation of Total Prostate-Specific Antigen, A Survey of Published Estimates and Consequences for Clinical Practice, Rhodos, 2005
431. Radical Prostatectomy for cT3 PrCa, Antalya, September 2005

432. Technique of open retropubic radical prostatectomy, PREX, Leuven, November 16, 2005
433. Adjuvant radiotherapy after radical prostatectomy : indications, PREX, Leuven, November 18, 2005
434. New look on hormonal treatment, PREX, Leuven, November 18, 2005
435. Extended lymphadenectomy in prostate cancer, Tenerife, EUWEM, December 2005
436. What is the Evidence for Benefit from Radiation After Prostatectomy: the EORTC Phase III Adjuvant Trial, SUO meeting Bethesda, December 2-3, 2005
437. Prostate cancer - localized, EPROFEX, January 14-15, 2005
438. Partial nephrectomy for RCC, 3rd Meeting of the ESOU, Brussels, January 2006
439. Open surgery, 3rd Meeting of the ESOU, Brussels, January 2006
440. Kidney cancer, 3rd Meeting of the ESOU, Brussels, January 2006
441. Update on surgical techniques and outcome results, Esmo International Symposium, Antwerp, March 2006
442. Kidney cancer, 15th European Urological Winter Forum, Davos, February 11, 2006
443. Recent progress in the medical management of HRPc, 15th European Urological Winter Forum, Davos, February 12, 2006
444. The current role of open surgery for urological pathologies, 15th European Urological Winter Forum, Davos, February 15, 2006
445. The rationale for early hormonal treatment of locally advanced prostate cancer, 15th European Urological Winter Forum, Davos, February 15, 2006
446. Vroege detectie en PSA: nieuwe inzichten, Informatienamiddag Prostaatcentrum Maria Middelaers Gent, March 14, 2006
447. Place of Open Surgery in Uro-Oncology, BJU International Visiting Professorship, Cardiff, April 27, 2006
448. Surgery for cT3 Prostate Cancer, BJU International Visiting Professorship, Cardiff, April 27, 2006
449. EBU Board Meeting/UEMS Section of Urology, Status Report European School of Urology, Stockholm Slussen, Sweden, May 6, 2006
450. Kidney tumour resection with use of TachoSil as haemostatic treatment, Wetenschappelijke Meeting, Nycomed, Brussels, May 16, 2006
451. Update prostaatcancer screening, AZ Heilig Hart, Tienen, May 19, 2006
452. Surgical Treatment of Muscle-Invasive Bladder Cancer
ESMO Genitourinary Cancer Symposium, Tartu Estonia, May 24, 2006
453. ESU Masterclass, Angiogenesis inhibitors for kidney cancer, Prostate Cancer – Surgery for locally advanced prostate cancer, Treatment strategy and penile

- cancer: evidence based? Oncology cases by participants, Salzburg, July 16-21, 2006
454. EUREP, Penile cancer : Epidemiology, diagnosis, staging and prognosis; treatment, Prague, September 1-6, 2006
 455. Uro-oncologisch multidisciplinair sumposium, Behandeling van gevorderde prostaatkanker:hormoon- en chemotherapie, Voorzitter van Chairmen, Inleiding, Cultureel Congrescentrum Elzenveld, Antwerp, September 9, 2006
 456. EAU Board Meeting, Education Office (ESU) – Minutes ESU brainstorming meeting, Paris, September 11, 2006
 457. Targeted therapy with sorafenib, a novel orally active multi-kinase inhibitor, in renal cell cancer, BAU 2006, Liège, September 22-23, 2006
 458. EBU Fall Meeting, Chairman: Superficial Bladder Cancer, Lecture: Treatment of Pt1 G3 disease, Tbilisi, Georgia, October 6, 2006
 459. Angioneese, LOK-groep 879 UZ Leuven, October 16, 2006
 460. Prostaatkanker : terug naar af? AZ Sint-Lucas, Provinciaal Hof, Brugge, October 17, 2006
 461. Alles wat u wilt weten over de prostaat: Anatomie-fysiologie, Therapie vroeg stadium prostaatkanker : open radicale prostatectomie, Vraagstelling & discussie, Campus Gasthuisberg, Leuven ,October 19, 2006
 462. Basic principles of oncological urology : lower tract cancers (peniscarcinoma)
 463. EORTC GU Group Meeting, Amsterdam, October 12-14, 2006
 464. Symposium Urology Beyond Boundaries, Point-Counterpoint: Laparoscopic versus open urological surgery (panel), Nijmegen, October 26 – 27, 2006
 465. Is there a role for conservative management of renal masses? 2nd World Urological Oncology Conference, Cape Town, South Africa, November 12, 2006
 466. Nephrectomy for Advanced RCC, 28th Congress of the Société Internationale d'Urologie, Cape Town, South Africa, November 16, 2006
 467. Is there still a place for open surgery in Uro-Oncology? State of the Art in Urology, International Symposium, Leuven, November 25, 2006
 468. Changing paradigms in the treatment of locally advanced prostate cancer. 13th Congress of the European Society of Surgical Oncology, Venice, December 1, 2006
 469. Renal cell carcinoma with venous involvement : determination of outcome predictors. 5th AAEU Meeting, Amsterdam, December 8, 2006
 470. The potential of RANKL inhibition in prostate cancer-induced bone disease. Satellite symposium - Introduction, European Urology Forum 2007- Challenge the experts, Davos, Switzerland, February 10-14, 2007
 471. Surgery for cT3 prostate cancer. State-of-the-art lecture 4, European Urology Forum 2007- Challenge the experts, Davos, Switzerland, February 10-14, 2007

472. Oncology cases – Panel discussion, European Urology Forum 2007- Challenge the experts, Davos, Switzerland, February 10-14, 2007
473. PSA and PCA3 in screening and early detection of Prostate Cancer, Le Meridien Hotel, Brussels, February 16, 2007
474. Phase II CS12 study results, Degarelix International Advisory Board: Shaping the future of hormonal prostate cancer treatment, NH Grand Hotel Krasnapolsky, Amsterdam, March 2, 2007
475. Hormonal treatment for localised and advanced prostate cancer, Degarelix EAU 2007, Berlin, Germany, March 21, 2007
476. Retropubic radical prostatectomy, Tips, tricks and pitfalls, ESU Course 4, EAU Congress 2007, Berlin, March 22, 2007
477. Prostate cancer and hormonal treatment, AstraZeneca Press Conference “Zolacoach program”, Sodehotel Brussels, April 25, 2007
478. Place of RFA in 2007, International Workshop on Radio-Frequency Ablation of Kidney Tumors, University Hospital UZ Leuven, April 27, 2007
479. T3 and pT3 Prostate Cancer: what to do? Challenges in Laparoscopy 2007, The European Congress of Laparoscopy 2007, Bordeaux, France, June 7-9, 2007
480. History of the Management of Bladder Cancer, SIU 2007, Paris, September 4, 2007
481. Evolution of Biopsy Methods, SIU 2007, Paris, September 6, 2007
482. Round table, Consensus meeting “Where 2 continents meet”: How to obtain early continence? Moderators: C.H. Rochat, M. Stöckle, H. Van Poppel, European Robotic Urology Symposium, 4th edition, Brussels, September 14, 2007
483. BAU-lecture: Place of surgery in locally advanced prostate cancer. European Robotic, Urology Symposium, 4th edition, Brussels, September 14, 2007
484. Prostaatanker in België, Lancering van PROGENSATM PCA3, Marriott Hotel Brussels, September 18, 2007
485. Personalized surgical treatment for localised prostate cancer, The European Society of Surgical Oncology (ESSO), ECCO, Barcelona, September 14-25, 2007
486. Poster discussion: Genitourinary cancer, chair: H. Van Poppel, ECCO 14, Barcelona, September 25, 2007
487. Educational symposium: Surgery alone for advanced prostate cancer?, ECCO 14, September 25, 2007
488. Debate: This house believes that active surveillance in patients 65 years with low-risk prostate cancer, is preferred to immediate local treatment. Speaker against: H. Van Poppel, ECCO 14, Barcelona, September 25, 2007
489. BVU Lecture: Surgical contribution to the management of cT3 prostate carcinoma, MIAOU Meeting, Château du Lac, Genval, Belgium, October 12, 2007

490. EAU 1st Eastern Mediterranean Meeting, Introduction, Antalya, Turkey, October 19, 2007
491. Management of locally advanced disease, EAU 1st Eastern Mediterranean Meeting, Antalya, Turkey, October 19, 2007
492. Poster session: Prostate cancer, EAU 1st Eastern Mediterranean Meeting, October 19, 2007
493. Laparoscopic/Robot vs Open radical prostatectomy (Pro-contra debate), EAU 1st Eastern Mediterranean Meeting, October 19, 2007
494. Is there a place for watchful waiting in early prostate cancer? EORTC GU Group Meeting, Hilton Hotel Cardiff, October 25, 2007
495. Results clinical study: PCA3 in European men scheduled for repeat biopsy, Advisory Board Meeting PCA3, Barcelona, Spain, November 1, 2007
496. Renal cell carcinoma: Surgery, Embracing Excellence in Prostate and Kidney Cancer, Barcelona, Spain, November 2-3, 2007
497. Renal cell carcinoma and minimal invasive procedures, ESU course Moscow, Russia, November 7, 2007
498. Indications et technique de la néphrectomie partielle ouverte, Journée des Urologues Francophones, AFU, Palais des Congrès, Paris, France, November 14, 2007
499. Alles wat u wilt weten over de prostaat. Anatomie-fysiologie, Therapie vroeg stadium prostaatanker: open radicale prostatectomie, Vraagstelling en discussie, UZ Leuven, Campus Gasthuisberg, Leuven, November 20, 2007
500. Moderator at the scientific program Nycomed Belgium, Brussels, November 22, 2007
501. Place de la chirurgie dans les stades cT3aN0M0 "à faible risque", 18e congrès de la Société Française de Radiothérapie oncologique Paris, Palais des congrès, November 28-30, 2007
502. European School of Urology, Welcome and introduction, 7th Annual Congress of the Belgian Association of Urology, BAU 2007, Kortrijk, Belgium, December 14-15, 2007
503. General principles of surgery in germ cell tumors, attitude regarding the contralateral testicle, attitude in case of previous surgery is still the place for surgery in the retroperitoneum? Interuniversity Postgraduate course Medical Oncology, EORTC Data Centre, Avenue Mounier 83/11, 1200 Brussels, March 8, 2008
504. State of the Art lecture, Nederland ontmoet België, Urologie over de grenzen, Vereniging Nederlandse Urologie, March 14, 2008
505. Retropubic radical prostatectomy (ESU course 4), Milan, Italy, March 27, 2008

506. What's new in Prostate Cancer? New Members Scientific Committee, General Assembly Europa Uomo, Milan, Italy, March 28, 2008
507. ESTRO, EAU presentation, H. Van Poppel & M. Wirth, Milan, Italy, March 28, 2008
508. Adjuvant Treatment Strategies, Leading lights in urology 2008, Meeting at a glance, Radisson SAS, Oslo, Norway, April 17-19, 2008
509. RCC treatment 2008, Guy's Hospital, Urology Department, London, April 23-24, 2008
510. cT3 Prostate Cancer Treatment, Guy's Hospital, Urology Department, London, April 23-24, 2008
511. Interview EOS magazine: "Prostaat: heeft screenen zin?", EOS; mei 2008; 5; 38-42
512. EBU Board of Urology – U.E.M.S. section of urology – Presentation of status reports: ESU, May 3, 2008
513. EORTC GU Group Executive Committee Meeting, Treasurer's report, Hospital del Mar, Barcelona, May 10, 2008
514. Panel Discussion: What the urologist should know about targeted treatments for renal cancer. AUA Annual Meeting, Orlando, Florida, May 18-21, 2008
515. Moderator: Adult reconstructive urology, state of the art lectures, University Hospitals Leuven, Campus Gasthuisberg, May 26, 2008
516. Prostaatkanker: wanneer en hoe behandelen? Vlaamse Liga tegen Kanker Inloophuis, Leuven, June 3, 2008
517. European School of Urology: Unique education opportunity for urologists, Bucharest, Romania, June 13, 2008
518. Partial Nx, ablative therapy and surveillance, Bucharest, Romania, June 13, 2008
519. Place of surgery in high risk and metastatic kidney cancer, Bucharest, Romania, June 13, 2008
520. e-grandround 14, European School of Oncology – Surgery of renal cell carcinoma in 2008, Expert: H. Van Poppel, Discussant: Z. Kirkaly, Videoconference, July 17, 2008.
521. Challenges for the clinicians, UICC World Cancer Congress, Geneva, Switzerland, August 31, 2008
522. Treatment of localized prostate cancer, 33rd ESMO Congress Stockholm, Sweden, September 14, 2008
523. Latest developments in prostate cancer, 33rd ESMO Congress Stockholm, Sweden, September 14, 2008
524. Co-chair proffered paper session Genitourinary tumors, 33rd ESMO Congress, Stockholm, Sweden, September 15, 2008

525. One-to-one interview with Bayer Schering Pharma, providing expert opinion on the role of sorafenib in the treatment of RCC, Stockholm International Fairs, September 15, 2008
526. Laparoscopic radical prostatectomy for locally advanced prostatic cancer: Indications and oncological principles and results – International Advanced Symposium: Laparoscopic treatment of urological pelvic cancers: prostate and bladder, Strasbourg, September 18, 2008
527. Chairman during Live Surgery: Laparoscopic transperitoneal radical prostatectomy, Robotic transperitoneal radical prostatectomy, Transperitoneal Approach, Robotic Assisted Prostatectomy - International Advanced Symposium: Laparoscopic treatment of urological pelvic cancers: prostate and bladder, Strasbourg, September 18, 2008
528. Introduction and objectives, “Oncological urology: Challenge the experts”, K-nal, Brussels, September 27, 2008
529. State of the Art Lecture, Watchful waiting for small renal masses, 19th Panhellenic Congress of Urology, Porto Carras Grand Resort, Chalkidiki, Greece, October 3, 2008
530. State of the Art Lecture, Radical cystectomy and orthotopic diversion, 19th Panhellenic Congress of Urology, Porto Carras Grand Resort, Chalkidiki, Greece, October 3, 2008
531. Small RCC today: partial nephrectomy, active surveillance or ablation, Refereeravond urologie, Niercelcarcinoom met visiting Prof Hein Van Poppel, Erasmus MC Rotterdam, Oktober 6, 2008
532. Introduction, BAU 2008, Dolce Hotel La Hulpe, Brussels, October 18, 2008
533. High risk localised RCC: Can we prevent metastatic progression and death? EORTC SORCE protocol information session during BAU 2008, Dolce Hotel La Hulpe, Brussels, October 17, 2008
534. Chairman: Localized prostate cancer: challenging the experts, BAU 2008, Dolce Hotel La Hulpe, Brussels, October 18, 2008
535. Role of urologists in systemic treatment of prostate cancer, BAU 2008, Dolce Hotel La Hulpe, Brussels, October 18, 2008
536. Prostate cancer diagnosis & Progens PCA3: quick overview, Progens PCA3 Round table for the Media, Hotel Crowne Plaza Brussels, October 29, 2008
537. Progens PCA3 proves to be superior to percent free PSA and a better predictor of the outcome of a repeat biopsy. Recent European Study demonstrates that PCA3 may be indicative of clinical stage and significance of prostate cancer. Progens PCA3, Round table for the Media, Hotel Crowne Plaza Brussels, October 29, 2008

538. One-to-one interview, Progensa PCA3 round table for the Media, Hotel Crowne Plaza Brussels, October 29, 2008
539. Partial nephrectomy: a comparison of techniques, BAUS Section of Oncology, Annual Meeting, Renal Cancer: A Time of Change, SECC Glasgow, November 14, 2008
540. Aanpak van gemetastaseerde nierkanker: stand van zaken, Tempo Medical, Update in Urology, 2008, 305, 8-12
541. De Prostaat. Fifty-One Club Leuven, Salons Georges, Hogeschoolplein 15, Leuven
542. Pentalfa-sessie: "Vroegtijdig prostaatacarcinoom. Actieve opvolging versus actieve behandeling: voor wie en hoe?" Pentalfa auditorium, UZ Leuven, Moderator: H. Van Poppel
543. Treasurer's Report, EORTC GU Group Executive Committee Meeting, Schiphol Airport Meeting Centre Amsterdam, January 21, 2009
544. Toespraak Nieuwe Voorzitter, Jaarlijkse Statutaire Vergadering van de BVU, Salons de Romrée Grimbergen, January 24, 2009
545. Sparende therapie bij het niercelcarcinoom, 3e Interdisciplinaire congres van de NVCO, NVMO en NVRO, Hotel en Congrescentrum Papendal Arnhem, Februari 6, 2009, Tekst in Oncology News pp. 3 & 5.
546. Renaalcelcarcinoom: Chirurgische aspecten, 6de Antwerpse Oncologiedag, Genito-urinaire maligniteiten; update en nieuwigheden, Congrescentrum Ter Els, Edegem, March 6, 2009
547. New concepts in the treatment of localized renal cancer, Joint session of the EAU and the CAU during the 24th Annual EAU Congress in Stockholm, March 17, 2009
548. Radical prostatectomy for T3 disease, Joint session of the EAU and the IUA during the 24th Annual EAU Congress in Stockholm, March 17, 2009
549. Plenary Session: Chair Case discussions on kidney cancer, 24th Annual EAU congress Stockholm, March 17, 2009
550. Update on prostate cancer, Steering committee meeting Europa Uomo, Stockholm, Sweden, March 18, 2009
551. State-of-the-Art-Lecture: Radical salvage prostatectomy and focal treatment 24th Annual EAU Congress, Stockholm, Sweden, March 18, 2009
552. Renal Cell Cancer - Expert Panel for EAU TV at 24th Annual EAU Congress, Stockholm, Sweden, March 19, 2009
553. ESU course 4: Retropubic radical prostatectomy, tips, tricks and pitfalls. ESU course at the time of the 24th Annual EAU Congress, Stockholm, Sweden, March 19, 2009

554. Chair Oral Session: Surgical therapy of renal cell carcinoma during the 24th Annual EAU Congress in Stockholm, March 20, 2009
555. Prostaatkanker; de open prostatectomie - Minisymposium: "Prostaatkanker en de Chirurgische Behandeling", Surf Side Marina te Aruba, April 7, 2009
556. Interview: 'Le cancer de la prostate touche près d'un homme sur dix, La Libre Belgique, March 30, 2009
557. Prognosis of positive surgical margins. Challenges in Laparoscopy & Robotics 2009, Paris, France, May 25, 2009
558. Localized T3. Which treatment? Challenges in Laparoscopy & Robotics 2009, Paris, France, May 26, 2009
559. LHRH antagonists in the management of PCa. Focal Therapy and Imaging in Prostate & Kidney Cancer, Hotels van Oranje, Noordwijk, Amsterdam, The Netherlands, June 10, 2009
560. Organ preservation to preserve organ function, Focal Therapy and Imaging in Prostate & Kidney Cancer, Hotels van Oranje, Noordwijk, Amsterdam, The Netherlands, June 12, 2009
561. An update on the surgical management of renal cancer, ESU Weill Cornell Masterclass in Urology, Salzburg, Austria, July 23, 2009
562. Medical oncology for the urologist, ESU Weill Cornell Masterclass in Urology, Salzburg, Austria, July 24, 2009
563. Open radical prostatectomy and its role in 2009: Surgical tips and techniques, ESU Weill Cornell Masterclass in Urology, Salzburg, Austria, July 24, 2009
564. Radical prostatectomy in clinical T3 disease, 10th National Prostate Cancer Symposium, The Royal Melbourne Hospital, Australia, August 19, 2009
565. Focus on clinical practice, moderator, 10th National Prostate Cancer Symposium, The Royal Melbourne Hospital, Australia, August 19, 2009
566. Localised prostate cancer, case presentation, 10th National Prostate Cancer Symposium, The Royal Melbourne Hospital, Australia, August 19, 2009
567. Significance of positive margins after radical prostatectomy, 10th National Prostate Cancer Symposium, The Royal Melbourne Hospital, Australia, August 20, 2009
568. Advanced prostate cancer, Case presentation, 10th National Prostate Cancer Symposium, The Royal Melbourne Hospital, Australia, August 20, 2009
569. Introduction of EUREP course, 7th European Urology Residents Education Programme, Prague, Czech Republic, September 28, 2009
570. GA topics: ESU, EBU, EU-ACME, 7th European Urology Residents Education Programme, Prague, Czech Republic, September 29, 2009

571. LHRH antagonisten bij de behandeling van prostaatkanker, Introductiesymposium Firmagon (Degarelix), Utrecht, The Netherlands, September 15, 2009
572. This house believes that radical surgery is better than radical therapy for locally-advanced prostate cancer. Speaker in Favour, Joint ECCO 15, 34th ESMO Multidisciplinary Congress, Berlin, Germany, September 20-24, 2009
573. cT3 Prostate cancer: Is hormone-radiotherapy the treatment of choice? EAU-ESU Forum at DGU-congress in Dresden, Germany, September 18, 2009
574. Is there a better marker than PSA? 2nd Aegean Urology Symposium "Office Urology", Crete, Greece, October 2, 2009
575. State of the Art Lecture: Surgical Management of cT3 prostatic carcinoma, 2nd Aegean Urology Symposium "Office Urology", Crete, Greece, October 3, 2009
576. Optimal treatment of locally advanced prostate cancer, 9th International Prostate Forum, Izmir, Turkey, October 9, 2009
577. Immediate adjuvant or early salvage therapy after radical prostatectomy?, 9th International Prostate Forum, Izmir, Turkey, October 9, 2009
578. Surgical tips, prostate cancer, 30th Congress of the SIU, Shanghai, November 2, 2009
579. Debate: Open vs. Lap/Robotic Partial Nephrectomy: Indications/Contraindications and Outcomes: Open, 30th Congress of the SIU, Shanghai, November 3, 2009
580. What are the results of surgery? Round table session: Optimal treatment of locally advanced prostate cancer, EMUC Barcelona, Spain, November 27, 2009
581. Round table session: Rising PSA after treatment with curative intent (moderator), EMUC Barcelona, Spain, November 27, 2009
582. Debate: The future of radical cystectomy is robotic surgery (moderator), EMUC Barcelona, Spain, November 27, 2009
583. Shift in paradigm in RPE: from T2 to T3, 7th meeting of the EAU Section of Oncological Urology (ESOU), January 15, 2010
584. Renal cancer, part 1, chair, 7th meeting of the EAU Section of Oncological Urology (ESOU), January 17, 2010
585. Significance of positive surgical margins in radical prostatectomy. 21st International congress on anti-cancer treatment, Palais des Congrès de Paris, France, February 2, 2010
586. Is radiotherapy and hormones the treatment of choice for locally and advanced prostate cancer? 21st International congress on anti-cancer treatment, Palais des Congrès de Paris, France, February 2, 2010
587. Prostate cancer: the cancer of elderly people. 21st ICACT: Session Oncogériatrie, Palais des Congrès de Paris, France, February 3, 2010

588. What hope do new therapies bring to the treatment of RCC? Renal Cell Carcinoma. Where do we stand in 2010? Auditorio Agostinho da Silva, Lisboa, February 20, 2010
589. Localized, locally advanced and disseminated carcinoma. Treatment, prognosis and economic considerations. Chair. Renal Cell Carcinoma. Where do we stand in 2010? Auditorio Agostinho da Silva, Lisboa, February 20, 2010
590. General Session VII: Renal Cancer-Surgical Management of Kidney Tumors. Adjuvant/Neoadjuvant Strategies Integrating Surgery and Targeted Therapies, Genitourinary Cancers Symposium, San Francisco Marriott, California, March 7, 2010
591. Will open surgery remain the gold standard in kidney cancer surgery? BeNeLug Days, K.U.Leuven, March 12, 2010
592. Welcome at the 3rd International Workshop on RFA of Kidney Tumors, University Hospitals Leuven, April 2, 2010
593. Role and extent of lymphadenectomy in kidney cancer, Joint session of the European Association of Urology and the Indonesian Urological Association, 25th Anniversary EAU Congress, April 16, 2010
594. Case discussion: Locally advanced prostate cancer, Surgery or hormonoradiotherapy, 25th Anniversary EAU Congress, April 16, 2010
595. Treatment of localized disease, ICUD-EAU International Consultation on Kidney Cancer 2010, 25th Anniversary EAU Congress, April 16, 2010
596. Partial nephrectomy: Where are te limits? Joint session of the European Association of Urology and the Arab Association of Urology, 25th Anniversary EAU Congress, April 16, 2010
597. Clinical importance and therapeutic consequences, Precancerous lesions of the urogenital organs, Meeting of the EAU Section of Uro pathology (ESUP), 25th Anniversary EAU Congress, April 17, 2010
598. Late breaking news session (EORTC 30904), 25th Anniversary EAU Congress, April 17, 2010
599. Step by step radical retropubic prostatectomy, Treatment of complications, ESU Course 4, 25th Anniversary EAU Congress, April 18, 2010
600. Poster session, chair, 25th Anniversary EAU Congress, April 19, 2010
601. Robot surgery: Quo Vadis? Europa Uomo: Key points program, 25th Anniversary EAU Congress, April 19, 2010
602. Interview Patient Care april 2010: Waakzaam afwachten bij prostaatcarcinoom
603. To treat or not to treat? Small Tumors, 5th European International Kidney Cancer Symposium, London, May 8, 2010.

604. Is extensive lymph node dissection beneficial to bladder cancer patients?
Multidisciplinaire leezene raka pecherza moczowego, Hotel Astor, Jastrzebia Gora, Poland, June 22, 2010
605. Welcome, Symposium: The history of urology, BVU, Faculty Club Leuven, November 13, 2010
606. Is partial nephrectomy the gold standard treatment of small renal masses? Results of the EORTC prospective randomized study 30904 comparing total and partial nephrectomy, BAU 2010, 10th annual meeting, Aula Magna, Louvain-la-Neuve, December 10-11, 2010
607. Is lymph node dissection unnecessary in radical nephrectomy for RCC. 22nd International Congress on Anti-Cancer Treatment (ICACT), Palais des Congrès, Paris, France, February 1-3, 2011
608. Hormone therapies for prostate cancer, 22nd International Congress on Anti-Cancer Treatment (ICACT), Palais des Congrès, Paris, France, February 1-3, 2011
609. Lymph node dissection of RCC and TCC patients - 24th Fűvészkeri Urológus Napok, UROCARNEVAL 2011 Budapest, Hungary, February 18-19, 2011
610. Low risk prostate cancer: Active therapy avoids pitfalls, Joint Session of the European Association of Urology and The Iranian Urological Association, 26th Annual EAU Congress, Vienna, Austria, March 18, 2011
611. Abiraterone, Board Lecture Europa Uomo, 26th Annual EAU Congress, Vienna, Austria, March 19, 2011
612. Clinical management, Rare tumours and pseudotumours of the genitourinary tract: from diagnosis to clinical management. Meeting of the EAU section of Urothology (ESUP), 26th Annual EAU Congress, Vienna, March 19, 2011
613. Partial vs. radical nephrectomy for RCC (debate), moderator, Plenary session4: Organ preserving treatment of urological cancers, 26th Annual EAU congress, Vienna, March 22, 2011
614. Late breaking news session: Adjuvant radiotherapy after radical prostatectomy in patients with pathologically high risk prostate cancer: 10-year follow-up results, 26th Annual EAU Congress, Vienna, March 22, 2011
615. Wanneer moet ik radiotherapie geven na een radical prostatectomie? LOK vergadering Paal-Beringen, May 3, 2011
616. Surgery, including nephron-sparing surgery, ESO Educational Cancer Convention Lugano, May 12, 2011
617. Controversy: Locally advanced prostate cancer, Pro surgery, ESO Educational cancer convention Lugano, May 13, 2011
618. Partial nephrectomy: open or laparoscopic? Portugese Urological Meeting 2011, Ofir, Portugal, June 18, 2011

619. EAU guest lecture: The role of surgery in locally advanced prostate cancer, BAUS Liverpool, UK, June 21, 2011
620. RCC: surgery, CUEP meeting Beijing, China, July 7, 2011
621. Nieuwe medicatie in de pijn, Seminarie over prostaatkanker: aanwinsten in de behandeling van prostaatkanker, o.l.v. Prof. Dr. H. Van Poppel en Dhr. Erik Briers, St-Joris-Winge, August 20, 2011
622. Adjuvant and salvage therapies after RALP – Robotic-Assisted Radical Prostatectomy Consensus meeting, Pasadena, US, September 10, 2011
623. Cystectomy and urinary diversion, lessons learned, EAU Society Session during 34th ECCO-ESMO Congress, Stockholm, September 25, 2011
624. Closing remarks, Belgian Oncoforum meeting, Brussels, September 29, 2011
625. Is surgery an option for high risk prostate cancer? Xth Urological Forum, Leuven, October 14, 2011
626. Treating advanced prostate cancer across the disease continuum of care, XXVIIth National Congress of Urology, ROMURO 2011, Timisoara, Romania, October 27, 2011
627. Chair: Prostate cancer failing curative therapy, XXVIIth National Congress of Urology, ROMURO 2011, Timisoara, Romania, October 28, 2011
628. With renal cell cancer? XXVIIth National Congress of Urology, ROMURO 2011, Timisoara, Romania, October 29, 2011
629. Chair: poster session 9: Renal cancer, XXVIIth National Congress of Urology, ROMURO 2011, Timisoara, Romania, October 29, 2011
630. Active surveillance of prostate cancer - XXVIIth National Congress of Urology, ROMURO 2011, Timisoara, Romania, October 29, 2011
631. Debate: Laparoscopic vs. open partial nephrectomy. Open partial nephrectomy. EMUC 2011, Embracing Excellence in prostate, bladder and kidney cancer. 3rd European Multidisciplinary Meeting on Urological Cancers, Barcelona, Spain, November 3, 2011
632. Partial nephrectomy versus nephrectomy for low stage RCC. 12th Annual Meeting of the Society of Urologic Oncology in Conjunction with the World Urological Oncology Federation, Bethesda North Marriott Hotel & Conference Center Bethesda, Maryland, December 2, 2011
633. When and how to treat patients with biochemical failure? Joint session of the EAU and the IUA during the 27th Annual EAU Congress in Paris, February 24, 2012
634. ESU Course 4: Retropubic radical prostatectomy, Tips, tricks and pitfalls. 27th Annual EAU Congress in Paris, February 25, 2012
635. Debate: The relevance of co-morbidity in managing early prostate cancer. 27th Annual EAU Congress in Paris, February 28, 2012

636. Anatomie-fysiologie. Alles wat u wilt weten over de prostaat. UZ Leuven, March 13, 2012
637. Surgery for high risk locally advanced disease: Patient selection, 9th Meeting of the EAU Section of Oncological Urology (ESOU), Hamburg, Germany, April 22, 2012
638. EAU lecture: Open nephron sparing surgery: Why and how? 5th Pomeranian Uro-Oncology Meeting, May 11, 2012
639. The role of lymph node dissection in RCC. 5th Pomeranian Uro-Oncology Meeting, May 11, 2012
640. Invoordracht prostaatanker, Rotary Leuven, Salons Kesseldal, Kessel-Lo, May 22, 2012
641. Radical prostatectomy for high-risk disease: a paradigm shift, 13th Australian Prostate Cancer Conference 2012, Melbourne, Australia, July 31 – August 3, 2012
642. Farewell lecture: High-risk prostate cancer: changing paradigm for surgery? Third International Symposium State-of-the Art in Urology, Leuven, Belgium, September 15, 2012
643. Chair of the session on prostate cancer, European Prostate Cancer Awareness Day, Brussels, Belgium, September 19, 2012
644. Diseases of the prostate that are not cancer, European Prostate Cancer Awareness Day, Brussels, Belgium, September 19, 2012
645. EAU Session: Partial nephrectomy 2012: When and how? 32nd Congress of the SIU, Fukuoka, Japan, September 30, 2012
646. What is the role of lymph node dissection in locally advanced renal cell carcinoma? 32nd Congress of the SIU, Fukuoka, Japan, October 3, 2012
647. Radical prostatectomy for high risk prostate cancer: a paradigm shift, Annual meeting of the Hungarian Society of Urologists, Szeged, Hungary, October 20, 2012.
648. Surgical treatment in high risk and locally advanced disease, Symposium: Cutting Edge, Prostate Cancer, Malmö, Sweden, November 9, 2012
649. Treatment of oligometastatic RCC (Chair), Embracing Excellence in Prostate, Bladder and Kidney Cancer (EMUC), Barcelona, Spain, November 17, 2012
650. Failure of NMIBC management and/or T1G3: when to do radical cystectomy, International Workshop on Muscle Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 21, 2012
651. The rationale of prepubic urethrectomy, International Workshop on Muscle Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 22, 2012
652. How to develop a State of the Art uro-oncology care: lesson from an EBU certified uro-oncology training centre, International Workshop on Muscle

- Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 22, 2012
653. Is open partial nephrectomy a definitive treatment for small renal tumors ≤ 4 cm? International Workshop on Muscle Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 23, 2012
 654. Surgery for locally advanced prostate cancer, Visiting Professor at the Auckland City Hospital, New Zealand, November 28, 2012
 655. Welcome and introduction, Eurostars: Oncology & Continence Update Meeting, UZ Leuven Pentalfa, Belgium, December 3, 2012
 656. Surgery for high risk prostate cancer, Eurostars: Oncology & Continence Update Meeting, UZ Leuven Pentalfa, Belgium, December 3, 2012
 657. High risk locally advanced prostate cancer management, Second EAU-IUA Educational Meeting, Kish Island Uro-Oncology / Infertility Updates, Kish Island, Iran, January 25, 2013
 658. Update on the management of muscle invasive bladder cancer, 24th International Congress on Anti-Cancer Treatment (ICACT), Paris, France, February 7, 2013
 659. 'Urologic oncological surgery' at the occasion of the visit of the Surgical Club of Great Britain, University Hospitals Leuven, Belgium, March 21, 2013
 660. The place of surgery in the management of high risk prostate cancer, 28th Annual EAU Congress, Milan, March 15, 2013
 661. Specific reports on the EAU offices by the EAU Executive, EAU General Assembly, Milan, March 16, 2013
 662. Member of panel: Debate: What should be the limits of residency training? Do you have to know it all? Are there upper and lower limits, EAU Annual Congress, Milan, March 16, 2013
 663. ESU Course 4: Retropubic radical prostatectomy, Tips, tricks and pitfalls - EAU Annual Congress, Milan, March 16, 2013
 664. Changes in surgical prostate cancer management, Europa Uomo Meeting during EAU Annual Congress, Milan, March 17, 2013
 665. Debate High risk PC: Surgery vs radiation vs systemic therapy, EAU Annual Congress, Milan, March 19, 2013
 666. New therapeutic approaches in CRPC, XVIII Workshop on Oncological Urology, Braga, Portugal, April 13, 2013
 667. European Association of Urology (EAU) lecture: High risk prostate cancer: the best indication for radical prostatectomy. AUA Annual Meeting, San Diego, USA, May 7, 2013
 668. Hoog risico prostaatcarcinoom, de beste indicatie voor Chirurgie, Seminarie Leuvens Kankerinstituut, UZ Leuven, May 21, 2013

669. Prostaatcarcinoom, Nascholingsavond Geneeskundige Kring Tienen & Omgeving, Tienen, May 21, 2013
670. State-of-the-art lecture: Nephron-sparing surgery: open or laparoscopic? Visiting Professor University Medical Center, Johannes Gutenberg University, June 3, 2013
671. State-of-the-art lecture: 'Place of surgery in the treatment of high-risk prostate cancer', Visiting Professor University Medical Center, Johannes Gutenberg University, June 4, 2013
672. Navigating the new landscape in CRPC, EAU 6th leading lights in urology meeting, Lisbon, Portugal, June 6, 2013
673. Systemic treatment should be directed by urologists, EAU 6th leading lights in urology meeting, Lisbon, Portugal, June 6, 2013
674. Surgical craftsmanship, Tips and tricks, EAU 6th leading lights in urology meeting, Lisbon, Portugal, June 7, 2013
675. De beste opleiding: België – Holland: 1-0 of 0-1? Afscheidssymposium Dr. Karl Delaere, Auberge de Rousch, Heerlen, June 14, 2013
676. Treatment of localised renal cell carcinoma: technical aspects of open partial nephrectomy, role of minimally invasive techniques, role and extent of lymph node dissection in renal cancer, ESU Weill Cornell Masterclass in General Urology, Salzburg, Austria, July 10, 2013
677. High risk prostate cancer in 2013: an update, ESU Weill Cornell Masterclass in General Urology, Salzburg, Austria, July 12, 2013
678. High risk and locally advanced prostate cancer, a surgical disease? 43rd Congress of the Polish Urological Association in Jachranka, Jachranka, Poland, September 5, 2013
679. ESO e-grandround: 'Surgery for high risk prostate cancer', webcast, September 12, 2013
680. Diagnosticering van prostaatkanker, overleving. Verschillende behandelopties voor prostaatkanker. Nabehandeling van prostaatkanker, Congres 'Prostaat' Incontinentie en seksuele disfuncties na robot en retropubische radicale prostatectomie, KU Leuven Faculteit Bewegings- en Revalidatiewetenschappen, September 17, 2013
681. CRPC nieuwe behandelingen, 8ste Europese patiëntendag prostaatkanker, Universiteit Antwerpen, September 17, 2013
682. What goes wrong with the prostate (BPH and prostate cancer), European Prostate Cancer Awareness Day, Brussels, Belgium, September 25, 2013
683. Surgery in oligometastatic RCC, 1st International "State-of-the-Art" conference on prostate and kidney cancers, Amsterdam, The Netherlands, September 26, 2013

684. Is there a place for surgery in really high risk PCA? 1st International “State-of-the-Art” conference on prostate and kidney cancers, Amsterdam, The Netherlands, September 26, 2013
685. New medical treatment options in prostate cancer. EAU Session at ECCO, Amsterdam, The Netherlands, October 1, 2013
686. Update on the management of muscle invasive bladder cancer. EAU Session at ECCO, Amsterdam, The Netherlands, October 1, 2013
687. High risk prostate cancer: the best indication for radical prostatectomy? 86° Congresso Nazionale SIU, Riccione, Italy, October 7, 2013
688. Genitourinary cancer: urologist and oncologist, ESU Medical Oncology course on Genitourinary Cancer (MOGUC), Marseille, France, November 14, 2013
689. Grote stappen in de urologie. Interview in Goed Gevoel; December 2013: 96-99.
690. High risk prostate cancer: the best indication for radical prostatectomy. – CUA Annual Meeting – Beijing, China - 20 December 2013
691. Radical prostatectomy: How I do it step by step (video) – 11th Meeting of the EAU Section of Oncological Urology (ESOU) – Prague, Czech Republic – 18 January 2014
692. Kidney – 11th Meeting of the EAU Section of Oncological Urology (ESOU) – Prague, Czech Republic – 19 January 2014
693. Chair: Disaster management and prevention in uro-oncological surgery (open, robotic and lap) – 11th Meeting of the EAU Section of Oncological Urology (ESOU) – Prague, Czech Republic – 19 January 2014
694. Is nephron sparing surgery reasonable in larger renal cell carcinoma? – 25th International Congress on Anti-Cancer Treatment – Paris, France - 4 February 2014
695. High risk prostate cancer best treated with surgery – USANZ Brisbane, Australia – 17 March 2014
696. Debate: Surgery or neoadjuvant chemotherapy for invasive bladder cancer: Where is the evidence: Surgery – USANZ Brisbane, Australia – 18 March 2014
697. Nephron Sparing Surgery – USANZ Brisbane, Australia – 18 March 2014
698. Surgery in locally advanced prostate cancer: Why and how? – Joint session of the EAU and the CAU – 29th Annual EAU Congress – Stockholm, Sweden – 11 April 2014
699. ESU Course: Retropubic radical prostatectomy – Tips, tricks and pitfalls – 29th Annual EAU Congress – Stockholm, Sweden – 12 April 2014
700. Chair: Innovative approaches in urological cancers - 29th Annual EAU Congress – Stockholm, Sweden – 12 April 2014
701. Chair: 1st ESP Prostate Cancer Observatory: Innovation and care in the next 12 months - 29th Annual EAU Congress – Stockholm, Sweden – 12 April 2014

702. Indicatie, symptomen, diagnose en behandeling – 3-daagse URO-ONCO Urobel – Novotel Leuven – 29 april 2014
703. Cystectomie, Bricker, cutaneo, neoblaas en pouch – 3-daagse URO-ONCO Urobel – Novotel Leuven – 29 april 2014
704. Wat in geval van falen van de hormonale behandeling? – Infovoormiddag Prostaatkanker – Stichting Tegen Kanker – Universiteit Antwerpen, Campus Middelheim, Antwerpen – 10 mei 2014
705. Educational opportunities uro-oncology – EAU National Societies Meeting – Arnhem, The Netherlands – 6 June 2014
706. Chairman: Panel discussion on the other Educational Opportunities in EAU – Arnhem, The Netherlands – 6 June 2014
707. Nieuwe behandelingsmethoden – Prostaatkanker Actuele Inzichten – Imeldaziekenhuis Bonheiden – 13 september 2014
707. High risk and locally advanced PCA: the BEST indication for Radical Prostatectomy in the elderly – 66. Kongress der Deutschen Gesellschaft für Urologie e.V. – Düsseldorf, Germany – 2 October 2014
708. WUOF: Management of biochemical failure – Role of surgical resection – SIU – Glasgow, Scotland – 12 October 2014
709. EAU: Individualized treatment of oligo-metastatic prostate cancer – SIU – Glasgow, Scotland – 14 October 2014
710. Ischemia and renal preservation during partial nephrectomy – SIU – Glasgow, Scotland – 14 October 2014
711. Best of journals: Surgery – 6th European Multidisciplinary Meeting on Urological Cancers – Lisbon, Portugal – 15 November 2014
712. Penile Cancer – 6th European Multidisciplinary Meeting on Urological Cancers – Lisbon, Portugal – 15 November 2014
713. Announcement best unmoderated posters – 6th European Multidisciplinary Meeting on Urological Cancers – Lisbon, Portugal – 16 November 2014
714. Cardiovascular risk with ADT: differences among agents and impact for patient selection – Ferring Regional Conference of Urology Experts (FOCUS) – Abu Dhabi – 27 November 2014
715. Intermittent treatment in prostate cancer – Ferring Regional Conference of Urology Experts (FOCUS) – Abu Dhabi – 27 November 2014

716. Open partial nephrectomy – 12th Meeting of the EAU Section of Oncological Urology – 16 January 2015
717. Renal cancer table chair - 12th Meeting of the EAU Section of Oncological Urology – 17 January 2015
718. Oligometastatic renal cell carcinoma, place of surgery? – ICACT 2015, 26th International Congress on Anti-Cancer Treatment – 3 February 2015
719. Collecting duct carcinoma - ICACT 2015, 26th International Congress on Anti-Cancer Treatment – 3 February 2015
720. 2nd ESO Prostate Cancer Observatory: Innovation and care in the next 12 months. Chair & Take home messages – 30th Annual EAU Congress – Madrid, Spain – 20 March 2015
721. Joint session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA). Chair, Welcome and Introduction, Moderator: Carcinoma of the urinary bladder/upper urinary tract. - 30th Annual EAU Congress
– Madrid, Spain – 20 March 2015
722. Case discussion - Moderator: Controversies in the management of the renal mass - 30th Annual EAU Congress – Madrid, Spain – 20 March 2015
723. Plenary Session 1 - Chair: Controversies in surgical oncology in bladder and kidney
30th Annual EAU Congress – Madrid, Spain – 21 March 2015
724. ESU Course 8: Retropubic radical prostatectomy – Tips, tricks and pitfalls - 30th Annual EAU Congress – Madrid, Spain – 21 March 2015
725. State of the art lecture – Management of the urethra in muscle invasive bladder cancer – Timisoara, Romania – 3 April 2015
726. Surgery for high risk and locally advanced prostate cancer – JUA/EAU joint session - 103rd Annual Meeting of the Japanese Urological Association – Kanazawa, Japan – 19 April 2015
727. Contemporary management of CRPC – JUA Sanofi Lucn Seminar - 103rd Annual Meeting of the Japanese Urological Association – Kanazawa, Japan – 20 April 2015
728. De Mulder Lecture – 10th European International Kidney Cancer Symposium – Lyon, France – 24 April 2015
729. Case discussion – Urologic Oncology and Robotic Surgery on the beach – Miami, US – 13 May 2015
730. Point/Counterpoint: Partial vs radical nephrectomy for T1b and T2 kidney tumors - Urologic Oncology and Robotic Surgery on the beach – Miami, US – 13 May 2015

731. High Risk Prostate Cancer – BAUS Annual Meeting 2015 – Manchester, UK – 17 June 2015
732. Prostatectomía radical en cancer de próstata de alto riesgo o localmente avanzado – XVII Congreso de Urología Oncológica – 22 July 2015
733. Controversias en torno a la linfadenctomía primaria y de rescate en cancer de próstata - XVII Congreso de Urología Oncológica – 22 July 2015
734. Nefrectomía parcial siempre que sea posible? - XVII Congreso de Urología Oncológica – 24 July 2015
735. Wat als hormonale therapie niet meer werkt? – Seminarie over prostaatkanker – St. Joris-Winge – 22 augustus 2015
736. High risk progression prostate cancer and open radical prostatectomy. - XV Congress of the Russian Society of Urology “Urology in the XXI Century” – 18 September 2015
737. Special Session: High Risk and Locally Advance Prostate Cancer (Chair) - 18th ECCO – 40th ESMO European Cancer Congress Vienna, Austria, 28 September 2015
738. Nephron Sparing surgery; whenever possible. BLUG Meeting – Uccle – 15 October 2015
739. European School of Urology: Unique education opportunity for urologists – ESU course at the national congress of the Moldavian Association of Urology – Chisinau, Moldova – 23 October 2015
740. European School of Urology: A unique possibility for urological education – EMUC 2015 – Barcelona, Spain – 12 November 2015
741. Nephron sparing surgery for renal cell carcinoma: technical aspects and limits – 50th Annual Meeting of the EUA – Cairo, Egypt – 1 December 2016
742. Optimal treatment of high risk prostate cancer - 50th Annual Meeting of the EUA – Cairo, Egypt – 1 December 2016
743. Is surgery the treatment of choice for high risk prostate cancer? 49th Annual Conference of Urological Society of India – Hyderabad, India – 8 January 2016.
744. Management of small renal masses. 49th Annual Conference of Urological Society of India – Hyderabad, India – 8 January 2016.
745. Invasieve Blaastumoren – UROBEL – Lier – 12 January 2016
746. Bricker, vervangblaas, pouch – UROBEL – Lier – 12 January 2016
747. Point of view of open surgeon - ESOU16 – 13th meeting of the EAU Section of Oncological Urology – 15 January 2016, Warsaw, Poland

748. The future of radical prostatectomy: will we improve our results, will we do the same cases, will it be replaced by other therapies? - Gemeinsame Sitzung des AUO und des AK 'Prostata' der ÖGU – 23 January 2016
749. Personalized approach to oligometastatic prostate cancer – 3rd EAU-IUA Educational Meeting – Kish Island, Iran – 28 January 2016
750. Individualized approach to recurrent prostate cancer after curative treatment - 27th International Congress on Anti-Cancer Treatment – Paris – 2 February 2016
751. High risk and locally advanced prostate cancer: the case for open surgery - Innovations in diagnosis and treatment of prostate cancer – 1 April 2016 – Nis, Serbia
752. Oligometastasen bij prostaatcarcinoma: een nieuwe kleur in het palet. AZ Groeninge, Kortrijk – 14 april 2016
753. What can EAU bring for EU Bladder cancer patients – Bladder Cancer – The forgotten cancer – Hotel Renaissance, Essen Room – 20 April 2016
754. Recent views on RMC – William Guy Forbeck Research Foundation Focus Meeting – 22 April 2016 – Nashville, US
755. Instrumenten en radicale prostatectomie – Oka verpleegkundigen – UZ Leuven – 23 mei 2016.
756. Medical treatment for advanced prostate cancer – ECOP 2016 – Dubrovnik, Croatia – 21 May 2016
757. Prostate and renal cancer diagnosis and follow up - 3rd EAU Baltic meeting – Tallinn – 27 May 2016
758. EAU lecture: High risk and locally advanced prostate cancer, the case for surgery - Annual meeting of the Slovak Urological Society – Zilina, Slovakia – 16 June 2016
759. Individualized approach to oligometastatic prostate cancer - 10th Forum of Prostate Disease – Shanghai, China – 29-30 July 2016
760. Why I do believe surgery is the best first line treatment for high risk prostate cancer - Controversies in urological surgical oncology – Torino – 22 September 2016
761. How can we improve surgical results in MIBC? In conventional open surgery - Controversies in urological surgical oncology – Torino – 23 September 2016
762. Partial nephrectomy is still a case for open surgery - Controversies in urological surgical oncology – Torino – 23 September 2016
763. Challenge the EAU guidelines – EPAD, Krakow – 30 September 2016
764. Surgery for high risk prostate cancer - 14th International Prostate Forum – Antalya – 7 October 2016

765. Individualized treatment of oligometastatic disease - 14th International Prostate Forum
Antalya – 7 October 2016
766. Challenging cases in prostate cancer - 14th International Prostate Forum –
Antalya – 7 October 2016
767. Challenging the guidelines recommendations – 89th Annual SIU Congress –
Venice, Italy – 18 October 2016
768. Partial Nephrectomy for RCC: whenever possible? 3rd National Urological Surgery
Congress – Antalya, Turkey – 2-6 November 2016
769. Locally advanced and oligometastatic prostate cancer – Optimal local treatment -
Challenges in the application of Guidelines in Genitourinary Cancer Congress –
Athens, Greece – 19 November 2016
770. Metastatic Prostate Cancer – Treatment of hormone-naïve mPC with
chemotherapy - Challenges in the application of Guidelines in Genitourinary
Cancer Congress – Athens, Greece – 19 November 2016
771. Partial Nephrectomy: Whenever possible? - 8th European Multidisciplinary
Meeting
on Urological Cancers – Milan, Italy – 26 November 2016
772. Renal cancer II: Locally advanced and metastatic – 14th meeting of the EAU
Section of Oncological Urology – Barcelona, Spain – 20-22 January 2017
773. Clinical cases: Partial nephrectomy: Targeting the best approach for the best
patients – 14th meeting of the EAU Section of Oncological Urology – Barcelona,
Spain – 20-22 January 2017
774. Recent developments in the local treatment of prostate cancer – European
Urology Forum 2017 – Davos, Switzerland – 4-7 February 2017
775. What an urologist needs to know about pharmacotherapy for onco-urology:
Highlight of the EMUC meeting – European Urology Forum 2017 – Davos,
Switzerland – 4-7 February 2017
776. Debate on kidney cancer: Partial nephrectomy/tumour enucleation is better done
by robot – EAU 2017 – London, UK – 24-28 March 2017
777. Step by step radical retropubic prostatectomy – EAU 2017 – London, UK – 24-28
March 2017
778. Treatment of complications – EAU 2017 – London, UK – 24-28 March 2017
779. Outcome van partiële nefrectomie versus nefrectomie – WIN-O symposium –
ReeHorst, Ede, The Netherlands – 14 March 2017
780. Global Burden of Kidney Cancer: Are we facing an epidemic of kidney cancer? –
IKCC meeting – Warsaw, Poland – 6 April 2017
781. Do we need extended node dissection for bladder and renal cancer? – AUA Boston
– 12-16 May 2017
782. Lecture prostate cancer - 3rd ESOP ESO Advanced Masterclass in Oncology
Pharmacy – 22-26 May 2017
783. Lecture Bladder - 3rd ESOP ESO Advanced Masterclass in Oncology Pharmacy –
22-26 May 2017

784. Lecture Kidney - 3rd ESOP ESO Advanced Masterclass in Oncology Pharmacy – 22-26 May 2017
785. Lecture Testis - 3rd ESOP ESO Advanced Masterclass in Oncology Pharmacy – 22-26 May 2017
786. Lecture Penile Cancer - 3rd ESOP ESO Advanced Masterclass in Oncology Pharmacy – 22-26 May 2017
787. Nephron sparing surgery – National Congress of urology – Prishtina Kosova – 26-27 May 2017
788. Bladder cancer in the EU: viewpoint of EAU - iCPS – Bladder Cancer Europe Roundtable – Brussels, Belgium – 20 June 2017
789. How to move AJU forward - 1st Congress of Chinese Urology and Andrology Consortiums Union (CUACU); 11th Forum of Prostate Disease – Shangai – 11-13 August 2017
790. Why is surgery first choice for high-risk prostate cancer? - 1st Congress of Chinese Urology and Andrology Consortiums Union (CUACU); 11th Forum of Prostate Disease – Shangai – 11-13 August 2017
791. High risk prostate cancer – A case for initial surgery? - Annual meeting of the Taiwan Urological Association (TUA) – Kaohsiung, Taiwan – 19-20 August 2017
792. Comprehensive management in partial nephrectomy for renal tumor - Annual meeting of the Taiwan Urological Association (TUA) – Kaohsiung, Taiwan – 19-20 August 2017
793. Renal Cell Carcinoma: Nephron-sparing whenever possible? - Uro Azhar Conference: The Golden Jubilee – Cairo – 8-10 September 2017
794. High-risk prostate cancer: Surgery? - Uro Azhar Conference: The Golden Jubilee – Cairo – 8-10 September 2017
795. Das organbegrenzte Prostatakarzinom-Radikale Prostatektomie - Kölner Urologentag 2017 – Köln, Germany – 02 September 2017
796. Nephrectomia radical ou parcial. Como decider? – Porto Ass Urology 2017 – Portugal – 22-24 September 2017
797. Surgery for high-risk Prostate cancer - The First International Congress of Georgian Association of Oncological Urology – Georgia – 4-5 October 2017
798. Nephron-sparing RCC surgery whenever possible? The First International Congress of Georgian Association of Oncological Urology – Georgia – 4-5 October 2017
799. European School fo Urology: A unique possibility for urological education - 26th National Congress of Urology – Kyrenia, TRNC – 12-15 October 2017
800. Advanced prostate cancer and/or oligometastatic disease: radical surgery? - 26th National Congress of Urology – Kyrenia, TRNC – 12-15 October 2017

801. Nephron Sparing Surgery for RCC: Whenever Possible? – 37th Congresses of the Société Internationale d’Urologie (SIU) – Lisboa – 19-22 October 2017
802. How to manage treatment – surgery – ESOR – 2-3 November 2017
803. The management of early stage prostate cancer – ESOR – 2-3 November 2017
804. Nephron Sparing Surgery: Whenever possible? – 3iPathways – Brussels, Belgium – 24-26 November 2017
805. Every Prostate cancer is unique – EAPM – Belfast, Northern Ireland – 27-30 November 2017
806. The EAU Guidelines on NSS can be challenged – AAEU meeting – Dresden, Germany – 14-17 December 2017
807. Controversy: Should we address biochemical recurrence of prostate cancer asap? – EANM Focus meeting – Valencia, Spain – 1-3 February 2018

III. Live demonstrations of surgery

1. Cystectomy and prepubic urethrectomy for bladder cancer, Invitation by Prof. R. Hohenfellner, Pilot Live-operations Demonstrationen zwischen Mainz und Hannover via Medkom, Mainz, February 22, 1991
2. Radical prostatectomy for prostate cancer and radical cystoprostatectomy for bladder cancer, Invitation by Prof. G. Jakse, European School of Oncology, Aachen, March 3-4, 1994
3. Cystoprostatectomy Invitation by Prof. J. Hertle. University Clinics Munster, January 22, 1996
4. Radical prostatectomy for prostate cancer, Invitation by Dr. A. Van der Meijden, 's Hertogenbosch, February 26, 1996
5. Radical nephrectomy and prepubic urethrectomy, Invitation by Prof. G. Jakse, European School of Oncology, Aachen, March 6-8, 1996
6. Radical cystoprostatectomy + Mainz pouch, cystoprostatectomy and Bricker, radical prostatectomy, Invitation by Dr. W. Loidl, Linz, November 19-22, 1997
7. Nephrectomy, Invitation by Peter Mulders, Nijmegen, December 11, 1998
8. Retropubic radical prostatectomy, Invitation by Prof. Dr. Ettore Martini, L'Aquila, May 24, 1999
9. Adrenalectomy and Radical prostatectomy Schorn Meeting, Linz, 18 September, 1999
10. Partial Nephrectomy, 2nd Iberian Course of Urological Oncology, Barcelona, 13-15-1999
11. Partial Nephrectomy, IX Curso Internacional de Urologia, Zaragoza, January 31, 1999 - February 3, 2000
12. Radical Prostatectomy, IX Curso Internacional de Urologia, Zaragoza, January 1, 1999 – February 3, 2000

13. Open radical prostatectomy, Workshop Treatment of Localised Prostate Cancer, Jönköping, 18 February, 2000
14. Nerve sparing radical retropubic prostatectomy, Invitation by Prof. G. Jakse, Aachen, April 3rd, 2000
15. Radical prostatectomy, Den Bosch, The Netherlands, December 1, 2000
16. Radical retropubic prostatectomy for cT3 Prostate cancer, Current Controversies in the management of Genitourinary Malignancies, Marburg, October 24-26, 2002
17. Non nerve sparing radical prostatectomy, PREX, Leuven, November 17, 2005
18. Nerve sparing radical cysto-prostatectomy, PREX, Leuven, November 17, 2005
17. Partial Nephrectomy, 3rd Meeting of the ESOU, Brussels, January 2006
18. Cystectomy and orthotopic bladder reconstruction, BJU International Visiting Professorship, Cardiff, April 27, 2006
19. Radical Prostatectomy, BJU International Visiting Professorship, Cardiff, April 27, 2006
20. 2 x Partial Nephrectomy, BJU International Visiting Professorship, Cardiff, April 28, 2006
21. Cystectomy + bladdersubstitute in female, Visiting Professorship, Guy's Hospital London, April 23-24, 2008
22. Radical Prostatectomy for cT3, Visiting Professorship, Guy's Hospital London, April 23-24, 2008
23. RPLND testis cancer, Visiting Professorship Guy's Hospital London, April 23-24, 2008
24. Open Partial Nephrectomy, Hospital Vall d'Hebron, Barcelona, II Course of Urology of the Spanish Urology Association, November 13, 2008
25. Radical prostatectomy for locally advanced prostate cancer, Xth Urological Forum, Leuven, 14 October 14, 2011
26. Cystoprostatectomy, University Hospital Heidelberg, Visiting Professor, January 26, 2012
27. Open radical nephrectomy with adrenalectomy, University Hospital Heidelberg, Visiting Professor, January 26, 2012
28. Open radical prostatectomy, nerve-sparing, University Hospital Heidelberg, Visiting Professor, January 26, 2012
29. Open kidney tumor resection, University Hospital Heidelberg, Visiting Professor, January 27, 2012
30. Radical cystectomy, urinary diversion (N-pouch) and PLND, International Workshop on Muscle Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 21, 2012

31. Radical cystectomy + prepubic urethrectomy, International Workshop on Muscle Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 22, 2012
32. Partial nephrectomy, International Workshop on Muscle Invasive Bladder Cancer and Kidney Cancer, Surabaya, Indonesia, November 23, 2012
33. High-risk prostate cancer with a super-extended lymph node dissection, Eurostars: Oncology & Continence Update Meeting, UZ Leuven Pentalfa, Belgium, December 3, 2012
34. Cystoprostatectomy with diversion (2x), radical prostatectomy (2x), partial nephrectomy, Visiting Professor University Medical Center, Johannes Gutenberg University, June 2-4, 2013
35. Radical cysto-prostato-urethrectomy with Bricker diversion. Cystectomy course – Timisoara, Romania – 1 April 2015
36. Ileal neobladder: the Leuven N-pouch – Cystectomy Course – Timisoara, Romania – 2 April 2015
37. N neobladder - Controversies in urological surgical oncology – Torino – 23 September 2016
38. Open Partial Nephrectomy - Controversies in urological surgical oncology – Torino – 23 September 2016
39. Radical Cystoprostatectomy and TUR-B – Laparoscopic Trainig Center – Georgia – 5 May 2017
40. Radical Cystoprostatectomy (7 patients) – St. Luke’s Hospital – Malta – 12-14 July 2017

IV. Publications

IV. 1. First author

1. Congenital cystic adenomatoid malformation or adenomatoid hamartoma of the lung. H. Van Poppel, E. Duponselle, J. Gruwez, P. Godderis, E. Eggermont, H. Malbrain. *Acta Paediatrica Belgica* 34: 83-88, 1981
2. Axillary radical lymph node dissection for breast cancer. H. Van Poppel, P.L. Corneillie, T. Lerut, J.A. Gruwez. *Acta Chirurgica Belgica* 4: 177-184, 1981
3. Anal actinomycosis. H. Van Poppel, M.R. Christiaens. *Colo-proctology* 5: 322-326, 1981
4. Kystes congénitaux de la prostate. H. Van Poppel, H. Verduyn, R. Vereecken, P. De Geeter. *Acta Urologica Belgica* 50: 359-367, 1982
5. Hemospermia owing to utricular cyst: Embryological summary and surgical review. H. Van Poppel, R. Vereecken, P. De Geeter, H. Verduyn. *Journal of Urology* 129: 608-609, 1983

6. Ileo-ureteraler Reflux nach Harnableitung durch ein Ileum-Conduit. H. Van Poppel, R.L. Vereecken, H. Verduyn, M. D'Hoedt, B. Claes. *Der Urologe A* 22: 446-449, 1983
7. Neuro-muscular dysfunction of the lower urinary tract in Multiple Sclerosis. H. Van Poppel, R.L. Vereecken, A. Leruitte. *Paraplegia* 21: 374-379, 1983
8. Introduction to neuro-muscular dysfunction of the lower urinary tract in M.S. H. Van Poppel, R. Vereecken, A. Leruitte. In: *Actual Problems in M.S. Research*. Eds. E. Pedersen et alii. Fadl's Forlag A.S., Copenhagen, pp. 143-144, 1983
9. Neuro-urological problems in M.S., diagnosis and treatment. H. Van Poppel, P. Ketelaer, R.L. Vereecken. In: *Immunological and Clinical Aspects of Multiple Sclerosis*. Eds. R. Gonsette and P. Delmotte, M.T.P. Press Ltd. Lancaster, pp. 263-269, 1984
10. Estracyt in the treatment of advanced prostatic cancer. H. Van Poppel, I. Billiet, R.L. Vereecken, H. Verduyn. *Progr. Clin. Biol. Res.* 153: 195-198, 1984
11. L'importance du reflux iléo-rénal dans les dérivations urinaires selon Bricker. H. Van Poppel, R.L. Vereecken, H. Verduyn. *Acta Urol. Belg.* 52: 430-438, 1984
12. Pseudomonas urinary tract infections in Multiple Sclerosis. H. Van Poppel, M. Wegge, A. Van Leeuwenhoek. *J. Microbiol.* 50: 293-295, 1984
13. Interferential therapy for detrusor-hyperreflexia in Multiple Sclerosis. H. Van Poppel, P. Ketelaer, A. Van de Weerd. *Urology* 25: 607-612, 1985
14. Ciprofloxacin treatment of multiresistant urinary infections in hospitalized patients. H. Van Poppel, M. Wegge, H. Dammekens. *Chemioterapia* 4(2): 409-410, 1985
15. La splénectomie simultanée en transplantation rénale. H. Van Poppel, J.M. Gil-Vernet. *Acta Urol. Belg.* 53: 685-692, 1985
16. Bilateral renal cell carcinoma diagnosed as renal abscesses. H. Van Poppel, R.L. Vereecken, G. Wilms. *Urology* 25: 548-550, 1985
17. Clinical evaluation of ^{99m}Tc-DMSA renogram. H. Van Poppel, R. Vereecken, K. Vekemans, H. Verduyn, L. Mortelmans, M. de Roo. *Urology* 25: 413-417, 1985
18. Interferential therapy for incontinence. H. Van Poppel. *Physiotherapy* 71: 232, 1985
19. Translumbar splenectomy in human kidney transplant recipients. H. Van Poppel, J.M. Gil-Vernet, A. Caralps, C. Fernandez Jr. *J. Urol.* 134: 247-248, 1985
20. Caliceal urinary fistula in renal allotransplantation. H. Van Poppel, O. Arango, J.M. Gil-Vernet. *Eur. Urol.* 11: 277-281, 1985
21. Vessie neurologique par sclérose en plaques. H. Van Poppel. *Réadaptation - Revalidatie* 2: 21-34, 1985
22. Oral treatment of Pseudomonas induced urinary tract infections with ciprofloxacin.

- H. Van Poppel, M. Wegge, H. Dammekens, V. Chysky. *Chemotherapy* 32: 83-87, 1986
23. Ciprofloxacin in the treatment of urinary tract infections in patients with Multiple Sclerosis. H. Van Poppel, M. Wegge, H. Dammekens, V. Chysky. *Eur. J. Clin. Microbiol.* 5: 251-254, 1986
 24. Efficacy of ciprofloxacin in urinary tract infections in Multiple Sclerosis and neurogenic bladder patients. H. Van Poppel, M. Wegge. In: *Current Clinical Practice*, series 34, Ed. H.C. Neu and H. Weuta, Amsterdam, pp. 297-299, 1986
 25. Fibro-epithelial polyps of the ureter. Etiology, diagnosis, treatment and pathology. H. Van Poppel, B. Nuttin, R. Oyen, R. Stessens, B. Van Damme, H. Verduyn. *Eur. Urol.* 12: 174-179, 1986
 26. Isolated condyloma acuminatum of the bladder in a patient with Multiple Sclerosis: Etiological and pathological considerations. H. Van Poppel, R. Stessens, R. Devos and B. Van Damme. *J. Urol.* 136: 1071-1073, 1986
 27. Importance de l'urographie intraveineuse dans le diagnostic des tumeurs des voies excrétrices. H. Van Poppel, R. Oyen, L. Baert, A. Baert. *Acta Urol. Belg.* 55: 31-35, 1987
 28. Short treatment regimen of lower urinary tract infections by Pivmecillinam. H. Van Poppel, G. Boeckx, J. Braeckman, M. Doupagne, R.J. Opsomer. *Acta Urol. Belg.* 55: 479-484, 1987
 29. Bromocriptine in benign prostatic hypertrophy. A double blind study. H. Van Poppel, G. Boeckx, K.J. Westelinck, R.L. Vereecken, L. Baert. *Brit. J. Urol.* 60: 150-152, 1987
 30. Late complications of Multiple Fraction Radiotherapy for prostate cancer. H. Van Poppel, L. Vanuytsel, H. Claes, L. Baert, E. van der Schueren. In: "Verhandlungsbericht der Deutschen Gesellschaft für Urologie", 38. Tagung, Würzburg, Springer Verlag, Berlin, pp. 253-254, 1987
 31. Treatment of multi-resistant urinary tract infections in patients with Multiple Sclerosis. H. Van Poppel, L. Baert. *Pharmaceutisch Weekblad* 9(Suppl.): 76-77, 1987
 32. Bullous pemphigoid associated with renal carcinoma. H. Van Poppel, H. Aswarie, L. Baert. *Brit. J. Urol.* 61: 361, 1988
 33. Endoscopic biopsies for quantitative nerve density evaluation of the urinary bladder. H. Van Poppel, R. Stessens, L. Baert, B. Van Damme, H. Carton. *Eur. Urol.* 14: 236-239, 1988
 34. Bullöses Pemphigoid bei Hypernephrom. H. Van Poppel, H. Aswarie, L. Baert, K. Debusschere, H. Degreef. *Hautarzt* 39: 121, 1988

35. Histochemical assessment of the intrinsic innervation of the normal urinary bladder. H. Van Poppel, L. Baert, R. Stessens, M.J. Van Stapel, B. Van Damme, H. Carton. *Urol. Int.* 43: 145-148, 1988
36. Vasoactive intestinal polypeptidergic innervation of the human urinary bladder in normal and pathological conditions. H. Van Poppel, R. Stessens, L. Baert, B. Van Damme, H. Carton. *Urol. Int.* 43: 205-210, 1988
37. Diabetic cystopathy: Neuropathological examination of urinary bladder biopsies. H. Van Poppel, R. Stessens, B. Van Damme, H. Carton, L. Baert. *Eur. Urol.* 15: 128-131, 1988
38. Intraarterial embolization in combination with surgery in the management of congenital pelvic arteriovenous malformation. H. Van Poppel, H. Claes, R. Suy, G. Wilms, R. Oyen, L. Baert. *Urol. Radiol.* 10: 89-91, 1988
39. Clinical experience with ciprofloxacin in the treatment of urinary tract infections: A review. H. Van Poppel, V. Chysky, R. Hullman, L. Baert. *Infection* 16: 337-344, 1988
40. Benign mesothelioma of the epididymis. Case report. H. Van Poppel, K. Van Renterghem, H. Claes, R. Oyen, P. Moerman, L. Baert. *Urol. Int.* 43: 370-371, 1988
41. Density of innervation in the stroma and musculosa in biopsies of normal and pathological bladder. H. Van Poppel, R. Stessens, L. Baert, B. Van Damme, H. Carton. *Ann. Urol.* 23: 398-401, 1989
42. Neuropathological examination of the alterations of the intrinsic innervation in Multiple Sclerosis cystopathy. H. Van Poppel, R. Stessens, M. Lazarides, B. Van Damme, H. Carton, L. Baert. *Urol. Int.* 44: 321-326, 1989
43. Prepubic urethrectomy. H. Van Poppel, E. Strobbe, L. Baert. *J. Urol.* 142: 1536-1537, 1989
44. Urinary diversion after cystectomy for bladder cancer. H. Van Poppel, L. Baert. *Tijdschr. voor Geneesk.* 46: 417-422, 1990
45. Präpubische Urethra-Resektion. H. Van Poppel, L. Baert. *Der Urologe A* 29 (Suppl.): A22, 1990
46. Antibiotic cover of transurethral maneuvers with Ciprofloxacin and susceptibility behavior of pathogens in patients with neurogenic bladder. H. Van Poppel, P. Willemen, M. Wegge, P. Kraseman, V. Chysky, L. Baert. *Urol. Int.* 45: 342-345, 1990
47. Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer. H. Van Poppel, P.W. Werbrouck, L. Baert. *Acta Urol. Belg.* 58: 89-96, 1990
48. The percutaneous operative gastrostomy for gastric decompression in major urological surgery. H. Van Poppel, L. Baert. *J. Urol.* 145: 100-102, 1991

49. Is there a place for conservative surgery in the treatment of renal carcinoma? H. Van Poppel, H. Claes, P. Willemen, R. Oyen, L. Baert. *Brit. J. Urol.* 67: 129-131, 1991
50. Spontaneous rupture of splenomegaly due to disseminated bone metastases from prostatic carcinoma. H. Van Poppel, H. Aswarie, J. Vandenhove, L. Baert. *Brit. J. Urol.* 67: 653-661, 1991
51. Innovative technique for urethrectomy. Prepubic technique and results in 41 patients.
H. Van Poppel, L. Baert. *Prog. Clin. Biol. Res.* 370: 147-150, 1991
52. Percutaneous operative gastrostomy in the uro-oncological surgery. Operative technique and results in 53 patients. H. Van Poppel, L. Baert. *Prog. Clin. Biol. Res.* 370: 157-160, 1991
53. The present role of estramustine phosphate in advanced prostate cancer. H. Van Poppel, L. Baert. *Prog. Clin. Biol. Res.* 370: 323-341, 1991
54. Präpubische Urethrektomie. H. Van Poppel, L. Baert. *Akt. Urologie* 22: I-X, 1991
55. Transurétéro-pyélostomie pour nécrose urétérale après dérivation urinaire continente ombilicale de Mainz. H. Van Poppel, L. Baert. *Acta Urol. Belg.* 59: 17-19, 1991
56. Experience with the intraprostatic spiral. H. Van Poppel, L. Baert, H. Aswarie, L. Oyen. *Brit. J. Urol.* 68: 604-607, 1991
57. Transureteropyelostomie als Behandlung einer Ureternekrose nach kontinenten umbilikaler Harnableitung mit Mainz-pouch. H. Van Poppel, P. Nicodemus, L. Baert. *Akt. Urologie* 22: 380-382, 1991
58. Radical prostatectomy for limited prostatic carcinoma. H. Van Poppel, F. Ameye, L. Baert. *Acta Urol. Belg.* 59: 55-67, 1992
59. A mysterious cyst of the corpora cavernosa in a patient with ulcerative colitis. H. Van Poppel, P. Willemen, L. Baert. *Acta Urol. Belg.* 60: 143-145, 1992
60. The case for conservative surgery for renal cell carcinoma. H. Van Poppel, L. Baert. *Prog. Clin. Biol. Res.* 378: 133-143, 1992
61. Radical prostatectomy for localized prostate cancer. H. Van Poppel, F. Ameye, R. Oyen, W. Van de Voorde, L. Baert. *Eur. J. Surg. Oncol.* 18: 456-462 1992
62. Hormonale therapie bij het gevorderd prostaatcarcinoom. H. Van Poppel, W. Du Fossé, L. Baert. *Tijdschrift voor Geneeskunde* 48: 1382-1390, 1992
63. Diagnostische en therapeutische aanpak van het lokaal beperkte prostaatcarcinoom. H. Van Poppel, D. De Ridder, L. Baert. *Tijdschrift voor Geneeskunde* 48: 1567-1574, 1992
64. Neoadjuvant hormoneotherapy does not facilitate radical prostatectomy. H. Van Poppel, F. Ameye, R. Oyen, W. Van de Voorde, L. Baert. *Acta Urol. Belg.* 60: 73-82, 1992

65. Experience with the intraprostatic spiral. H. Van Poppel, L. Baert, H. Aswarie, R. Oyen. Yearbook of Urology 20: 139-140, 1992
66. Information on the EORTC GU Group Activities. H. Van Poppel. Acta Urol. Belg. 60: V-VII, 1992
67. Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial. H. Van Poppel, F. Van den Broucke, J. Derluyn, G. Popelier, J. Casselman, I. Billiet, L. Vanuytsel, R. Paridaens, L. Baert. J. Urol. 149: 1485-1487, 1993
68. Diagnostische en therapeutische aanpak van het lokaal beperkte prostaatcarcinoom. H. Van Poppel, D. De Ridder, L. Baert. Tijdschrift Vlaamse Vereniging Verpleegkundigen Radiotherapie en Oncologie (VVRO) 2:m 83-91, 1993
69. Lymph node staging by CT-scan before radical prostatectomy. H. Van Poppel, F. Ameye, R. Oyen, W. Van de Voorde, L. Baert. Journal de Actualidades Grupo Português Génito-Urinario EORTC 3: 21, 1993
70. Estramustine phosphate: neo-adjuvant, first and second line treatment. H. Van Poppel, L. Baert. Journal de Actualidades Grupo Português Génito-Urinario EORTC 3: 25, 1993
71. Prophylactic prepubic urethrectomy strongly recommended. H. Van Poppel. Urology Times 21(N° 6): pp. 13, 1993
72. Overview on diagnosis and treatment of urinary disorders in Multiple Sclerosis. H. Van Poppel, D. De Ridder, L. Baert. In: Symposium on Bladder, Sexual and Bowel Disorders. D. Castro and P. Ketelaer (eds.), MARCH programme, pp. 9-18, 1994
73. Accuracy of combined computerized tomography and fine needle aspiration cytology in lymph node staging of localized prostatic carcinoma. H. Van Poppel, F. Ameye, R. Oyen, W. Van de Voorde, L. Baert. J. Urol. 151: 1310-1314, 1994
74. Elective conservative surgery for renal cell carcinoma. H. Van Poppel, L. Baert. Am. Urol. Assoc. Update Series, lesson 31, vol. XIII, pp. 246-251, 1994
75. Prostaatkanker: de meest voorkomende kanker bij mannen. H. Van Poppel, R. Vandeursen, L. Baert. UZ Gezondheidsbrief 39: 6-7, 1994
76. Clinical results of radical prostatectomy. H. Van Poppel, L. Baert. Contrib. Oncol. 47: 57-72, 1994. In: Local Prostatic Carcinoma. Bolla M., Rambeaud J.J., Vincent F. (eds.). Karger, Basel, 1994
77. Palliatieve behandeling van het gevorderd prostaatcarcinoom. H. Van Poppel, L. Baert. Urologie Practikum 4,1: 13-14, 1995
78. T3pT3 prostate cancer. H. Van Poppel, R. Oyen, A. Elgamal, W. Van de Voorde, L. Baert. Urologia Polska 48: 14-19, 1995
79. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of

- prospective randomized trial. H. Van Poppel, D. De Ridder, A.A. Elgamal, W. Van de Voorde, P. Werbrouck, K. Ackaert, R. Oyen, G. Pittomvils, L. Baert and Members of the BUOS. *J. Urol.* 154: 429-434, 1995
80. Partial nephrectomy for kidney cancer. H. Van Poppel, L. Baert. *Eur. Urol. Today* 5: 7, 1995
 81. Renal fibromuscular dysplasia treated with partial nephrectomy. H. Van Poppel, J. Stragier, F. Vandenbroucke, L. Baert. *Urol. Int.* 56 (1): 36-40, 1996
 82. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. H. Van Poppel, L. Baert. *Acta Urol. Belg.* 65: 11-17, 1996
 83. Oncologie. Nieren. H. Van Poppel. In: *Urologie*. H.J. de Voogt, T.A. Boon (Red.). Wetenschappelijke Uitgeverij Bunge, Utrecht, pp. 72-81, 1996
 84. Surgical treatment of cancer of the prostate. H. Van Poppel, D. De Ridder, H. Goethuys, A.A. Elgamal, L. Baert. In: *Carcinoma of the Prostate: Innovations in Management*. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg-New York, pp. 105-124, 1996
 85. Patterns of failure in surgically treated patients. H. Van Poppel, A.A. Elgamal, H. Goethuys, D. De Ridder, W.M. Van de Voorde, R.H. Oyen, L. Baert. In: *Carcinoma of the Prostate: Innovations in Management*. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg-New York, pp. 125-137, 1996
 86. Gerandomizeerde prospectieve studies. H. Van Poppel. *Dossier Prostaatanker, Kanker Infomagazine* 33: 13, 1996
 87. Non-metastatic renal cell carcinoma. H.P. Van Poppel, B.F. Bamelis, L.V. Baert. *Curr. Op. Urol.* 6: 241-244, 1996
 88. Oncologie. Nieuren. H. Van Poppel. In: *Urologie*: Eds. H.J. de Voogt, T.A. Boon, Bunge, Utrecht, pp. 72-81, 1996
 89. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer. H. Van Poppel, J. Billen, H. Goethuys, A.A. Elgamal, M. Gerits, L. Mortelmans, N. Blanckaert, L. Baert. *Anticancer Research* 16: 2205-2208, 1996
 90. Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma. H. Van Poppel, H. Vandendriessche, K. Boel, V. Mertens, H. Goethuys, K. Haustermans, B. Van Damme, L. Baert. *J.Urol.* 158: 45-49, 1997
 91. Elective nephron-sparing surgery for renal cell carcinoma. H. Van Poppel, B. Bamelis, L. Baert. *The EBU Update Series, Volume 6, Issue 1*: 8-12, 1997
 92. Elective conservative surgery for renal carcinoma versus radical nephrectomy. H. Van Poppel. *Selected Abstract NCC Telefax news* 14-05, 1997
 93. Adjuvant treatment after radical prostatectomy: radiotherapy - hormonal manipulation. H. Van Poppel, I. De Dobbeleer, A.A. Elgamal, L. Baert. In:

- Adjuvant treatment in Urological Cancer. Eds Antoine S. Abi-Aad, MD. The Parthenon publishing group Inc. New York, pp. 81-83,1997
94. Prepubic Urethrectomy. H. Van Poppel, L. Baert. In: Innovations in Urologic Surgery. R. Hohenfellner, A. Novick, J. Fichtner (Eds). Isis Medical Media Ltd. Oxford, pp. 295-302, 1997
 95. Surgical or medical castration for prostate cancer. H. Van Poppel, L. Baert. Urofax Forum, NCC Telefax News 17-10, 1997
 96. Treatment of advanced prostate cancer. H. Van Poppel, L. Baert, L. Vanuytsel, A. Van Oosterom. Urofax Forum, NCC Telefax News 1-12, 1997
 97. Neo-adjuvante behandeling bij gelokaliseerde prostaatkanker H. Van Poppel. Uroview 18:4-6, 1998
 98. Prophylactic urethrectomy. When and how? H. Van Poppel, L. Baert. In: Carcinoma of the Bladder. Innovations in management. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg, pp. 143-153, 1998
 99. Long-term results of brachytherapy with Iridium 192 implants. H. Van Poppel, M. Van den Heuvel, Y. Lievens, E. Van Limbergen, L. Vanuytsel, L. Baert. In: Carcinoma of the Bladder. Innovations in management. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg, pp. 187-195, 1998
 100. Surgical treatment of renal cancer. Van Poppel, L. Baert. Urofax Forum. NCC Telefax News, 3-2-1998
 101. Microvascular invasion key prognostic factor after nephrectomy. H. Van Poppel. Urology Times 26 (N°5) pp 19, 1998
 102. Partial nephrectomy for renal cell carcinoma can achieve long-term tumor control Hein Van Poppel, Bruno Bamelis, Raymond Oyen and Luc Baert. Urology, Vol 160, 674-678, 1998
 103. Nephron-Sparing Surgery. H. Van Poppel and L. Baert In: Carcinoma of the Kidney and Testis, and Rare Urologic Malignancies. Innovations in Management . Eds. Z. Petrovich, L. Baert and LW. Brady. Springer-Verlag Berlin Heidelberg pp: 79-93,1999
 104. Palliative Surgical Therapy. H. Van Poppel and L. Baert. In: Carcinoma of the Kidney and Testis, and Rare Urologic Malignancies. Innovations in Management . Eds. Z. Petrovich, L. Baert and LW. Brady. Springer-Verlag Berlin Heidelberg pp: 95-109,1999
 105. Cancer prostatique: données récentes sur le PSA. H. Van Poppel, L. Baert. J.E.M.U., 20, n°2-3, 176-178, 1999
 106. De waarde van vrij PSA in de diagnostiek van prostaatkanker. H. Van Poppel. Huisarts nu, 28 ste jaargang, n° 5, 206-207,1999
 107. De behandeling van prostaatkanker. H. Van Poppel. Huisarts nu, 28 ste jaargang, n°5, 208-211, 1999

108. Current controversies Postoperative Irradiation after Radical Prostatectomy necessary? H. Van Poppel, L. Vanuytsel, Z. Petrovich, L. Baert. *European Journal of Cancer*, Vol. 35 No 13, pp 1763-1770, 1999
109. Brachytherapy with Iridium-192 for bladder cancer. Hein Van Poppel, Yolande Lievens, Eric Van Limbergen, Luc Baert. *Eur. Urology* 37, 605-608, 2000
110. Prostaatkanker, een vermijdbare doodsoorzaak. H. Van Poppel. *UZ Gezondheidsbrief*, April 2000
111. Nephron sparing surgery in renal cell carcinoma. Hein Van Poppel. *Brazilian Journal of Urology*, Vol 26(4): 342-353, 2000
112. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostatecancer. Hein Van Poppel, Hans Goethuys, Piet Callewaert, Luc Vanuytsel, Wim Van de Voorde, Luc Baert. *Eur. Urol.* :38:372-379, 2000
113. La cistectomia en el tratamiento del cancer superficial de vejiga. H. Van Poppel. In: *Tumores Vesicales Superficiales*. Eds. J. VicenteR., G. Chechile, J. Salvador. *Accion Medica*, Madrid, pp. 191-200, 2000
114. Precancerous lesions in the kidney. Hein Van Poppel, Sten Nilsson, Ferran Algaba, Ulf Bergerheim, Paola Dal Cin, Stewart Fleming, Sverker Hellsten, Ziya Kirkali, Laurence Klotz, Per Lindblad, Börje Ljungberg, Peter Mulders, Tania Roskams, Ronald K. Ross, Cheryl Walker and Peter Wersäll. *Scand. J. Urol. Nephrol. Suppl.* 205:136-165, 2000
115. Neoadjuvant hormone therapy and radical prostatectomy: The jury is still out. H. Van Poppel. *Eur. Urol.* 39 (suppl 1): 10-14, 2001
116. Quality control of radical prostatectomy: a feasibility study. H. Van Poppel, L. Collette, Z. Kirkali, M. Brausi, W. Hoekstra, D. W. Newling, M. Decoster and members of the EORTC GU Group. *European Journal of Cancer*, 37: 884-891, 2001
117. Incidental renal cell carcinoma and nephron sparing surgery. H. Van Poppel, Kurt Dilen and Luc Baert. *Curr Opin Urol* 11: 281-286, 2001
118. Current opinion on surgery and immunotherapy! Hein Van Poppel. *The Interface*, 2: 6-7, 2001
119. Hoofdstuk 7 Oncologie –Nieren. H. Van Poppel. In: *Basisboek Urologie*, Prof. Dr. T.A. Boon {red}, De Tijdstroom, Pag 72-81, 2001
120. Orgaansparende techniek bij invasieve niet-uitgebreide blaastumoren. H. Van Poppel, E. Van Limbergen. In: *Orgaansparende technieken in de oncologie*, Erik Van Limbergen, Pierre Delaere, Hein Van Poppel, Walter Van den Bogaert(eds), Kluwer, p. 59-71, 2001
121. Orgaansparende chirurgie voor nierkanker. H. Van Poppel. In: *Orgaansparende technieken in de oncologie*, Erik Van Limbergen, Pierre Delaere, Hein Van Poppel, Walter Van den Bogaert(eds), Kluwer, p. 73-87, 2001

122. Renal Cell Carcinoma. H. Van Poppel, G. Beckers and Luc Baert. In: Prognostic factors in cancer, M.K. Gospodarowicz, D.E. Henson, R.V.P. Hutter, B. O'Sullivan, L.H. Sobin, Ch Wittekind, Wiley-Liss p 609-626, 2001
123. Kan prostaatkanker voorkomen worden? H. Van Poppel. UZ Gezondheidsbrief, augustus 2001
124. Die Rolle der radikalen Prostatektomie beim cT3-Prostatakarzinom. *Radical Prostatectomy in cT3 Prostate Cancer*. H. Van Poppel, H. Goethuys, P. Callewaert, L. Vanuysel, W. Van de Voorde, L. Baert. Praxis, 90: 1623-1631, 2001
125. Neoadjuvant therapy before radical prostatectomy: impact on progression free survival. Hein Van Poppel, Hans Goethuys, Dirk De Ridder, Pieter Verleyen, Koen Ackaert, Patrick Werbrouck, Marina De Coster and Luc Baert and the members of the Belgian Uro-Oncological Study Group (BUOS). Uro-Oncology, Vol 1 pp. 301-307, 2001
126. Radical prostatectomy in patients with previous groin hernia repair using synthetic nonabsorbable mesh. H. Borchers, B. Brehmer, H. Van Poppel, G. Jakse. Urol Int; 67: 213-215, 2001
127. Troubleshooting in Radical Prostatectomy. H. Van Poppel. EAU Congress News, page 9, 2002
128. Prostatitis, een infectie van de prostaat. Hein Van Poppel, Dirk De Ridder, Guy Bogaert, Ben Van Cleynenbreugel. UZ Gezondheidsbrief nr 127, p 4-6, 2002
129. Troubleshooting in radical prostatectomy. H. Van Poppel. European Hospital, Apr./May, p 6-7, 2002
130. Ureternekrose nach Ileozökalpouch. H. Van Poppel, R. Oyen. In: Komplikationen in der Urologie. Ed. J. Steffens, P.H. Langen. Steinkopff Verlag. Pp 329-332, 2002
131. Zurückgelassenes perirenales tuch nach nierenteilresektion. H. Van Poppel, R. Oyen In: Komplikationen in der Urologie. Ed. J. Steffens, P.H. Langen. Steinkopff Verlag. Pp 354-356, 2002
132. Comment to: Intraabdomineller abszess nach zystektomie und ileum-ersatzblase. C. Doehn, A. Böhle. In: Komplikationen in der Urologie. Ed. J. Steffens, P.H. Langen. Steinkopff Verlag. Pp 315-319, 2002
133. Prostaatkankerbehandeling. H. Van Poppel. Leven, nr. 18, 2003
134. The optimal use of available techniques with reference to imaging for prostate cancer. H. Van Poppel, R. Oyen. EAU Congress News, March, 2003
135. Partial nephrectomy: the standard approach for small renal cell carcinoma? H. Van Poppel. Current opinion in urology, Vol 13: n° 6, 431-438, 2003
136. Radical cystectomy with or without urethrectomy? Hein Van Poppel, Tomas Sorgeloose. Critical reviews in oncology/hematology 47, 141-145, 2003
137. Press release: Kwart minder risico op prostaatkanker. H. Van Poppel. De Morgen, p8, July 27, 2003

138. Hoofdstuk 23: Nierparenchymkanker. H. Van Poppel en L. Baert. IN: Praktijkgids Oncologie, Kluwer Uitgevers, Uitgave 1999-2002
139. Press release: Quality of surgery not quantity matters most. Cancerfacts.com, September 22, 2003
140. Open surgical treatment of localized renal cell cancer. H. Van Poppel, F. Deroo, S. Joniau. EAU update series I:220-225, 2003
141. Hormonal treatment for prostate cancer. H. Van Poppel. Business briefing: European Pharmacotherapy, pp 60-63, 2003
142. Lycopoen en zaadlozingen. H. Van Poppel, S. Joniau. UZ Gezondheidsbrief, nr 146, pag 7-8, 2003
143. Early prostate cancer. Anti-androgen hormoontherapie voor vroege stadia van prostaatkanker? H. Van Poppel. Artsenkrant 1603, p17, 2004
144. The optimal margins in nephron-sparing surgery. Hein Van Poppel. Current opinion in Urology, 14:227-228, 2004
145. Systemisch therapie voor prostaatkanker. Deel I: Hormonale therapie. H. Van Poppel, S. Joniau, H. Van Den Bulck, R. Paridaens. Tijdschrift voor Geneeskunde, 60 nr. 20: 1597-1606
146. Effects and Side Effects of Hormonal Treatment of Prostate Cancer. H Van Poppel. Business briefing: North American Pharmacotherapy, pp 79-82, 2004
147. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. H. Van Poppel. The Canadian Journal of Urology, 12 (Supplement 1), February 2005
148. Development and validation of a new questionnaire to assess gynaecomastia and breast pain in patients receiving bicalutamide. Van Poppel H, Tombal B., Van Cangh P.J. European Urology Supplements 4, No. 3, pp. 80, 2005
149. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. H. Van Poppel. The Canadian Journal of Urology; 12(Supplement 1), February 2005
150. Efficacy and Tolerability of Radiotherapy as Treatment for Bicalutamide-induced Gynaecomastia and Breast Pain in Prostate Cancer. H. Van Poppel, C.J. Tyrrell, K. Haustermans, P. Van Cangh, F. Keuppens, P. Colombeau, T. Morris, L. Garside
151. Conservative vs radical surgery for renal cell carcinoma. H. Van Poppel. BJU International, 94, 766-768, 2004
152. Pentalfa: Radicale of partiële nefrectomie voor nierkanker? H. Van Poppel. Tijdschr. voor Geneeskunde, 61, nr. 8, 2005
153. Radical prostatectomy for locally advanced prostate cancer : Results of a feasibility study (EORCT 30001). H. Van Poppel, K. Vekemans, L. Da Pozzo, A. Bono, J. Kliment, R. Montironi, M. Debois, L. Collette. European Journal of Cancer 42, 1062-1067, 2006

154. Management of the urethra in the cystectomy patient. Hendrik Van Poppel.
Textbook of Bladder Cancer, Taylor & Francis, p.515 – 525, 2006
155. La cistectomía en el tratamiento del cancer superficial de vejiga. Hendrik Van Poppel. Tumores Vesicales Superficiales, Acción Médica, p. 191 – 200, 2000
156. Surgical Volume and Quality of results in prostate cancer treatment. H. Van Poppel – Interview 23 March 2007 – EAU Berlin 2007 Congress EAU – UroSource.com
157. Editorial Comment on: Tamoxifen as Prohphylaxis for Prevention of Gynaecomastia and Breast Pain Associated with Bicalutamide 150 mg Mono-therapy in Patients with Prostate Cancer: A Randomised, Placebo-Controlled, Dose-Response Study. H. Van Poppel – Eur. Urol (2007); 52: 106-115.
158. Is Surveillance an Option for the Treatment of Small Renal Masses? H. Van Poppel, S. Joniau. Eur Urol 2007; 52; 1323-1330
159. How Important Are Surgical Margins in Nephron-Sparing Surgery? H. Van Poppel, S. Joniau. Eur. Urol. Suppl. 2007; 6; 533-539
160. Chapter 3: Indications for radical prostatectomy. H. Van Poppel, C.Y. Hsu, S. Joniau. In book: Radical Prostatectomy: from open to robotic – Informa Healthcare – 23-37
161. Commentary on: Should the pT2 tumor classification for renal cell carcinoma be subdivided according to tumor size? H. Van Poppel. Nature Clinical Practice 2007; 4(12); 648-649
162. Place de la chirurgie dans les cancers de la prostate de stades cT3-4 N0M0. H. Van Poppel, S. Joniau, K. Haustermans. Cancer/Radiothérapie 2007; 11; 483-489
163. An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate Cancer. H. Van Poppel, S. Joniau. Eur Urol (2008) ; 53 ; 253-259
164. Problemen tijdens en na radicale prostatectomie. H. Van Poppel. Onco 2008; 2 (1); 15-17
165. Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker – Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer. H. Van Poppel, B. Tombal, J.J. de la Rosette, B-E. Persson, J-K. Jensen, T. Kold Olesen. Eur. Urol. 2008; 54; 805-815
166. Commentary on: Is nephron-sparing surgery as safe and effective as radical nephrectomy in patients with locally advanced RCC? H. Van Poppel. NCPU 2008; 5 (6); 296-297
167. Chapter 8g: How much margin to spare in partial nephrectomy. H. Van Poppel, R. Van Reusel. Renal Cell Cancer, Diagnosis and therapy (Springer) – Editors: J.M.C.H. De La Rosette, C.N. Sternberg, H. Van Poppel; 229-235
168. Neoadjuvant and Adjuvant Hormone Therapy: How and When? H. Van Poppel. Eur Urol 2008; doi:10.1016/j.eursup.2008.09.001

169. Treatment of advanced and metastatic renal cancer: A revolution? H. Van Poppel. *Eur Urol Suppl.* 2009;8; 483-488
170. Is Radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy? H. Van Poppel. *Eur Urol* 2009; 55; 1012-1013
171. Vaccine Therapy in Patients with Renal Cell Carcinoma. H. Van Poppel. *Eur Urol* 2009; 55; 1333-1344
172. (Neo)adjuvant hormone therapy to radical prostatectomy. H. Van Poppel. In *Androgens and Prostate Cancer – Ets.:* R. Berges, B. Tombal – PP:145-150.
173. Wat is er nieuw in niercelcarcinoom in 2009? H. Van Poppel. *Andrologic* 2009; 5; 37-42.
174. De PCA3 test, een eenvoudige urinetest die kan helpen bij de diagnose van prostaatkanker en keuze van therapie. H. Van Poppel. *Urobel Magazine* 2009; 15/4: 20-24
175. Renal cell carcinoma in 2009. H. Van Poppel. *BJMO* 2009, 3: 145-152.
176. PSA based screening reduces the rate of prostate cancer death by 20 %. H. Van Poppel, C. Bangma. *BJMO* 2009, 3: 209-211
177. Degarelix for the treatment of hormone-sensitive prostate cancer. H. Van Poppel. *Hospital Pharmacy Europe* 2009, 47: 33-35
178. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. K. Bensalah, AJ. Pantuck, N. Rioux-Leclercq, R. Thuret, F. Montorsi, PI. Karakiewicz, N. Mottet, L. Zini, R. Bertini, L. Salomon, A. Villers, M. Soulie, L. Bellec, P. Rischmann, A. De La Taille, R. Avakian, M. Crepel, J-M. Ferriere, J-C. Bernhard, T. Dujardin, F. Pouliot, J. Rigaud, C. Pfister, B. Albouy, L. Guy, S. Joniau, H. Van Poppel, T. Lebreton, T. Culty, F. Saint, A. Zisman, O. Raz, H. Lang, R. Spie, A. Wille, J. Roigas, A. Aguilera, B. Rambeaud, LM. Pineiro, O. Nativ, R. Farfara, F. Richard, M. Roupert, C. Doehn, PJ. Bastian, SC. Muller, J. Tostain, AS. Beldegrun, J-J. Patard. *Eur Urol* 2010, 57: 466-473
179. LHRH agonists versus GnRH antagonists for the treatment of prostate cancer. H. Van Poppel. *BJMO* 2010; 4: 18-22
180. Prophylaktische präpubische Urethrektomie. H. Van Poppel, S. Joniau, G. Bogaert. *Aktuelle Urologie* 2010; 41: 137-146
181. Efficacy and safety of nephron-sparing surgery. H. Van Poppel. *International Journal of Urology* 2010; 17: 314-326
182. Evaluation of degarelix in the management of prostate cancer. H. Van Poppel. *Cancer Management and Research* 2010; 2: 39-52
183. Verschuiving van het paradigma voor radical prostatectomy: van T2 naar T3. H. Van Poppel. *Andrologic* 2010; 6:46-47

184. External beam radiotherapy for prostate cancer: do new Technologies really create a paradigm shift? H. Van Poppel. *Belg J Med Oncol* 2010; 4: 114-117
185. Lymph node dissection is not obsolete in clinically node-negative renal cell carcinoma patients. H. Van Poppel. *Eur Urol* 2011; 59: 24-25
186. A prospective, randomized EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. H. Van Poppel, L. Da Pozzo, W. Albrecht, V. Matveev, A. Bono, A. Borkowski, M. Colombel, L. Klotz, E. Skinner, T. Keane, S. Marreaud, S. Collette, R. Sylvester. *Eur Urol* 2011; 59 : 543 – 552
187. Highlights of the 2010 Genitourinary Cancers Symposium. H. Van Poppel, A. Van Baelen. *Belg J Med Oncol* 2010; 4: 189-191
188. Cardiovascular risk during hormonal treatment in patients with prostate cancer. H. Van Poppel, B. Tombal. *Cancer Management and Research* 2011;3 : 49-55
189. Treatment of localized renal cell carcinoma. H. Van Poppel, F. Becker, J.A. Cadeddu, I.S. Gill, G. Janetschek, M.A.S. Jewett, M.P. Laguna, M. Marberger, F. Montorsi, T.J. Polascik, O. Ukimura, G. Zhu. *Eur Urol* 2011; 60: 662-672.
190. Treatment of localized renal cell carcinoma. H. Van Poppel, F. Becker, J.A. Cadeddu, I.S. Gill, G. Janetschek, M.A.S. Jewett, M.P. Laguna, M. Marberger, F. Montorsi, T.J. Polascik, O. Ukimura, G. Zhu. In: *Kidney Cancer* eds. Z. Kirkali and P. Mulders. 1st EAU-ICUD International Consultation on Kidney Cancer Barcelona 2010, Edition 2011, pp 99-152.
191. Chapter 13: Chemotherapeutic agents for urologic oncology. H. Van Poppel, F. Ameye. In: *Practical Urology: Essential principles and practice*. Eds. CR. Chapple and WD. Steers, Springer-Verlag London Limited 2011, pp: 175-185
192. Is partial nephrectomy a better surgical option for the treatment of renal cell carcinoma? H. Van Poppel, H. Vandeursen. *Therapy* 2011, 8: 339-342
193. Chemoprevention of prostate cancer with nutrients and supplements. H. Van Poppel, B. Tombal. *Cancer Management and Research* 2011: 91-100
194. Prostaatkanker: een behandeling met bijwerkingen. H. Van Poppel. *Andrologic* 2011, 7: 97-99
195. Comment to “Results of expanded use of PCA3 score in a Spanish population with suspicion of prostate cancer”. H. Van Poppel. *Actas Urol Esp* 2011, 35: 597-598
196. Letter to the editor. Reply to Raguram Ganesamoni, Ravimohan Mavuduru, Mayank Mohan Agarwal’s letter to the editor re: Hendrik Van Poppel, Luigi Da Pozzo, Walter Albrecht et al. A prospective, randomized EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol* 2011, 59: 543-552

197. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. H. Van Poppel, A. Haese, M. Graefen, A. de la Taille, J. Irani, T. de Reijke, M. Remzi, M. Marberger. *BJU Int* 2011, 109: 360 – 366
198. Optimising prostate cancer management in senior adults – place of radical prostatectomy. H. Van Poppel, H. Goethuys. *Eur Urol Review* 2012, 7: 15-16
199. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. H. Van Poppel, L. Klotz. *Int J Urol* 2012: 19: 594 – 601
200. Abiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel. H. Van Poppel, S. Osanto, S. Joniau. *Clin Invest* 2012, 2: 995-1002
201. Active surveillance and focal therapy: a European perspective. H. Van Poppel, S. Joniau. Book chapter 3 in 'Imaging and Focal Therapy of Early Prostate Cancer', *Current Clinical Urology* – T.J. Polascik (ed.) – DOI 10.1007/978-1-62703-182-0_3, Springer Science
202. Open partial nephrectomy for complex tumours and > 4 cm: is it still the gold standard technique in the minimally invasive era? H. Van Poppel, S. Joniau and H. Goethuys. *Arch. Esp. Urol.* 2013, 66: 129-138
203. Update on the management of invasive bladder cancer 2012. H. Van Poppel. *UroToday.com Beyond the Abstract*, Published on 18 January 2013
204. Open partial nephrectomy for complex tumours and > 4 cm: is it still the gold standard technique in the minimally invasive era? H. Van Poppel, S. Joniau, H. Goethuys. *Arch. Esp. Urol.* 2013, 66: 129-138
205. Role of Lymphadenectomy. H. Van Poppel in *Renal Cancer: Contemporary Management*. J.A. Libertino (ed). Springer Science + Business Media New York 2013: 271-282
206. Locally advanced and high risk prostate cancer: the best indication for initial radical prostatectomy? H. Van Poppel. *Asian Journal of Urology* 2014; 1: 40-45
207. Highlights from the 13th meeting of the EAU Section of Oncological Urology. H. Van Poppel. *Belg J Med Oncol* 2016; 10: 143-146.
208. Selected highlights from the 31st European Association of Urology Annual Congress. H. Van Poppel. *Belg J Med Oncol* 2016; 10: 228-231.
209. Oligometastatic prostate cancer: Metastases directed therapy? H. Van Poppel, G. De Meerleer, S. Joniau. *Arab Journal of Urology* 2016; 179-182.
210. Nephron sparing for renal cell carcinoma: whenever possible? H. Van Poppel, S. Joniau, M Albersen. *European Urology Focus* 2 (2016) 656-659

IV.2. Co-author

1. Surgical treatment of esophageal neoplasms by Belsey approach. T. Lerut, H. Van Poppel, J.A. Gruwez. *Acta Chirurgica Belg.* 4: 367-371, 1982

2. Long-term alpha-adrenergic blocking therapy in detrusor-urethra dyssynergia. R. Vereecken, H. Van Poppel, G. Boeckx. *Eur. Urol.* 9: 167-169, 1983
3. Prostaatcarcinoma. II. Therapeutische gedragslijnen. K.K. Ang, E. van der Schueren, L. Dewit, R. Vereecken, H. Verduyn, H. Van Poppel. *Tijdschrift voor Geneeskunde* 40: 565-574, 1984
4. Seksuele problemen bij Multiple Sclerosis. R. Vermote, H. Van Poppel, J. Peuskens. In: *Handboek Seksuele Hulpverlening*, Ed. Van Loghum-Slaterus, Nederland, II.B.5.6. ver. 1-10, 1986
5. De conservatieve behandeling van goedaardige prostaathypertrofie. I. Billiet, H. Van Poppel, L. Baert. *Tijdschrift voor Geneeskunde* 43: 803-807, 1987
6. Urologie: Behandeling van acute ziektebeelden. L. Baert, H. Van Poppel. In: *Diagnostische en Therapeutische Gids*, Univ. Pers, Leuven, pp. 319-322, 1987
7. Small bowel obstruction by intussusception in a bladder diverticulum: complication of inguinal hernia repair. L. Baert, H. Van Poppel, I. Billiet. *Brit. J. Urol.* 60: 591, 1987
8. CT demonstration of a ureterosciatic hernia. R. Oyen, J. Gielen, L. Baert, H. Van Poppel, A.L. Baert. *Urol. Radiol.* 9: 174-176, 1987
9. Laser in de urologie. L. Baert, A. Leonard, H. Van Poppel. *Tijdschrift voor Geneeskunde* 44: 45-49, 1988
10. Seminal vesical cyst and ipsilateral renal agenesis. R. Oyen, J. Gielen, H. Van Poppel, L. Baert. *Eur. J. Radiol.* 8: 122-124, 1988
11. Actual approach to cystic nephroma. I. Billiet, H. Van Poppel, L. Baert. *Eur. Urol.* 14: 280-286, 1988
12. Marked increase of *Pseudomonas aeruginosa* serotype 012 in Belgium since 1982. D. Allemeersch, J. Beumer, M. Devleeschouwer, S. De Maeyer, J. Dony, C. Godard, P. Osterrieth, A. Pithsy, P. Van Der Auwera, H. Van Poppel, G. Vreschraegen, M. Wegge. *Eur. J. Clin. Microbiol. Infect. Dis.* 7: 265-269, 1988
13. Solitary leiomyoma of the prostate. A. Leonard, L. Baert, F. Van Praet, W. Van de Voorde, H. Van Poppel, J. Lauweryns. *Brit. J. Urol.* 62: 184-185, 1988
14. Diagnostic evaluation in carcinoma of the uterine cervix: imaging methods. R. Usewils, R. Oyen, H. Degrijse, L. Baert, H. Van Poppel, J. Janssens, M. Grieten, A. De Schepper, J. Bonte. *JBR-BTR* 71: 393-401, 1988
15. Renal Thorium deposition associated with transitional cell carcinoma: Radiologic demonstration in two patients. R.H. Oyen, J.L. Gielen, H.P. Van Poppel, E.K. Verbeken, B.J. Van Damme, L.V. Baert, A.L. Baert. *Radiology* 169: 705-707, 1988
16. Second-generation Lithotripsy: a safe, non-invasive, ambulatory procedure. L. Baert, H. Claes, I. Billiet, M. D'Hallewin, H. Vandeursen, H. Van Poppel. *Urol. Int.* 44: 38-40, 1989

17. Biotyping and susceptibility behaviour of pathogens in patients treated with ciprofloxacin. C. Kraseman, H. Van Poppel, M. Wegge, V. Chysky. *J. Chemother.* 4 (Suppl.): 386-388, 1989
18. Bladder conserving treatment with interstitial implantation for invasive bladder cancer. E. Van Limbergen, H. Van Poppel. In: *Advances in Clinical Oncology, European School of Urology*, 179-184, 1989
19. Balloon dilatation of the external urethral sphincter. P. Werbrouck, L. Baert, J.E. Binard, R.K. Chiou, H. Van Poppel. *J. Am. Paraplegia Soc.* 13: 13-14, 1990
20. The urethra stent: new treatment for strictures. L. Baert, H. Van Poppel, A. Eldin. *T. Geneeskunde* 46: 1160-1162, 1990
21. Uw patiënt ondergaat een ingreep wegens gevorderd blaascarcinoma. L. Baert, H. Van Poppel. *BMA* 227: 16-17, 1990
22. Bladder tumors: aspects of an underestimated disease. E.L. Van Thillo, H. Van Poppel, L. Baert. *Verpleegkundigen en Gemeenschapszorg* 46: 219-222, 1990
23. Orchiectomy versus Zoladex® plus Flutamide in patients with metastatic prostate cancer. L. Denis and the members of the EORTC Genito-Urinary Group. *Eur. Urol.* 18(Suppl. 3): 34-40, 1990
24. Results of a double-blind randomized study: orchiectomy + anandron versus orchiectomy + placebo. G.D. Chisholm and the members of the International Anandron Study Group. In: *Recent Advances in Urological Cancers. Diagnosis and Treatment*. Ed. C. Murphy, S. Khoury, C. Chatelain, L. Denis, 1990, pp. 63-65
25. Implantation of the urethral stent for treatment of complex urethral strictures. Evaluation of the functional and radiological results. L. Baert, H. Van Poppel, P. Werbrouck. *Urol. Int.* 47: 35-39, 1991
26. Review of modern trends in the treatment of chronic bacterial prostatitis. L. Baert, H. Van Poppel, H. Vandeursen. *Infection* 19(Suppl. 3): 157-159, 1991
27. Balloon dilatation of the prostate. Critical evaluation. L. Baert, P. Werbrouck, B. Bamelis, H. Van Poppel, J.E. Binard. *Urol. Int.* 47: 74-76, 1991
28. Renal pseudotumor due to a retained perirenal sponge: CT features. M. Grieten, H. Van Poppel, L. Baert, A.L. Baert, R. Oyen. *J. Comput. Assist. Tomogr.* 16: 305-307, 1992
29. Urinoma: a complication of local infiltration of the coeliac plexus. J. Baert, H. Van Poppel, H. Vandeursen, L. Baert. *Prog. Urol.* 2: 433-435, 1992
30. Heeft de urethrastent de verwachtingen ingelost bij de behandeling van stricturen? L. Verhamme, H. Van Poppel, L. Baert. *T. Geneesk.* 48: 1082-1084, 1992
31. A pseudotumoral edema of the urinary bladder secondary to an intramural impacted ureteral lithiasis. L. Bosmans, H. Vandeursen, H. Van Poppel, L. Baert. *Acta Urol. Belg.* 60: 89-91, 1992

32. Ectopic colonic epithelium of the bladder complicated by development of an adenocarcinoma. P. Willemen, H. Van Poppel, L. Baert. *Acta Urol. Belg.* 60: 147-149, 1992
33. Valeur de la lymphadénectomie dans le cancer du rein non-métastatique. Résultats préliminaires d'une étude phase III de l'EORTC. D. Jacqmin, J.H.M. Blom, H. Van Poppel, J.M. Maréchal, W. de Riese, K. Vermeulen, R. Sylvester, et EORTC GU Group. *Progr. Urol.* 2(Suppl.): n° 4, pp. A3, 1992
34. Anatomische beschouwingen omtrent diagnose en behandeling van prostaatkanker. W. Van de Voorde, H. Van Poppel, L. Baert, R. Oyen, J. Lauweryns. *Tijdschriften voor Geneesk.* 48: 1575-1582, 1992
35. Trisomy 7 and trisomy 10 characterize subpopulations of tumor-infiltrating lymphocytes in kidney tumors and in the surrounding kidney tissue. P. Dal Cin, M.S. Aly, J. Delabie, J.L. Ceuppens, S. Van Gool, B. Van Damme, L. Baert, H. Van Poppel, H. Van den Berghe. *Proc. Natl. Acad. Sci.* 89: 9744-9748, 1992
36. Treatment of lower urinary tract dysfunction in patients with Multiple Sclerosis. C.J. Fowler, Ph. E.V. van Kerrebroeck, A. Nordenbo, H. Van Poppel. *J. Neurol. Neurosurg. Psych.* 55: 986-989, 1992
Implantation of the Urethral Stent for Treatment of Complex Urethral Strictures. L. Verhamme, L. Baert, H. Van Poppel. *Urol. Int.* 48: 471, 1992
37. Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. R.A. Janknegt, C.C. Abbou et al., L. Baert, H. Van Poppel, Roussel Cooperative Group. *J. Urol.* 149: 77-83, 1993
38. Surgical versus endoscopic treatment of non malignant uretero-ileal anastomotic strictures. F. van den Broucke, H. Van Poppel, H. Vandeursen, L. Baert. *Brit. J. Urol.* 71: 408-412, 1993
39. Long-term consequences of urethral stents. L. Baert, L. Verhamme, H. Van Poppel, H. Vandeursen, J. Baert. *J. Urol.* 150: 853-855, 1993
40. Hypervascularization of the glans penis after venous leakage and revascularization procedure. H. Claes, H. Van Poppel, L. Baert. *Acta Urol. Belg.* 61: 17-19, 1993
41. Urinary retention due to urethral metastases from rectal adenocarcinoma. E.L. Van Thillo, H. Van Poppel, L. Baert. *Acta Urol. Belg.* 61: 41-42, 1993
42. Benign hyperplastic nodules that originate in the peripheral zone of the prostate gland. R.H. Oyen, W.M. Van de Voorde, H.P. Van Poppel, P.P. Brys, F.E. Ameye, Y.M. Janssens, A.L. Baert, L.V. Baert. *Radiology* 189: 707-711, 1993
43. Total fibrotic obliteration of urethral stent. L. Verhamme, H. Van Poppel, W. Van de Voorde, L. Baert. *Brit. J. Urol.* 12: 389-390, 1993
44. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). L.J. Denis, and the Members of the EORTC GU Group. *Urology* 42: 119-130, 1993

45. Mucin-secreting adenocarcinoma of the prostate with neuro-endocrine differentiation and Paneth-like cells. W. Van de Voorde, H. Van Poppel, K. Haustermans, L. Baert, J. Lauweryns. *Am. J. Surg. Pathol.* 18(2): 200-207, 1994
46. Lymph node staging of localized prostatic carcinoma with CT and CT guided fine-needle aspiration biopsy: prospective study of 285 patients. R. Oyen, H. Van Poppel, F. Ameye, W. Van de Voorde, A.L. Baert, L. Baert. *Radiology* 190: 315-322, 1994
47. Chromosome abnormalities in benign prostatic hyperplasia. M.S. Aly, P. Dal Cin, W. Van de Voorde, H. Van Poppel, F. Ameye, L. Baert, H. Van den Berghe. *Genes, Chromosomes and Cancer* 9: 227-233, 1994
48. Hormonal treatment before radical prostatectomy. Effect on the surgery and the surgical margins. D. De Ridder, A. Elgamal, P. Werbrouck, K. Ackaert, H. Van Poppel, W. Van de Voorde, R. Oyen, L. Baert and the Members of the B.U.O.S. *Acta Urol. Belg.* 632: 61-65, 1994
49. Exophytic papillary prostatic duct adenocarcinoma with endometrioid features, occurring in the prostatic urethra after TURP. A.A. Elgamal, W. Van de Voorde, H. Van Poppel, H. Vandeursen, L. Baert, J. Lauweryns. *Urology* 43: 737-742, 1994
50. Lymph node staging by CT scan before radical prostatectomy. F. Ameye, H. Van Poppel, R. Oyen, W. Van de Voorde, L. Baert. *Acta Urol. Belg.* 62: 57, 1994
51. Radical prostatectomy for chronic bacterial prostatitis. L. Baert, H. Van Poppel. In: *Prostatitis. Etiopathology, Diagnosis and Therapy*. Eds. W. Weidner, P.O. Madsen, H.G. Schiefer. Springer Verlag. Berlin-Heidelberg, pp. 206-209, 1994
52. The use of endoprosthesis in the management of benign prostatic hyperplasia. H. Vandeursen, H. Van Poppel, L. Baert. In: *Benign Prostatic Hyperplasia. Innovations in Management*. Eds. Z. Petrovich, L. Baert. Springer Verlag. Berlin-Heidelberg, pp. 157-165, 1994
53. Immunohistochemical localization of prostate-specific markers within the accessory male sex glands of Cowper, Littré and Morgagni. A.E. Elgamal, W. Van de Voorde, H. Van Poppel, J. Lauweryns, L. Baert. *Urology* 54: 84-90, 1994
54. Nocturnal penile tumescence evaluation before and after corporeal plication for Peyronie's disease. H. Claes, H. Van Poppel, L. Baert. *Acta Urol. Belg.* 62: 57-60, 1994
55. A histopathological study of deep dorsal penile vein in venogenic impotence. H. Claes, W. Van de Voorde, S. Vandeginste, A. Gnanasakthy, H. Van Poppel, L. Baert, J. Lauweryns. *Acta Urol. Belg.* 62: 61-68, 1994
56. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. J. Verhelst, L. Denis, P. Van Vliet, H. Van Poppel, J. Braeckman, P. Van Cangh, J. Mattelaer, D. D'Hulster, Ch. Mahler. *Clin. Endocrinol.* 41: 525-530, 1994

57. External irradiation and adjuvant hormonal treatment, and postoperative irradiation in prostatic carcinoma revisited. M. Bolla, D. Gonzalez, G. Tienhoven, J.B. Dubois, P. Warde, G. Storme, J. Benier, J. Lopez Torecilla, R. Mirimanoff, H. Van Poppel. *Contrib. Oncol.* 47: 111-123. In: *Local Prostatic Carcinoma*. M. Bolla, J.J. Rambeaud, F. Vincent (Eds.), Karger, Basel, 1994
58. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. W.M. Van de Voorde, A.E. Elgamal, H.P. Van Poppel, E.K. Verbeke, L.V. Baert, J.M. Lauweryns. *Cancer* 74: 3164-3175, 1994
59. Adenocarcinoma of the rectum with a solitary metastasis to the urethra in a female. J. Stragier, H. Van Poppel, V. Mertens, K. Geboes, L. Baert. *Eur. J. Surg. Oncol.* 20: 696-697, 1994
60. Juxtaglomerular cell tumor: importance of clinical suspicion. J. Baert, B. Van Damme, R. Oyen, H. Van Poppel, L. Baert. *Urol. Int.* 54: 171-174, 1995
61. Peripherally localized benign hyperplastic nodules of the prostate. W.M. Van de Voorde, R.H. Oyen, H.P. Van Poppel, K. Woutes, L.V. Baert, J.M. Lauweryns. *Modern Pathology* 8: 46-50, 1995
62. Benign angiomyolipoma involving the renal vein and vena cava as a tumor thrombus: case report. J. Baert, B. Van Damme, R. Sciot, R. Oyen, H. Van Poppel, L. Baert. *J. Urol.* 153: 1205-1207, 1995
63. Renovasculaire hypertensie door fibromusculaire dysplasie: indicatie voor partiële nefrectomie? J. Stragier, H. Van Poppel, L. Baert. *Tijdschr. v. Geneesk.* 51: 575-581, 1995
64. The status of bladder-preserving therapeutic strategies in the management of patients with muscle-invasive bladder cancer. K. Koiso, W. Shipley, F. Keuppens, L. Baert, R. Hall, M'Liss A. Hudson, S. Khoury, Y. Kubota, H. Van Poppel. *Int. J. Urol.* 2(Suppl. 2): 49-57, 1995
65. Interim results on a randomized trial of Mitomycin-C in combination with orchiectomy for newly diagnosed metastatic prostate cancer. F. Van den Broecke, H. Van Poppel, J. Derluyn, G. Popelier, J. Casselman, I. Billiet, L. Vanuytsel, R. Paridaens, L. Baert. *Am. J. Clin. Oncol.* 18: 263-266, 1995
66. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. W.M. Van de Voorde, H.P. Van Poppel, E.K. Verbeke, R.H. Oyen, L.V. Baert, J.M. Lauweryns. *Modern Pathology* 8: 591-598, 1995
67. The new generation Siemens Multiline lithotripter tube "M": early results in ureteral calculi. Goethuys H., Winnepenninckx B., Van Poppel H., Baert L. J. *Endourol.* 10(5): 403-6, 1996

68. Het oncocytroom van de nier. B. Kimpe, P. Meylaerts, J. Van Nueten, L. Baert, H. Van Poppel. Tijdschr. v. Geneesk. 52: 1219-1222, 1996
69. Complications of radical prostatectomy. L. Baert, A.A. Elgamal, H. Van Poppel. In: Carcinoma of the Prostate. Innovations in Management. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg-New York, pp. 139-156, 1996
70. The role of PSA in the management of prostate cancer. A.A. Elgamal, Z. Petrovich, H. Van Poppel, L. Baert. In: Carcinoma of the Prostate. Innovations in Management. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg-New York, pp. 179-196, 1996
71. Hyperthermia for carcinoma of the prostate. S. Szmigielski, B. Stawarz, H. Goethuys, L. Baert, H. Van Poppel, H. Zielinski, N. Piotrkowicz, A.M. Nissar Syed, Z. Petrovich. In: Carcinoma of the Prostate. Innovations in Management. Z. Petrovich, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg-New York, pp. 327-346, 1996
72. The case against fine-needle aspiration cytology for small solid kidney tumors. H. Goethuys, H. Van Poppel, R. Oyen, L. Baert. Eur. Urol. 29: 284-287, 1996
73. del(1)(q12) in adenocarcinomas of the prostate. Heng Qi, P. Dal Cin, W. Van de Voorde, A.A. Elgamal, H. Van Poppel, L. Baert, H. Van Den Berghe. Cancer Genet. Cytogenet. 87: 79-81, 1996
74. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. A.A. Elgamal, N.L. Ectors, S. Sunardhi-Widyaputra, H.P. Van Poppel, B.J. Van Damme, L.V. Baert. J. Urol. 156: 464-468, 1996
75. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. A.A. Elgamal, F.J. Cornillie, H.P. Van Poppel, W.M. Van de Voorde, R. McCabe, L. Baert. J. Urol. 156: 1042-1049, 1996
76. Cytogenetic investigations of synchronous bilateral renal tumors. P. Dal Cin, H. Van Poppel, B. Van Damme, L. Baert, H. Van den Berghe. Cancer Genet. Cytogenet. 89: 57-60, 1996
77. Primary localized amyloidosis of the ureter. B. Van Cleynenbreugel, H. Van Poppel, R. Oyen, A. Leemans, L. Baert. Acta Urol. Belg. 64: 43-45, 1996
78. Letter to the editor: "Prostate cancer: An insight into screening and local treatment". M. Bolla, H. Van Poppel. Eur. J. Cancer 32A: 1434-1435, 1996
79. The t(1;12) (p36;q13) in a renal oncocytoma. P. Dal Cin, H. Van Poppel, R. Sciot, R. De Vos, B. Van Damme, L. Baert, H. Van den Berghe. Genes, Chromosomes and Cancer 17: 136-138, 1996

80. Screening for cancer. R.H. Oyen, H. Van Poppel, A.L. Baert. In: International Uroradiology '96. Eds. U.V. Willy, P.J. Kenney, H.S. Thomsen. FADL Publishers, Copenhagen, pp. 205-211, 1996
81. Eéndagshospitalisatie op de dienst urologie. H. Goethuys. H. Van Poppel, D. De Ridder, L. Baert. Tijdschr. voor Geneeskunde, 52 (16): 1020-1022, 1996
82. Large egg-shell-like calcified cyst in a case of renal cell carcinoma. Vandeputte, R. Oyen, H. Van Poppel. Eur. Radiol. 6, 462-464, 1996
83. Maximal androgen blockade versus total androgen suppression. H.Dumez, H. Van Poppel, L. Baert, and R. Paridaens. Acta Urol. Belg. 65(1): 49-54, 1996
84. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Thierry Pignon, Jean Claude Horiot, Michel Bolla, Hein Van Poppel, Harry Bartelink, Felicitas Roelofsen, François Pene, Andre Gerard, Nina Einhorn, Tan D. Nguyen, Martine Vanglabbeke, Pierre Scalliet. Radiotherapy and Oncology 42, 107-120, 1997
85. The time course of development of late side effects after irradiation of the prostate with multiple fractions per day. Y. Lievens, L. Vanuytsel, A. Rijnders, H. Van Poppel, E. Van der Schueren. Radiotherapy and Oncology 40: 147-152, 1996
86. Randomisierte Phase II Studie (EORTC 30944): Emp VS. EMP/VBL Chemotherapie des Hormonrefraktären Prostatakarzinoms. W. Albrecht, S. Horenblas, J.M. Marechal, G. Mickisch, A. Horwich, V. Serretta, G. Cassetta, H. Van Poppel, S. Kalman, R. Sylvester. J. Urol. Urogynäkol. Sonderheft 1/1997
87. Cell kinetic measurements in prostate cancer. K.M.G. Haustermans, I. Hofland, H. Van Poppel, R. Oyen, W. Van de Voorde, A.C. Begg, J.F. Fowler. Int. J. Radiation Oncology Biol. Phys.37(5): 1067-1070, 1997
88. Adenocarcinoma of the Prostate: Innovations in Management. Z. Petrovich, L. Baert, M.A. Bagshaw, L.W. Brady, A.Elgamal, H. Goethuys, H.P. Heilman, W.J. Kirkels, G. Lieskovsky, C.A. Perez, H. Van Poppel, R.D. Williams. Am. J. Clin. Oncol. (CCT) 20(2): 111-119, 1997
89. Identification of an enriched CD4⁺ CD8^{α++} CD8^{β+} T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. L.E. Van den Hove, S.W. Van Gool, H. Van Poppel, L. Baert, L. Coorevits, B. Van Damme, P. Dal Cin, H. Van den Berghe, J.L. Ceuppens. Int. J. Cancer 71: 178-182, 1997
90. Treatment of Metastatic Carcinoma of the Prostate. H. Goethuys, L. Baert, H. Van Poppel, G. Lieskovsky, L.W. Brady, Z. Petrovich. Am. J. Clin. Oncol. (CCT) 20(1): 40-45, 1997
91. Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. H. Teng, M. Jorissen, H. Van Poppel, E. Legius, J.J. Cassiman, H. Cuppens. Human Molecular Genetics, 6(1): 85-90, 1997

92. Impalpable invisible stage T1c Prostate Cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view. A.A. Elgamal, H.P. Van Poppel, W.M. Van de Voorde, J.A. Van Dorpe, R. Oyen, L.V. Baert. *J. Urol.* 157: 244-250, 1997
93. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T-lymphocytes in human renal cell carcinoma. L.E. Van den Hove, S.W. Van Gool, H. Van Poppel, L. Baert, L. Coorevits, B. Van Damme, J.L. Ceuppens. *Clin. Exp. Immunol.* 109: 501-509, 1997
94. Complications of radical cystectomy. L. Baert, A.A. Elgamal, H. Van Poppel. In: *Carcinoma of the Bladder. Innovations in management.* Z. Petrovitch, L. Baert, L.W. Brady (Eds.). Springer Verlag Berlin-Heidelberg, pp. 170-185, 1998
95. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term follow-up. D. De Ridder, V. Chandiramani, P. Dasgupta, H. Van Poppel, L. Baert, C.J. Fowler. *J. Urol.* 158: 2087-2092, 1997
96. Chromosome analysis in angiomyolipoma. P. Dal Cin, R. Sciot, H. Van Poppel, L. Baert, B. Van Damme, H. Van den Berghe. *Cancer Genet. Cytogenet.* 99: 132-134, 1997
97. Sarcomatoid renal cell carcinoma: case report and review of the literature. L. Staelens, H. Van Poppel, L. Vanuytsel, A. Van Oosterom, B. Van Damme, L. Baert. *Acta Urol. Belg.* 65: 39-42, 1997
98. Urinary incontinence following transurethral, transvesical and radical prostatectomy. Retrospective study of 482 patients. M. Van Kampen, W. De Weerdt, H. Van Poppel, L. Baert. *Acta Urol. Belg.* 1-7, 1997
99. From time dependent intermittent selfcatherisation to volume dependent selfcatheterisation in multiple sclerosis using the PCI 5000 Bladdermanager. De Ridder D, Van Poppel H, Baert L, Binard J. *Spinal Cord* 35 (9): 613-616, 1997
100. Management of Carcinoma of the Bladder. Z. Petrovich, L. Baert, S.D. Boyd, L. W. Brady, M. D'Hallewin, H-P. Heilmann, G. Jakse, P.A. Jones, A.P.M. Van der Meijden, R. Oyen, H. Van Poppel, M. Rotman, R. Sauer, W. Shipley, E. Skinner. *Am. J. Clin Oncol* 21(3): 217-222, 1998
101. Prediction of Urinary Incontinence following Radical Prostatectomy. Van Kampen, W. De Weerdt, H. Van Poppel, H. Feys, A. Castell Campesino, J. Stragier, L. Baert. *Urol. Int.* 60:80-84, 1998
102. Bladder Cancer in patients with multiple sclerosis treated with cyclophosphamide. De Ridder, H. Van Poppel, L. Demonty, B. D'Hooghe, R. Gonsette, H. Carton and L. Baert. *J. of Urology*, Vol. 159, 1881-1884, 1998
103. Clinical Assessment of Pelvic Floor Dysfunction in Multiple Sclerosis: Urdynamic and Neurological Correlates. De Ridder, C. Vermeulen, E. De Smet, H. Van Poppel, P. Ketelaer and L. Baert. *Neurology and Urodynamics* 17:537-542, 1998

104. Histology May depend on the presence of partial monosomy or partial trisomy 3 in renal cell carcinoma. Pierra Balzarini, Paolo Dal Cin, Tania Roskams, Pietro Polito, Hein Van Poppel, Boudewijn Van Damme, Luc Baert and Herman Van den Berghe. *Cancer Genet Cytogenet.* 105:6-10, 1998
105. The role of pelvic lymph node dissection in the management of invasive bladder cancer. William Bedford Waters, Pierfrancesco Bassi, Yoshitada Ohi, Shinichi Ohshima, Hein Van Poppel, Joseph A. Smith, Atsushi Tajima. *Urologic Oncology* 4, 168-171, 1998
106. Involvement of 12q12-13 is a Nonrandom Chromosome Change in Renal Oncocytoma” Dal Cin, H. Van den Berghe, H. Van Poppel, Tania Roskams. *Genes, Chromosomes & Cancer* 24:94, 1999
107. Pelvic Floor rehabilitation in multiple sclerosis. D. De Ridder, C. Vermeulen, P. Ketelaer, H. Van Poppel, L. Baert. *Acta Neurol. Belg.* 99: 61-64, 1999
108. Nitric oxide synthase expression in neurogenic bladder disease: a pilot study. De Ridder, T. Roskams, H. Van Poppel, L. Baert. *Acta Neurol. Belg.* 99:57-60, 1999
109. L’Echographie endorectale dans le bilan d’extension des cancers de la prostate. Oyen, G. Verswijvel, H Van Poppel, L. Baert, T. Roskams. *JEMU*, 20, n°2-3, 184-187, 1999
110. Mitomycin C for Metastatic Prostate Cancer: Final Analysis of a Randomized Trial. K. Boel, H. Van Poppel, H. Goethuys, J. Derluyn, F. Vandembroucke, G. Popelier, J. Casselman, I. Billiet, L. Vanuytsel, R. Paridaens and L. Baert. *Anticancer Research* 19:2157-2161, 1999
111. Clinical application of the Bardex IC foley catheter. P. Verleyen, D. De Ridder, H. Van Poppel, L. Baert. *Eur. Urol.* 1999; 36:240-246
112. Letter to the editor: Uncontrollable diabetes mellitus: a rare paraneoplastic manifestation of renal cell carcinoma. P. Callewaert, H. Van Poppel, D. Vanderschueren, L. Baert. *Nephrol. Dial. Transplant*, 14:2264, 1999
113. Cytogenetic Investigations of Transitional Cell Carcinomas of the Upper Urinary Tract. Paola Dal Cin, Tania Roskams, Hein Van Poppel, Pierra Balzarini and Herman Van den Berghe. *Cancer, Genetics and Cytogenetics*, 114:117-120, 1999
114. Serum Tissue Polypeptide Antigen (TPA): Monoclonal or Polyclonal Radio-Immunometric Assay for the Follow-up of Bladder Cancer. R. Bennink, H. Van Poppel, J. Billen, M. Decoster, L. Baert, L. Mortelmans, N. Blanckaert. *Anticancer Research* 19: 2609-2614, 1999
115. Tumour Markers in Prostate Cancer: EGTm Recommendations. Semjonow, W. Albrecht, P. Bialk, A. Gerl, R. Lamerz, H-P. Schmid, H. Van Poppel. *Anticancer Research* 19: 2785-2820, 1999
116. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. M. Van Kampen, W. De

- Weerdt, H. Van Poppel, D. De Ridder, H. Feys, L. Baert. *The Lancet*, Vol 355, January 8, 2000
117. Management strategies for patients with locally advanced prostate cancer. M. Gospodarowicz, M. Bolla, F. Di Silverio, R. Gibbons, A. Mendoza, D. Prezioso, H. Schulze, M. Soloway, E. Solsona, H. Van Poppel, A. Porter, J. McAninch. In: *Prostate Cancer*, G. Murphy, S. Khoury, A. Partin, L. Denis (eds.), Health Publication Ltd, UK, 2000
118. Xanthogranulomatous pyelonephritis: MRI findings in the diffuse and the focal type. G. Verswijvel, R. Oyen, H. Van Poppel, T. Roskams. *Eur. Radiol.* 10, 586-589, 2000
119. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. Peter Iversen, Chris J. Tyrrell, Amir V. Kaisary, John B. Anderson, Hein Van Poppel, Teuvo L. J. Tammela, Michael Chamberlain. *The Journal of Urology*, Vol.164, 1579-1582, November 2000
120. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Johannes V. Swinnen, Frank Vanderhoydonc, Abdelaziz A. Elgamel, Marianne Eelen, Inge Vercaeren, Steven Joniau, Hein Van Poppel, Luc Baert, Karine Goossens, Walter Heyns and Guido Verhoeven. *Int. J. Cancer*: 88, 176-179, 2000
121. Carcinoma of the Kidney, Testis and Rare Urologic Malignancies. Zbigniew Petrovich, Luc V. Baert, Luther W. Brady, Dirk J.M. K. De Ridder, Hans Goethuys, Rien Nijman, Raymond Oyen, Howard Ozer, Tania Roskams, John P. Stein, Luc Stockx, Allan Van Oosterom, Hein P. Van Poppel, Luc Vanuytsel. *Am. J. Clin. Oncol (CCT)* 23(5): 431-437, 2000
122. Radiotherapy for PSA Recurrence after Radical Prostatectomy. Luc Vanuytsel, Geert Janssens, Hein Van Poppel, Alex Rijnders, Luc Baert. *Eur Urol*, 39:425-429, 2001
123. Renal Cancer. D. Jacqmin, H. Van Poppel, Z. Kirkali, G. Mickisch. *Eur Urol*, 39/3 (Curric Urol 6.8:1-9), 2001
124. De strijd tegen prostaatkanker gaat onverminderd voort. P. Callewaert, Hein Van Poppel, Luc Baert. *UZ Gezondheidsbrief*, nr 112, 2001
125. Chapter 33: Radiotherapy and Hyperthermia. Hans Goethuys, Luc Vanuytsel, Hein Van Poppel, Raymond H. Oyen, Zbigniew Petrovich and Luc Baert. In: *Radiotherapy of prostate Cancer*. Carlo Greco, Michael J. Zelefsky{eds}. Harwood academic publishers, pp 393-401, 2000
126. Chapter 41: Adjuvant radiotherapy following radical prostatectomy. Luc Vanuytsel and Hein Van Poppel. In: *Radiotherapy of prostate Cancer*. Carlo Greco, Michael J. Zelefsky{eds}. Harwood academic publishers, pp 377-384, 2000

127. Guidelines on prostate cancer. G. Aus, CC Abbou, D. Pacik, H-P Schmid, H. Van Poppel, J.M. Wolff, F. Zattoni. In: EAU Guidelines, 2001
128. Chapter 18: Prostate Disease. Luc V. M. Baert, Hein Van Poppel, Zbigniew Petrovich. In: Clinical Pharmacology. Cesare Sirtori, Jochen Kuhlmann, Jean-Paul Tillement, Bozidar Vrhovac, Marcus Reidenberg, Mc Graw-Hill, Clinical Medicine Series, pp 191-198, 2000
129. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. G.H.J. Mickisch, A. Garin, H. Van Poppel, L. de Prijck, R. Sylvester, and members of the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. THE LANCET, Vol. 358, September 22: 966-970, 2001
130. EAU Guidelines on Prostate Cancer. G. Aus, C.C. Abbou, D. Pacik, H.-P. Schmid, H. van Poppel, J.M. Wolff, F. Zattoni and the EAU Working Group on Oncological Urology. Eur Urol, 40: 97-101, 2001
131. Editorial: Qué es el Grupo Genito-Urinario de la EORTC? The EORTC GU Group: What is it? Bono, A. Van der Meijden, Z.Kirkali, H. Van Poppel, R. Sylvester. Revisiones en Urologia, Voumen II, Numéro 4, pp 129-130, 2001
132. Hepatic coma after urea-splitting urinary tract infection in a continent T-pouch. S. Joniau, D. Ponette, D. De Ridder, H. Van Poppel and L. Baert. Case reports on the web. BJU International 88:803, 2001
133. Chapter 13.2: Bladder Cancer. Pieter H. M. De Mulder, Adrian P. M. van der Meijden, Hein Van Poppel, and Pierre Scalliet In: Oxford Book of Oncology, Ed. R.L. Souhami, I. Tannock, P. Hohenberger, J.C. Horiot, Oxford University Press, 1973-1995, 2002
134. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Johannes V. Swinnen, Tania Roskams, Steven Joniau, Hein Van Poppel, Raymond Oyen, Luc Baert, Walter Heyns and Guido Verhoeven. Int. J. Cancer 98, 19-22, 2002
135. Cryochirurgie voor gelokaliseerd prostaatacarcinoom. P. Callewaert, H. Van Poppel, L. Baert. Tijdschrift voor Geneeskunde, 58, nr. 7, 2002
136. A large primary malignant melanoma of the female urethra presenting as postmenopausal vaginal bleeding. Frank Van der Aa, Steven Joniau, Hendrik Van Poppel, Ignace Vergote, Raymond Oyen, Kristof Cokelare, Luc Baert. Journal of Pelvic Surgery, Vol.8, No. 1, 47-49, 2002
137. Emphysematous pyelonephritis no longer a surgical disease? M. Mallet, D.C. Knockaert, R.H. Oyen and H.P. Van Poppel. European Journal of Emergency Medicine, 9:266-269, 2002

138. Polyarteritis nodosa mimicking a testis tumour: a case report and review of the literature. P. Braeckman, S. Joniau, R. Oyen, R. Croes and H. Van Poppel. *Cancer imaging* 2, 96-98, 2002
139. Cystectomy for superficial bladder cancer. Patrick Braeckman, Hein Van Poppel. *Journal of pelvic surgery*, Vol 8; 5:271-278, 2002
140. Is a 1-cm margin necessary during nephron-sparing surgery for renal cell carcinoma? N. Piper, J. Bishoff, C. Magee, J. Haffron, R. Flanigan, A. Mintiens, H. Van Poppel, I. Thompson, W. Harmon. *Urology*, 58,6:849-852,2001
141. A prospective survey of surgical approaches in clinically localized renal cell carcinoma – A preliminary attempt at surgical quality control. Z. Kirkali, H. Van Poppel, E. Tuzel, U. Mungan, D.W. Newling, D. Jacqmin and members of the EORTC GU Group. *Uro-oncology*, Vol. 2 (4) 169-174, 2003
142. The dietary basis of prevention of prostate carcinoma. W. Blyweert, H. Van Poppel. *Current medical literature:Urology*, 8, 4:85-91, 2002
143. A lymph node metastasis from a burned out germ cell tumor presenting as an inguinal mass. C. Ghysel, D. Ponette, R. Oyen, A. Van Oosterom, H. Van Poppel. *Case reports on the web, BJU International* 91, 124, 2002
144. Masson's tumour of the kidney. S. Van den Bogaert, K. Boel, H. Van Poppel, R. Oyen and B. Van Damme. *Cancer imaging*, 2:1-4,2002
145. Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery. F. Van der Aa, S. Joniau, D. De Ridder, H. Van Poppel. *Prostate cancer and prostatic diseases*, 6, 61-65, 2003
146. Treatment of erectile dysfunction by perineal exercise, electromyographic biofeedback and electrical stimulation. Marijke Van Kampen, Willy De Weerd, Hubert Claes, Hilde Feys, Mira De Maeyer, Hendrik Van Poppel. *Physical therapy*, Volume 83, 6, 536-543, 2003
147. Idiopathic partial thrombosis of the corpus cavernosum: conservative management is effective and possible. Lieven Goeman, Steven Joniau, Raymond Oyen, Hubert Claes, Hein Van Poppel. *European Urology* 44: 119-123, 2003
148. Debate: T3 patients: Is radical prostatectomy advisable? Bob Djavan, Hein Van Poppel. *ASCO Audio Journal of Oncology*, vol. 11,3, 2003
149. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomized controlled trial. M. Van Kampen, W. De Weerd, H. Van Poppel, D. De Ridder, H. Feys, L. Baert, *Urology Today*, Vol. 10, 2: 23-27, 2003
150. Malignant Renal Parenchymal Epithelial Neoplasms: Some imaging features of different histological subtypes. R. Oyen, G. Verswijvel, T. Roskams, H. Van Poppel. *Medical imaging*, 35, 1-7, 2003

151. Syndroom van Von Hippel-Lindau. J. Menten, L. Van Eyken, E. Legius, G. Evers-Kiebooms, L. Van den Bergh en de UZ Werkgroep Von Hippel-Lindau. Tijdschriften voor Geneeskunde, 59 ,nr 18, p. 10082-10087, 2003
152. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer. L. Goeman, S. Joniau, D. Ponette, F. Van der Aa, T. Roskams, R. Oyen, H. Van Poppel. Prostate Cancer and Prostatic Diseases, 6, 305-310, 2003
153. Heeft sport een invloed op het prostaat specifiek antigeen? S. Joniau, H. Van Poppel, J. Etienne. Bodytalk, 251, 2-3, 2003
154. Emphysematous pyelonefritis – no longer a surgical disease? M. Mallet, D.C. Knockaert, R.H. Oyen, H.P. Van Poppel. The Orion Pharma Journal of Urology, Review Series Urology, 1/2004, 16-17
155. Whole bladder wall photodynamic therapy of transitional cell carcinoma rat bladder tumors using intravesically administered hypericin. Appolinary A. R. Kamuhabwa, Tania Roskams, Marie-Ange D'Hallewin, Luc Baert, Hein Van Poppel and Peter A.M. De Witte. Int. J. Cancer, 107: 460-467, 2003
156. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. Robert C. Flanigan, G. Mickisch, Richard Sylvester, Cathy Tangen, H. Van Poppel and E. David Crawford. J.Urol. 171: 1071-1076, 2004
157. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. W. Albrecht, H. Van Poppel, S. Horenblas, G. Mickisch, A. Horwich, V. Serreta, G. Casetta, JM. Maréchal, WG Jones, S. Kalman and R. Sylvester. British Journal of Cancer 90: 100-105, 2004
158. Handling and pathology reporting of adrenal gland specimens. M. Scarpelli, F. Algaba, Z. Kirkali, H. Van Poppel. European Urology, 45: 722-729, 2004
159. Handling and pathology reporting of renal tumor specimens. F. Algaba, I. Trias, M. Scarpelli, L. Boccon-Gibod, Z. Kirkali, H. Van Poppel. European Urology, April 2004, 45(4): 437-43
160. Benign Renal mesenchymoma in the pediatric age group: a novel pathologic and karyotype entity. Steven Joniau, Lieven Goeman, Susanne Kreuzbauer, Guy Bogaert, Paola Dal Cin, Raymond Oyen, Raf S Sciote and Hein Van Poppel. Urology, 63(5): 981-4, 2004
161. A lymph node metastasis from a burned out germ cell tumor presenting as an inguinal mass. C. Ghysel, D. Ponette, R. Oyen, A. Van Oosterom, H. Van Poppel. BJU International, 91 (1cr), 124, 2003
162. Interferon- α -2a with or without 13-Cis Retinoic Acid in Patients with Progressive, Measurable Metastatic Renal Cell Carcinoma. S.D. Fossa, G.H.J. Mickisch, P.H.M. De Mulder, S. Horenblas, A. T. Van Oosterom, H. Van Poppel, M. Fey, J.J. Croles, L. De Prijck and M. Van Glabbeke. American Cancer Society, 101:533-540, 2004

163. Developments in organ preserving treatments for renal cell cancer: open surgery. Ziya Kirkali, Hein Van Poppel. *European Urology*, supplements 3: 9-13, 2004
164. Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Kamuhabwa, A., Agostinis, P., Ahmed, B., Landuyt W., Van Cleynenbreugel B., Van Poppel H., De Witte P. *Photochem. Photobiol. Sci.* 3: 772-780, 2004
165. The use of immunotherapy for metastatic renal cell carcinoma. L. Goeman, S. Joniau, H. Van Poppel. *Russian Journal of Onco-Urology*, N° 3, 16-24, 2005
166. Histopathology of radical prostatectomy specimens in HG pin-detected prostate cancer. Joniau S., Goeman L., Van Poppel H. *European Urology Supplements* 4, No. 3, pp. 78, 2005
167. Is there a relationship between early changes in sex hormone profile and gynaecomastia induced by bicalutamide 150 mg? Comhaire, F., Van Cangh, P., Van Poppel H. *European Urology Supplements* 4, No. 3, pp. 227, 2005
168. The feasibility of prophylactic prepubic urethrectomy during cystectomy for bladder cancer: retrospective analysis of 124 patients. Joniau, S., Verlinde B., Van Poppel H. *European Urology Supplements* 4, No. 3, pp. 181, 2005
169. Clinical Experience with the N-shaped Ileal Neobladder: Assessment of complications, Voiding Patterns, and Quality of Life in Our Series of 58 patients. S. Joniau, J. Benijts, M. Van Kampen, M. De Waele, J. Ooms, B. Van Cleynenbreugel, H. Van Poppel. *European Urology* 47, 666-673, 2005
170. Hemorrhagic Complications After Nephron-Sparing Surgery: Angiographic Diagnosis and Management by Transcatheter Embolization. Sam Heye, Geert Maleux, Hendrik Van Poppel, Raymond Oyen, Guy Wilms. *AJR*:184, May 2005
171. Renal Cell Carcinoma: percutaneous radio frequency thermal ablation for malignant renal tumours: intermediate results in 15 patients. Joniau S., Goeman L., Oyen R., Van Poppel H. *European Urology Supplements* 4, No. 3, pp. 230, 2005
172. Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy. Chao-Yu Hsu, Steven Joniau, Hein Van Poppel. *EAU Update Series* 3, 90-97, 2005
173. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells. Ann Huygens, Appolinary R. Kamuhabwa, Tania Roskams, Ben Van Cleynenbreugel, Hendrik Van Poppel and Peter A. M. de Witte. *J. Urol.*, Vol. 174, 69-72, July 2005
174. The use of immunotherapy for metastatic renal cell carcinoma. L. Goeman, S. Joniau, H. Van Poppel. *Russian Journal of Onco-Urology* 2005, nr. 3, 16-21
175. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer : a review. P. Schöffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P.

- Wolter, S. Joniau, T. Roskams & H. Van Poppel. *Annals of Oncology*, January 17, 2006
176. Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy. L. Goeman, S. Joniau, R. Oyen, H. Van Poppel. *J. Urology* 67 : 199.e17-199.e19, 2006
 177. The indications for partial nephrectomy in the treatment of renal cell carcinoma. Steven Joniau, Kathy Vander Eeckt & Hein Van Poppel. *Nature Clinical Practice Urology*, Volume 3, number 4, April 2006
 178. Urachal Carcinoma during Pregnancy. K. Van Calsteren, K. Van Mensel, S. Joniau, R. Oyen, M. Hanssens, F. Amant, H. Van Poppel. *J. Urology* 67 : 1290.e19-1290.e21, 2006
 179. The role of whole pelvic radiotherapy in locally advanced prostate cancer. P. Dirix, K. Haustermans, S. Junius, R. Withers, R. Oyen, H. Van Poppel. *Radiotherapy and Oncology* 79, 1-14, 2006
 180. Muscle-invasive urothelial carcinoma of the Bladder. S.B. Malkowicz, H. Van Poppel, G. Mickisch, V. Pansadoro, J. Thüroff, M. Soloway, S. Chang, M. Benson, I. Fukui. *Bladder Tumors*, committee 6, p. 219-237, Health Publication Ltd 2006
 181. Prostate Cancer Prevention. P.H. Gann, H. Akaza, F. Habib, R. Kirby, A. Valdes Mendoza, I. Thompson, H. Van Poppel. *Prostate Cancer*, edition 2006, committee 11, p. 247 – 274, Health Publications, 2006
 182. Renal Cell Cancer. C. Ghysel, S. Joniau, H. Van Poppel. *Prognostic Factors in Cancer*, chapter 36, p. 257 – 260, John Wiley & Sons, Edited by M. Gospodarowicz, B. O'Sullivan, L. Sobin, third edition, 2006
 183. Metanephric adenoma during pregnancy : clinical presentation, histology and cystogenetics. E. Lerut, T. Roskams, S. Joniau, R. Oyen, R. Achten, H. Van Poppel, M. Debiec-Rychter. *Human Pathology*, 37, p 1227-1232, 2006
 184. Salvage radical prostatectomy for radiorecurrent prostate cancer : indications and results. J. Darras, S. Joniau, H. Van Poppel. *EJSO*, 32, p 964 – 969, 2006
 185. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). T. van der Kwast, L. Collette, P. Van Cangh, K. Vekemans, L. DaPozzo, J.F. Bosset, K. Kurth, F. Schröder, M. Bolla on behalf of the European organisation for research and treatment of cancer radiotherapy and genito-urinary cancer groups. *Virchows Arch*, 449(4):428-434, 2006
 186. Chemotherapy for older patients with prostate cancer. J. Anderson, H. Van Poppel, J. Bellmunt, K. Miller, JP. Droz, J.M. Fitzpatrick. *BJU International*, 2006
 187. Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience. C. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel. *European Urology*, 51, 121 – 129, 2007

188. Long-Term Results of Simple Enucleation for the Treatment of Small Renal Cell Carcinoma. Editorial Comment: S. Joniau, H. Van Poppel. *Clin. Urol.*; 32(6); November – December 2006
189. Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Mouraviev V., Joniau S., Van Poppel H., Polascik T.J. *Eur. Urol.* 2007 Feb. 51(2): 328-336
190. Prostaatkanker voorkomen? Peeters K., Joniau S., Van Poppel H. *UROBEL Mag.* 4/1; 6-11
191. A Pretreatment Table for the Predication of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer. S. Joniau, C. Hsu, E. Lerut, A. Van Baelen, K. Haustermans, T. Roskams, R. Oyen, H. Van Poppel. *Eur. Urol.* 51, 388-396, 2007
192. Transrectal ultrasound in the staging of clinical T3a prostate cancer. C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel. *EJSO* 33, 79-82, 2007
193. Comparison between Open Partial and Radical Nephrectomy for Renal Tumours: Perioperative Outcome and Health-Related Quality of Life. K. Lesage, S. Joniau, K. Fransis, H. Van Poppel. *Eur. Urol.* 51, 614-620, 2007
194. Muscle-Invasive Urothelial Carcinoma of the Bladder. S.B. Malkowicz, H. Van Poppel, G. Mickisch, V. Pansadoro, J. Thüroff, M.S. Soloway, S. Chang, M. Benson, I. Fukui. *J. Urol.* 69/1A, 3-16, 2007
195. Prepubic Urethrectomy during Radical Cystoprostatectomy. S. Joniau, W. Shabana, B. Verlinde, H. Van Poppel. *Eur. Urol.* 51, 915-921, 2007
196. Een beslissingshulp voor patiënten met gelokaliseerde prostaatkanker: eerste resultaten. S. Isebaert, C. Van Audenhove, K. Haustermans, K. De Ridder, S. Junius, S. Joniau, H. Van Poppel. *Tijdschr. voor Geneeskunde*, 63, nr. 1, 2007
197. What does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens? Z. Kirkali, F. Algaba, M. Scarpelli, I. Trias, F.P. Selvaggi, H. Van Poppel. *Eur. Urol.* 51, 1194-1201, 2007
198. Prepubic Urethrectomy during Radical Cystoprostatectomy. S. Joniau, W. Shabana, B. Verlinde, H. Van Poppel. *Eur. Urol.* 51(4), 915-921, 2007
199. Efficacy and Safety of Tachosil® as Haemostatic Treatment versus Standard Suturing in Kidney Tumour Resection: A Randomised Prospective Study. S. Siemer, S. Lahme, S. Altziebler, S. Machtens, W. Strohmaier, H-W. Wechsel, P. Goebell, N. Schmeller, R. Oberneder, J-U. Stolzenburg, H. Becker, W. Lüftenegger, V. Tetens, H. Van Poppel. *Eur. Urol.* 52, 1156-1163, 2007
200. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and

- qRT-PCR mRNA expression profile. *British Journal of Cancer* 2007;
doi:10.1038/sj.bjc.6603796
201. Effect of Nutritional Supplement Challenge in Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia. S. Joniau, L. Goeman, T. Roskams, E. Lerut, R. Oyen, H. Van Poppel. *Urology* 69, 1102-1106, 2007
 202. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Z. Kirkali, H. Van Poppel. *European Urology* 52, 658-662, 2007
 203. Treatment of clinical stage T3 prostate cancer: A surgical disease? S. Joniau, A. Van Baelen, C.Y. Hsu, R. Oyen, H. Van Poppel. *Rev. Arg. de Urol. Vol. 71(1)* 2006
 204. Urea-splitting urinary tract infection contributing to hyperammonemic encephalopathy. M. Albersen, S. Joniau, H. Van Poppel, P.J. Cuyle, D.C. Knockaert, W. Meersseman. *Nature Clinical Practice Urology*, August 2007, 4 (8), 455-458
 205. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. P. Poortmans, A. Bossi, K. Vandeputte, M. Bosset, R. Miralbell, P. Maingon, D. Boehmer, T. Budiharto, Z. Symon, A.C.M. van den Bergh, C. Scrase, H. Van Poppel, M. Bolla. *Radiotherapy and Oncology* 84 (2): 121-127, 2007
 206. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study. S. Junius, K. Haustermans, B. Bussels, R. Oyen, B. Vanstraelen, T. Depuydt, J. Verstraete, S. Joniau, H. Van Poppel. *Radiation Oncology* 2007, 2:29 – doi:10.1186/1748-717X-2-29
 207. Open Surgery for Localized RCC. S. Joniau, K. Vandereecht, H. Van Poppel. *TheScientific WorldJournal* 2007, 7, 742-752
 208. A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. H. Van Poppel, L. Da Pozzo, W. Albrecht, V. Matveev, A. Bono, A. Borkowski, J-M Marechal, L. Klotz, E. Skinner, T. Keane, I. Claessens, R. Sylvester. *Eur. Urol.* 51, 1606-1615, 2007
 209. Segmental Testicular Infarction: Conservative Management is Feasible and Safe. S. Madaan, S. Joniau, K. Klockaerts, L. DeWever, E. Lerut, R. Oyen, H. Van Poppel. *Eur. Urol* (2007), doi:10.1016/j.eururo.2007.03.061
 210. Analysis of renal cell carcinoma with subdiaphragmatic macroscopic venous invasion (T3b). S. Klaver, S. Joniau, R. Suy, R. Oyen, H. Van Poppel.
 211. Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression. M. Bolla, H. Van Poppel, L. Collette. *Cancer/Radiothérapie* 11, 363-369, 2007

212. Reply to Apostolos P. Labanaries et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. *Eur. Urol.* 52, 658-62, 2007
213. Salvage Reconstructive Surgery in an Adult Patient with Failed Previous Repair of an Extrophy-Epispadias Complex. An operation with a Functional and Aesthetic Purpose. S. Joniau, A-M Stoel, H. Van Poppel, R. Hierner. *Int. Braz J Urol* 33 (6), 2007
214. Localized prostate cancer: can we better define who is at risk of unfavourable outcome? S. Joniau, H. Van Poppel. *BJU Int* 101, Suppl. 2; 5-10, 2008
215. Segmental Testicular Infarction: Conservative Management is Feasible and Safe: Part 2. S. Madaan, S. Joniau, K. Klockaerts, L. DeWever, E. Lerut, R. Oyen, H. Van Poppel. *Eur Urol* 53, 656-658, 2008
216. Localized prostate cancer: can we better define who is at risk of unfavourable outcome? S. Joniau, H. Van Poppel. *BJU Int.* 101, Suppl. 2, 5-10, 2008
217. Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881. J.H.M. Blom, H. Van Poppel, J.M. Maréchal, D. Jacqmin, F.H. Schröder, L. de Pijck, R. Sylvester. *Eur Urol* 2008, doi:10.1016/j.eururo.2008.09.052
218. Splitting and lumping adult renal epithelial tumors can help the urologists in the prognostic risk stratification and in the treatment decision-making. V. Ficarra, Z. Kirkali, H. Van Poppel. *Eur Urol* 53, 676 – 680, 2008
219. Principes van geoptimaliseerde adjuvante intravesicale therapie na transurethrale resectie van oppervlakkig transitioneel carcinoom van de blaas. C. Cordemans, P. Schoonooghe, B. Van Cleynenbreugel, H. Van Poppel. *Tijdschr. voor Geneeskunde* 64 (7), 329 – 336, 2008
220. New surgical approaches in the management of RCC. S. Joniau, F. Van der Aa, H. Van Poppel. *International Oncology updates – Recent advances in renal cell carcinoma (RCC) – Editor Joaquim Bellmunt Molins – 13-34*
221. Chapter 15: Future Directions. J.M.C.H. de la Rosette, C.N. Sternberg, H. Van Poppel. *Renal Cell Cancer, Diagnosis and therapy (Springer) – Editors: J.M.C.H. De La Rosette, C.N. Sternberg, H. Van Poppel, 567-568, 2008*
222. Surveillance as an option for the treatment of small renal masses. S. Klaver, S. Joniau, H. Van Poppel. *Advances in Urology; 2008; doi:10.1155/2008/705958*
223. Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical Prostatectomy. F. Montorsi, G. Brock, J. Lee, J. Shapiro, H. Van Poppel, M. Graefen, C. Stief. *Eur Urol* 54, 924-931, 2008

224. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. A. Haese, A. de la Taille, H. Van Poppel, M. Marberger, A. Stenzl, P.F.A. Mulders, H. Huland, C-C. Abbou, M. Remzi, M. Tinzi, S. Feyerabend, A.B. Stillebroer, M.P.M.Q. van Gils, J. A. Schalken. *Eur Urol* 54, 1081-1088, 2008
225. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. M. Albersen, S. Joniau, H. Claes, H. Van Poppel. *Advances in Urology* 2008; 10.1155/594868
226. Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. C-Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel. *Asian Journal of Andrology* 11, 131-137, 2009
227. Urological Reconstructive Procedures in Patients with Gynaecological Cancer in Atlas of Gynaecological Cancer Surgery. Editors: Ignace Vergote, Uma K Devi. – Jaypee Brothers Medical Publishers pp.: 237-263, 2009
228. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. J.H.M. Blom, H. Van Poppel, J.M. Maréchal, D. Jacqmin, F.H. Schröder, L. de Prijck, R. Sylvester. *Eur Urol* 55, 28-34, 2009
229. The motion: Nomograms should become a routine tool in determining prostate cancer prognosis. A. Briganti, P.I. Karakiewicz, S. Joniau, H. Van Poppel. *Eur Urol* 55, 743-747, 2009
230. EORTC-GU group expert opinion on metastatic renal cell cancer. T.M. de Reijke, J. Bellmunt, H. Van Poppel, S. Marreaud, M. Aapro. *European Journal of Cancer* 45, 765-773, 2009
231. (Neo)adjuvant hormone therapy to radical prostatectomy. In: *Androgens and prostate cancer*. 2009. Edt. R. Berges, B. Tombal. PP: 145-150
232. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. C.N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, H. Graham, P. Carpentier, F. Calabro, L. Collette, D. Lacombe. *Annals of Oncology* doi;10.1093/annonc:mdn784
233. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. V. Ficarra, G. Novara, W. Artibani, A. Cestari, A. Galfano, M. Graefen, G. Guazzoni, B. Guillonneau, M. Menon, F. Montorsi, V. Patel, J. Rassweiler, H. Van Poppel. *Eur Urol* 55, 1037-1063, 2009
234. Open radical retropubische prostatectomy. H. Van Poppel, T. Tailly. In: *Handboek Prostaataandoeningen (de Tijdstroom 2009)*. Redactie: T. Boon, J. Bosch, H. Van Poppel, J. Witjes. PP: 343-353, 2009

235. Zenuwsparende radiale prostatectomy. S. Joniau, L. Goeman, P. Gontero, H. Van Poppel. In: Handboek Prostaataandoeningen (de Tijdstroom 2009). Redactie: T. Boon, J. Bosch, H. Van Poppel, J. Witjes. PP:387-396, 2009
236. Radiofrequente ablatie en cryoablatie voor de behandeling van renale tumoren: een literatuurstudie met analyse van de complicaties en de kortetermijnresultaten. *Andrologic* 5, 47-51, 2009
237. Le cancer de la prostate touche près d'un homme sur dix. Interview in speciale editie 'Santé' bij 'La Libre Belgique' op 31 maart 2009.
238. What's your diagnosis? S. Deconinck, W. Blyweert, S. Joniau, H. Van Poppel. *BJMO* 2009; 3: 128
239. New developments in the treatment of localized penile cancer. E. Solsona, A. Bahl, S.B. Brandes, D. Dickerson, A. Puras-Baez, H. Van Poppel, N.A. Watkin. In: *Penile Cancer*, eds. Antonio Carlos L. Pompeo, Chris F. Heyns, Paul Abrams – International Consultation on Penile Cancer, Santiago, Chile, November 2008 – Edition 2009
240. Management of the Lymph Nodes in Penile Cancer – C.F. Heyns, N. Fleshner, V.K. Sangar, B. Schlenker, Y.B. Thyavihally, H. Van Poppel. In: *Penile Cancer*, eds. Antonio Carlos L. Pompeo, Chris F. Heyns, P. Abrams – International Consultation on Penile Cancer, Santiago, Chile, November 2008 – Edition 2009
241. An easy prediction of urinary incontinence duration after retropubic radical prostatectomy based on urine loss the first day after catheter withdrawal. M. Van Kampen, I. Geraerts, W. De Weerd, H. Van Poppel. *J Urol* 2009; 181: 2641-2646
242. Hurdles in modern trial management: as overbureaucracy and commercialization of clinical trials suffocate independent academic research, it's time for a change. S. Osanto, H. Van Poppel, J. Burggraaf, R.R. Hall. *Eur Urol* 56, 622-624, 2009
243. Prostate Cancer Gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. F.K. Chun, A. de la Taille, H. Van Poppel, M. Marberger, A. Stenzl, P. F.A. Mulders, H. Huland, C.C. Abbou, A.B. Stillebroer, M. P.M.Q. van Gils, J.A. Schalken, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, A. Haese. *Eur Urol* 56, 659-668, 2009
244. Assessing the impact of ischaemia time during partial nephrectomy. F. Becker, H. Van Poppel, O.W. Hakenberg, C. Stief, I. Gill, G. Guazzoni, F. Montorsi, P. Russo, M. Stöckle. *Eur Urol* 56, 625-635, 2009
245. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene. M.M. Baldewijns, I.J.H. van Vlodrop, K.M. Smits, P.B. Vermeulen, G.G. Van den Eynden, F. Schot, T. Roskams, H. Van Poppel, M. van Engeland, A.P. de Bruine. *Cellular Oncology* 31, 371-382, 2009

246. Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology. CY. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel. *BJMO* 3, 270-274, 2009
247. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. K. Touijer, D. Jacqmin, L.R. Kavoussi, F. Montorsi, J.J. Patard, C.G. Rogers, P. Russo, R.G. Uzzo, H. Van Poppel. *Eur Urol* 57, 214-222, 2010
248. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. JP. Droz, L. Balducci, M. Bolla, M. Emberton, JM. Fitzpatrick, S. Joniau, MW. Kattan, S. Monfardini, JW. Moul, A. Naeim, H. Van Poppel, F. Saad, CN Sternberg. *Critical reviews in oncology/hematology* 73, 68-91, 2010
249. Prognostic significance of Gremlin 1 (GREM1) promoter CpG Island Hypermethylation in Clear Cell Renal Cell Carcinoma. I.J.H. van Vlodrop, M.M.L. Baldewijns, K.M. Smits, L.J. Schouten, L. van Neste, W. van Criekinge, H. Van Poppel, E. Lerut, K. E. Schuebel, N. Ahuja, J. G. Herman, A.P. de Bruïne, M. van Engeland. *The American Journal of Pathology* 176, 575-584, 2010
250. A giant mucinous adenocarcinoma arising within a villous adenoma of the urachus: case report and review of the literature. S. Joniau, E. Lerut, H. Van Poppel. *Case Reports in Medicine* 2009; doi:10.14155/2009/818646
251. Reply to Juan Morote's letter to the editor re: FK. Chun, A. de la Taille, H. Van Poppel, et al. Prostate cancer gene 3 (PCA3) : development and internal validation of a novel biopsy nomogram. *Eur Urol* 56, 659-68, 2009
252. Laparoscopic nephroureterectomy: the distal ureteral dilemma. SJ. Srirangam, B. Van Cleynenbreugel, H. Van Poppel. *Advances in Urology* 2009; 316807. Epub 2008 Nov 5. PMID:19020654
253. Results of buccal mucosa grafts for repairing long bulbar urethral strictures. K. Fransis, K. Vander Eeckt, H. Van Poppel, S. Joniau. *BJU Int.* 105, 1170-1172, 2009
254. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology? J-P. Droz, L. Balducci, M. Bolla, M. Emberton, JM. Fitzpatrick, S. Joniau, MW. Kattan, S. Monfardini, JW. Moul, A. Naeim, H. Van Poppel, F. Saad, CN. Sternberg. *BJU Int* 2010; doi:10.1111/j.1464-410X.2010.09334.x
255. Prognostic factor for and outcome of locally advanced prostate cancer after radical prostatectomy. C-Y. Hsu, MF. Wildhagen, H. Van Poppel, C. Bangma. *BJU Int* 105, 1536-1540, 2009
256. The use of IIEF-5 for reporting erectile dysfunction following nerve-sparing radical retropubic prostatectomy. M. Albersen, S. Joniau, H. Van Poppel. *The Open Prostate Cancer Journal* 2, 1-9, 2009

257. Ablative therapies in the treatment of small renal tumors: How far from standard of care? P. Gontero, S. Joniau, A. Zitella, T. Tailly, A. Tizzani, H. Van Poppel, Z. Kirkali. *Urologic Oncology* 2009; doi:10.1016/j.urolonc.2009.06.008
258. A case of urachal adenocarcinoma. A. Verbrugghe, H. Van Poppel, S. Joniau. *Belg J Med Oncol* 4, 82-82, 2010
259. Is radical nephroureterectomy and lymph node dissection necessary for upper-tract TCC? S. Joniau, B. Van Cleynenbreugel, W. Blyweert, I. Romics, H. Van Poppel. *Eur. Urol. Suppl.* 9, 442-445, 2010
260. The history of the EORTC GU Group. S. Osanto, H. Van Poppel, R. Sylvester. In: *Europe – The cradle of urology*, edited by J.J. Mattelaer & D. Schultheiss – Chapter 10: Internationalisation of European Urology pp. 365-369.
261. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. M. Spahn S. Joniau, P. Gontero, S. Fieuws, G. Marchioro, B. Tombal, B. Kneitz, C-Y. Hsu, K. Van Der Eeckt, P. Bader, D. Frohneberg, A. Tizzani, H. Van Poppel. *Eur Urol* 58, 1-7, 2010
262. A critical need for national guidelines. S. Osanto, H. Van Poppel. *Onkologie* 33, 351-352, 2010
263. Prevention of tumor cell reimplantation during transurethral resection: the in-vitro antiadhesive and cytotoxic properties of an irrigant containing polyethylene glycol 400. RZ. Sanchez, J. Vandepitte, A. Huygens, B. Van Cleynenbreugel, H. Van Poppel, PA. De Witte. *Anticancer Drugs* 21, 645-650, 2010
264. Management of the lymph nodes in penile cancer. CF. Heyns, N. Fleshner, V. Sangar, B. Schlenker, TB. Yuvaraja, H. Van Poppel. *SIU Penile Cancer Supplement. Urology* 76 (supplement 2A), 43-57, 2010
265. New developments in the treatment of localized penile cancer. E. Solsona, A. Bahl, S.B. Brandes, D. Dickerson, A. Puras-Baez, H. Van Poppel, N.A Watkin. Reply from authors re: L. Gerber, L.L. Banez, S.J. Freeland. *Defining and treating high-risk prostate cancer: can we do better?* *Eur Urol* 58, 8-9, 2010. M. Spahn, S. Joniau, B. Kneitz, P. Gontero, H. Van Poppel. *Eur Urol* 58, 8-11, 2010
266. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. J. Walz, S. Joniau, F.K. Chun, H. Isbarn, C. Jeldres, O. Yossepowitch, C-Y. Hsu, E.A. Klein, P.T. Scardino, A. Reuther, H. Van Poppel, M. Graefen, H. Huland, P.I. Karakiewicz. *BJU Int* 2010; doi:10.1111/j.1464-410X.2010.09594.x
267. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. V. Ficarra, M. Brunelli, L. Cheng, Z. Kirkali, A. Lopez-Beltran, G. Martignoni, R. Montironi, G. Novara, H. Van Poppel, *Eur Urol* 58, 655-668, 2010

268. Follow-up of men with an elevated PCA3 score indeed predict the presence of prostate cancer? M. Remzi, A. Haese, H. Van Poppel, A. de la Taille, A. Stenzl, J. Hennenlotter, M. Marberger, *BJU Int* 106, 1138-1142, 2010
269. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? G. Ploussard, A. Haese, H. Van Poppel, M. Marberger, A. Stenzl, P. F. A. Mulders, H. Huland, L. Bastien, C.C. Abbou, M. Remzi, M. Tinzl, S. Feyerabend, A.B. Stillebroer, M. P.M.Q. van Gils, J.A. Schalken, A. de la Taille, *BJU Int* 106, 1143-1147, 2010
270. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. A. Bex, E. Jonasch, Z. Kirkali, A. Mejean, P. Mulders, S. Oudard, J.J. Patard, T. Powles, H. Van Poppel, C.G. Wood, *Eur Urol* 58, 819-828, 2010
271. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. T. Budiharto, C. Perneel, K. Haustermans, S. Junius, B. Tombal, P. Scalliet, L. Renard, E. Lerut, K. Vekemans, S. Joniau, H. Van Poppel, *Radiotherapy and oncology* 97, 474-479, 2010
272. Human serum albumin as key mediator of the differential accumulation of hypericin in normal urothelial cell spheroids versus urothelial cell carcinoma spheroids. M. Roelants, B. Van Cleynenbreugel, E. Lerut, H. Van Poppel, P.A. de Witte, *Photochem. Photobiol Sci.* 10, 151-159, 2011
273. PVP-hypericin as a photodiagnostic and phototherapeutic tool for bladder cancer: a preclinical study. J. Vandepitte, H. Van Poppel, P.A. De Witte, *Belg J Med Oncol* 4, 261-263, 2010
274. Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. S. Isebaert, F. De Keyzer, K. Haustermans, E. Lerut, T. Roskams, I. Roebben, H. Van Poppel, S. Joniau, R. Oyen, *Eur. Urol* 2011 Article in press doi: 10.1016/j.ejrad.2011.01.107
275. Metabolic changes after urinary diversion. F. Van der Aa, S. Joniau, M. Van Den Branden, H. Van Poppel, *Advances in Urology* 2011 Article in press doi:10.1155/2011/764325
276. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a Multi-institutional collaboration. D.C. Chade, S.F. Shariat, A.M. Cronin, C.J. Savage, R.J. Karnes, M.L. Blute, A. Briganti, F. Montorsi, H.G. van der Poel, H. Van Poppel, S. Joniau, G. Godoy, A. Hurtado-Coll, M.E. Gleave, M. Dall'Oglio, M. Srougi, P.T. Scardino, J.A. Eastham. *Eur Urol* 60, 205-201, 2011

277. Emerging role of nutrients and bio-active food components in prostate cancer chemoprevention. K. Ackaert, S. Joniau, H. Van Poppel. *Belg J Med Oncol* 5, 139-143, 2011
278. Hoofdstuk 26: Tumoren van de urinewegen. R.J.A. van Moorselaar, M.C. C.M. Hulshof, G.J.L.H. van Leenders, C.M.L. van Herpen, H. Van Poppel. In: *Kernboek Oncologie* – Eds. C.J.H. van de Velde, W.T.A. van der Graaf, J.H.J.M. van Krieken, C.A.M. Marijnen, J.B. Vermorcken, PP 479 – 494
279. Biodistribution and photodynamic effects of polyvinylpyrrolidone-hypericin using multicellular spheroids composed of normal human urothelial and T24 transitional cell carcinoma cells. J. Vandepitte, M. Roelants, B. Van Cleynenbreugel, K. Hettinger, E. Lerut, H. Van Poppel, P.A. de Witte. *J Biomed Opt* 16, 018001, 2011
280. Metabolic changes after urinary diversion. F. Van der Aa, S. Joniau, M. Van Den Branden, H. Van Poppel. *Advances in Urology* 2011; article in press: doi.10.1155/2011/764325
281. Use of fluorescein isothiocyanate-human serum albumin for the intravesical photodiagnosis of non-muscle-invasive bladder cancer: an in vitro study using multicellular spheroids composed of normal human urothelial and urothelial cell carcinoma cell lines. *BJU Int* 108, 455-459, 2010
282. Overleving van high-risk prostaatkankerpatiënten met lymfekliermetastasen: bevindingen van een Europese Multi-institutionele analyse. *Andrologic* 5, 122-124, 2011
283. Renal cell carcinoma with synchronous metastasis to the calcaneus and metachronous metastases to the ovary and gallbladder. J. Decoene, F. Ameye, E. Lerut, R. Oyen, H. Van Poppel, S. Joniau, *Case Reports in Medicine* 2011; article in press; doi:10.1155/2011/671645
284. Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder. J. Vandepitte, B. Van Cleynenbreugel, K. Hettinger, H. Van Poppel, P.A.M. de Witte, *Cancer Chemother Pharmacol* 67, 775-781, 2011
285. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. M. Roscigno, M. Brausi, A. Heidenreich, Y. Lotan, V. Margulis, S.F. Shariat, H. Van Poppel, R. Zigeuner. *Eur Urol* 60, 776-783, 2011
286. Is there a prostate-specific antigen upper limit for radical prostatectomy? P. Gontero, M. Spahn, B. Tombal, P. Bader, C.Y. Hsu, G. Marchioro, B. Freja, K. Van der Eeckt, K. Kneitz, D. Frohneberg, A. Tizzani, H. Van Poppel, S. Joniau, *BJU Int* 108, 1093-1100, 2011
287. Prospective evaluation of ¹¹C-Choline Positron Emission Tomography/Computed Tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. T. Budiharto,

- S. Joniau, E. Lerut, L. Van de Bergh, F. Mottaghy, C.M. Deroose, R. Oyen, F. Ameye, K. Bogaerts, K. Haustermans, H. Van Poppel. *Eur Urol* 60, 125-130, 2011
288. Evans blue as a selective dye marker for white-light diagnosis of non-muscle-invasive bladder cancer: an in vitro study. M. Roelants, A. Huygens, I. Crnolatac, B. Van Cleynenbreugel, E. Lerut, H. Van Poppel, P.A.M. de Witte. *BJU Int* 2011; article in press: doi:10.1111/j.1464-410X.2011.10465.x
289. Fluoroquinolone-resistant *E. coli* in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – should we reassess our practices for antibiotic prophylaxis? D. Steensels, K. Slabbaert, L. De Wever, P. Vermeersch, H. Van Poppel, J. Verhaegen, *Clin Microbiol Infect* 2011; article in press: doi:10.1111/j.1469-0691.2011.03638.x
290. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damiao, T.L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gomez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, C. Goessl, *Lancet* 2011, article in press: doi:10/1016/S0140-6736(11)61226-9
291. Lymph node dissection in renal cell carcinoma. U. Capitanio, F. Becker, M.L. Blute, P. Mulders, J.-J. Patard, P. Russo, U.E. Studer, H. Van Poppel, *Eur Urol* 60, 1212-1220, 2011
292. Chapter 8: Open radical prostatectomy, W. Van Haute, H. Van Poppel. In: *ABC of Prostate Cancer*. Eds.: P. Dasgupta, R. Kirby, PP: 25 – 28, 2012
293. Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium, Goossens M, Buntinx F, Joniau S, Ackaert K, Ameye F, Billiet I, Braeckman J, Breugelmans A, Darras J, Dilen K, Goeman L, Kellen E, Tombal B, Van Bruwaene S, Van Cleynenbreugel B, Van der Aa F, Vekemans K, Van oppel H, Zeegers M, *BMC Urology* 12, 8, 2012
294. Epithelioid hemangioendothelioma of the kidney treated with Sunitinib, Tolkach Y, Petrov S, Lerut E, Van Poppel H, *Onkologie* 2012; 35 – doi:10.1159/000338944
295. Pelvic exenterations for gynecological malignancies. A study of 36 cases. Kaur M, Joniau S, D’Hoore A, Van Calster B, Van Limbergen E, Leunen K, Penninckx F, Van Poppel H, Amant F, Vergote I. *Int J of Gynecological Cancer*, 5, 889-896, 2012
296. Genome-wide MicroRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing, S. Osanto, Y. Qin, H.P. Buermans, J. Berkers, E. Lerut, J.J. Goeman, H. Van Poppel. *PloS ONE* 2012; 7(6)
297. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease, M. Spahn, A. Briganti, U. Capitanio, B. Kneitz, P. Gontero,

- J.R. Karnes, M. Schubert, F. Montorsi, C-J. Scholz, P. Bader, H. Van Poppel, S. Joniau. *J of Urol* 2012, doi:10.1016/j.juro.2012.02.2572.
298. Huidige vaccinatiestrategieën voor prostaatcancer, S. Joniau, S. Van Bruwaene, H. Van Poppel, S. Osanto, *Andrologic* 8, 6 – 13, 2012
299. When the bowel becomes the bladder: changes in metabolism after urinary diversion, F. Van der Aa, D. De Ridder, H. Van Poppel. *Practical Gastroenterology*, 107, 15 – 28, 2012
300. Update on the management of invasive bladder cancer 2012, H. Goethuys, H. Van Poppel. *Cancer Management and Research* 4, 177-182, 2012
301. Pelvic floor muscle training after prostate surgery, M. Van Kampen, I. Geeraerts, H. Van Poppel. *The Lancet* 379, 121, 2012
302. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis, A. Briganti, T. Wiegel, S. Joniau, C. Cozzarine, M. Bianchi, M. Sun, B. Tombal; Karin Hautsermans, T. Budiharto, W. Hinkelbein, N. di Muzio, P.I. Karakiewicz, F. Montorsi, H. Van Poppel. *Eur Urol* 62, 472-487, 2012
303. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena consensus panel, F. Montorsi, T.G. Wilson, R.C. Rosen, T.E. Ahlering, W. Artibani, P.R. Carroll, A. Costello, J.A. Eastham, V. Ficarra, G. Guazzoni, M. Menon, G. Novara, V.R. Patel, Jens-Uwe Stolzenburg, H. Van der Poel, H. Van Poppel, A. Mottrie. *Eur Urol* 62, 368-381, 2012
304. Systemic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy, G. Novara, V. Ficarra, S. Mocellin, T. E. Ahlering, P.R. Carroll, M. Graefen, G. Guazzoni, M. Menon, V.R. Patel, S. F. Shariat, A.K. Tewari, H. Van Poppel, F. Zattoni, F. Montorsi, A. Mottrie, R.C. Rosen, T.G. Wilson. *Eur Urol* 62, 382-404, 2012
305. Systemic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy, G. Novara, V. Ficarra, R.C. Rosen, W. Artibani, A. Costello, J.E. Eastham, M. Graefen, G. Guazzoni, S.F. Shariat, J-U. Stolzenburg, H. Van Poppel, F. Zattoni, F. Montorsi, A. Mottrie, T.G. Wilson, *Eur Urol* 62, 431-452, 2012
306. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature, D.C. Chade, J. Eastham, M. Graefen, J.C. Hu, R.J. Karnes; L. Klotz, F. Montorsi, H. Van Poppel, P.T. Scardino, S.F. Shariat. *Eur Urol* 61, 961-971, 2012
307. Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors, S. Joniau, C.Y. Hsu, P. Gontero, M. Spahn, H. Van Poppel, *Scan J Urol Nephrol* 46, 164-171, 2012

308. High-risk prostate cancer: from definition to contemporary management, P.J. Bastian, S.A. Boorjian, A. Bossi, A. Briganti, A. Heidenreich, S.J. Freedland, F. Montorsi, M. Roach III, F. Schröder, H. Van Poppel, C.G. Stief, A.J. Stephenson, M.J. Zelefsky, *Eur Urol* 61, 1096-1106, 2012
309. Is there an additional value of 11C-Choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? L. Van den Bergh, M. Koole, S. Isebaert, S. Joniau, C. Deroose, R. Oyen, E. Lerut, T. Budiharto, F. Mottagy, G. Bormans, H. Van Poppel, K. Haustermans. *Int J Radiation Oncol Biol Phys*, 83, 1486-1492, 2012
310. Patterns of care in the management of seminoma stage I: results from a European survey, *BJU Int* 110, 524-532, 2012
311. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis, M. Schubert, S. Joniau, P. Gontero, S. Kneitz, C.-j. Scholz, B. Kneitz, A. Briganti, R.J. Karnes, B. Tombal, J. Walz, C.-Y. Hsu, G. Marchioro, P. Bader, C. Bangma, D. Frohneberg, M. Graefen, F. Schröder, P. van Cangh, H. Van Poppel, M. Spahn. *Advances in Urology* 2012, doi.10.1155/2012/612707
312. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases, B. Beuselinck, P. Wolter, A. Karadimou, R. Elaidi, H. Dumez, A. Rogiers, T. Van Cann, L. Willems, J.-J. Body, J. Berkers, H. Van Poppel, E. Lerut, P. Debruyne, R. Paridaens, P. Schöffski, *British Journal of Cancer* 107, 1665-1671, 2012
313. Emerging novel therapies for advanced prostate cancer, S. Osanto, H. Van Poppel *Ther Adv Urol* 4, 3-12, 2012
314. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy, A.J. Stephenson, M. Bolla, A. Briganti, C. Cozzarini, J.W. Moul, M. Roach III, H. Van Poppel, A. Zietman, *Eur Urol* 61, 443-451, 2012
315. Positive surgical margins after nephron-sparing surgery, M. Marszalek, M. Carini, P. Chlosta, K. Jeschke, Z. Kirkali, R. Knüchel, S. Madersbacher, J.-J. Patard, H. Van Poppel. *Eur Urol* 61, 757-763, 2012
316. Effect on parenteral nutrition of an improved recovery oral nutrition protocol after radical uncomplicated cystectomy, P. Declercq, G. De Win, F. Van der Aa, E. Beels, I. Spriet, H. Van Poppel, L. Willems, *Eur J Hosp Pharm* 19, 219, 2012
317. Complications and functional results of surgery for locally advanced prostate cancer. S.G. Joniau, A.A. Van Baelen, C.Y. Hsu, H.P. Van Poppel. *Advances in Urology* 2012, doi: 10.1155/2012/706309
318. Intratumoral injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease. *Eur Urol* 63, 551-560, 2013

- 319.F. Castiglione, P. Hedlund, F. Van der Aa, T.J. Bivalacqua, P. Rigatti, H. Van Poppel, F. Montorsi, D. De Ridder, M. Albersen, Xenogeneic adipose stem cell treatment in a rat model of Peyronie's Disease, *Eur Urol* 63, 561-564, 2013
- 320.B. Beuselinck, A. Karadimou, D. Lambrechts, B. Claes, P. Wolter, G. Couchy, J. Berkers, H. Van Poppel, R. Paridaens, P. Schöffski, A. Méjean, V. Verkarre, E. Lerut, F. Joly, T. Leuret, G. Gravis, G. Deplanque, A. Descazeaud, N. Rioux Leclercq, V. Molinié, J.J. Patard, C. Teghom, R. Elaidi, J. Zucman-Rossi, S. Oudard, VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis, *Acta Oncologica* 2013, doi: 10.3109/0284186X.2013.770600
- 321.A. Briganti, M. Spahn, S. Joniau, P. Gontero, M. Bianchi, B. Kneitz, F. K.H. Chun, M. Sun, M. Graefen, F. Abdollah, G. Marchioro, D. Frohenberg, S. Giona, B. Frea, P.I. Karakiewicz, F. Montorsi, H. Van Poppel, R.J. Karnes, Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. *Eur Urol* 63, 693-701, 2013
- 322.L. Tosco, H. Van Poppel, B. Frea, G. Gregoraci, S. Joniau, Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma, *Eur Urol* 63, 646-652, 2013
- 323.S. Joniau, K. Vander Eeck, A. Briganti, P. Gontero, S. Van Bruwaene, R.J. Karnes, M. Spahn, H. Van Poppel, Current role of surgery for high risk prostate cancer, *Arch. Esp. Urol* 66, 259-273, 2013
- 324.S. Joniau, S. Van Bruwaene, H. Van Poppel, S. Osanto. Huidige vaccinatiestrategieën voor prostaatkanker, *Onco* 7, 24-31, 2013
- 325.P. Gontero, S. Joniau, M. Oderda, M. Ruutu, H. Van Poppel, M.P. Laguna, J. de la Rosette, Z. Kirkali. Active surveillance for small renal tumors: Have clinical concerns been addressed so far? *Int J Urol* 20, 356-361, 2013
- 326.J. Berkers, O. Govaere, P. Wolter, B. Beuselinck, P. Schöffski, L.C. van Kempen, M. Albersen, J. Van den Oord, T. Roskams, J. Swinnen, S. Joniau, H. Van Poppel, E. Lerut. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchyma transition and hypoxia resistance. *J. Urol* 189, 1930-1938, 2013
- 327.Y. Tolkach, S. Joniau, H. Van Poppel. Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors? *BJU Int* 111, 1021-1030, 2013
- 328.M. Albersen, J. Berkers, P. Dekoninck, J. Deprest, T.F. Lue, P. Hedlund, C-S. Lin, T.J. Bivalacqua, H. Van Poppel, D. De Ridder, F. Van der Aa, Expression of a distinct set of chemokine receptors in adipose tissue-derived stem cells is responsible for in vitro migration toward chemokines appearing in the major pelvic

- ganglion following cavernous nerve injury, *Sexual Medicine* 2013;
doi:10.1002/sm2.1
- 329.A. Heidenreich, PA. Abrahamsson, W. Artibani, J. Catto, F. Montorsi, H. Van Poppel, M. Wirth, N. Mottet, Early detection of prostate cancer: European Association of Urology recommendation, *Eur Urol* 2013: article in press
330. E. Scosyrev, E.M. Messing, R. Sylvester, S. Campbell, H. Van Poppel, Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. *Eur Urol* 2013: article in press
331. H. Van Poppel, B. Tombal – Belgische Gids voor de Arts: Aandoeningen van de Prostaat – Vivio – Gids voor Huisartsen, June 2013
- 332.S. Joniau, L. Tosco, A. Briganti, T. Vanden Broeck, P. Gontero, R.J. Karnes, M. Spahn, H. Van Poppel, Results of surgery for high-risk prostate cancer, *Curr Opin Urol* 23, 342-348, 2013
- 333.S. Joniau, L. Tosco, A. Briganti, T. Van den Broeck, P. Gontero, RJ Karnes, M. Spahn, H. Van Poppel. Results of surgery for high-risk prostate cancer. *Curr. Opin. Urol.* 2013; 23(4): 342-8
- 334.S. Joniau, L. Tosco, H. Van Poppel, M. Spahn, Minimally invasive vs open radical prostatectomy in high-risk prostate cancer: comparing apples and pears? *BJU Int* 2013
- 335.M. Albersen, J. Berkers, P. Dekoninck, J. Deprest, T.F. Lue, P. Hedlund, C-S Lin, T.J. Bivalacqua, H. Van Poppel, D. De Ridder, F. Van der Aa, Expression of a distinct set of chemokine receptors in adipose tissue-derived stem cells in responsible for in vitro migration toward chemokines appearing in the major pelvic ganglion following cavernous nerve injury, *Sex Med* 2013; article in press
- 336.I. Geraerts, H. Van Poppel, N. Devoogdt, S. Joniau, B. Van Cleynenbreugel, A. De Groef, M. Van Kampen. Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial, *Eur Urol* 64, 766-772, 2013
- 337.T. Roza, L. Hakim, H. Van Poppel, S. Joniau, Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions, *Drugs Aging* 30, 877-886, 2013
- 338.S. Joniau, L. Tosco, H. Van Poppel, M. Spahn, Minimally invasive vs open radical prostatectomy in high-risk prostate cancer: comparing apples and pears? *BJU Int*, Editor's Choice, 711-712, 2013
- 339.M. Albersen, J. Berkers, P. Dekoninck, J. Deprest, T.F. Lue, P. Hedlund, C-S Lin, T.J. Bivalacqua, H. Van Poppel, D. De Ridder, F. Van der Aa, Expression of a distinct set of chemokine receptors in adipose tissue-derived stem cells in responsible for in vitro migration toward chemokines appearing in the major pelvic ganglion following cavernous nerve injury, *Sex Med* 2013, DOI:10.1002/sm2.1.

- 340.I. Geraerts, H. Van Poppel, N. Devoogdt, A. Laenen, A. De Groef, M. Van Kampen. Progression and predictors of physical activity levels after radical prostatectomy. *BJU Int* 2014; 114: 185-192
- 341.M. Aitchison, C.A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon, P.A. Vasey. Adjuvant 5-fluorouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomized European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/ National Cancer Research Institute trial. *Eur J Cancer* 2014; 50: 70-77.
- 342.B. Beuselinck, Y-A. Vano, S. Oudard, P. Wolter, R. De Smet, L. Depoorter, C. Teghom, A. Karadimou, J. Zicman-Rossi, P.R. Debruyne, H. Van Poppel, S. Joniau, E. Lerut, M. Strijbos, H. Dumez, R. Paridaens, B. Van Calster, P. Schöffski. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. *BJU Int* 2013; doi.10.1111/bju.12494
- 343.S. Joniau, A. Briganti, P. Gontero, G. Gandaglia, L. Tosco, S. Fieuws, B. Tombal, G. Marchioro, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, R.J. Karnes, F. Montorsi, H. Van Poppel, M. Spahn. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. *Eur. Urol* 2014; article in press
- 344.T. Van den Broeck, S. Joniau, L. Clinckemalie, C. Helsen, S. Prekovic, L. Spans, L. Tosco, H. Van Poppel, F. Claessens. The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. *Biomed Research International* 2014; 627510.
- 345.M. van Leeuwen, F. Efficace, S.D. Fossa, M. Bolla, U. De Giorgi, R. de Wit, B. Holzner, L.V. van de Poll-Franse, H. Van Poppel, J. White, L. Collette, S. Osanto, N.K. Aaronson. Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities. *Eur J Cancer* 2014; article in press.
- 346.F. Claessens, C. Helsen, S. Prekovic, T. Van den Broeck, L. Spans, H. Van Poppel, S. Joniau. Emerging mechanisms of enzalutamide resistance in prostate cancer. *Nat Rev Urol.* 2014 Dec; 11(12):712-6
- 347.K. De Baets, M. Albersen, S. Joniau, H. Van Poppel. Klinische richtlijnen van de ESMO voor de diagnose, behandeling en opvolging van peniscarcinoom- Deel 1: diagnose en staggering. *ONCO* 2014; 8: 31-34.
- 348.B. Beuselinck, E. Lerut, P. Wolter, H. Dumez, J. Berkers, H. Van Poppel, S. Joniau, R. Oyen, L. De Wever, M. Strijbos, R. Paridaens, P. Schöffski. Sarcomatoid dedifferentiation in metastatic clear cell renal carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase

- inhibitors: a retrospective analysis. *Clinical Genitourinary Cancer* 2014; article in press.
- 349.MP. Laguna, F. Algaba, J. Cadddu, R. Clayman, I. Gill, G. Gueglio, M. Hohenfellner, A. Joyce, J. Landman, B. Lee, H. Van Poppel. Current patterns of presentation and treatment of renal masses: a clinical research office of the endourological society prospective study. *Journal of Endourology* 2014; 28: 861-870.
- 350.K. De Baets, M. Albersen, S. Joniau, H. Van Poppel. Diagnose en staggering van peniscarcinoom. *Andrologic* 2014; 10: 10-13
- 351.C. Helsen, T. Van den Broeck, A. Voet, S. Prekovic, H. Van Poppel, S. Joniau, F. Claessens. Androgen receptor antagonists for prostate cancer therapy. *Endocrine-related cancer* 2014; 21: 105-118
- 352.W. Artibani, V. Ficarra, BJ. Challacombe, CC. Abbou, J. Bedke, R. Boscolo-Berto, M. Brausi, JJ. De la Rosette, S. Deger, L. Denis, G. Guazzoni, B. Guillonueau, JP Heesakkers, D. Jacqmin, T. Knoll, L. Martinez-Pineiro, F. Montorsi, A. Mottrie, PT. Piechaud, A. Rane, J. Rassweiler, A. Stenzl, J. Van Moorselaar, RF Van Velthoven, H. Van Poppel, M. Wirth, PA. Abrhamsson, KF Parsons. EAU policy on live surgery events. *Eur Urol* 2014; 66: 87-97.
- 353.RJ. Karnes, S. Joniau, ML. Blute, H. Van Poppel. Caveat Emptor. *Eur Urol* 2014; 66: 673-676.
- 354.H. Abboudi, M. Shamim Khan, K.A. Guru, S. Froghi, G. de Win, H. Van Poppel, P. Dasgupta, K. Ahmed. Learning curves for urological procedures: a systematic review. *BJU Int* 2014; 114: 617-629.
- 355.P. Gontero, M. Spahn, G. Marchioro, J.R. Karnes, A. Briganti, B. Frea, U. Ricardi, H. Van Poppel, S. Joniau. Salvage radical prostatectomy in nonmetastatic castration-resistant prostate cancer patients who received previous radiotherapy: a feasibility study. *Eur Urol* 2014; 65: 254-262
- 356.E. Scosyrev, EM. Messing, R. Sylvester, S. Campbell, H. Van Poppel. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. *Eur Urol* 2014; 65: 372-377. – Best Scientific Paper Published in European Urology Award (EAU Congress Madrid 2015)
- 357.J. Gysen, H. Van Poppel. Penile cancer practice guidelines. *Belg J Med Oncol* 2014; 8: 213-216.
- 358.A. Alberts, S. Joniau, H. Van Poppel. Resection of two metachronous solitary pulmonary metastases of prostate cancer after radical prostatectomy: an exceptional case. *Belg J Med Oncol* 2014; 8: 217-219.
- 359.S. Joniau, H. Van Poppel. High-risk localised prostate cancer: the role of surgery and the development of clinical outcome prediction models. *Belg J Med Oncol* 2014; 8: 220-223.

360. Y. Tolkach, F. Imkamp, K. Godin, H. Van Poppel. Clinically relevant genetic characterization of prostate tumors: How close are we to the goal? *KJU* 2015; 56: 90-98.
361. C.H. Bangma, R. Valdagni, P.R. Carroll, H. Van Poppel, L. Klotz, J. Hugosson. Active surveillance for low-risk prostate cancer: developments to date. *Eur Urol* 2015; 67: 646-648.
362. F. Abdollah, A. Briganti, F. Montorsi, A. Stenzl, C. Stief, B. Tombal, H. Van Poppel, K. Touijer. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. *Eur Urol* 2015; 67: 839-849.
363. R. Valdagni, H. Van Poppel, M. Aitchison, P. Albers, D. Berthold, A. Bossi, M. Brausi, L. Denis, L. Drudge-Coates, M. De Santis, G. Feick, C. Harrison, K. Haustermans, D. Hollywood, M. Hoyer, H. Hummel, M. Mason, V. Mirone, S.C. Müller, C. Parker, M. Saghatchian, C.N. Sternberg, B. Tombal, E. van Muilekom, M. Watson, S. Wesselmann, T. Wiegel, T. Magnani, A. Costa. Prostate Cancer Unit Initiative in Europe: a position paper by the European School of Oncology. *Crit Rev Oncol/Hematol* 2015: <http://dx.doi.org/10.1016/j.critrevonc.2015.05.2014>
364. H. Van Den Bossche, R. Kokx, M. Albersen, C. Assenmacher, H. Van Poppel, S. Joniau. Prostatopubic fistula and osteomyelitis of the pubic bone as severe complication after salvage high intensity focused ultrasound for prostate cancer: report of two cases. *BJMO* 2015; 9: 290-294.
365. E. Lerut, H. Van Poppel, S. Joniau, O. Gruselle, T. Coche, P. Therasse. Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. *Int J Clin Exp Pathol* 2015; 8: 9522-9532.
366. S. Joniau, A. Briganti, P. Gontero, G. Gandaglia, L. Tosco, S. Fieuws, B. Tombal, G. Marchioro, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, R.J. Karnes, F. Montorsi, H. Van Poppel, M. Spahn. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. *Eur Urol* 2015; 67: 157-164.
367. A. Briganti, R.J. Karnes, G. Gandaglia, M. Spahn, P. Gontero, L. Tosco, B. Kneitz, F.K.H. Chun, E. Zaffuto, M. Sun, M. Graefen, G. Marchioro, D. Frohneberg, S. Giona, P.I. Karakiewicz, H. Van Poppel, F. Montorsi, S. Joniau. Natural history of surgically treated high-risk prostate cancer. *Urologic Oncology* 2015; 33: 163.e7-163.e13.
368. L. Van den Bergh, E. Lerut, K. Haustermans, C.M. Deroose, R. Oyen, S. Isebaert, T. Budiharto, F. Ameye, F.M. Mottaghy, K. Bogaerts, H. Van Poppel, S. Joniau. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. *Urologic Oncology* 2015; 33: 109.e23-109.e31.

- 369.R. Valdagni, H. Van Poppel, M. Aitchison, P. Albers, D. Berthold, A. Bossi, M. Brausi, L. Denis, L. Drudge-Coates, M. De Santis, G. Feick, C. Harrison, K. Haustermans, D. Hollywood, M. Hoyer, H. Hummel, M. Mason, V. Mirone, SC. Müller, C. Parker, M. Saghatchian, CN. Sternberg, B. Tombal, E. van Muilekom, M. Watson, S. Wesselmann, T. Wiegel, T. Magnani, A. Costa. Prostate cancer unit initiative in Europe: a position paper by the European School of Oncology. *Critical Reviews in Oncology/Hematology* 2015; doi.org/10.1016/j.critrevonc.2015.05.014.
- 370.F. Moltzahn, J. Karnes, P. Gontero, B. Kneitz, B. Tombal, P. Bader, A. Briganti, F. Montorsi, H. Van Poppel, S. Joniau, M. Spahn. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. *Prostate Cancer and Prostatic Disease* 2015; 18: 31-37.
- 371.S. Joniau, M. Spahn, A. Briganti, G. Gandaglia, B. Tombal, L. Tosco, G. Marchioro, CY Hsu, J. Walz, B. Kneitz, P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. van Cangh, RJ Karnes, F. Montorsi, H. Van Poppel, P. Gontero. Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. *Eur Urol* 2015; 67: 319-325.
- 372.N. Fossati, RJ. Karnes, C. Cozzarini, C. Fiorino, G. Gandaglia, S. Joniau, SA. Boojian, G. Goldner, W. Hinkelbein, K. Haustermans, B. Tombal, S. Shariat, PI. Karakiewicz, F. Montorsi, H. Van Poppel, T. Wiegel, A. Briganti. Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. *Eur Urol* 2016; 69: 728-733.
- 373.H. Van Den Bossche, R. Kokx, M. Albersen, C. Assenmacher, H. Van Poppel, S. Joniau. Prostatopubic fistula and osteomyelitis of the pubic bone as severe complication after salvage high intensity focused ultrasound for prostate cancer: report of two cases. *BJMO* 2015; 9: 290-295
374. A. Engelen, J. Vanderhaegen, H. Van Poppel, C. Van Audenhove. The use of decision aids on early detection of prostate cancer: views of men and general practitioners. *Health Expectations* 2016; doi:10.1111/hex.12451
- 375.T. De Sutter, M. Akand, M. Albersen, W. Everaerts, B. Van Cleynenbreugel, D. De Ridder, H. Goethuys, L. Moris, U. Milenkovic, H. Van Poppel, F. Van der Aa, S. Joniau. The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. *SpringerPuls* 2016; 5: 646
- 376.P. Dell'Oglio, RJ Karnes, S. Joniau, M. Spahn, P. Gontero, L. Tosco, N. Fossati, B. Kneitz, P. Chlosta, M. Graefen, G. Marchioro, M. Bianchi, R. Sanchez-Salas, P.I. Karakiewicz, H. Van Poppel, F. Montorsi, A. Briganti. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. *Urologic Oncology* 2016; 34: 234.e13-234e.19

- 377.C. Fiorino, S. Broggi, N. Fossati, C. Cozzarini, G. Goldner, T. Wiegel, W. Hinkelbein, R.J. Karnes, S.A. Boorjian, K. Haustermans, S. Joniau, F. Palorini, S. Shariat, F. Montorsi, H. Van Poppel, N. Di Muzio, R. Calandrino, A. Briganti. Predicting the 5-year risk of biochemical relapse after postprostatectomy radiation therapy in \geq PT2, pN0 patients with a comprehensive tumor control probability model. *Int J Radiation Oncol Biol Phys* 2016; article in press.
- 378.A. Bex, B. Ljungberg, H. Van Poppel, T. Powles. The role of cytoreductive nephrectomy: European Association of Urology recommendations in 2016. *Eur Urol* 2016; 70: 901-905
- 379.E. Baten, M. Akand, M.S. Floyd, B. Van Cleynenbreugel, M. Albersen, W. Everaerts, H. Van Poppel, F. Van der Aa, S. Joniau. Evaluation of conservative approach in the management of ureteroenteric strictures following radical cystectomy with Bricker ileal conduit: a single-center experience. *Scan. J Urol* 2016; doi.org/10.1080/21681805.2016.1232307
- 380.S. Elsen, E. Lerut, B. Van Cleynenbreugel, F. Van der Aa, H. Van Poppel, P.A. de Witte. Evans blue as a diagnostic tool for non-muscle-invasive bladder cancer: a preclinical study. *BJMO* 2016; 10: 281-284
- 381.S. Villa, F. Kendel, L. Venderbos, T. Rancati, C. Bangma, P. Carroll, L. Denis, L. Klotz, I.J. Korfage, A.J. Lane, T. Magnani, K. Mastris, A. Rannikko, M. Roobol, B. Trock, R. Van den Bergh, H. Van Poppel, R. Valdagni, L. Bellardita. Setting an agenda for assessment of health-related quality of life among men with prostate cancer on active surveillance: a consensus paper from a European School of Oncology Task Force. *Eur Urol* 2016; article in press: <http://dx.doi.org/10.1016/j.eururo.2016.09.041>
- 382.M.E. Goossens, M.P. Zeegers, H. Van Poppel, S. Joniau, K. Ackaert, F. Ameye, I. Billiet, J. Braeckman, A. Breugelmans, J. Darras, K. Dilen, L. Goeman, B. Tombal, S. Van Bruwaene, B. Van Cleynenbreugel, F. Van der Aa, K. Vekemans, F. Buntinx. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer trial. *Eur J of Cancer* 2016; 69: 9-18
- 383.A. Van Holsbeeck, A. Degroote, L. De Wever, E. Vanhoutte, F. De Keyzer, H. Van Poppel, R. Oyen. Staging of prostatic carcinoma at 1.5-T MRI: correlation of a simplified MRI exam with whole-mount radical prostatectomy specimens. *Br J Radiol* 2016; 89: 20160101.
- 384.C.M. Moore, F. Giganti, P. Albertsen, C. Allen, C. Bangma, A. Briganti, P. Carroll, M. Haider, V. Kasivisvanathan, A. Kirkham, L. Klotz, A. Ouzzane, A.R. Padhani, V. Panebianco, P. Pinto, P. Puech, A. Rannikko, R. Renard-Penna, K. Touijera, B. Turkbey, H. Van Poppel, R. Valdagni, J. Walz, I. Schoots. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE

- recommendations – a report of a European School of Oncology task force. *Eur Urol* 2016; article in press: <http://dx.doi.org/10.1016/j.eururo.2016.06.011>
385. N. Fossati, R.J. Karnes, S.A. Boorjian, M. Moschini, A. Morlacco, A. Bossi, T. Seisen, C. Cozzarini, C. Fiorino, B. Noris Chiorda, G. Gandaglia, P. Dell'Oglio, S. Joniau, L. Tosco, S. Shariat, G. Goldner, W. Hinkelbein, D. Bartkowiak, K. Haustermans, B. Tombal, F. Montorsi, H. Van Poppel, T. Wiegel, A. Briganti. Long-term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: results from a multi-institutional series. *Eur Urol* 2016; article in press: <http://dx.doi.org/10.1016/j.eururo.2016.07.028>
386. F. Castiglione, P. Dell'Oglio, L. Tosco, W. Everaerts, M. Albersen, L. Hakim, T. Van den Broeck, L. Moris, F. Claessens, A. Briganti, F. Montorsi, H. Van Poppel, S. Joniau, EMPaCT. Tumor volume and clinical failure in high-risk prostate cancer patients treated with radical prostatectomy. *Prostate* 2016; Epub ahead of print.
387. L. Moris, T. Van den Broeck, L. Tosco, A. Van Baelen, P. Gontero, R.J. Karnes, W. Everaerts, M. Albersen, P.J. Bastian, P. Chlosta, F. Claessens, F.K. Chun, M. Graefen, C. Gratzke, B. Kneitz, G. Marchioro, R. Sanchez Salas, B. Tombal, H. Van Der Poel, J.C. Walz, G. De Meerleer, A. Bossi, K. Haustermans, F. Montorsi, H. Van Poppel, M. Spahn, A. Briganti, S. Joniau. Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection. *Frontiers in Surgery* 2016; 3, doi:10.3389/fsurg.2016.00065
388. R.J. Sylvester, S.E. Canfield, T.B.L. Lam, L. Marconi, S. MacLennan, Y. Yuan, G. MacLennan, J. Norrie, M.I. Omar, H.M. Bruins, V. Hernandez, K. Plass, H. Van Poppel, J. N'Dow. Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree. *Eur Urol* 2016: doi.org/10.1016/j.eururo.2016.11.023.
389. L. Moris, T. Van den Broeck, L. Tosco, A. Van Baelen, P. Gontero, R.J. Karnes, W. Everaerts, M. Albersen, P.J. Bastian, P. Chlosta, F. Claessens, F.K. Chun, M. Graefen, C. Gratzke, B. Kneitz, G. Marchioro, R.S. Salas, B. Tombal, H. Van Der Poel, J.C. Walz, G. De Meerleer, A. Bossi, K. Haustermans, F. Montorsi, H. Van Poppel, M. Spahn, A. Briganti, S. Joniau for the European Multicenter prostate cancer clinical and translational research group (EMPaCT). Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection. *Front Surg*. 2016 dec; 3:65
390. S. Van Bruwaene, A. J. Costello, H. Van Poppel. Prognosis of node-positive bladder cancer in 2016. *Minerva Urol Nefrol*. 2016 Apr;68(2):125-37
391. E. Scosyrev, E.M. Messing, R. Sylvester, H. Van Poppel. Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial Nephron-sparing Surgery

Versus Radical Nephrectomy. *European Urology Focus* 2017:

doi.org/10.1016/j.euf.2017.02.15

392. Nicola Fossati, R. Jeffrey Karnes, Stephen A. Boorjian, Marco Moschini, A Morlacco, A Bossi, T Seisen, C Cozzarini, C Fiorino, B Noris Chiorda, G Gandaglia, P Dell'Oglio, Steven Joniau, Lorenzo Tosco, S Shariat, G Goldner, W Hinkelbein, D Bartkowiak, K Haustermans, Bertrand Tombal, Francesco Montorsi, H Van Poppel, T Wiegel, A Briganti. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. *European Urology* (71): doi.org/10.1016/j.eururo.2016.07.028
393. Castiglione F, Dell'Oglio P, Tosco L, Everaerts W, Albersen M, Hakim L, Van Den Broeck T, Moris L, Claessens F, Briganti A, Montorsi F, Van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Tumor volume and clinical failure in high-risk prostate cancer patients treated with radical prostatectomy. *The prostate*, 2017 January; 77(1):3-9. <http://onlinelibrary.wiley.com/doi/10.1002/pros.v77.1/issuetoc>
394. Nicola Fossati, R. Jeffrey Karnes, Stephen A. Boorjian, Marco Moschini, Alessandro Morlacco, Alberto Bossi, Thomas Seisen, Cesare Cozzarini, Claudio Fiorino, Barbara Noris Chiorda, Giorgio Gandaglia, Paolo Dell-Oglio, Steven Joniau, Lorenzo Tosco, Shahrokh Shariat, Gregor Goldner, Wolfgang Hinkelbein, Detlef Bartkowiak, Karin Haustermans, Bertrand Tombal, Francesco Montorsi, Hein Van Poppel, Thomas Wiegel, Alberto Briganti. Long-Term impact of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer patients treated with radical prostatectomy: Results from a multi-institutional series. *European urology* 71 (2017) 886-893: doi.org/10.1016/j.eururo.2016.07.028
395. Kathryn E. Beckermann, Deva Sharma, Shruti Chaturvedi, Pavlos Msaouel, Miguel R. Abboud, Yves Allory, Franck Bourdeaut, Julie Calderaro, Aguirre A. de Cubas; Vimal K. Derebail, Andrew L. Hong, Rakhi P. Naik, Gabriel G. Malouf, Elizabeth A. Mullen, Victor E. Reuter, Charles W.M. Roberts, Cheryl L. Walker, Christopher G. Wood, Michael R. DeBaun, Hendrik. Van Poppel, Nizar M. Tannir and W. Kimryn Rathmell. Renal Medullary Carcinoma: Establishing Standards in Practice. *Journal of Oncology Practice*, volume 3, issue 7, July 2017
396. Sara J. MacLennan, Steven MacLennan, Axel Bex, James W.F. Catto, Maria De Santis, Adam W. Glaser, Borje Ljunberg, James N'Dow, Karin Plass, Marta Trapero-Bertran, Hendrik Van Poppel, Penny Wright, Rache H. Giles. Changing Current Practice in urology: Improving Guideline Development and Implementation Through Stakeholder Engagement. *European Urology* 72 (2017) 161-163: dx.doi.org/10.1016/j.eururo.2017.02.008

397. Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Seater G, Schrappe M, Soffiatti R, Travado L, Van Poppel H, Wait S, Naredi P. Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. *European Urology of Cancer* 82 (2017) 193-202
398. B Tombal, M Borre, P Rathenborg, P Werbrouck, H Van Poppe, A Heidenreich, P Iversen, J Breackman, J Heracek, B Baron, A Krivoschik, M Hirmand, MR Smith. Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 3-year, Open-label, Follow-up Results. *Journal of Urology* 14960 (DOI: <http://dx.doi.org/10.1016/j.juro.2017.08.103>)
399. T Knoll, MI Omar, S MacLennan, V Hernandez, S Canfield, Y Yua, M Bruins, L Marconi, H Van Poppel, J N'Dow. Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. *European Urology* (<https://doi.org/10.1016/j.eururo.2017.08.016>)
400. A. Verbiest, G. Couchy, S. Job, J. Zucman-Rossi, L. Caruana, E. Lerut, R. Oyen, A. de Reynies, B. Laguerre, N. Rioux-Leclercq, A. Wozniak, S. Joniau, H. Van Poppel, K. Van Den Eynde, B. Beuselinck. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. (<https://doi.org/10.1016/j.clgc.2017.10.017>)
401. E.J. Smith, S. MacLennan, A. Bjartell, A. Briganto, T. Knoll, T. Loch, M.J. Ribl, R. Sylvester, H. Van Poppel, J. N'Dow. Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better? *Biomed Hub* 2017; 2 (suppl 1): 479725 ([doi:10.1159/000479725](https://doi.org/10.1159/000479725))
402. M.E. Goossens, M.P. Zeegers, H. Van Poppel, F. Buntinx. Risk factors associated with bladder cancer occurrence and recurrence: an epidemiological and clinical approach. *BJMO Oncothesis*, volume 11, December 2017; 393-395 (www.aries.com)
403. L. Tosco, A. Laenen, A. Briganti, P. Gontero, RJ, Karnes, M. Albersen, PJ. Bastian, P. Chlosta, F. Claessens, FK. Chun, W. Everaerts, C. Gratzke, M. Graefen, B. Kneitz, G. Marchioro, RS. Salas, B. Tombal, T. Van den Broeck, L. Loris, A. Battaglia, H. Van der Poel, J. Walz, A. Bossi, G. De Meerleer, K? Haustermans, H. Van Poppel, M. Spahn, S. Joniau. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. *Prostate cancer Prostatic Dis.* 2017 May. [Epub ahead of print]
404. L. Tosco, A. Laenen, A. Briganti, P. Gontero, RJ . Karnes, PJ. Bastian, P. Chlosta, F. Claessens, FK. Chun, W. Everaerts, C. Gratke, M. Albersen, M. Graefen, B. Kneitz, G. Marchioro, RS Salas, B. Tombal, T. Van den Broeck, H. Van den Poel, J. Walz, G. De Meerleer, A. Bossi, K. haustermans, H. Van Poppel, M. Spahn, S. Joniau. The

- EMPaCT classifier for patients with adverse pathological features after radical prostatectomy and lymph node dissection: preliminary results of a validated model to predict prostate cancer related death using competing risk analysis. *EU Focus*. [Epub ahead of print]
405. F. Castiglione, P. Dell-Oglio, L. Tosco, W. Everaerts, M. Albersen, L. Hakim, T. Van den Broeck, L. Moris, F. Claessens, A. Briganti, F. Montorsi, H. Van Poppel, S. Joniau; European Multicenter Prostate Cancer Clinical and Translation Group (EMPaCT). Tumor volume and clinical failure in high-risk prostate cancer patients treated with radical prostatectomy. *Prostate*. 2017 Jan; 77 (1): 3-9
406. R. Veys, F. Abdollah, A. Briganti, M. Albersen, H. Van Poppel, S. Joniau. Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages \geq T1b: a single institution, matched analysis. *Cent European J Urol*. 2017 ([doi: 10.5173/ceju.2017.1611](https://doi.org/10.5173/ceju.2017.1611))
407. R. Montironi, A. Lopez-Beltran, A. Briganti, J. N'Dow. Update on genitourinary pathology: from the latest morphological novelties to molecular pathology and genomics. *European Urology Supplement* 16 (2017); 197-198 (doi.org/10.1016/j.eursup.2017.10.002)
408. T. Knoll, M.I. Omar, S. Maclennan, V. Hernandez, S. Canfield, Y. Yuan, M. Bruins, L. Marconi, H. Van Poppel, J. N'Dow, R. Sylvester. Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. *European Urology* (73) 2018; 290-300 (<http://dx.doi.org/10.1016/j.eururo.2017.08.016>)
409. T. Van den Broeck, T. Gevaert, S. Prekovic, K. Ong, L. Tosco, L. Mois, E. Smeets, J. Lehrer, Z. Hadded, C. Helsen, J. Margrave, H. Van Poppel, W. Everaerts, N. Erho, C. Berki, E. Davicioni, F. Claessens, S. Joniau. Decipher test predicts metastatic disease in a European, high-risk prostate cancer publication. Submitted

IV.3. Proceedings or abstract-publication

1. Introduction to neurogenic bladder and pelvic floor dysfunction. Incidence and diagnostic problems.
H. Van Poppel et al.
Abstr. Jubilee Conference on M.S., Copenhagen, pp. 74, 1982
2. Ileo-ureteral reflux in Bricker derivations.
H. Van Poppel et al.
Abstr. 24. Tagung der Vereinigung Norddeutscher Urologen, Kassel, pp. 64, 1982
3. Longterm alpha-adrenergic blocking therapy in detrusor-urethra dyssynergia.
R.L. Vereecken, H. Van Poppel et al.
Abstr. 19th International Congress of the Soc. Int. Urol., San Francisco, pp. 22, 1982

4. External spinal cord stimulation in neuropathic detrusor dysfunction.
H. Van Poppel et al.
Proc. 6th E.A.U.: 74, 1984
5. Assessment of neuropathic urethral dysfunction by static pressure recording.
H. Van Poppel et al.
Proc. 6th E.A.U.: 178, 1984
6. Heavy urinary tract infections in neurogenic bladders treated with ciprofloxacin.
H. Van Poppel et al.
Abstr. 4th Mediterranean Congress of Chemotherapy, Rhodes, pp. 361, 1984
7. Werden Harnwegs-Infektionen zum Problem - Ciprofloxacin.
H. Van Poppel.
Praxis-Kurier 29: 14-16, 1986
8. Importance de l'urographie intraveineuse dans le diagnostic des tumeurs des voies excrétrices.
H. Van Poppel et al.
Abstr. 51st Congress of the Soc. Belge d'Urologie, Brussels, pp. 14, 1986
9. Oral treatment of Pseudomonas-induced urinary tract infection with ciprofloxacin.
H. Van Poppel.
Infect. Dis. Digest., pp. 7-8, October 1986
10. Oral treatment of Pseudomonas-induced urinary tract infection with ciprofloxacin.
H. Van Poppel.
Urology Digest, pp. 21-22, December 1986
11. Preoperative evaluation of small renal masses.
H. Van Poppel et al.
Abstr., 3rd Congress of the Eur. Soc. of Surg. Oncology, Lisboa, p. 71, 1986
12. Clinical experience with ciprofloxacin in the therapy of urinary tract infections.
H. Van Poppel, V. Chysky, L. Baert.
Abstr. Quinolonen: Basisgegevens en klinische ervaringen, Eindhoven, p. 20, 1987
13. Vesico-sphincteriële stoornissen bij Multiple Sclerose.
H. Van Poppel.
Syllabus "International Society of Prosthetics and Orthotics", 1987
14. Prostate specific antigen (PSA): Methodological and clinical aspects.
P. Devos, H. Claes, M. Gerits, H. Van Poppel, M. Deroo, L. Baert.
Abstr. European Nuclear Medicine Congress, Budapest, 1987
15. Biotyping and susceptibility behaviour of pathogens in patients treated with ciprofloxacin (CIP).
C. Kraseman, H. Van Poppel, M. Wegge, V. Chysky.
Abstr. 6th Mediterranean Congress of Chemotherapy, Taormina, pp. 258, 1988

16. Relevance of dynamic cavernosography to the diagnosis of venous leak in erectile dysfunction.
H. Claes, H. Van Poppel, L. Baert.
Abstr. 6th Forum of International Andrology, Paris, pp. 168, May 1988
17. Surgical treatment of renal cell carcinoma.
L. Baert, H. Van Poppel.
Abstr. 3rd International Symposium on Interventional Radiology, Luxembourg, October 13-15, 1988
18. Surgical treatment of urinary bladder carcinoma.
L. Baert, H. Van Poppel.
Abstr. 3rd International Symposium on Interventional Radiology, Luxembourg, October 13-15, 1988
19. Bladder conserving treatment with interstitial implantation for invasive bladder cancer.
E. Van Limbergen, H. Van Poppel.
Proc. E.S.O. meeting, Greece, pp. 179-184, May 4-6, 1989
20. Urétréctomie prépubienne.
H. Van Poppel, L. Baert.
Abstr. 83ième Congrès Français d'Urologie, Paris, pp. 177, November 15-17, 1989
21. Chirurgie conservatrice pour cancer rénal.
H. Van Poppel, L. Baert.
Abstr. 83ième Congrès Français d'Urologie, Paris, pp. 165, November 15-17, 1989
22. Interstitial radiotherapy for invasive bladder cancer.
H. Van Poppel, E. Van Limbergen, E. van der Schueren, L. Baert.
Abstr. 5th Congress ESSO, Brussels, October 17-20, 1990
23. Präpubische Urethra Resektion.
H. Van Poppel, L. Baert.
Mitteilungen der Deutsche Gesellschaft für Urologie, 4: pp. 19 en pp. 32, 1990
24. Präpubische Urethra Resektion.
H. Van Poppel, L. Baert.
Abstr. 42. Kongress der Deutsche Gesellschaft für Urologie, Hamburg, September 26-29, 1990
25. Transuretero-pyelostomy for ureteral necrosis after continent umbilical Mainz pouch urinary diversion.
H. Van Poppel, L. Baert.
Abstr. 56th Congress of the Société Belge d'Urologie, Brussels, May 25-26, 1991
26. Cytogenetic investigations in normal and malignant kidney tissues.
M. Aly, P. Dal Cin, H. Van Poppel, L. Baert, B. Van Damme, J.-J. Cassiman, H. Van

- den Berghe.
Abstr. European Society of Human Genetics, Leuven, July 13-16, 1991
27. Exploration histochimique de l'innervation vésicale et le rôle de l'innervation peptidergique de la vessie dans les dysfonctions neurogènes de la sclérose en plaques.
 H. Van Poppel, L. Baert, H. Carton.
 Rapport decennal. Fondation Van Goethem-Brichant, pp. 31-32, 1992
28. Longterm results of interstitial radiotherapy for invasive bladder cancer.
 H. Van Poppel, E. Van Limbergen, R. Tan, L. Baert.
Abstr. Euro-American Conference on Urological Cancer, pp. 42, Athens, September 15-18, 1992
29. Accuracy of CT and FNAB of localized prostatic carcinoma and bladder carcinoma.
 R. Oyen, F. Ameye, H. Van Poppel, L. Baert, A.L. Baert.
Abstr. European Congress of Radiology, Vienna, September 15-20, 1991
 Eur. Radiol. 1: S35 (Abstr. 205), 1991
30. Cytogenetic investigations in normal and malignant kidney tissues.
 H. Van Poppel, P. Dal Cin, M.S. Aly, J. Delabie, J. Ceuppens, B. Van Damme, L. Baert, H. Van den Berghe.
Abstr. Euro-American Conference on Urological Cancer, Athens, pp. 54, September 15-18, 1992
31. Sense or non-sense of neo-adjuvant hormonotherapy before radical prostatectomy.
 H. Van Poppel, F. Ameye, R. Oyen, W. Van de Voorde, L. Baert.
Abstr. Euro-American Conference on Urological Cancer, Athens, pp. 63, September 15-18, 1992
32. Valeur de la lymphadénectomie dans le cancer du rein non-métastatique. Résultats préliminaires d'une étude phase III de l'EORTC.
 D. Jacqmin, J.H.M. Blom, H. Van Poppel, J.M. Maréchal, W. de Riese, K. Vermeylen, R. Sylvester, et EORTC GU Group.
Abstr. Assoc. française d'Urologie, Paris, pp. A3, October 21-23, 1992
33. Konservative Operation: Stellenwert in der Behandlung von Nierenzellkarzinomen.
 H. Van Poppel et al.
 Extracta Urologica 15: 4, 1992
34. Treatment of lower urinary tract dysfunction in patients with Multiple Sclerosis.
 C.J. Fowler, Ph.E.V. van Kerrebroeck, A. Nordenbo, H. Van Poppel.
Abstr. J. Urol. 149: 1648, 1993
35. Benign hyperplastic nodules originating in the peripheral zone of the prostate.
 R.H. Oyen, W.M. Van de Voorde, H.P. Van Poppel, P.P. Brijs, F.E. Ameye, Y.M. Franssens, L.V. Baert, A.L. Baert.

- European Congress of Radiology, Vienna, September 13-17, 1993
Eur. Radiol., Suppl., SS605; Abstr. 481, 1993
36. Cirurgia conservadora nos carcinomas de células renais.
H. Van Poppel, L. Baert.
VIII Simpósio internacional de urologia. Update 1993, Espinho, Portugal, pp. 22
37. Cytogenetic study of renal cell carcinoma.
M.S. Aly, P. Dal Cin, B. Van Damme, H. Van Poppel, L. Baert, H. Van den Berghe.
4th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumors, Noordwijkerhout, April 23-26, 1994
38. Bricker urinary diversion after cysto(prostato)-urethrectomy. Still an acceptable diversion.
H. Van Poppel, R. Vandeursen, L. Baert.
Abstr. XIth Congress of the European Association of Urology, July 13, 1994
39. Hormonal treatment before radical prostatectomy is beneficial only in clinical T2 patients.
H. Van Poppel, P. Werbrouck, K. Ackaert, D. De Ridder, L. Baert.
Abstr. XIth Congress of the European Association of Urology, July 13, 1994
40. Mitomycin-C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: interim results on a randomized trial.
H. Van Poppel, F. Vandembroucke, J. Derluyn, G. Popelier, L. Baert.
Abstr. XIth Congress of the European Association of Urology, July 13, 1994
41. Trisomy 7 and trisomy 10 in the healthy parenchyma of RCC bearing kidneys is not a premalignant lesion.
H. Van Poppel, P. Dal Cin, M.S. Aly, B. Van Damme, H. Van den Berghe, L. Baert.
Abstr. XIth Congress of the European Association of Urology, July 13, 1994
42. Non-papillary renal cell carcinoma is characterized by monosomy 3p and papillary renal cell carcinoma by trisomy 17 and other chromosome changes.
H. Van Poppel, M.S. Aly, P. Dal Cin, B. Van Damme, H. Van den Berghe, L. Baert.
Abstr. XIth Congress of the European Association of Urology. July 13, 1994
43. CT-scan and fine needle aspiration cytology for lymph node staging in 285 radical prostatectomy candidates.
H. Van Poppel, R. Oyen, F. Ameye, W. Van de Voorde, R. Vandeursen, L. Baert.
Abstr. XIth Congress of the European Association of Urology. July 13, 1994.
44. Chairman Oral Session Renal Cell Cancer Treatment II.
XIth Congress of the European Association of Urology. July 13, 1994
45. Elective kidney sparing surgery for renal cell carcinoma in 33 patients.
H. Van Poppel, G. Beckers, B. Van Damme, L. Baert.
Abstr. XIth Congress of the European Association of Urology. July 13, 1994

46. Endoscopically assisted nephro-ureterectomy.
H. Van Poppel, P. Pattijn, R. Vandeursen, L. Baert.
Abstr. XIth Congress of the European Association of Urology. July 13, 1994
47. T₃pT₃ prostate cancer. Situation of the problem.
H. Van Poppel, W. Van de Voorde, R. Oyen, L. Baert.
Abstr. of the XXIVth Congress of the Polish Urological Association. September 2, 1994. Urologica Polska, suppl. 3A, pp. 6, Abstr. N° 8, 1994
48. Occurrence of premalignant lesions in radical prostatectomies.
W. Van de Voorde, A. Elgamal, M. Baldewyns, H. Van Poppel, L. Baert, J. Lauweryns.
Abstr. of the 1st International Consultation Meeting on Prostatic Intraepithelial Neoplasia and the Origins of Prostatic Carcinoma, Ancona, pp. 53, September 11-12, 1994
49. Urostoma's en pouches: verschillende types van urineafleidingen: heelkundige en medische aspecten.
H. Van Poppel, L. Baert.
Abstr. of the 5th Congress of the Wound Care Consultant Society, Brussels, November 10, 1994. WCS Nieuws 4: 49, 1994
50. Selective zonal distribution of tumor volume versus grade in T1c prostate cancer.
A. Elgamal, W. Van de Voorde, H. Van Poppel, J. Lauweryns, L. Baert.
AUA Meeting, Las Vegas, J. Urol. 153 (Suppl.), Abstr. 1024, pp. 484A, 1995
51. Extraprostatic sources of PSA, does it infer the subjective biochemical recurrence after radical prostatectomy.
A. Elgamal, J. Billen, W. Van de Voorde, H. Van Poppel, N. Blanckaert, M. De Roo, L. Baert.
AUA Meeting, Las Vegas, J. Urol. 153 (Suppl.), Abstr. 1157, pp. 518A, 1995
52. Microscopic vascular invasion: the most significant prognostic factor in renal cell carcinoma.
H. Van Poppel, K. Boel, B. Van Damme, L. Baert.
AUA Meeting, Las Vegas, J. Urol. 153 (Suppl.), Abstr. 106, pp. 255A, 1995
53. The influence of transcutaneous nitroglycerine on nocturnal erections.
H. Claes, H. Van Poppel, G. Smet, L. Baert.
AUA Meeting, Las Vegas, J. Urol. 153 (Suppl.), Abstr. 980, pp. 473A, 1995
54. The use of serum tissue polypeptide antigen as a tumor marker for bladder cancer.
H. Van Poppel, J. Billen, M. De Roo, L. Baert.
Anticancer Research 15(5A), Abstr. 522, pp. 1387, 1995
55. Radical prostatectomy.
H. Van Poppel, W. Van de Voorde, R. Oyen, L. Baert.
Eur. J. Cancer 31A (Suppl. 5), Abstr., 17, pp. S4, 1995

56. Risultati preliminaria di una sperimentazione randomizzata sulla Mitomicine C in associazione a orchietomia nel carcinoma prostatico metastatico diagnosticato de novo.
F. Van den Broucke, H. Van Poppel, J. Derluyn et al.
Urology Digest 1: 21-22, 1996
57. Free/total PSA ratio (F/T) as a simple test for detection of significant T1c prostate cancer.
A.A. Elgamal, F. Cornillie, H. Van Poppel, J. Van Dorpe, E. Gero, C. Habertzettl, R. McGabe, L.V. Baert.
J. Urol. 155 (Suppl.), Abstr. 233, pp. 369A, 1996
58. Management of intractable bladder hyperreflexia in M.S. by Capsaicin instillation.
D. De Ridder, H. Van Poppel, L. Baert.
J. Urol. 155 (Suppl.), Abstr. 1113, pp. 589A, 1996
59. Nephron sparing surgery in renal cell carcinoma.
H. Van Poppel, B. Bamelis, L. Baert.
Turk. J. Urol., Abstr. O33, pp. 24, 1996
60. Nephrectomy for metastatic renal cell carcinoma.
H. Van Poppel, L. Baert.
Turk. J. Urol., Abstr. O34, pp. 24, 1996
61. Is serum TPA a valuable marker for transitional cell carcinoma ?
H. Van Poppel, A. Elgamal, J. Billen, N. Blanckaert, L. Baert.
ISOBM, Abstr. 088, pp. 102, 1996
62. The use of free/total (F/T) PSA ratio enhances detection of the impalpable invisible T1c prostate cancer.
A.A. Elgamal, H. Van Poppel, R. Bustami, L. Baert.
Eur. Urol. 30(S2), Abstr. N° 20, pp. 21, 1996
63. The efficacy of the Siemens multiline tube 'M' lithotripter.
B. Winnepeninckx, H. Goethuys, H. Van Poppel, L. Baert.
Eur. Urol. 30(S2), Abstr. N° 581, pp. 162, 1996
64. Alterations in the morphology of prostate cancer after neoadjuvant treatment.
Eur. Urol. 30(S2), Abstr. N° 771, pp. 209, 1996
65. T1c prostate cancer characteristics and clinical relevance in 100 radical prostatectomy specimens, Leuven experience.
A.A. Elgamal, H. Van Poppel, J. Van Dorpe, W. Van de Voorde, J. Lauweryns, L. Baert.
Eur. Urol. 30(S2), Abstr. N° 825, pp. 223, 1996
66. Microvascular invasion: the most significant prognostic factor in renal cell carcinoma.

- R. Oyen, H.V. Van Poppel, B. Van Damme, L. Baert, A. Baert.
Abstr. International Uroradiology '96, pp. 43, 1996
67. Radiotherapy-Hyperthermia combination for localized carcinoma of the prostate.
H. Goethuys, F. Ameye, D. De Bal, R. Oyen, H. Van Poppel, L. Baert, Z. Petrovich.
Abstr. 43rd Annual Meeting of the Radiation Research Society/15th Annual Meeting of the North American Hyperthermia Society, San José California, pp. 137, April 1-6, 1995
68. Is serum tissue polypeptide antigen (TPA) a valuable marker for transitional cell carcinoma?
H. Van Poppel, A. Elgamal, J. Billen, N. Blanckaert and L. Baert.
Abstr. VI International symposium on biology and clinical usefulness of tumor markers, Barcelona, n° L-35, February 12-15, 1997
69. Expression of Prostate Specific Antigen (PSA) mRNA in salivary glands: implications for detection using RT-PCR.
A.A. Elgamal, J.V. Swinnen, H.P. Van Poppel, G. Verhoeven, L.V. Baert.
Abstr. American Urological Association Meeting New Orleans April 12-17, J. Urol. 157(Suppl.), 13, p.4, 1997
70. Serum Tissue Polypeptide Antigen (TPA): A valuable marker for monitoring transitional cell carcinoma.
H.P. Van Poppel, A.A. Elgamal, J. Billen, N. Blanckaert, L.V. Baert.
Br. J. Urol. 80, Suppl. 2, Abstr. 102, pp. 27, 1997
71. A warranted indication of free/total (F/T) prostate specific antigen (PSA) ratio measurement for the diagnosis of impalpable stage T1c prostate cancer (CaP).
A.A. Elgamal, H.P. Van Poppel, L.V. Baert.
Br. J. Urol. 80, Suppl. 2, Abstr. 974, pp. 248, 1997
72. Radical prostatectomy for PSA detected stage T1c prostate cancer. It could be better after tumor stratification.
A.A. Elgamal, H.P. Van Poppel, J.A. Van Dorpe, R.H. Oyen, L.V. Baert.
Br. J. Urol. 80, Suppl. 2, Abstr. 1005, pp. 256, 1997
73. Serum tissue polypeptide antigen (TPA): A valuable marker for monitoring the transitional cell carcinoma.
H.P. Van Poppel, A. Elgamal, J. Billen, N. Blanckaert, L.V. Baert
Anticancer Research 17 (suppl.), Abstr. 70, pp. 4203-4204, 1997
74. Randomisierte Phase II Studie (EORTC 30944): EMP vs. EMP/VBL.
Chemotherapie des hormonrefraktären Prostatakarzinoms
Albrecht W., Horenblas S., Marechal J.M, Mickisch G, Horwich A., Serreta V., Cassetta G., Van Poppel H., Kalman S., and Sylvester R
J. Urol. Urogynäkol. 1997; 4, Sonderheft 1:5
75. Prediction of Urinary continence following radical prostatectomy

- M. Van Kampen, W. De Weerdt, H. Van Poppel, H. Feys, J. Stragier, L. Baert
Abstract book: Abstract n°146, ICS '98 Jerusalem
76. Results of partial nephrectomy for renal cell carcinoma, single center experience in 76 patients
Van Poppel H., Bamelis B., Goethuys H. and Baert L.
European Urology Vol. 33 (suppl 1) Abstr.70 pp. 18,1998
77. A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
Albrecht W., Horenblas S., Marechal J.M, Mickisch G, Horwich A., Serreta V., Cassetta G., Van Poppel H., Kalman S., and Sylvester R
European Urology Vol. 33 (suppl 1) Abstr. 187 pp. 47,1998
78. A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
Albrecht W., Horenblas S., Marechal J.M, Mickisch G, Horwich A., Serreta V., Cassetta G., Van Poppel H., Kalman S., and Sylvester R
Br J. Urol. 81 (suppl. 4): 69, 1998
79. A randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
Albrecht W., Horenblas S., Marechal J.M, Mickisch G, Horwich A., Serreta V., Cassetta G., Van Poppel H., Kalman S., and Sylvester R
Anticancer Research, 18:4823 ,1998
80. Estramustin vs. Estramustin/Vinblastin Chemotherapie beim hormonrefraktären
Albrecht W., Horenblas S., Marechal J.M, Mickisch G, Horwich A., Serreta V., Cassetta G., Van Poppel H., Kalman S., and Sylvester R
Prostatakarzinom (Randomisierte Phase II studie)
Urologe 1998: 37 (suppl1):32
81. Incontinence after radical prostatectomy. Results of a randomised trial comparing pelvic floor physiotherapy versus no treatment
Van Kampen M., De Weerdt W. Van Poppel H., De Ridder D. and Baert L
European Urology Vol. 33 (suppl 1) Abstr. 413, pp.104,1998
82. Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-T3 but has no impact on PSA progression or survival in cT2-T3.
Luc V. Baert, Hans J. Goethuys, Dirk J. De Ridder, Patrick Werbrouck, Koen Ackaert, M. I. Decoster, Hein P. Van Poppel
J. Urology, Vol. 159 , N° 5 (suppl.1) Abstr. 229, 1998

83. Organ sparing surgery: magic bullet or tragic insanity? Abstr: S 1.03. Progress and Controversies in Oncological Urology V, an update of renal bladder and prostate cancer. Rotterdam, October 15-17, 1998
84. Moderator of the session: Renal Cancer. Progress and Controversies in Oncological Urology V, an update of renal bladder and prostate cancer. Rotterdam, October 15, 1998
85. TRUS-guided staging biopsies in patients with clinical T2-T3 prostate cancer: are they useful?
R. Oyen, K. Maes, G. Verswijvel, H. Goethuys, H. Van Poppel, L. Baert
Abstr: 6th European Symposium on Uroradiology, September 12-16, 1998
86. Neoadjuvant hormonal therapy before radical prostatectomy: impact on downstaging and disease free survival.
Van Poppel H., Goethuys H. De Ridder D., Werbrouck P., Ackaert K., Verleyen P., Decoster M., Baert L.
Abstr. XXII Biennial congress of the urological association of South Africa, Sea Point, pp. 39, March 1-5, 1998
87. Neoadjuvante hormonale behandeling voor radikale prostatectomie: impact of stadiëring en ziektevrije overleving.
Verleyen, H. Van Poppel, H. Goethuys, D. De Ridder, L. Baert, J.L. Vanhoucke en andere leden van de Belgische Uro-Oncologische Studiegroep.
Abstr. Professor Elaut prijs, Roeselare, January 23, 1999
88. Urinary Incontinence after radical prostatectomy can be treated by pelvic floor reëducation and predicted by measuring urine loss at catheter withdrawal: a controlled study
M. Van Kampen, W. De Weerdt, H. Van Poppel, L. Baert
89. Annual International Continence Society Meeting, Abstract n°250, Denver, USA, 1999
Is radicale prostatectomie zinvol voor klinisch T3 prostaatcarcinoom?
Boel, H. Van Poppel, H. Goethuys, L. Baert
Abstr. Professor Elaut prijs, Roeselare, January 23, 1999
90. Verhoogde expressie van neuronale no-synthase in weefsel van de neurogene blaas, maar niet van de obstructieve blaas
S. Joniau, D. De Ridder, T. Roskams, H. Van Poppel, L. Baert
Abstr. Professor Elautprijs, Roeselare, January 23, 1999
91. Primary malignant renal epithelial neoplasms radiological-pathological correlation of 5 histological subtypes - is preoperative radiological diagnosis feasible?
G. Verswijvel, T. Roskams, H. Van Poppel, P. Dal Cin, R.H. Oyen
Abstr : European Radiology Vol. 9 Supplement 1, n° 377: European Congress of Radiology, March 7-12, 1999

92. Indeterminate renal masses
Oyen, G. Verswijvel, H. Van Poppel
Abstr: European Radiology Vol. 9 Supplement 1, n° 774 European Congress of Radiology, March 7-12, 1999
93. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer.
Walter Albrecht, Simon Horenblas, Jean M. Marechal, Gerald Mickisch, Alan Horwich, Vincenzo Serreta, Giovanni Cassetta, Hein Van Poppel, Sandra Kalman, Richard Sylvester.
J. of Urology, Vol 161, Supplement 4, n° 1144, 1999
94. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs. estramustine alone in patients with hormone escaped progressive metastatic prostate cancer.
Walter Albrecht, Simon Horenblas, Jean M. Marechal, Gerald Mickisch, Alan Horwich, Vincenzo Serreta, Giovanni Cassetta, Hein Van Poppel, Sandra Kalman, Richard Sylvester.
Eur. J. Cancer. 1999, 35 S4: 342A1379
95. Can Surgery provide cure in clinical T3?
Hein Van Poppel
European Journal of Cancer, Vol: 35, Suppl. 4, Abstract n°1563, 1999
ECCO 10 meeting. The European Cancer Conference, Vienna, September 12-16,1999
96. Malignant renal and adrenal tumors
R.H. Oyen, G. Verswijvel, H. Van Poppel, T. Roskams
European Radiology, Suppl. 1 to Volume 10/Number 2, Abstract n° 226
February 2000
97. MR-urography for the evaluation of patients with urinary diversion or neobladder after cystectomy
G. Verswijvel, H. Van Poppel, R.H. Oyen
European Radiology, Suppl 1 to Volume 10/Number 2, Abstract n° 790,
February 2000
98. Ultrasound: Detection of prostate tumors
R.H. Oyen, G. Verswijvel, H. Van Poppel
European Radiology, Suppl 1 to Volume 10/Number 2, Abstract n° 1269, February 2000
99. Incidentally detected masses
R.H. Oyen, G. Verswijvel, H. Van Poppel

European Radiology, Suppl 1 to Volume 10/Number 2, Abstract n° 1221, February 2000

100. Mitomycin C added to orchiectomy does not improve survival in hormone naive prostate cancer.
Boel Kristien, Van Poppel Hein, Goethuys Hans, Derluyn Jan, Vandenbroucke Frank, Popelier Guy, Casselman Jacques, Billiet Ignace, Vanuytsel Luc, Paridaens Robert, Baert Luc.
Abstract n° 509. XVth congress of the European Association of Urology, Brussels, April 2000
European Urology, 37 (Suppl 2) March 2000.
101. Is quality control of radical prostatectomy feasible?
Van Poppel Hein, Collette Laurence, Newling Donald and the members of the EORTC GU Group
Abstract n° 387 XVth congress of the European Association of Urology, Brussels, April 2000
European Urology, 37 (Suppl 2), March 2000
102. Radiotherapy for PSA recurrence after radical prostatectomy
Vanuytsel Luc, Janssens Geert, Rijnders Alex, Baert Luc, Van Poppel Hein
Abstract n° 532 XV th congress of the European Association of Urology, Brussels, April 2000
103. Die rolle der radikalen prostatektomie beim cT3 Prostatakarzinom
H. Van Poppel, H. Goethuys, P. Callewaert, L. Vanuytsel, W. Van de Voorde, L. Baert
Proceedings Klinische Onkologie, 2000/01, Fortbildungsveranstaltung, p. 329-335, 2000
104. Abstr. Topography of the vanilloid receptor in the normal human bladder: preliminary data
D. De Ridder, T. Roskams, D. Ost, H. Van Poppel, L. Baert
Neurourology and Urodynamics, Vol. 19 (4); 466-467, 2000
105. Abstr. Safety update of a long-term follow-up of "Casodex" (Bicalutamide) 150 mg monotherapy vs castration.
A.V. Kaisary, P. Iversen, C.J. Tyrell, J. B. Anderson, H. Van Poppel, M. Chamberlain, T. Tammela
BJU International, 86, Suppl. 3, 56, 2000
106. Abstr. Casodex may preserve bone mineral density of patients with advanced prostate cancer.
C.J. Tyrell, G.M. Blake, P. Iversen, A.V. Kaisary, J. B. Anderson, H. Van Poppel and M. Chamberlain

- BJU International, 86, Suppl. 3, 220-221, 2000
107. Abstr. The effect on sexual interest of Casodex (bicalutamide) 150 mg compared with castration in patients with advanced prostate cancer
J. B. Anderson, P. Iversen, J. Tyrell, H. Van Poppel, M. Chamberlain, A.V. Kaisary, T. Tammela
BJU International, 86, Suppl. 3, 220, 2000
108. Die Rolle der radikalen Prostatektomie beim cT3-Prostatakarzinom
H. Van Poppel, H. Goethuys, P. Callewaert, L. Vanuytsel, W. Van De Voorde, L. Baert
Proceedings: Klinische Onkologie 2000/'01, 329-335
109. Abstr. De Hautmann neoblaas
J. Benijts, M. Van Kampen, B. Van Cleynenbreugel, D. De Ridder, G. Bogaert, H. Van Poppel
Prof. Elautprijs, Aalst, 25 Januari, 2003
109. Abstr. Efficacy and predictive factors of full-spectrum therapy for nocturnal enuresis. M. Van Kampen, G. Bogaert, B. Van Deun, H. Van Poppel, W. De Weerd
BJU International, 91, Suppl. 1, 20-22, 2003
110. Abstr. Prepubische urethrectomie: onze techniek en nieuwe indicaties
B. Verlinde, H. Van Poppel
Prof. Elautprijs, Aalst, 25 Januari, 2003
111. Abstr. Renaal angiomyolipoma: is behandeling noodzakelijk?
T. Sorgeloose, F. Veduyck, R. Oyen, R. Stessens, H. Van Poppel
Prof. Elautprijs, Aalst, 25 Januari, 2003
112. Abstr. How severe is acute and late toxicity of post-operative radiation treatment for PT3N0 prostate cancer? EORTC trial 22911
Van Poppel H, Bolla M, Van Cangh P, Vekemans K, Rigatti P, De Reijke
European Urology suppl. 2, 1: 154, 2003
113. Abstr. Prostate cancer and nerve sparing surgery
H. Van Poppel
Int. J. of Gynaecological Cancer, 13,1:120, 2003
114. Hormonal treatment of prostate cancer
H. Van Poppel
Proceedings: 8th European Winter Oncology conference, Flims, Switzerland, January 19-24, 2003
115. Abstr. Is immediate post-operative radiation of PT3N0 prostate cancer a safe treatment? Results of EORTC Trial 22911
Hein Van Poppel et al
J.Urol. Vol. 169:4, supplement, Abstr. N° 1843, 2003

116. Abstr. Interstitial cells in the human prostate: future treatment strategy?
Frank Van der Aa, Wim Blyweert, Dieter Ost, Tania Roskams, Hendrik Van Poppel Dirk De Ridder
J.Urol. Vol. 169: 4, supplement Abstr. N° 1119, 2003
117. Abstr. Does intra-operative ketamine effect postoperative analgetic consumption in radical prostatectomy under CSE?
M. Wille, B. Vanacker, E. Vandermeulen, J. Van Hemelrijck, E. Vandermeersch, H. Van Poppel
European Journal of Anesthesiology, Abstr. N° A-705, 2003
118. Abstr. :Is quality control of radical prostatectomy feasible?
H. Van Poppel
EJC supplement, Vol. 1, n° 5, abstr. n° 91, 2003
119. Abstr.:Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced breast pain and gynaecomastia in prostate cancer.
H. Van Poppel, C. Tyrrell, P. Van Cangh, F. Keuppens, T. Morris, L. Garside
EJC supplement, Vol. 1, n° 5, abstr. n° 881, 2003
120. Abstr. Preoperative lymph node and metastasis staging of bladder cancer using FDG-pet.
O. Drieskens, P. Flamen, Y. Vankan, R. Oyen, H. Van Poppel, L. Mortelmans.
The journal of Nuclear Medicine, p 118, abstr. N° 423, 2003
121. Abstr.: Interstitial cells in the human prostate: future treatment strategy?
Frank Van der Aa, Wim Blyweert, Dieter Ost, Tania Roskams, Hendrik Van Poppel, Dirk De Ridder
The Journal of Urology, Vol 169, n° 4, supplement, abstr. 1119, 2003
122. Abstr.: Role of the P13-kinase/Akt pathway in the overexpression of fatty acid synthase in prostate cancer.
T. Van de Sande, T. Roskams, S. Joniau, H. Van Poppel, et al.
Abstr. N° 941. Federation of European Biochemical Societies special meeting on Signal transduction, July 3-8, 2003
123. Abstr.: Is immediate postoperative radiation of PT3N0 prostate cancer a safe treatment? Results of EORTC-Trial 22911.
Hein Van Poppel, et al.
The Journal of Urology, Vol 169, n°4, supplement, abstr. 1843, 2003
124. Abstr.: Purinergic signalling through the interstitial cells of the bladder: preliminary immunohistochemical and calcium imaging data
Blijweert Wim, Van der Aa F, Roskams T, Tack J, Van Poppel H, De Ridder D
European Urology, Supplements 3, No 2, pp 109, 2004

- 125.Abstr.: Results of the randomized trial comparing radical and partial nephrectomy for small kidney neoplasms EORTC protocol 30904
European Urology, Supplements 3, No 2, pp 72, 2004
- 126.Abstr.: The effect of chemoprevention on PSA and clinical management in patients with high grade prostatic intraepithelial neoplasia
Joniau S, Goeman L, Roskams T, Oyen R, Van Poppel H.
European Urology, Supplements 3, No 2, pp67, 2004
- 127.Developments in organ preserving treatments for renal cell cancer: open surgery.
Ziya Kirkali, Hein Van Poppel
European Urology, supplements 3: 9-13, 2004
- 128.Abstr.: Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911)
M. Bolla, H. Van Poppel, P. Van Cangh et al.
Asco Proceedings Vol 23, 2004
- 129.Quality of radical prostatectomy. Does a higher surgical volume make you a better surgeon?
H. Van Poppel
Evidence for Urology, Chapter 20, pp. 191-194, 2004
- 130.Quality of radical prostatectomy. Does a higher surgical volume make you a better surgeon?
Hein Van Poppel
Evidence for Urology, Chapter 22 pp. 1-4, 2004
- 131.Abstr. Hypofractionated intensity modulated irradiation for prostate cancer: results from a phase I/II study
K. Haustermans, B. Bussels, R. Oyen, B. Verstraelen, S. Joniau, H. Van Poppel
Proffered papers, Oral 168, 2004
- 132.Conservative vs radical surgery for renal cell carcinoma
H. Van Poppel
BJU International, Vol. 94, pp. 766-768, 2004
- 133.Interstitial cells of the bladder: the missing link?
W.Blyweert, F. Van der Aa, D. Ost, M. Stagnaro, D. De Ridder
BJOG: an International Journal of Obstetrics and Gynaecology, Vol. 111, pp. 57-60, 2004
- 134.Effects and Side Effects of Hormonal Treatment of Prostate Cancer
H. Van Poppel
Business Briefing: North American Pharmacotherapy, Issue 2, 2004
- 135.Hemorrhagic Complications After Nephron-Sparing Surgery: Angiographic Diagnosis and Management by Transcatheter Embolization

- S. Heye, G. Maleux, H. Van Poppel, R. Oyen, G. Wilms
Original Report, nr.184, pp. 1661-1664, 2005
136. Pentalfa: Radicale of partiële nefrectomie voor nierkanker?
H. Van Poppel
Tijdschrift voor Geneeskunde, vol. 61, nr. 8, pp. 636-637, 2005
137. Clinical Experience with the N-shaped Ileal Neobladder: Assessment of Complications, Voiding Patterns, and Quality of Life in Our Series of 58 Patients
S. Joniau, J. Benijts, M. Van Kampen, M. De Waele, J. Ooms, B. Van Cleynenbreugel, H. Van Poppel
European Urology, vol. 47, pp. 666-673, 2005
138. Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice
G. Sölétormos, A. Semjonow, P. E.C. Sibley, R. Lamerz, P.H. Petersen, W. Albrecht, P. Bialk, M. Gion, F. Junker, H-P Schmid, H. Van Poppel
Clinical Chemistry, vol. 51:8, pp. 1342-1351, 2005
139. Recent docetaxl studies establish a new standard of care in hormone refractory prostate cancer
H. Van Poppel
The Canadian Journal of Urology, Vol. 12 (supplement 1), 2005
140. Quality assurance issues in radical prostatectomy
H. Van Poppel, S.F.F. Boulanger, S. Joniau
EJSO The Journal of Cancer Surgery, vol. 31, pp. 650-655, 2005
141. Prostatic Intraepithelial Neoplasia (PIN): Importance and Clinical Management
S. Joniau, L. Goeman, J. Pennings, H. Van Poppel
European Urology, DTD 5 (art. in press), pp. 1-7, 2005
142. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells
A. Huygens, R. Appolinary, Kamuhabwa, T. Roskams, B. Van Cleynenbreugel, H. Van Poppel, P. De Witte
The Journal of Urology, vol. 174, pp. 69-72, 2005
143. Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy
Chao-Yu H., S. Joniau, H. Van Poppel
EAU Update Series, Vol. 3, pp. 90-97, 2005
144. Surgery for Clinical T3 Prostate Cancer
H. Van Poppel
European Urology Supplements, vol. 4, pp. 12-14, 2005
145. Efficacy and Tolerability of Radiotherapy as Treatment for Bicalutamide-induced Gynaecomastia and Breast Pain in Prostate Cancer

- H. Van Poppel, C.J. Tyrell, K. Haustermans, P. Van Cangh, F. Keuppens, P. Colombeau, T. Morris, L. Garside
European Urology, vol. 47, pp. 587-592, 2005
146. Enhancing the photodynamic effect of hypericin in tumour spheroids by fractionated light delivery in combination with hyperoxygenation
A. Huygens, A.R. Kamuhabwa, A. Van Laethem, T. Roskams, B. Van Cleynenbreugel, H. Van Poppel, P. Agostinis, P. De Witte
International Journal of Oncology, vol. 26, pp. 1691-1697, 2005
147. Immunotherapie voor het gemetastaseerde niercelcarcinoom
L. Goeman, S. Joniau, S. Van Gool, A. Van Oosterom, H. Van Poppel
Tijdschrift voor Geneeskunde, vol. 61, pp. 14-15, 2005
148. In vivo accumulation of different hypericin ion pairs in the urothelium of the rat bladder
A. Huygens, A.R. Kamuhabwa, B. Van Cleynenbreugel, H. Van Poppel, T. Roskams, P. De Witte
BJU International, vol. 95, pp. 436-441, 2005
149. EAU Guidelines on Prostate Cancer
G. Aus, CC. Abbou, M. Bolla, A. Heidenreich, HP. Schmid, H. Van Poppel, J. Wolff, F. Zattoni
European Urology, 48, 2005, pp. 546-551
150. Abstr. EORTC trial 22911: Immediate post-prostatectomy irradiation improves biochemical and clinical progression-free survival in patients with pathologically high risk prostate cancer
M. Bolla, H. Van Poppel, L. Collette, P. Van Cangh, K. Vekemans, L. Da Pazzo, T.M. de Reijke, A. Verbaeys, J.F. Bosset, R.F.P. Van Velthoven
European Journal of Cancer Supplements, Vol. 3, No 2, pp. 230, 2005
151. Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)
L. Collette, H. Van Poppel, M. Bolla, P. Van Cangh, K. Vekemans, L. Da Pozzo, T. de Reijke, A. Verbaeys, J.F. Bosset, M. Piérart
European Journal of Cancer, Vol. 41, pp. 2662-2672, 2005
152. FDG-PET for preoperative staging of bladder cancer
O. Drieskens, R. Oyen, H. Van Poppel, Y. Vankan, P. Flamen, L. Mortelmans
European Journal of Nuclear and Molecular Imaging, pp.1-10, 2005
153. Renal cell carcinoma: percutaneous radio frequency thermal ablation for malignant renal tumours: intermediate results in 15 patients
S. Joniau, L. Goeman, R. Oyen, H. Van Poppel
Kidney Tumours: Treatment III, 2005
154. Development and validation of a new questionnaire to assess gynaecomastia and

- breast pain in patients receiving bicalutamide
H. Van Poppel, B. Tombal, P.J. Van Cangh
European Urology Supplements, Vol. 4, No. 3, PP. 80, 2005
155. Prophylaktische präpubische Uretrektomie
H. Van Poppel, S. Joniau, G. Bogaert
Standardoperationen in der Urologie, pp. 290-296, 2005
156. The feasibility of prophylactic prepubic urethrectomy during cystectomy for bladder cancer: retrospective analysis of 124 patients
S. Joniau, B. Verlinde, H. Van Poppel
European Urology Supplements, Vol. 4, No 3, pp. 181, 2005
157. Additional to caudal bupivacaine preemitive oral ibuprofen does not improve postoperative pain, nausea or vomiting, and resumption of normal activities in children after ambulatory pediatric urologic surgery.
G. Bogaert, D. Trouet, J. Bernaerts, P. Luysmans, G. Evers, M. Wille
Journal of Pediatric Urology, Vol. 1, pp. 61-68, 2005
158. High-level expression of fatty acid synthase in human prostate cancer tissues is linked to activation and nuclear localization of Akt/PKB
T. Van de Sande, T. Roskams, E. Lerut, S. Joniau, H. Van Poppel, G. Verhoeven, J. Swinnen
Journal of Pathology, Vol. 206, pp. 214-219, 2005
159. Conservative bladder management in advanced multiple sclerosis
D. De Ridder, D. Ost, F. Van der Aa, M. Stagnaro, C. Beneton, K. Gross-Paju, P. Eelen, H. Limbourg, M. Harper, J.C. Segal, C.J. Fowler, A. Nordenbo
Multiple Sclerosis, Vol. 11, pp. 694-699, 2005
160. Intermittent Catheterisation with Hydrophilic-Coated Catheters (SpeediCath) Reduces the Risk of Clinical Urinary Tract Infection in Spinal Cord Injured Patients: A Prospective Randomised Parallel Comparative Trial.
D.J.M.K. De Ridder, K. Everaert, L. García Fernández, J.V. Forner Valero, A. Borau Durán, M.L. Jauregui Abrisqueta, M.G. Ventura, A. Rodriguez Sotillo
European Urology, Vol. 48, pp. 991-995, 2005
161. Is there a relationship between early changes in sex hormone profile and gynaecomastia induced by bicalutamide 150 mg?
F. Comhaire, P. Van Cangh, H. Van Poppel
European Urology Supplements, Vol. 4 No 3, pp. 227, 2005
162. Advanced prostate cancer: place of surgery
H. Van Poppel
Ecco 13, Vol. 3 No 3, pp. 305-308, 2005
163. Abstr. Gastrointestinal Stromal Tumor of the Prostate
F. Van der Aa, R. Sciote, W. Blyweert, D. Ost, H. Van Poppel, A. Van Oosterom, M.

- Debiec-Rychter, D. De Ridder
Urology, Vol. 65, pp. 388-389, 2005
164. Abstr. (Oral presentations) GU-Prostate Cancer, EORTC trial 22911: Immediate post-prostatectomy irradiation improves biochemical and clinical progression-free survival in patients with pathologically high risk prostate cancer
M. Bolla, H. Van Poppel, L. Collette, P. Van Cangh, K. Vekemans, L. Da Pozzo, T.M. de Reijke, A. Verbaeys, J.F. Bosset, R.F.P. Van Velthoven
Proffered Papers, No. 806, pp. 230, 2005
165. Offering surgical quality to the uro-oncologic patients remains my main professional goal.
H. Van Poppel
Firma Gözüyle Kongre, 2005
166. Thoughts and views of erectile dysfunction in the 50+ population in Belgium
H. Claes, H. Van Poppel
European Urology Supplements, Volume 5, p. 102, April, 2006
167. Kidney tumour resection with use of Tachosil as haemostatic treatment
H. Van Poppel, S. Siemer, S. Lahme, S. Altziebler, S. Machtens, W. Strohmaier, H.W. Wechsel, P. Goebell, N. Schmeller, R. Oberneder, J.U. Stolzenburg, H. Becker, W. Lüftenegger, V. Tetens, S. Joniau
European Urology Supplements, Volume 5, p. 180, April, 2006
168. Nephron-sparing surgery: experience in 159 consecutive cases
S. Joniau, H. Van Poppel
European Urology Supplements, Volume 5, p. 182, April, 2006
169. Staging of unilateral clinical T3A prostate cancer: digital rectal examination or transrectal ultrasound?
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
European Urology Supplements, Volume 5, p. 206, April, 2006
170. Impact of pathological view of radical prostatectomy specimens on prognosis and predicted benefit from immediate postoperative irradiation for high-risk patients (EORTC 22911)
T. Van der Kwast, M. Bolla, H. Van Poppel, K. Vekemans, P. Van Cangh, F. Schroder, T. De Reijke, L. Dapozza, J.F. Bosset, L. Collette
European Urology Supplements, Volume 5, p. 205, April, 2006
171. Treatment of clinical stage T3 prostate cancer: a surgical disease?
S. Joniau, A. Van Baelen, C.Y. Hsu, R. Oyen, T. Roskams, H. Van Poppel
European Urology Supplements, Volume 5, p. 213, April, 2006
172. The role of metastasectomy in renal cell carcinoma
C. Ghysel, S. Joniau, H. Van Poppel
European Urology Supplements, Volume 5, p. 221, April, 2006

173. Renal cell carcinoma with venous tumour thrombus: prognostic significance of the level of the tumour thrombus and of associated metastases on long-term survival
S. Klaver, S. Joniau, H. Goethuys, R. Suy, H. Van Poppel
European Urology Supplements, Volume 5, p. 258, April, 2006
174. Abstr. Gleason score and margin status are the strongest predictors for benefit of radiotherapy after radical prostatectomy
T. Van der Kwast, M. Bolla, H. Van Poppel, P. Van Cangh, T. de Reijke, K. Vekemans, L. da Pozzo, J. Bosset, F. Schröder, L. Collette
The Journal of Urology, Vol. 175, no 4, supplement, abstr. 1391, p 449, May 23, 2006
175. Abstr. Thoughts and views on erectile dysfunction in the 50+ population in Belgium
H. Claes, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 320, p.102, April 2006
176. Abstr. Kidney tumour resection with use of Tachosil as haemostatic treatment
H. Van Poppel, S. Siemer, S. Lahme, S. Altziebler, S. Machtens, W. Strohmaier, HW Wechsel, P. Goebell, N. Schmeller, R. Oberneder, J. Stolzenburg, H. Becker, W. Lüftenegger, V. Tetens, S. Joniau
European Urology Supplements, Vol. 5, Issue 2, abstr. 630, p.180, April 2006
177. Abstr. Nephron-sparing surgery: experience in 159 consecutive cases
S. Jonsiau, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 640, p.182, April 2006
178. Abstr. Impact of pathological review of radical prostatectomy specimens on prognosis and predicted benefit from immediate postoperative irradiation for high-risk patients (EORTC 22911)
T. Van der Kwast, M. Bolla, H. Van Poppel, K. Vekemans, P. Van Cangh, F. Schröder, T. De Reijke, L. Dapozza, J.F. Bosset, L. Collette
European Urology Supplements, Vol. 5, Issue 2, abstr. 729, p.204, April 2006
179. Abstr. Staging of unilateral clinical T3a prostate cancer: digital rectal examination or transrectal ultrasound?
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 735, p. 212, April 2006
180. Abstr. Treatment of clinical stage T3 prostate cancer : a surgical disease ?
S. Joniau, A. Van Baelen, C.Y. Hsu, R. Oyen, T. Roskams, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 761, p. 213, April 2006
181. Abstr. Outcome for clinical unilateral T3a prostate cancer : a single-institution experience
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 763, p. 213, April 2006

182. Abstr. The role of metastasectomy in renal cell carcinoma
C. Ghysel, S. Joniau, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 794, p. 221, April 2006
183. Abstr. A one-year, multicentre, randomised study of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, in prostate cancer patients
H. Van Poppel, J. de la Rosette, B.E. Persson, J.K. Jensen, T.K. Olesen
European Urology Supplements, Vol. 5, Issue 2, abstr. 915, p. 251, April 2006
184. Abstr. Renal cell carcinoma with venous tumour thrombus : prognostic significance of the level of the tumour thrombus and of associated metastases on long-term survival.
S. Klaver, S. Joniau, H. Goethuys, R. Suy, H. Van Poppel
European Urology Supplements, Vol. 5, Issue 2, abstr. 942, p. 258, April 2006
185. Abstr. Percutaneous ultrasound-guided radiofrequency ablation of recurrent renal cell carcinoma in renal allograft after partial nephrectomy
L. Goeman, S. Joniau, R. Oyen, H. Van Poppel
Urology 67:199-200, 2006
186. Abstr. Urachal carcinoma during pregnancy
K. Van Calsteren, K. Van Mensel, S. Joniau, R. Oyen, M. Hanssens, F. Amant, H. Van Poppel
Urology 67:1290-1291, 2006
187. Abstr. Prospektiv randomisierte multizentrische Studie zur Effektivität von TachoSil® als Hämostyptikum nach Nierenteilresektion (NT)
S. Siemer, H. Van Poppel, S. Machtens, W.L. Strohmaier, H.W. Wechsel, P.J. Goebell, N. Schmeller, R. Oberneder, J.U. Stolzenburg, V. Tetens
Der Urologe, band 45, supplement 1, September 2006
188. Words of Wisdom Re: Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumours 4 cm or larger
H. Van Poppel
European Urology 49, p. 1130-1135, 2006
189. Abstr. Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC).
E. Lerut, T. Roskams, E. Goossens, D. Bootle, S. Dimitrijevic, M. Stumm, N. Shand, H. Van Poppel
Journal of Clinical Oncology, vol 23, no16S, part I of II, June 2005
190. Abstr. Determining the dose of Degarelix for effective therapy of prostate cancer patients as investigated by the Degarelix study groups.
B. Tombal, P. Iversen, H. Van Poppel, T. Tammela, J. de la Rosette, J. Johansson, B. Persson, J. Jensen, T. Kold Olesen,
Annals of Oncology, supplement 9, Abstract Book of the 31st ESMO Congress,

Istanbul, Turkey September 29 – October 3, 2006

191. Abstr. A table to predict final histopathology after radical prostatectomy for clinical unilateral T3a prostate cancer
C. Hsu, S. Joniau, A. Van Baelen, T. Roskams, R. Oyen, H. Van Poppel
Urology 68 Suppl 5A: 96-97, 2006
192. Abstr. Determining the optimal initiation and maintenance dose of degarelix for hormone therapy of prostate cancer patients
P. Iversen, H. Van Poppel, T. Tammela, J. de la Rosette, JE. Johansson, BE. Persson, JK. Jensen, TK. Olesen
Urology 68 Suppl 5A: 102-103, 2006
193. Abstr. Does transrectal ultrasound add value in the staging of clinical T3a prostate cancer?
C. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
Urology 68 Suppl 5A: 206-261, 2006
194. Abstr. Long-Term Evaluation of Degarelix, A Gonadotrophin-releasing Hormone (GNRH) receptor Blocker, investigated in a multicentre randomised study in prostate cancer (CAP) patients.
H. Van Poppel, J.J. De La Rosette, B.E. Persson, T.K. Olesen, Degarelix Study Group
Eur. Urol. Suppl. 2007;6(2):28
195. Abstr. The value of the PCA3 assay in guiding decision which men with a negative prostate biopsy need immediate repeat biopsy: preliminary european data
A. Haese, H. Van Poppel, M. Marberger, P. Mulders, C.C. Abbou, L. Boccon-Gibod, A. Stenzl, H. Huland, A. De La Taille, J. Schalken
Eur. Urol. Suppl. 2007;6(2):48
196. Abstr. The use of the IIEF-5 questionnaire for evaluation of erectile dysfunction following nerve-sparing radical prostatectomy
M. Albersen, S. Joniau, H. Claes, H. Van Poppel
Eur. Urol. Suppl. 2007;6(2):207
197. Abstr. Radiofrequency ablation of small renal cell carcinoma: Belgian multicentre experience
S. Joniau, R. Oyen, L. Goeman, K. Vekemans, A. Valcke, R. Vandeursen, F. Ameye, H. Van Poppel
Eur. Urol. Suppl. 2007;6(2)233
198. Abstr. Outcome of nephron sparing surgery for T1B renal cell carcinoma.
K. Vander Eeckt, S. Joniau, H. Van Poppel
Eur. Urol. Suppl. 2007;6(2)265
199. Abstr. Comparing the outcome of patients with adjuvant or salvage treatment in clinical unilateral T3A prostate cancer

- C.Y. Hsu, S; Joniau, R. Oyen, T. Roskams, H. Van Poppel
Eur. Urol. Suppl. 2007;6(2)278
200. Abstr. The relationship between body mass index and clinical unilateral T3A prostate cancer
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
Eur. Urol. Suppl. 2007;6(2)278
201. Abstr. Adjuvant Therapy after Surgery for High-Risk Prostate Cancer: EORTC Trial. Bolla, H. Van Poppel, L. Collette, T.H. Van der Kwast
The Prostate Cancer Symposium, February 22-24, 2007, Orlando Florida, p.49
202. Abstr. Multicenter randomized EORTC trial 30021 of docetaxel + oblimersen and docetaxel in patients (pts) with hormone refractory prostate cancer (HRPC)
C.N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, L. Collette
The Prostate Cancer Symposium, p.143, Orlando, Florida, February 22-24, 2007
203. Abstr. Long-Term Evaluation of Degarelix, A Gonadotrophin-Releasing Hormone (GnRH) Receptor Blocker, Investigated in A Multicentre Randomised Study in Prostate Cancer (CAP) Patients
H. Van Poppel, J.J. De La Rosette, B.E. Persson, T.K. Olesen, Degarelix Study Group
Eur. Urol. Suppl. 2007; 6(2); 28
204. Abstr. The Value of the PCA3 assay in guiding decision with men with a negative prostate biopsy need immediate repeat biopsy: preliminary European data.
A. Haese, H. Van Poppel, M. Marberger, P. Mulders, C.C. Abbou, L. Boccon-Gibod, A. Stenzl, H. Huland, A. De La Taille, J. Schalken
Eur. Urol. Suppl. 2007; 6(2); 48
205. Abstr. The use of the IIEF-5 questionnaire for evaluation of erectile dysfunction following nerve-sparing radical prostatectomy.
M. Albersen, S. Joniau, H. Claes, H. Van Poppel
Eur. Urol. Suppl. 2007; 6(2); 207
206. Abstr. Radiofrequency ablation of small renal cell carcinoma: Belgian Multicentre experience.
S. Joniau, R. Oyen, L. Goeman, K. Vekemans, A. Valcke, R. Vandeursen, F. Ameye, H. Van Poppel
Eur. Urol. Suppl.; 6(2); 233
207. Abstr. Outcome of nephron sparing surgery for T1B renal cell carcinoma.
K. Vander Eeck, S. Joniau, H. Van Poppel
Eur. Urol. Suppl. 2007; 6(2); 265
208. Abstr. The Relationship between Body Mass Index and clinical unilateral T3A Prostate Cancer

- C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
Eur. Urol. Suppl. 2007; 6(2); 278
- 209.Abstr. Comparing the outcome of patients with adjuvant or salvage treatment in clinical unilateral T3A prostate cancer
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
Eur. Urol. Suppl. 2007; 6(2); 278
- 210.Abstr. The role of metastasectomy in renal cell carcinoma.
C. Ghysel, S. Joniau, H. Van Poppel
Eur. Urol. Suppl. 2006; 5(2); 221
- 211.POD-08.02: Prostate biopsy indications: practice patterns and the potential role of PCA3
B. Tombal, H. Van Poppel, C. Schulman, J. Irani, A. de la Taille, R. Berges, A. Haese, P. Mulders, T. de Reijke, M. Emberton, D. Gillatt
Urol. 70, Suppl. 3A, 2007: 25
- 212.POD-08.05: The PCA3 assay is useful in guiding prostate biopsy (PB) decision in men with a prior negative biopsy
A. Haese, H. Van Poppel, M. Marberger, P. Mulders, C. Abbou, L. Boccon-Gibod, A. Stenzl, H. Huland, A. de la Taille, J. Schalken
Urol. 70, Suppl. 3A, 2007: 26-27
- 213.POD-04.01: Postoperative nomogram for clinical unilateral T3a prostate cancer.
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
Urol. 70, Suppl. 3A, 2007: 11
- 214.MP-08.10: The relationship between Charlson score and clinical unilateral T3a prostate cancer.
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
Urol. 70, Suppl. 3A, 2007: 80
- 215.MP-11.17: Pathological review of radical prostatectomy specimens identifies patients who benefit most from immediate post-operative irradiation.
T. Van Der Kwast, M. Bolla, H. Van Poppel, K. Vekemans, P. Van Cangh, KH. Kurth, F. Schroder, L. Dapozzo, J.F. Bosset, L. Collette
Urol. 70, Suppl. 3A, 2007: 99
- 216.POS-03.126: SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men.
JP. Droz, L. Balducci, M. Bolla, M. Emberton, J. Fitzpatrick, S. Joniau, M. Kattan, S. Monfardini, J. Moul, A. Naeim, H. Van Poppel, F. Saad, C. Sternberg
Urol. 70, Suppl. 3A, 2007: 311-312
- 217.Abstr.: Personalized surgical treatment for localised prostate cancer
H. Van Poppel

- EJC Supplements 2007; 5 (4); 20-21
218. Abstr.: The relationship between age and cancer related outcomes in clinical unilateral T3a prostate cancer
C.Y. Hsu, S. Joniau, R. Oyen, T. Roskams, H. Van Poppel
EJC Supplements 2007; 5 (4); 286
219. Abstr.: Le test urinaire PCA3 permet de préciser l'indication de ré-biopsies chez les patients ayant une première série de biopsies négatives.
A. De La Taille, A. Haese, H. Van Poppel, M. Marberger, P. Mulders, C.C. Abbou, A. Stenzl, L. Boccon-Gibod, H. Huland, J. Schalken
Progrès en Urologie 2007; 17; Suppl. 1; 48A
220. Proc.: Clinical T3 prostate cancer treated with radical prostatectomy: Results from the European Society of Oncological Urology (ESOU). A. Heidenreich, M. Brausi, V. Ravery, L. Martinez-Pineiro, L. Turkeri, H. Van Poppel.
ASCO, ASTRO, SUO; 2008 Genitourinary Cancers Symposium: A Multidisciplinary Approach, Proceedings Book; p.169; 148.
221. Words of Wisdom: Identification of Patients with Prostate Cancer Who Benefit from Immediate Postoperative Radiotherapy: EORTC22911
T.H. Van der Kwast, M. Bolla, H. Van Poppel, P. Van Cangh, K. Vekemans, L. Da Pozzo, J.F. Bosset, K.H. Kurth
J. Clin. Oncol. 2007; 25: 4178-4186.
222. Abstr.: Clinical T3 prostate cancer treated with radical prostatectomy: Results from the European Society of Oncological Urology (ESOU)
A. Heidenreich, M. Brausi, V. Ravery, L. Martinez-Pineiro, L. Turkeri, H. Van Poppel
J Urol 2008; 178 (4) suppl.; 556
223. Abstr.: Quality control in nerve-sparing radical retropubic prostatectomy – results of the European Society of oncological urology (ESOU)
A. Heidenreich, M. Brausi, H. Van Poppel, L. Martinez-Pineiro, V. Ravery, L. Turkeri
J Urol 2008; 178 (4) suppl.; 650
224. Abstr.: Performance analysis of different PCA3 cut-offs
F. K.H. Chun, A. Haese, A. de la Taille, H. Van Poppel, M. Marberger, P.F. Mulders, CC Abbou, A. Stenzl, H. Huland, M. Tinzl, M. Remzi, S. Feyerabend, A. Stillebroer, M. Van Gils, J. A. Schalken
J Urol 2008; 178 (4) suppl.; 705
225. Abstr.: Prostate cancer 3 (PCA3) represents a clinically meaningful predictor of prostate cancer at repeat biopsy
A. Haese, F.K.H. Chun, A. de la Taille, H. Van Poppel, M. Marberger, P.F. Mulders,

- CC Abbou, A. Stenzl, H. Huland, M. Tinzl, M. Remzi, S. Feyerabend, M. Van Gils, A. Stillebroer, J. A. Schalken
J Urol 2008; 178 (4) suppl.; 724
226. Poster discussion: Preliminary results from a randomized phase III trial of adjuvant interleukin-2 interferon alpha and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC)
M. Aitchison, C. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon, P.A. Vasey
JCO 2008; 26 (15) suppl.: 5040
227. Abstr.: Diagnostic evaluation of PSA recurrence and review of hormonal management after radical prostatectomy.
H. Van Poppel
UroToday.com Beyond the Abstract, May 11, 2009
228. Abstr.: Outcome of multimodality treatment with radical prostatectomy as initial step for prostate cancer with PSA > 20ng/ml: a multi-institutional outcome study of 801 patients.
M. Spahn, P. Gontero, S. Joniau, B. Tombal, C. Bangma, J. Walz, K. Vander Eeckt, P. Bader, CY Hsu, G. Marchioro, H. Isbarn, D. Frohneberg, M. Graefen, F. Schröder,
A. Tizzani, P. Van Cangh, H. Van Poppel
J Urol 2009; 181; 456
229. Abstr.: Outcome of multimodality treatment of high-risk localized prostate cancer (cT3-4 or PSA \geq 20 ng/ml or biopsy Gleason Score \geq 8) with radical prostatectomy as initial step: a multi-institutional outcome study of 1413 patients
S. Joniau, M. Spahn, P. Gonero, B. Tombal, C. Bangma, J. Walz, CY Hsu, K. Vander Eeckt, G. Marchioro, P. Bader, H. Isbarn, D. Frohneberg, M. Graefen, F. Schröder, A. Tizzani, P. Van Cangh, H. Van Poppel
J Urol 2009; 181, 574
230. Abstr.: Radical prostatectomy in very high risk localized prostate cancer.
P. Gontero, S. Joniau, M. Spahn, B. Tombal, K. Vander Eect, P. Bader, D. Frohneberg, A. Tizzani, P. Van Cangh, H. Van Poppel
J Urol 2009; 181; 576
231. Abstr.: A multi-institutional analysis comparing adjuvant and salvage postoperative radiation therapy for prostate cancer patients with indetectable PSA and high-risk features in the prostatectomy specimen.

T. Budiharto, C. Perneel, K. Haustermans, S. Junius, B. Tombal, P. Scalliet, K. Vekemans, S. Joniau, H. Van Poppel
 Joint ECCO 15 – 34th ESMO: multidisciplinary Congress, Berlin, Germany,
 September 20-24, 2009

232. Abstr.: The role of positive section margins (PSM) in patients with high risk prostate cancer treated by radical prostatectomy – prospective analysis of 566 patients
 M. Spahn, S. Joniau, P. Gontero, B. Kneitz, P. Bader, H. Van Poppel, D. Frohneberg
 Der Urologe Suppl 1 2009; 75-76
233. Abstr.: Radical prostatectomy in very high risk localized prostate cancer (PSA > 20 ng/ml + cT3/T4 + biopsy Gleason Score ≥ 8)
 M. Spahn, S. Joniau, B. Tombal, P. Bader, D. Frohneberg, A. Tizzani, P. Van Cangh, H. Van Poppel, P. Gontero
 Der Urologe Suppl 1 2009; 107-108
234. Abstr. : Radical Prostatectomy for Prostate Cancer with PSA > 100 ng/ml
 Joniau S., Gontero P., Spahn M., Frohneberg D., Tizzani A., Van Poppel H.
 Urology, Volume 74, Supplement 4A, October 2009, S15-16, POD-05.07
 30th Congress of the Société Internationale d’Urologie, November 1-5, 2009
235. Abstr. Complete Urinary Tract Extirpation: A Single Centre Series of 17 Patients
 Blyweert W., Joniau S., Van Poppel H.
 Urology, Volume 74, Supplement 4A, October 2009, S110, MP-14.06
 30th Congress of the Société Internationale d’Urologie, November 1-5, 2009
236. Abstr. Is Prostate Cancer Index a Stronger Prognostic Factor than Cancer Volume for adverse Final Histopathologic Outcomes in Ct3a Prostate Cancer?
 Hsu C., Joniau S., Oyen R., Roskams T., Van Poppel H.
 Urology, Volume 74, Supplement 4A, October 2009, S131, MP-18.02
 30th Congress of the Société Internationale d’Urologie, November 1-5, 2009
237. Abstr. A Pre-Treatment Table for the Prediction of Final Histopathology after Radical Prostatectomy in Clinical Unilateral T3a Prostate Cancer Using PSA Density and Biopsy Gleason Score
 Joniau S., Hsu C., Oyen R., Roskams T., Van Poppel H.
 Urology, Volume 74, Supplement 4A, October 2009, S203, UP-1.107
 30th Congress of the Société Internationale d’Urologie, November 1-5, 2009
238. Abstr. Contribution of PET-CT in the Diagnosis of Transitional Cell Carcinoma of the Upper Urinary Tract: Analysis of 20 Cases
 De Wil P., Joniau S., Oyen R., De Wever L., Lieben M., Van Cleynenbreugel B., Van Poppel H.
 Urology, Volume 74, Supplement 4A, October 2009, S258, UP-2.088
 30th Congress of the Société Internationale d’Urologie, November 1-5, 2009

239. Abstr. Determining Under- and Over-Grading by Biopsy Gleason Score in Clinical T3 Prostate Cancer
Hsu C., Joniau S., Oyen R., Roskams T., Van Poppel H.
Urology, Volume 74, Supplement 4A, October 2009, S268-269, UP-2.120
30th Congress of the Société Internationale d'Urologie, November 1-5, 2009
240. Abstr. Significance of positive surgical margins in radical prostatectomy
H. Van Poppel
ICACT, Palais des Congrès, Paris, February 1-5, 2010
241. Abstr. Is radiotherapy and hormones the treatment of choice for locally and advanced prostate cancer?
H. Van Poppel, S. Joniau
ICACT, Palais des Congrès, Paris, February 1-5, 2010
242. Abstr. Adjuvant/Neoadjuvant strategies integrating surgery and targeted therapies.
H. Van Poppel
Genitourinary Cancers Symposium, San Francisco, California, March 5-7, 2010
243. Abstr. Detection and characterization of prostatic carcinoma by means of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
S. Isebaert, F. De Keyzer, K. Haustermans, E. Lerut, T. Roskams, I. Roebben, H. Van Poppel, S. Joniau, R. Oyen
244. Abstr. External validation of PCA3- based nomograms for predicting positive biopsy for prostate cancer
M. Auprich, A. Haese, M. Graefen, A. Stenzl, M. Marberger, A. De La Taille, T. De Reijke, P. Kil, P. Gontero, H. Van Poppel, J. Irani, F. Chun
Eur Urol Suppl 2010; 9(2): 307
245. Abstr. The role of positive section margins in patients with high risk prostate cancer treated by radical prostatectomy: prospective analysis of 566 patients
Eur Urol Suppl 2010; 9: 224
246. Abstr. Is lymph node dissection unnecessary in radical nephrectomy for RCC?
ICACT 2010 Abstract book p. 45
247. Abstr. Hormone therapies for prostate cancer.
ICACT 2010 Abstract book p. 77
248. Abstr. Denosumab treatment for prolonging bone metastasis-free survival in men with castrate-resistant prostate cancer
F. Saad, M. Smith, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damiao, T. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, Carsten Goessl
AUA South Central Meeting 2010
249. Abstr. Adjuvant radiation for pathologically advanced prostate cancer: a head to head comparison of SWOG and EORTC trials

- L. Collette, M. Bolla, H. Van Poppel
 Eur Urol suppl 2011; 10(2): 90
 26th Annual EAU Congress, Vienna, March 18-22, 2011
250. Abstr. Adjuvant radiotherapy leads to superior biochemical recurrence free survival compared to early salvage radiotherapy in patients with locally advanced prostate cancer: results of a matched-controlled multi-institutional analysis
 A. Briganti, T. Budiharto, S. Joniau, U. Capitanio, C. Cozzarini, K. Haustermans, B. Tombal, N. Di Muzio, P. Rigatti, H. Van Poppel
 Eur Urol suppl 2011; 10(2): 93
 26th Annual EAU Congress, Vienna, March 18-22, 2011
251. Abstr. In high-risk prostate cancer, the number of lymph nodes removed at radical prostatectomy does not affect the risk of cancer related death or death from any cause
 S. Joniau, A. Van Baelen, M. Spahn, A. Briganti, G. Marchioro, U. Capitanio, B. Tombal, CY. Hsu, B. Akdogan, P. Bader, B. Frea, D. Frohneberg, B. Kneitz, H. Riedmiller, A. Tizzani, H. Van Poppel, P. Gontero
 Eur Urol suppl 2011; 10(2): 185
 26th Annual EAU Congress, Vienna, March 18-22, 2011
252. Abstr.: Mapping of pelvic lymph node metastases in prostate cancer
 L. Van Den Bergh, S. Joniau, T. Budiharto, E. Lerut, C. Deroose, R. Oyen, F. Ameye, K. Haustemans, H. Van Poppel
 Eur Urol suppl 2011; 10(2): 187
 26th Annual EAU Congress, Vienna, 18-22 March 2011
253. Abstr. Critical assessment of urinary prostate cancer gene 3 (PCA3) in the prediction of aggressive prostate cancer (Gleason Score \geq 7) at biopsy
 M. Auprich, A. Haese, A. De La Taille, H. Van Poppel, M. Marberger, CC. Abbou, A. Stenzl, P. Mulders, JA. Schalken, H. Huland, AB. Stillebroer, PMQ. Gils, Y. Fradet, LS. Marks, W. Ellis, AW. Partin, FKH. Chun
 Eur Urol suppl 2011; 10(2): 207
 26th Annual EAU Congress, Vienna, 18-22 March 2011
254. Abstr.: Time to biochemical recurrence is a strong and independent predictor of CSS and OS in high-risk prostate cancer
 M. Spahn, P. Gontero, A. Griganti, G. Marchioro, B. Tombal, J. Walz, CY. Hsu, P. Bader, D. Frohneberg, M. Graefen, A. Tizzani, P. Van Cangh, F. Montorsi, H. Van Poppel, S. Joniau
 Eur Urol suppl 2011; 10(2): 217
 26th Annual EAU Congress, Vienna, 18-22 March 2011
255. Abstr.: MicroRNA-141 expression in clear cell renal cell carcinoma is linked with sunitinib response

- J. Berkers, O. Govaere, P. Wolter, B. Beuselinck, P. Schöffski, T. Roskams, S. Joniau, H. Van Poppel, E. Lerut
 Eur Urol suppl 2011; 10(2): 235
 26th Annual EAU Congress, Vienna, March 18-22, 2011
256. Abstr.: Downregulation of MIR-221 is a strong and independent predictor of clinical progress and CSS in high-risk prostate cancer
 M. Spahn, S. Joniau, S. Kneitz, CJ. Scholz, M. Schubert, C. Kalogiru, P. Ströbel, H. Van Poppel, H. Riedmiller, B. Kneitz
 Eur Urol suppl 2011; 10(2): 238
 26th Annual EAU Congress, Vienna, March 18-22, 2011
257. Abstr.: The number of positive section margins in high-risk prostate cancer is a powerful and independent predictor of cancer-specific and overall survival in high-risk localized prostate cancer
 S. Joniau, P. Gontero, A. Briganti, G. Marchioro, U. Capitanio, B. Tombal, CY. Hsu, B. Akdogan, P. Bader, B. Freja, D. Frohneberg, B. Kneitz, H. Riedmiller, A. Tizzani, H. Van Poppel, M. Spahn
 Eur Urol suppl 2011; 10(2): 285
 26th Annual EAU Congress, Vienna, March 18-22, 2011
258. Abstr.: Three or more positive nodes at radical prostatectomy represent a significant cut-off value for CSS in high-risk prostate cancer, while 1 or 2 positive nodes do not influence CSS
 S. Joniau, A. Van Baelen, P. Gontero, A. Briganti, G. Marchioro, U. Capitanio, B. Tombal, CY. Hsu, B. Akdogan, P. Bader, B. Freja, D. Frohneberg, B. Kneitz, H. Riedmiller, A. Tizzani, H. Van Poppel, M. Spahn
 Eur Urol suppl 2011; 10(2): 323
 26th Annual EAU Congress, Vienna, March 18-22, 2011
259. Abstr.: Development and internal validation of nomograms predicting prostate cancer specific survival in patients with high risk disease. Results of a multi-institutional analysis
 A. Briganti, M. Spahn, S. Joniau, G. Marchioro, B. Tombal, H. Hsu, P. Bader, M. Graefen, A. Tizzani, P. Van Cangh, P. Gontero, H. Van Poppel
 Eur Urol suppl 2011; 10(2): 324
 26th Annual EAU Congress, Vienna, March 18-22, 2011
260. Abstr.: Prostate cancer: management of pelvic nodes. Surgical perspective.
 H. Van Poppel
 Critical reviews in Oncology Hematology 2011; 78: 19
 ESO – Educational cancer convention Lugano, What's new and what's true in genito-urinary oncology? May 12-14, 2011

- 261.Abstr.: Kidney cancer: surgery including nephron-sparing surgery
 H. Van Poppel
 Critical reviews in Oncology Hematology 2011; 78: 8
 ESO – Educational cancer convention Lugano, What’s new and what’s true in genito-urinary oncology? May 12-14, 2011
- 262.Abstr.: Survival impact of surgery in metastatic renal cell carcinoma
 L. Tosco, H. Van Poppel, S. Joniau
 AUA Abstract Book, J. Urol 2011
- 263.Abstr.: Cystectomy and urinary diversion – Lessons learned.
 H. Van Poppel
 EJC 2011; 47: S50
- 264.Post. Presentation: Survival impact of surgery in metastatic renal cell carcinoma.
 L. Tosco, H. Van Poppel, S. Joniau
 AUA Abstract Book – J. Urol 2011
- 265.Abstr.: Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC).
 M. Aitchison, C.A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon and P.A. Vasey.
 Abstract presentation from the 2011 ASCO Annual Meeting – J Clin Oncol 2011; 29: 4505
- 266.Post. Presentation: Adapting a clinical trial design due to changing clinical practice: lessons learned from the EORTC prostate cancer trial 22043-30041.
 M. Bolla, H. Van Poppel, L.H. Pylkkanen, V. Pouillon, P. Maingon, J.F. Bosset, A.E. Villafranca Iturre, I. Billiet, A. Boladeras, A. Bossi, W. Budach, G. De Meerleer, A. Doneux, F. Herrera, W. Hinkelbein, P. Kitsios, G. Lammering, J. Lozano, M. Martens, L. Renard, A. Richetti, A. Scholten, M. Stuschke, E. Te Slaa, A.C.M. Van Den Bergh, K. Vekemans, P. Verhagen, S. Villa, R. Weytjens, E.S. Baskin-Bey, L. Collette.
 EMUC, November 2011
- 267.Abstr.: Adapting a clinical trial design due to changing clinical practice: lessons learned from the EORTC prostate cancer trial 22043-30041.
 M. Bolla, H. Van Poppel, L.H. Pylkkanen, V. Pouillon, P. Maingon, J.F. Bosset, A.E. Villafranca Iturre, I. Billiet, A. Boladeras, A. Bossi, W. Budach, G. De Meerleer, A. Doneux, F. Herrera, W. Hinkelbein, P. Kitsios, G. Lammering, J. Lozano, M. Martens, L. Renard, A. Richetti, A. Scholten, M. Stuschke, E. Te Slaa, A.C.M. Van Den Bergh, K. Vekemans, P. Verhagen, S. Villa, R. Weytjens, E.S. Baskin-Bey, L. Collette.
 AUA 2012

- 268.Abstr.: Addressing barriers to patient accrual in clinical trials: lessons from the EORTC prostate cancer trial 22043-30041.
M. Bolla, S. Joniau, L.H. Pylkkanen, V. Pouillon, P. Maingon, JF. Bosset, I. Billiet, A. Boladeras, A. Bossi, W. Budach, G. De Meerleer, A. Doneux, F. Herrera, W. hinkelbein, P. Kitsios, G. Lammering, J. Lozano, M. Martens, L. Renard, A. Richetti, A. Scholten, M. Stuschke, E. Te Slaa, ACM Van Den Bergh, K. Vekemans, P. Verhagen, S. Villa, R. Weytjens, E. Baskin-Bey, S. Collette.
AUA 2012
- 269.Abstr.: Survival impact, clinical prognostic factors and safety of metastasectomy for treatment of advanced renal cell carcinoma.
L. Tosco, H. Van Poppel, B. Frea, S. Joniau
27th Annual EAU Congress Paris, February 24-28, 2012
- 270.Abstr.: Comparing open versus laparoscopic partial nephrectomy for large renal tumors of stage cT1b.
S. Joniau, F. Baekelandt, M.N. Simmons, I.S. Gill, H. Van Poppel
27th Annual EAU Congress Paris, February 24-28, 2012
- 271.Abstr.: Pretreatment tables for the prediction of pathological outcomes of patients with locally advanced prostate cancer.
S. Joniau, M. Spahn, A. Briganti, G. Marchioro, B. Tombal, J. Walz, C.Y. Hsu, D. Frohneberg, M. Graefen, A. Tizzani, H. Van Poppel, P. Gontero.
27th Annual EAU Congress Paris, February 24-28, 2012
- 272.Abstr.: Stratification of high-risk prostate cancer into prognostic categories; a European multi-institutional study.
S. Joniau, M. Spahn, A. Briganti, B. Tombal, G. Marchioro, J. Walz, C.Y. Hsu, D. Frohneberg, M. Graefen, A. Tizzani, H. Van Poppel, P. Gontero.
27th Annual EAU Congress Paris, February 24-28, 2012
- 273.Abstr.: A pharmacogenomics scoring system predicting median time-to-progression on sunitinib as first line treatment in patients with metastatic renal cell carcinoma.
B. Beuselinck, A. Karadimou, B. Claes, D. Lambrechts, J. Berkers, R. Paridaens, P. Schöffski, H. Van Poppel, P. Wolter, A. Méjean, E. Lerut, A. Descazeaud, J. Berger, J.M. Tourani, V. Verkarre, B. Terris, V. Monilié, N. Rioux-Leclercq, J. Zucman-Rossi, S. Oudard.
27th Annual EAU Congress Paris, February 24-28, 2012
- 274.Abstr.: Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi institutional cohort.
M. Auprich, A. Haese, A. De La Taille, H. Van Poppel, M. Marberger, P.F.A. Mulders, C.C. Abbou, A.B. Stillebroer, P.M.Q. Van Gils, J-A. Schalken, A. Stenzl,

- Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, J. Walz, F.K.H. Chun.
27th Annual EAU Congress Paris, February 24-28, 2012
275. Abstr.: Radical prostatectomy for very high risk T3b/4 prostate cancer – results of a multi-institutional experience.
M. Spahn, P. Gontero, A. Briganti, B. Kneitz, P. Bader, C.Y. Hsu, H. Van Poppel, D. Frohneberg, S. Joniau.
27th Annual EAU Congress Paris, February 24-28, 2012
276. Abstr.: Outcome of multimodality treatment of cT4 very high-risk prostate cancer with radical cystectomy as initial step: A multi-institutional outcome study of 62 patients.
M. Spahn, S. Joniau, F. Abdollah, M. Tutolo, E. Di Trapani, P. Gontero, B. Kneitz, P. Bader, D. Frohneberg, H. Van Poppel, R.J. Karnes.
27th Annual EAU Congress Paris, February 24-28, 2012
277. Abstr.: Let-7b is down-regulated in high risk prostate cancer and correlates with clinical failure.
M. Schubert, B. Kneitz, S. Kneitz, C.J. Scholz, S. Joniau, H. Van Poppel, H. Riedmiller, M. Spahn.
27th Annual EAU Congress Paris, February 24-28, 2012
278. Abstr.: The orthotopic N-shaped ileal neobladder: Complications and voiding patterns in 121 consecutive patients.
T. De Sutter, S. Joniau, F. Van Der Aa, H. Van Poppel
27th Annual EAU Congress Paris, February 24-28, 2012
279. Abstr.: Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate.
F.K. Chun, J. Hansen, A. De La Taille, H. Van Poppel, M. Marberger, A. Stenzl, P.F.A. Mulders, H. Huland, C.C. Abbou, A.B. Stillebroer, M.P.M.Q. Van Gils, J.A. Schalken, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, A. Haese, K. Pummer, M. Auprich
27th Annual EAU Congress Paris, 24-28 February 2012
280. Abstr.: Sentinel node procedure for lymph node staging in prostate cancer.
L. Van Den Bergh, E. Lerut, C.M. Deroose, F. Ameye, K. Haustermans, H. Van Poppel, S. Joniau
27th Annual EAU Congress Paris, February 24-28, 2012
281. Abstr.: Radiofrequency ablation versus nephron sparing surgery in patients with solitary kidneys: Oncologic and functional outcomes
S. Joniau, T. Meert, F. Vandercruysse, L. De Wever, F. Claus, R. Oyen, H. Van Poppel
27th Annual EAU Congress Paris, February 24-28, 2012

282. Abstr.: 7-year experience with radiofrequency ablation for small renal masses: Oncologic and functional outcomes.
S. Joniau, F. Vancercruysse, T. Meert, L. De Wever, F. Claus, R. Oyen, H. Van Poppel
27th Annual EAU Congress Paris, February 24-28, 2012
283. Poster: A pharmacogenomics scoring system predicting median time-to-progression on sunitinib as first line treatment in patients with metastatic renal cell carcinoma.
B. Beuselinck, A. Karadimou, G. Couchy, B. Claes, D. Lambrechts, J. Berkers, R. Paridaens, P. Schöffski, H. Van Poppel, P. Wolter, A. Méjean, E. Lerut, B. Laguerre, C. Theodore, C. Linassier, R. Delva, E. Sevin, F. Goldwasser, J. Zucman-Rossi, S. Oudard.
AUA 2012
284. Poster: Mage-A3 and Prame: new targets for cancer immunotherapeutics (CI) in bladder cancer?
H. Van Poppel, S. Joniau, E. Lerut, D. D'Agostino, O. Gruselle, T. Coche, V. Brichard, P. Therasse
27th Annual EAU Congress Paris, February 24-28, 2012
285. Abstr. + poster: What are the mechanisms underlying the improved prostate cancer (PCa) control with degarelix compared to leuprolide?
H. Van Poppel, J.E. Damber, B-E. Persson
Global Congress on Prostate Cancer Brussels, June 28-30, 2012
286. Abstr.: Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. B. Beuselinck, P. Wolter, A. Karadimou, R. Elaidi, H. Dumez, A. Rogiers, T. Van Cann, L. Willems, J.J. Body, J. Berkers, H. Van Poppel, E. Lerut, P. Debruyne, R. Paridaens, P. Schöffski. *Br J Cancer* 2012; 107: 1665-1671.
287. Abstr.: Learning curves for urological procedures – a systematic review. H. Abboudi, M. Khan, K. Guru, S. Froghi, G. De Win, H. Van Poppel, P. Dasgupta, K. Ahmed. 1st price poster, EAU Annual Congress, Milan, March 15-19, 2013
288. Abstr.: Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy. H. Van Poppel, D. Rathkopf, M.R. Smith, J.S. De Bono, C.J. Logothetis, N.D. Shore, P. De Souza, K. Fizazi, P.F.A. Mulders, P. Mainwaring, J.D. Hainsworth, T.M. Beer, S. North, Y. Fradet, T. Griffin, Y.C. Park, T. Kheoh, E.J. Small, H.I. Scher, A. Molina, C.J. Ryan, EAU Annual Congress, Milan, March 15-19, 2013
289. Abstr.: Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) < 6 months. K. Miller, M.R. Smith, D.

- Dearnaley, L. Dogliotti, B. Egerdie, K. Fizazi, F. Kueppers, L. Montes De Oca, J. Morote, I. Pavlic, P. Sieber, T.L. Tammela, H. Van Poppel, M. Wirth, S. Wong, Z. Ye, A. Braun, EAU Annual Congress, Milan, March 15-19, 2013
- 290.Abstr.: Development and internal validation of a nomogram predicting biochemical recurrence after early salvage radiotherapy in prostate cancer patients treated with radical prostatectomy. A. Briganti, M. Bianchi, S. Joniau, C. Cozzarini, B. Tombal, K. Haustermans, W. Hinkelbein, N. Di Muzio, N. Suardi, H. Van Poppel, T. Wiegel, EAU Annual Congress, Milan, March 15-19, 2013
- 291.Abstr.: Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases, N. Suardi, J.R. Karnes, S. Joniau, K.A. Touijer, D. Osmonov, A. Aksenov, A. Briganti, P. Rigatti, H. Van Poppel, K.P. Jünemann. - EAU Annual Congress, Milan, March 15-19, 2013
- 292.Abstr.: Choline PET-CT and diffusion-weighted MRI for nodal staging in prostate cancer at high risk for nodal metastases, S. Joniau, L. Van Den Bergh, E. Lerut, R. Oyen, C.M. Deroose, T. Budiharto, F. Ameye, K. Haustermans, S. Isebaert, H. Van Poppel, EAU Annual Congress, Milan, March 15-19, 2013
- 293.Abstr.: Predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in men with pT3 N0 prostate cancer. Implications for multimodal therapies, M. Bianchi, A. Briganti, T. Wiegel, S. Joniau, F. Abdollah, M. Tutolo, C. Cozzarini, B. Tombal, K. Haustermans, W. Hinkelbein, N. Di Muzio, H. Van Poppel, EAU Annual Congress, Milan, March 15-19, 2013
- 294.Abstr.: Influence of pre- and post versus postoperative pelvic floor muscle training on urinary incontinence after open and robotic radical prostatectomy: A randomized controlled trial, I. Geraerts, H. Van Poppel, N. Devoogdt, S. Joniau, B. Van Cleynenbreugel, M. Van Kampen, EAU Annual Congress, Milan, March 15-19, 2013
- 295.Poster presentation: Learning curves for urological procedures – a systematic review, H. Abboudi, M. Khan, S. Froghi, G. De Win, H. Van Poppel, P. Dasgupta, K. Ahmed, 28th Annual EAU Congress, Milan, March 15-19, 2013
- 296.Poster presentation: Updated interim analysis: results of randomized phase 3 study COU-AA-302 of Abiraterone Acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy, H. Van Poppel, D. Rathkopf, M.R. Smith, J.S. de Bono, C. Logothetis, N.D. Shore, P. de Souza, K. Fizazi, P.F.A. Mulders, P. Mainwaring, J.D. Hainsworth, T.M. Beer, S. North, Y. Fradet, T. Griffin, Y.C. Park, T. Kheoh, E.J. Small, H.I. Scher, A. Molina, C. J. Ryan, 28th Annual EAU Congress, Milan, March 15-19, 2013
- 297.Abstr.: Renal function after nephron-sparing surgery (NSS) vs. radical nephrectomy (RN): data from the EORTC trial 30904. E. Messing, E. Scosyrev, S.

- Campbell, R. Sylvester, H. Van Poppel, 122nd meeting of the American Association of Genitourinary Surgeons, New Orleans, Louisiana, April 3-6, 2013
- 298.Abstr.: Prognostic factor for locally advanced prostate cancer: A multi-center experience. C.Y Hsu, M. Spahn, P. Gontero, A. Briganti, G. Marchioro, B. Tombal, H. Van Poppel, S. Joniau. 101st Annual Meeting of the Japanese Urological Association, April 25-28, 2013
- 299.Abstr.: Salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and imaging-detected nodal metastases, N. Suardi, J. Karnes, S. Joniau, K. Touijer, D. Osmonov, A. Briganti, M. Bianchi, H. Van Poppel, P. Rigatti, F. Montorsi, K. Peter, AUA Annual Meeting, San Diego, USA, May 4-8, 2013
- 300.Abstr.: Is there a role for salvage extended lymph node dissection for patients with nodal recurrence of prostate cancer on androgen deprivation therapy? Results based on a multi-institutional analysis, D. Osmonov, A. Briganti, J. Karnes, S. Joniau, K. Touijer, P. Rigatti, N. Suardi, K-P. Junemann, F. Montorsi, H. Van Poppel, AUA Annual Meeting, San Diego, USA, May 4-8, 2013
- 301.Abstr.: Association between time to biochemical recurrence and cancer specific and other cause mortality in men with high risk prostate cancer treated with radical prostatectomy with adjuvant treatments. A multi-institutional analysis, M. Bianchi, J. Karnes, M. Spahn, P. Gontero, F.K.H. Chun, J. Hansen, G. Marchioro, F. Abdollah, B. Tombal, U. Capitanio, P. Bastian, H. Van der Poel, R. Sanchez-Salas, F. Montorsi, H. Van Poppel, A. Briganti, AUA Annual Meeting, San Diego, USA, May 4-8, 2013
- 302.Abstr.: Predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in men with PT3N0 prostate cancer. Implications for multi-modal therapies, M. Bianchi, T. Wiegel, S. Joniau, F. Abdollah, M. Tutolo, C. Cozzarini, B. Tombal, K. Haustermans, N. Di Muzio, H. Van Poppel, F. Montorsi, A. Briganti, AUA Annual Meeting, San Diego, USA, May 4-8, 2013
- 303.Abstr.: Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy – interim analysis of the COU-AA-302 phase 3 trial, F. Saad, Neal D. Shore, H. Van Poppel, D. Rathkopf, M.R. Smith, J.S. de Bono, C. Logothetis, P. de Souza, K. Fizazi, P. Mulders, P. Mainwaring, J. D. Hainsworth, TM. Beer, S. North, Y. Fradet, T. Griffin, T. Kheoh, E.J. Small, A. Molina, C.J. Ryan, AUA Annual Meeting, San Diego, USA, May 4-8, 2013
- 304.Abstr.: Development and internal validation of a nomogram predicting biochemical recurrence after early salvage radiotherapy in prostate cancer patients treated with radical prostatectomy, A. Briganti, M. Bianchi, S. Joniau, C. Cozzarini, B. Tombal, K. Haustermans, W. Hinkelbein, N. Di Muzio, F. Montorsi, T. Wiegel, AUA Annual Meeting, San Diego, USA, May 4-8, 2013

- 305.Abstr.: Renal function after nephron-sparing surgery vs. radical nephrectomy: data from the EORTC trial 30904, E. Scosyrev, E. Messing, S. Campbell, R. Sylvester, H. Van Poppel, AUA Annual Meeting, San Diego, USA, May 4-8, 2013
- 306.Abstr.: Is there a role for salvage extended lymph node dissection for patients with nodal recurrence of prostate cancer on androgen deprivation therapy? Results based on a multi-institutional analysis? J. Urol 2013; 189, Suppl.: e318.
- 307.Abstr.: Efficacy and safety of enzalutamide monotherapy in hormone-naïve prostate cancer (HNPN)? Van Poppel H., Smith MR., Borre M. et al. 5th European Multidisciplinary Meeting on Urological Cancers (EMUC), November 15-17, 2013, Marseille, France – Eur Urol Suppl 2013; 12: 152.
- 308.Abstr.: MicroRNA-141 expressie in sunitinib-resistente heldercellig renal cel carcinomen. Berkers J., Swinnen J., Van Poppel H., Lerut E. Elautprijs 2014, 25 January 2014
- 309.Abstr. Oncologische en functionele resultaten van partiële nefrectomie versus radicale nefrectomie in cT1b-4 RCC: een cae-matched analyse van de resultaten van UZ Leuven. Veys R., Van Poppel H., Joniau S. Elautprijs 2014, 25 January 2014
- 310.Abstr.: Role of 11C choline-PET-CT in defining patients eligible for salvage lymph node dissection (LND). Deconinck S. Tosco L. Janssen P., Goffin K., Van Poppel H., Joniau S. Elautprijs 2014, 25 January 2014.
311. P. Mainwaring, E.Y. Yu, A. Londhe, H. Van Poppel, D.E. Rathkopf, M.R. Smith, P. Souza, T.W. Griffin, C.J. Ryan.
Abstr.: Association of alkaline phosphatase with clinical outcomes in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302.
BJUI 2014; 113 Suppl 4: 21 - USANZ Brisbane, Australia
312. I. Geraerts, L. Tosco, S. Joniau, B. Van Cleynenbreugel, H. Van Poppel, M. Van Kampen.
Abstr.: High-risk and non-high risk PCa patients have comparable time to continence, voiding symptoms and quality of life after radical prostatectomy.
29th Annual EAU Congress Stockholm, Sweden 2014
313. E. Baten, S. Joniau, H. Van Poppel, F. Van Der Aa
Abstr.: When is a conservative management recommended for ureterointestinal strictures following radical cystectomy with ileal conduit?
29th Annual EAU Congress Stockholm, Sweden 2014
314. G. Gandaglia, T. Wiegel, S. Joniau, F. Abdollah, M. Tutolo, M. Bianchi, C. Cozzarini, B. Tombal, K. Haustermans, N. Di Muzio, H. Van Poppel, A. Briganti.
Abstr.: Predictors of early failure after timely administered salvage radiotherapy for biochemical recurrence after radical prostatectomy.
29th Annual EAU Congress Stockholm, Sweden 2014

315. L. Tosco, A. Laenen, P. Bastian, A. Briganti, F.K. Chun, P. Gontero, C.Y. Hsu, J. Karnes, G. Marchioro, R. Sanchez-Salas, M. Spahn, B. Tombal, T. Van de Broeck, H. Van Der Poel, H. Van Poppel, S. Joniau.
Abstr.: In high-risk prostate cancer, prognostic factors predict cancer related death in a time-dependent fashion following surgery: a multi-institutional competing risk analysis.
 29th Annual EAU Congress Stockholm, Sweden 2014
316. G. Gandaglia, M. Spahn, S. Joniau, P. Gontero, M. Bianchi, B. Kneitz, F.K.H. Chun, M. Sun, M. Graefen, F. Abdollah, G. Marchioro, D. Frohenberg, S. Giona, B. Frea, P.I. Karakiewicz, H. Van Poppel, J. Karnes, A. Briganti.
Abstr.: The impact of time to biochemical recurrence on cancer-specific mortality in patients with high-risk prostate cancer treated with radical prostatectomy: a competing-risks regression analysis.
 29th Annual EAU Congress Stockholm, Sweden 2014
317. L. Tosco, P. Bastian, F. Chun, P. Gontero, C.Y. Hsu, J. Karnes, G. Marchioro, R. Sanchez-Salas, M. Spahn, B. Tombal, T. Van Den Broeck, H. Van Der Poel, H. Van Poppel, S. Joniau.
Abstr.: In high-risk prostate cancer, more than 3 positive nodes at radical prostatectomy represent an independent predictor of worse CSS, while 1 to 3 positive nodes do not influence CSS.
 29th Annual EAU Congress Stockholm, Sweden 2014
318. L. Tosco, E. Ammirati, V. Ficarra, B. Frea, P. Gontero, A. Gurioli, B. Tombal, H. Van Poppel, S. Joniau
Abstr.: Incidence of urinary tract obstructions due to prostate cancer progression differs according to primary treatments.
 29th Annual EAU Congress Stockholm, Sweden 2014
319. D.R. Hay, M.S. Khan, H. Van Poppel, B. Van Cleynenbreugel, J. Peabody, K. Guru, P. Dasgupta, B. Challacombe, K. Ahmed.
Abstr.: Systematic review of effectiveness of mentorship programmes in urology.
 29th Annual EAU Congress Stockholm, Sweden 2014
320. S. Deconinck, L. Tosco, P. Janssen, H. Van Poppel, S. Joniau.
Abstr.: Mapping of true positive, false positive and false negative lymph nodes after salvage lymph node dissection in prostate cancer patients with positive nodes at 11C choline positron emission tomography/computed tomography.
 J Urol 2014; 191, suppl: e469
321. A. Heidenreich, M.R. Smith, M. Borre, P. Rathenborg, P. Werbrouck, H. Van Poppel, P. Iversen, J. Braeckman, J. Heracek, E. Baskin-Bey, T. Ouatas, F. Perabo,

D. Phung, M. Hirmand, B. Tombal.

Abstr.: Enzalutamide monotherapy in hormone-naïve prostate cancer (HNPC) patients: 1-year extended follow-up of a phase 2 study.

66. Kongress der Deutschen Gesellschaft für Urologie e.V. 1-4 Oktober 2014, Düsseldorf, Germany

322. M. Barale, M. Agnella, M. Oderda, S. Giona, F. Pisano, L. Daniele, D. Pacchioni, L. Delsedime, P. Dalmasso, N. Nicolaiew, A. De La Taille, B. Frea, H. Van Poppel, S. Joniau, P. Gontero.

Abstr.: Natural history of HG PIN and ASAP

30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015

323. N. Fossati, R.J. Karnes, C. Cozzarini, C. Fiorino, S. Joniau, W. Hinkelbein, K. Haustermans, B. Tombal, S.F. Shariat, P.I. Karakiewicz, G. Goldner, F. Montorsi, H. Van Poppel, T. Wiegel, A. Briganti.

Abstr.: Impact of pre-treatment PSA level on cancer control after early salvage radiation therapy post-radical prostatectomy: Need for patients stratification according to prostate cancer features.

30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015

324. M. Bianchi, R.J. Karnes, S. Joniau, G. Gandaglia, M. Spahn, P. Gontero, L. Tosco, R. Sanchez-Salas, X. Cathelineau, B. Kneitz, F.K.H. Chun, P. Karakiewicz, M. Graefen, P. Chlosta, G. Marchioro, D. Frohneberg, H. Van Poppel, F. Montorsi, A. Briganti.

Abstr.: Long-term survival patterns of young patients with high risk prostate cancer treated with radical prostatectomy. Results of a multi-institutional, conditional survival analysis.

30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015

325. J.H.M. Berkers, C. Vandenbriele, O. Govaere, B. Beuselinck, R. Conotte, B. Blankert, S. Joniau, H. Van Poppel, E. Lerut.

Abstr.: MIR-141 expression in clear cell carcinoma is linked with augmented susceptibility to sunitinib therapy in vivo.

30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015

326. M. Bianchi, R.J. Karnes, S. Joniau, G. Gandaglia, M. Spahn, P. Gontero, R. Sanchez-Salas, X. Cathelineau, B. Kneitz, F.K.H. Chun, P.I. Karabiewicz, M. Graefen, G. Marchioro, D. Frohneberg, H. Van Poppel, F. Montorsi, A. Briganti.

Abstr.: Long-term outcomes of very high risk prostate cancer patients treated with

radical prostatectomy with or without adjuvant treatments. Results of a competing risks, multi-institutional analysis.

30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015

327. S. Elsen, E. Lerut, B. Van Cleynenbreugel, F. Van der Aa, H. Van Poppel, P. De Witte.
Abstr.: Evans blue as a diagnostic tool for non-muscle-invasive bladder cancer.
 EMUC 2015 – Eur Urol Suppl 2015; 14: 149-221.
328. M. Oderda, M. Agnello, M. Barale, M. Falcone, G. Marra, A. Palazzetti, D. Pacchioni, L. Daniele, L. Delsedime, N. Nicolaiew, S. Joniau, H. Van Poppel, A. De La Taille, B. Frea, P. Gontero.
 Abstr.: Natural history of prostate widespread HGPIIN and ASAP: When to rebiopsy?
 EMUC 2015 – Eur Urol Suppl 2015; 14: 149-221
329. H. Van Poppel. Medical treatment for advanced prostate cancer – EJOP 2016; 10: 26
330. Poster: U. Milenkovic, M. Akand, L. Moris, L. Demaegd, Y. Bekhuis, B. Van Cleynenbreugel, W. Everaerts, H. Van Poppel, H. Dumez, S. Joniau, M. Albersen
 Impact of neoadjuvant chemotherapy on early complications of radical cystectomy for bladder cancer: a real life retrospective analysis.
331. Fossati, Nicola; Karnes, R. Jeffrey; Bossi, Alberto; Cozzarini, Cesare; Wiegel, Thomas; Shariat, Shahrokh F.; Joniau, Steven; Fonteyne, Valérie; Van Poppel, Hein; Montorsi, Francesco et al. PD72-06 ADJUVANT VERSUS EARLY SALVAGE RADIATION THERAPY IN NODE POSITIVE PROSTATE CANCER PATIENTS: A LONG-TERM SURVIVAL ANALYSIS
 The Journal of Urology , Volume 197 , Issue 4 , e1363 – AUA Boston 12-16 May 2017
332. PD72-10 ASSESSING THE RISK OF EARLY AND LATE TOXICITY OF POST-PROSTATECTOMY RADIATION THERAPY: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. Fossati, Nicola; Karnes, R. Jeffrey; Bossi, Alberto; Cozzarini, Cesare; Wiegel, Thomas; Shariat, Shahrokh F. Joniau, Steven; Fonteyne, Valérie; Van Poppel, Hein; Montorsi, Francesco et al. The Journal of Urology , Volume 197 , Issue 4 , e1365 - e1366 – AUA Boston 12-16 May 2017

333. Zattoni, Fabio; Thompson, Robert H.; Capitanio, Umberto; Crestani, Alessandro; Kutikov, Alexander; Larcher, Alessandro; Lane, Brian R.; Leibovich, Bradley C.; McIntosh, Andrew; Montorsi, Francesco; Moon, Daniel; Muilwijk, Tim; Murray, Katie; Noyes, Sabrina; Russo, Paul; Uzzo, Robert G; Van Poppel, Hein; Yang, David; Zattoni, Filiberto; Mottrie, Alexander; Novara, Giacomo et al. MP55-05 PARTIAL NEPHRECTOMY IN THE TREATMENT OF RENAL TUMORS WITH CONCOMITANT VENOUS TUMOR THROMBOSIS (VTT) OF RENAL VEIN BRANCHES: RETROSPECTIVE, MULTI-CENTER ANALYSIS OF PERIOPERATIVE, FUNCTIONAL, AND ONCOLOGIC OUTCOMES. *The Journal of Urology* , Volume 197 , Issue 4 , e731 - e732 – AUA Boston 12-16 May 2017
334. Fossati, Nicola; Karnes, R. Jeffrey; Bossi, Alberto; Cozzarini, Cesare; Wiegel, Thomas; Shariat, Shahrokh F.; Joniau, Steven; Fonteyne, Valérie; Van Poppel, Hein; Montorsi, Francesco et al. PD72-05 NATURAL HISTORY OF PATIENTS TREATED WITH SALVAGE RADIATION THERAPY FOR RISING PSA AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS. *The Journal of Urology* , Volume 197 , Issue 4 , e1363 – AUA Boston 12-16 May 2017
335. Fossati, Nicola; Karnes, R. Jeffrey; Bossi, Alberto; Cozzarini, Cesare; Wiegel, Thomas; Shariat, Shahrokh F.; Joniau, Steven; Fonteyne, Valérie; Van Poppel, Hein; Montorsi, Francesco et al. PD72-03 TIMING OF SALVAGE RADIATION THERAPY AND USE OF CONCOMITANT HORMONAL THERAPY FOR PATIENTS WITH PSA RISING AFTER RADICAL PROSTATECTOMY: A LONG-TERM SURVIVAL ANALYSIS. *The Journal of Urology* , Volume 197 , Issue 4 , e1362 – AUA Boston 12-16 May 2017
336. Fossati, Nicola; Colicchia, Michele; Haidl, Friederike; Gratzke, Christian; Battaglia, Antonino; Aksenov, Alexey V.; Abreu, ADL; Fay, C.; Mottrie, Alexandre; Montorsi, Francesco et al. MP77-01 11C-CHOLINE VERSUS 68GA-PSMA PET/CT SCAN FOR THE DETECTION OF NODAL RECURRENCE FROM PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SALVAGE LYMPH NODE
337. DISSECTION SERIES. *The Journal of Urology* , Volume 197 , Issue 4 , e1021 – AUA Boston 12-16 May 2017
338. Fossati, Nicola; Karnes, R. Jeffrey; Bossi, Alberto; Cozzarini, Cesare; Wiegel, Thomas; Shariat, Shahrokh F.; Joniau, Steven; Fonteyne, Valérie; Van Poppel, Hein; Montorsi, Francesco et al. PD51-02 IDENTIFYING THE OPTIMAL CANDIDATE FOR EARLY SALVAGE RADIATION THERAPY AFTER RADICAL

PROSTATECTOMY FOR PROSTATE CANCER: A LONG-TERM MULTI-INSTITUTIONAL ANALYSIS. *The Journal of Urology* , Volume 197 , Issue 4 , e984 - e985 – AUA Boston 12-16 May 2017

339. Fossati, Nicola; Karnes, R. Jeffrey; Bossi, Alberto; Cozzarini, Cesare; Wiegel, Thomas; Shariat, Shahrokh F.; Joniau, Steven; Fonteyne, Valérie; Van Poppel, Hein; Montorsi, Francesco et al. PD15-11 MORE EXTENSIVE LYMPH NODE DISSECTION AT RADICAL PROSTATECTOMY IS ASSOCIATED WITH IMPROVED OUTCOMES AFTER SALVAGE RADIOTHERAPY FOR RISING PSA AFTER SURGERY: A LONG-TERM, MULTI-INSTITUTIONAL ANALYSIS. *The Journal of Urology* , Volume 197 , Issue 4 , e286 - e287 – AUA Boston 12-16 May 2017
340. Fossati, Nicola; Colicchia, Michele; Haidl, Friederike; Gratzke, Christian; Battaglia, Antonino; Aksenov, Alexey V.; Abreu, ADL; Fay, C.; Mottrie, Alexandre; Montorsi, Francesco et al. PD15-09 IDENTIFYING THE OPTIMAL CANDIDATE FOR SALVAGE LYMPH NODE DISSECTION FOR NODAL RECURRENCE OF PROSTATE CANCER: RESULTS FROM A LARGE, MULTI-INSTITUTIONAL ANALYSIS. *The Journal of Urology* , Volume 197 , Issue 4 , e286 – AUA Boston 12-16 May 2017
341. Marieke van Leeuwen, Jacobie M. Kieffer, Fabio Efficace, Sophie D. Fossa, Michel Bolla, Laurence Colette, Marc Colombel, Ugo De Giorgi, Bernhard Holzer, Lonneke V. van de Poll-Franse, Hendrik Van Poppel, Jeff White, Ronald de Wit, Susane Osanto, Neil K. Aaronson for the European Organisation for Research and Treatment of Cancer Quality of Life Group and Radiation Oncology Group and the NCRN Testis Clinical Studies Group. International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. *Van Leeuwen et al. Health and Quality of Life Outcomes* (2017) 15:97. Doi 10.1186/s12955-017-0670-4
342. Abstr.: AS Heikki, M Tutolo, L Tosco, A Battaglia, L Moris, T Van den Broeck, M Albersen, G De Meerleer, H Van Poppel, W Everaerts, S Joniau. Comparison of functional outcome after extended versus super-extended pelvic lymph node dissection during radical prostatectomy in high-risk localized prostate cancer. *Frontiers*, 07 september 2017, ID: 309448. www.frontiersin.org
410. Abstr.: S. Joniau, B. Chys, A. Brignati, P. Chlosta, G. De Meerleer, W. Everaerts, P. Gontero, M. Greafen, C. Gratzke, R.J. Karnes, G. Marchioro, R. Sanchez-Salas, M. Spahn, B. Tombal, H. Van der Poel, H. Van Poppel. Validation of STAMPEDE

criteria for non-metastatic prostate cancer - an EMPaCT study (18-7479) – EAU 2018

IV.4. Video's

1. Percutaneous operative gastrostomy.
H. Van Poppel, L. Baert.
Video Urology Times (U.S.A.), vol. 7, program 2, 1994.
2. Prepubic urethrectomy.
H. Van Poppel, L. Baert.
Video Urology Times (U.S.A.), vol. 8, program 1, 1995.

V. Postgraduate education

1. Great Britain, London (9-12/1983)
 - a. Institute of Urology
 - with certificate of post-graduate instruction in Urology and Nephrology of the University of London.
 - with personal certificates of Mr. J.E.A. Wickham, Mr. R.T. Turner-Warwick, Prof. J.P. Blandy, Mr. J. P. Williams, Mr. P.G. Ransley, Mr. J.P. Pryor, Mr. W.F. Hendry, Mr. P.H.L. Worth, Mr. C.R.J. Woodhouse, Mr. J.R. Hindmarsh, Mr. R.A. Miller and Dr. M.J. Kellett.
 - b. The Royal Marsden Hospital and Guy's Hospital.
 - with personal certificates of Mr. W.F. Hendry and Mr. A.R. Mundy
2. Spain, Barcelona (1-4/1984)
 - a. Escuela profesional de Urologia de la Universidad de Barcelona
 - with certificate of postgraduate instruction in Urology.
 - b. Hospital Clinic I Provincial de Barcelona and Clinica San José Barcelona, Department of Urology and Renal Transplantation.
 - with Prof. Dr. J.M. Gil-Vernet, Dr. P. Carretero, Dr. R. Talbot-Wright, Prof. Dr. A. Caralps and Dr. J. Andreu.
 - with personal certificate of Prof. Dr. J.M. Gil-Vernet.
3. Denmark, Copenhagen (5-6/1984)
 - a. Department of Ultrasound, University Hospital, Herlev, under guidance of Dr. H.H. Holm, and Dr. N. Juul
 - with personal certificate.
 - b. Department of Urology, University Hospital, Herlev, under guidance of Dr. T. Hald and Dr. F. Rasmussen.

- with personal certificate
4. Mainz, Germany (8-9/1984)
Department of Urology, Johannes Gutenberg Universität, under guidance of Prof. Dr. R. Hohenfellner.
 - with personal certificates of Prof. Dr. R. Hohenfellner and Prof. Dr. P. Alken.
 5. Rotterdam, The Netherlands (9-12/1984)
Department of Urology, Erasmus Universiteit, under guidance of Prof. Dr. F.H. Schröder.
Integrated as consultant urologist.
 - with personal certificates of Prof. Dr. F.H. Schröder.
 6. Mainz, Germany (12/1988)
Department of Urology, Johannes Gutenberg Universität, under guidance of Prof. Dr. R. Hohenfellner.
 - training course in performance of Mainz pouch continent urinary diversion.
 7. Saint Louis, Missouri (U.S.A.) (12/1992)
Department of Urology, St. Lukes Hospital under guidance of Dr. Sherman Silber.
 - training in microsurgical epididymal sperm aspiration technique.
 8. Innsbruck, Austria (2/1998)
Dept. of Urology, Universitätsklinik für Urologie, Prof. Dr. H. Bartsch, Prof. Dr. A. Stenzl. Bladder substitution in the female.
 9. Postgraduate training “Radioprotection and dosimetry”, KULeuven Academiejaar ‘97-98

VI. Nominations

1. Chief of the Division of Urology, National Institute for Multiple Sclerosis, Melsbroek, Belgium. January 1992
2. Lecturer in Urology, Nurse School St. Elisabeth Leuven, Belgium. August 1983
3. Lecturer in Urology, Medical School of the Katholieke Universiteit Leuven, Belgium. September 1987
4. Chef de Clinique-Adjoint in the Department of Urology, Katholieke Universiteit Leuven, Belgium. May 1988
5. Doctor in Medical Sciences of the Catholic University of Leuven, after presentation of a thesis on “Study of the autonomic nerve fibres of the urinary bladder wall”, June 1988
6. Member of the administrative board of the “Belgische Vereniging Urologie”. 1989-1991
7. Chairman of the European Study Group on Sexual and Urological Disturbances in Multiple Sclerosis (SUDIMS). 1991-1995

8. National Coordinator for Belgium at the European Organisation on the Research and Treatment of Cancer, GU Group since 1992-1996
9. Fellow of the European Board of Urology since September 1992
10. Study Coordinator of the EORTC GU Group since 1992
11. Chairman of the Kidney Cancer Subcommittee of the EORTC GU Group. 1992-1995
12. Scientific Board of the Belgische Vereniging Kankerbestrijding. 1993
13. Member of the Interuniversity Scientific Board of Belgian Urology. 1994
14. Member of the Nederlandstalige Kamer van de Erkenningscommissie voor Urologie since 1995
15. Member of the Quality Control Committee of the EORTC GU Group since 1995
16. Member of the Accrediteringscommissie voor Urologie since 1995
17. Member of the European group for recommendations and guidelines in oncology since 1996
18. Member of the Strategiecommissie University Hospitals of the Katholieke Universiteit Leuven since 1995
19. Team member of URO web since 1996
20. Treasurer EORTC GU Group. 1997 – 2011
21. Member of the Genito-Urinary Subgroup of the European Working Group on Quality Control and Standardization since 1997
22. Representative BVU to the EAU - EBU since May 1999
23. Member of the EBU Residency Review Committee since 1999
24. Executive Committee member of the Belgian Association of Urology since October 1999
25. Member of the Accreditation Council of the EBU since November 1999
26. Representative for Belgian Urology at the UEMS (Union Européenne des Médecin Spécialistes) since March 2001
27. National oncologic expert to the Advisory Committee for Cancer Prevention of the European Commission, since September 2001
28. Member of the Executive Committee of the Residency Review Committee (RRC) of the European Board of Urology since November 2001
29. Board member of the European Society of Oncological Urology since November 2001
30. Reviewer UICC grant applications since 2002
31. Chairman workgroup Urologic tumors, Vlaams Ziekenhuisnetwerkvorming KULeuven
32. Board member of the ESSO since October 2003
33. Chairman fo the Education office of the EAU since May 2004
34. Member of the scientific office of the EAU since May 2004

35. Member of the accreditation and continued medical education office of the EAU since May 2004
36. Member of the American Association of Genitourinary Surgeons (AAGUS) since 2006
37. Vice President Belgische Vereniging voor Urologie 2006-2009
38. ESMO and Faculty Member for Genitourinary cancer for the years 2006-2008
39. Europa Uomo, Chairman Scientific Committee, 2006
40. Member of the Executive Committee of the 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases, 2006
41. President Belgische Vereniging voor Urologie since January 2009
42. Treasurer ICUD since July 2009 – February 2012
43. Member of the Executive Committee of the ICUD since July 2009
44. Congress President of 9th Annual BAU Congress – Brabant Leuven – 11, 12 December 2009
45. Guest Professor of the Peking University Wu Jieping Urology Center, July 2011
46. EAU Adjunct Secretary General – Education, since February 2012

VII. Reviewer of scientific journals

1. Acta Urologica Belgica
2. Adis International
3. European Journal of Cancer
4. European Journal of Emergency Medicine
5. European Urology
6. Journal of Cancer Research and Clinical Oncology
7. Radiotherapy and Oncology
8. Tijdschrift voor Geneeskunde
9. Journal of Urology (USA)
10. Urology (USA)
11. Annals of Oncology
12. Brazilian Journal of Urology
13. Golden Urology
14. Emergency medicine
15. Journal of Sexual Medicine
16. Progrès en urology
17. Kidney Cancer Journal International
18. The Lancet Oncology
19. Urologia Internationalis
20. World Journal of Urology

21. UroOncology
22. Turkish Journal of Urology
23. Annals of Urology
24. Arab Journal of Urology
25. European Urological Review
26. Annals of Oncology
27. African Journal of Urology

VIII. Review for international meetings

1. European Association Urology (team leader on kidney cancer 1996, 1998)
2. European Cancer Conference (team leader on prostate and bladder cancer, 1997)
3. Member of the scientific committee of the XVth EAU congress, Brussels, April 2000

IX. Redaction of journals/books

1. Acta Urologica Belgica, since 1992
2. Urologie Practicum, since 1994
3. UROFAX, since 1997
4. European Journal of Pelvic Surgery, since 1998
5. Uro-Oncology, since 1999
6. Member of the Editorial board of Urobel, since 2006
7. Member of the Editorial Board of European Urology Today, since 2005
8. Member of the Editorial board of "Current Urology", since 2006
9. Urobel magazine, since 2007
10. Editorial Advisory Board of Kidney Cancer Journal International, since 2007
11. Member of the Editorial Board of UroOncology, since 2007
12. Member of the Editorial Board of the Turkish Journal of Urology, since January 2008.
13. Redacteur van het Nederlands Tijdschrift voor Urologie (NTvU), since April 2008
14. Member of the editorial board of The Open Prostate Cancer Journal, since September 2008.
15. Member of the editorial board of UroOncology, since September 2008
16. Associate Editor of the Editorial Board of Romanian Journal of Urology, since October 2008.
17. Member of the editorial board of Onco, since 2008
18. Guest editor Tempo Medical, Update in Urology November 2008

19. Member of the Editorial Advisory Board of Türkiye Klinikleri Journal of Medical Sciences, since May 2009
20. Redactielid van PROSTAATinfo – Nieuwsbrief Wij Ook Belgium, since July 2009
21. Member of the editorial board of European Urology, since 2009
22. Member of the editorial board of Annals of Urology, since December 2009
23. Member of the International Editorial Board of “The 5-minute urology consult” – L.G. Gomella – Wolters Kluwer / Lippincott Williams & Wilkins
24. Member of the Editorial Board of European Urological Review, since 2010
25. Member of the Editorial Board of Turkish Journal of Urology, since 2010
26. Member of Faculty F1000, 2011
27. Member of the International Advisory Board of Tijdschrift voor Urologie, November 2011
28. Member of the Advisory Board of Framingham on Prostate Cancer, January 2013
29. Editor-in-chief. Mirrors of medicine: Summary of Science for Practice: High-risk non metastatic and metastatic prostate cancer, e-HIMS bvba 2014
30. Editor-in-chief. Mirrors of medicine: Summary of Science for Practice: Localised prostate cancer: management of remaining or recurrent disease, e-HIMS bvba 2014
31. Editor-in-chief: Mirros of medicine: Summary of Science for Practice: Prostate cancer diagnosis. e-HIMS bvba 2014
32. Book editor: Renal Cell Carcinoma – Published by In Tech, December 2011
33. Associate editor of the Asian Journal of Urology – September 2014
34. Member of Editorial Board for the Clinics of Oncology – May 2016

X. Memberships

1. Vlaams Geneesheren Verbond, since 1980.
2. Belgische Vereniging Urologie, since 1981.
3. Soci t  Belge d’Urologie, since 1982.
4. International Continence Society, since 1983.
5. Belgian Research Group for Multiple Sclerosis, since 1984.
6. EORTC Genito-Urinary Group, since 1986. (National coordinator and study coordinator since 1992).
7. European Society Surgical Oncology, since 1989.
8. European Study Group on Sexual and Urological Disorders in Multiple Sclerosis, since 1990 (Chairman 1991-1995).
9. European Association of Urology, since October 1990.
10. Deutsche Gesellschaft f r Urologie, since November 1990.
11. American Urological Association, since June 1991.
12. Soci t  Internationale d’Urologie, since May 1992.

13. European Board of Urology, Fellow since September 1992.
14. European group for guidelines in onco-urology, since February 1996.
15. Member of the Genitourinary subgroup of the European Working Group on Quality Control and Standardisation.
16. Member of the Belgian Society of Surgical Oncology (BSSO), since February 2000
17. Member of the editorial board of the XV th EAU Congress, April 2000, Brussels
18. Member of the AstraZeneca Prostate cancer speakers list.
19. Member of the Prostate Cancer Disease Oriented Group of the EORTC, since January 2001
20. Member of Prostate Disease Oriented Group of EORTC GU Group, since January 2001
21. Lid werkgroep oncologie, Ministerie van Sociale Zaken, Volksgezondheid en leefmilieu, since 2004.
22. Founding member of Europa Uomo, Milan, June 11, 2004
23. Member of the European Society of European Pathology, since May 2004
24. Member of the new Advisory Board of EUT, since September 27, 2004
25. Member of the Board of the European Society of Surgical Oncology (ESSO), since 2004.
26. Member of the Advisory Board, Belgian Urologists, sorafenib in renal cell cancer, April 2006
27. Honorary Member, Georgian Urological Association, October 2006
28. Faculty member ESMO, since 2006
29. Member of the Editorial Advisory Board of the Kidney Cancer Journal International, since February 2007.
30. Member of the Advisory Board, Antigenics, since 2007
31. Member of the Advisory Board, PCA3, since 2007
32. Member of the Dendreon Advisory Board, since 2007
33. Member of the Advisory Board, Wyeth, since February 2008
34. Honorary Member, Dutch Urological Association, March 2008
35. Member of the Advisory Board, Celgene, May 2008
36. Honorary Member of the Asociația Română de Urologie (ARU), since June 2008
37. Member of the Advisory Board, Cougar Biotechnology, since July 2008
38. Member of the ESSO Executive Committee, since 2008
39. Member of the Advisory Board, Amgen, since November 2009
40. Expert in the field, Astellas, since November 2009
41. Member of the Advisory Board, Janssen-Cilag, since December 2009
42. Member of the Evaluation Committee of the French National Cancer Institute (INCa), since January 2010
43. Consultant of Ferring, since January 2010

44. Member of the Advisory Board, Oncomethylome, since 2010
45. Member of the Proactive Prostate Coalition Task Force, since March 2010
46. Member of the Digital Collaboration Board of Janssen-Cilag, since December 2010
47. Member of the Bristol-Myers Squibb Prostate Advisory Board, since September 2011
48. Member of Advisory Board, Framingham bv, since June 2012
49. Member of Advisory Board, Bayer, since November 2012
50. Member of the ESMO Guidelines Working Group – review of the ESMO Clinical Practice Guidelines, since April 2013
51. Honorary Member of the Polish Urological Association, since September 2013
52. Member of the Clinical Working Group of Europa Uomo, since September 2013
53. Ehrenmitgliedschaft Die Deutsche Gesellschaft für Urologie e.V., 2014
54. Honorary Member of the Chinese Urological Association, 2014.
55. Member of the advisory board of Framingham on Prostate Cancer, 2015
56. Member of the Management Board of the European Medicines Authority (EMA), January 2016
57. Member of the Editorial Board of the Asian Journal of Urology, since August 2017

XI. Promotor or Co-promotorship, member of jury

- R. Van Bellingen: Co-promotor, 1994
Levenskwaliteit bij blaaskanker patiënten met een urinederivatatie volgens Bricker.
Licentiaat in Medisch-Sociale Wetenschappen, School voor Maatschappelijke Gezondheidszorg K.U.Leuven
- R. Oyen: Member of jury, 1995
Prostatic carcinoma: diagnosis and staging by transrectal ultrasonography, magnetic resonance imaging and computed tomography.
Doctor in Medical Sciences, Katholieke Universiteit Leuven
- J. Bogaerts: Member of jury, 1995
The aetiology and treatment of genital ulcers in Rwanda: a laboratory based study.
Doctor in Medical Sciences, Katholieke Universiteit Leuven
- Heng Qi: Member of jury, 1996
Cytogenetics and molecular cytogenetics in prostate cancer.
Masters degree of Medical Sciences, K.U.Leuven
- A.A. Elgamal: Co-promotor, 1996
Contribution in the management of clinically localized prostate cancer.
Doctor in Medical Sciences, K.U.Leuven
- L. Van den Hove: Member of jury, 1997
Studies on host-tumor interactions in hemato-oncological patients and patients with

- renal cell carcinoma.
 Doctor in Medical Sciences, K.U.Leuven
- M. Van Kampen: Co-promotor, 1998
 Invloed van bekkenbodemspieroefeningen, biofeedback en blaastraining op de graad en de duur van incontinentie na radicale prostatectomie.
 Doctoraat Lichamelijke Opvoeding en Kinesitherapie, K.U.Leuven
 - D. De Ridder: Promotor, 1998
 Advances in the treatment of voiding dysfunctions and detrusor hyperreflexia in Multiple Sclerosis.
 Doctor in Medical Sciences, K.U. Leuven
 - P. M. A. Groenen: Member of Jury 1999
 Genetic studies on renal malformations
 Doctor in Medical Sciences, KU Leuven
 - Karine Goossens: Member of Jury 2002
 Epithelial and stromal cultures of the human prostate.
 Doctor in Medical Sciences, KU Leuven
 - Inge Geraerts: Co-promotor, 2002
 Prediction of duration of urinary incontinence after radical prostatectomy
 Licentiaat Lichamelijke Opvoeding en Kinesitherapie, K.U.Leuven
 - Annelies Derycke: Member of Jury 2004
 Photodynamic therapy with liposomal photosensitizers targeted to superficial bladder tumors
 Doctor in Farmaceutical Sciences, KULeuven
 - Ontwikkeling van een decision aid voor patiënten met gelokaliseerde prostaatkanker: Pilotstudie naar de visie van betrokkenen.
 - Inge Nuyttens
 Licentiaat in de biomedische wetenschappen, KULeuven
 Fatty acid synthase: a potential target for antineoplastic therapy?
 - Ellen de Schrijver
 Prostate cancer: prognostic factors markers of outcome and design of clinical trials.
 - Thesis Phd Laurence Collette: Member of Jury 2006
 Determinants of bladder cancer: an epidemiological study.
 - Doctoraal proefschrift in de Medische Wetenschappen, Eliane Kellen: Member of Jury 2007
 - Tom Budiharto: Co-promotor 2009
 The optimization of treatment selection and of external beam radiotherapy for prostate cancer patients.

- Chao-Yu Hsu: Promotor 2009
Prognostic factors in locally advanced prostate cancer as determined by biochemistry, imaging studies and pathology.
- Martijn van Gils: lid van de promotiecommissie
Molecular diagnosis in prostate cancer. PCA3
September 2009
- Joachim Vandepitte: Promotor September 2010
PVP-hypericin as a photodiagnostic and phototherapeutic tool for bladder cancer: A preclinical study.
- Mieke Roelants: Co-Promotor September 2010
Hypericin-Albumin and other diagnostics for non-muscle-invasive bladder cancer.
- Tom Budiharto: Co- Promotor January 2011
The optimization of treatment selection and of external beam radiotherapy for prostate cancer patients.
- Piet Ost: Member of Jury January 2011
Postoperative prostate bed intensity-modulated radiotherapy: dose-escalation for an invisible moving target.
- Yves Ozog: lid van de examencommissie – secretaries. December 2011
Theoretical and experimental evaluation of implant materials used in pelvic organ prolapse repair.
- Maarten Albersen: protocol voorzitter. Juni 2012
Treatment of cavernous nerve injury-induced erectile dysfunction with adipose tissue-derived stem cells.
- Steven Joniau: promotor. Juli 2012
High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models.
- Yvette Dubbelman: Member of Jury January 2013
- Functional outcome of radical retropubic prostatectomy: sexual function and urinary continence.
- Sanne Elsen: Co-Promotor February 2016
Evans blue as a diagnostic tool for non-muscle-invasive bladder cancer.
- Mieke Goossens: Co-Promotor June 2017
Risicofactoren voor het ontstaan en herval van blaaskanker: een klinische en epidemiologische benadering.

XII. Obtained grants and awards

1. Clinical research on the efficiency of interferential therapy on bladder dysfunction by Multiple Sclerosis; granted by the “Belgian Research Group for Multiple Sclerosis”, 184,000 BEF, May 1983

2. Postgraduate education in Rotterdam; October, November and December 1984; bursary of the “Ministerie van Onderwijs en Wetenschappen van Nederland”, 64,000 BEF, August 1984
3. Experimental and clinical research on peptidergic innervation of the bladder in neurogenic bladder dysfunction by Multiple Sclerosis; granted by the “Van Goethem-Brichant Foundation”, 595,220 BEF, December 1984
4. Clinical pathological research on bladder innervation disorders in Multiple Sclerosis; granted by the “Belgian Research Group for Multiple Sclerosis”, 200,000 BEF, December 1984
5. Erectile dysfunctions in patients with Multiple Sclerosis; granted by the “Belgian Research Group for Multiple Sclerosis”, 250,000 BEF, March 1986
6. Präpubische Urethra Resektion, Bard Award 1990 of the “Deutsche Gesellschaft für Urologie e.V.”, 3,000 DEM, November 1990
7. Nocturnal penile tumescence recording in Multiple Sclerosis patients: granted by NFWO Levenslijn project n° 7.0046.92, 1,207.000 BEF, October 1992
8. Urological revalidation of M.S. patients: pelvic floor muscular reeducation and intravesical stimulation. Granted by the Belgian Research Group for Multiple Sclerosis, 250,000 BEF, April 1994
9. Trisomy 7 in renal cell carcinoma: granted by the Elaut Price of the Belgian Society Urology (Dr. M. Van den Heuvel), 80,000 BEF, January 1996
10. T1c prostate cancer: granted by the Elaut Price Belgian Society Urology (Dr. B. Bamelis), 30,000 BEF, January 1996
11. BIOMED PL 3386 Participant. Measurement of hematogeneous micrometastases associated with prostate cancer by RT/PCR and DNA probe detection of prostate specific antigen mRNA (leader: C. Sternberg, Rome).
12. Is radicale prostatectomie zinvol voor klinisch T3 prostaatcarcinoom? granted by the Elaut Price Belgian Society of Urology (Dr.K. Boel), January 1999
13. The Folke Edsmyr Award 1999, October 1, 1999, Karolinska Institute, WHO Center
for Urological Tumours, Stockholm
14. Astellas Leerstoel voor Oncologische Urologie, KU Leuven, 16 september 2010
15. J. De Wever Fonds voor Prostaatkankerpreventie, KU Leuven, 16 september 2010
16. Prize for the best scientific paper published on clinical research in European Urology
by a young urologist in 2012.
D.C. Chade, S.F. Shariat, A.M. Cronin, C.J. Savage, R.J. Karnes, M.L. Blute, A. Briganti,
F. Montorsi, H.G. van der Poel, H. Van Poppel, S. Joniau. G.Godoy, A. Hurtado-Coll,

M.E. Gleave, M. Dall'Oglio, M. Srougi, P.T. Scardino, J.A. Eastham

27th Annual EAU Congress Paris, 24-28 February 2012

17. Prize for the best scientific paper on clinical research in European Urology by a urologist in training. E. Scosyrev, E. Messing, R. Sylvester, S. Campbell, H. Van Poppel.

Renal function after nephron sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904.

30th Annual EAU Congress – Madrid, Spain – 20-24 March 2015

18. P.H.M. de Mulder Award – 10th European International Kidney Cancer Symposium – Lyon, France – 24-25 April 2015

19. Société Internationale d'Urologie - Distinguished Career Award 2016 – Buenos Aires, Argentina – 20 October 2016

INDEX

I. Assisted courses, symposia, scientific meetings and congresses	2
II. Lectures and communications	37
III. Live demonstrations of surgery	83
IV. Publications	85
IV. 1. First author	85
IV.2. Co-author.....	99
IV.3. Proceedings or abstract-publication.....	137
IV.4. Video's.....	179
V. Postgraduate education	179
VI. Nominations	180
VII. Reviewer of scientific journals.....	182
VIII. Review for international meetings.....	183
IX. Redaction of journals/books.....	183
X. Memberships	184
XI. Promotor or Co-promotorship, member of jury.....	186
XII. Obtained grants and awards	188